0000318154-22-000041.txt : 20220805 0000318154-22-000041.hdr.sgml : 20220805 20220804195342 ACCESSION NUMBER: 0000318154-22-000041 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220805 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 221138258 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 10-Q 1 amgn-20220630.htm 10-Q amgn-20220630
0000318154false2022Q212/3100003181542022-01-012022-06-300000318154exch:XNGSus-gaap:CommonStockMember2022-01-012022-06-300000318154exch:XNGSamgn:A2.00SeniorNotesDue2026Member2022-01-012022-06-3000003181542022-08-01xbrli:shares0000318154us-gaap:ProductMember2022-04-012022-06-30iso4217:USD0000318154us-gaap:ProductMember2021-04-012021-06-300000318154us-gaap:ProductMember2022-01-012022-06-300000318154us-gaap:ProductMember2021-01-012021-06-300000318154us-gaap:ProductAndServiceOtherMember2022-04-012022-06-300000318154us-gaap:ProductAndServiceOtherMember2021-04-012021-06-300000318154us-gaap:ProductAndServiceOtherMember2022-01-012022-06-300000318154us-gaap:ProductAndServiceOtherMember2021-01-012021-06-3000003181542022-04-012022-06-3000003181542021-04-012021-06-3000003181542021-01-012021-06-30iso4217:USDxbrli:shares00003181542022-06-3000003181542021-12-310000318154us-gaap:CommonStockMember2021-12-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-12-310000318154us-gaap:RetainedEarningsMember2021-12-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000318154us-gaap:RetainedEarningsMember2022-01-012022-03-3100003181542022-01-012022-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000318154us-gaap:CommonStockMember2022-01-012022-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-01-012022-03-310000318154us-gaap:CommonStockMember2022-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-03-310000318154us-gaap:RetainedEarningsMember2022-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100003181542022-03-310000318154us-gaap:RetainedEarningsMember2022-04-012022-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000318154us-gaap:CommonStockMember2022-04-012022-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-04-012022-06-300000318154us-gaap:CommonStockMember2022-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-06-300000318154us-gaap:RetainedEarningsMember2022-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000318154us-gaap:CommonStockMember2020-12-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-12-310000318154us-gaap:RetainedEarningsMember2020-12-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100003181542020-12-310000318154us-gaap:RetainedEarningsMember2021-01-012021-03-3100003181542021-01-012021-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000318154us-gaap:CommonStockMember2021-01-012021-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-01-012021-03-310000318154us-gaap:CommonStockMember2021-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-03-310000318154us-gaap:RetainedEarningsMember2021-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100003181542021-03-310000318154us-gaap:RetainedEarningsMember2021-04-012021-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000318154us-gaap:CommonStockMember2021-04-012021-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-04-012021-06-300000318154us-gaap:CommonStockMember2021-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-06-300000318154us-gaap:RetainedEarningsMember2021-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000003181542021-06-30amgn:segment0000318154amgn:TeneobioMember2022-01-012022-06-300000318154amgn:TeneobioMember2022-06-300000318154amgn:TeneobioMemberamgn:RDTechnologyrightsMember2022-06-300000318154us-gaap:LicensingAgreementsMemberamgn:TeneobioMember2022-06-300000318154amgn:TeneobioMemberus-gaap:InProcessResearchAndDevelopmentMemberamgn:AMG340Member2022-06-300000318154amgn:TeneobioMemberamgn:RDTechnologyrightsMember2022-01-012022-06-300000318154us-gaap:LicensingAgreementsMemberamgn:TeneobioMember2022-01-012022-06-300000318154amgn:FivePrimeTherapeuticsIncMember2021-04-162021-04-160000318154amgn:FivePrimeTherapeuticsIncMember2021-04-160000318154amgn:GensentaIlacSanayiVsTicaretMember2022-06-300000318154srt:ScenarioForecastMemberamgn:GensentaIlacSanayiVsTicaretMember2022-07-012022-09-300000318154us-gaap:OtherOperatingIncomeExpenseMemberamgn:GensentaIlacSanayiVsTicaretMember2022-04-012022-06-300000318154amgn:EnbrelMembercountry:US2022-04-012022-06-300000318154amgn:EnbrelMemberus-gaap:NonUsMember2022-04-012022-06-300000318154amgn:EnbrelMember2022-04-012022-06-300000318154amgn:EnbrelMembercountry:US2021-04-012021-06-300000318154amgn:EnbrelMemberus-gaap:NonUsMember2021-04-012021-06-300000318154amgn:EnbrelMember2021-04-012021-06-300000318154country:USamgn:ProliaMember2022-04-012022-06-300000318154us-gaap:NonUsMemberamgn:ProliaMember2022-04-012022-06-300000318154amgn:ProliaMember2022-04-012022-06-300000318154country:USamgn:ProliaMember2021-04-012021-06-300000318154us-gaap:NonUsMemberamgn:ProliaMember2021-04-012021-06-300000318154amgn:ProliaMember2021-04-012021-06-300000318154country:USamgn:OtezlaMember2022-04-012022-06-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2022-04-012022-06-300000318154amgn:OtezlaMember2022-04-012022-06-300000318154country:USamgn:OtezlaMember2021-04-012021-06-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2021-04-012021-06-300000318154amgn:OtezlaMember2021-04-012021-06-300000318154amgn:XgevaMembercountry:US2022-04-012022-06-300000318154amgn:XgevaMemberus-gaap:NonUsMember2022-04-012022-06-300000318154amgn:XgevaMember2022-04-012022-06-300000318154amgn:XgevaMembercountry:US2021-04-012021-06-300000318154amgn:XgevaMemberus-gaap:NonUsMember2021-04-012021-06-300000318154amgn:XgevaMember2021-04-012021-06-300000318154country:USamgn:AranespMember2022-04-012022-06-300000318154amgn:AranespMemberus-gaap:NonUsMember2022-04-012022-06-300000318154amgn:AranespMember2022-04-012022-06-300000318154country:USamgn:AranespMember2021-04-012021-06-300000318154amgn:AranespMemberus-gaap:NonUsMember2021-04-012021-06-300000318154amgn:AranespMember2021-04-012021-06-300000318154country:USamgn:NeulastaMember2022-04-012022-06-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2022-04-012022-06-300000318154amgn:NeulastaMember2022-04-012022-06-300000318154country:USamgn:NeulastaMember2021-04-012021-06-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2021-04-012021-06-300000318154amgn:NeulastaMember2021-04-012021-06-300000318154amgn:RepathaevolocumabMembercountry:US2022-04-012022-06-300000318154amgn:RepathaevolocumabMemberus-gaap:NonUsMember2022-04-012022-06-300000318154amgn:RepathaevolocumabMember2022-04-012022-06-300000318154amgn:RepathaevolocumabMembercountry:US2021-04-012021-06-300000318154amgn:RepathaevolocumabMemberus-gaap:NonUsMember2021-04-012021-06-300000318154amgn:RepathaevolocumabMember2021-04-012021-06-300000318154amgn:KyprolisMembercountry:US2022-04-012022-06-300000318154amgn:KyprolisMemberus-gaap:NonUsMember2022-04-012022-06-300000318154amgn:KyprolisMember2022-04-012022-06-300000318154amgn:KyprolisMembercountry:US2021-04-012021-06-300000318154amgn:KyprolisMemberus-gaap:NonUsMember2021-04-012021-06-300000318154amgn:KyprolisMember2021-04-012021-06-300000318154amgn:NplateMembercountry:US2022-04-012022-06-300000318154amgn:NplateMemberus-gaap:NonUsMember2022-04-012022-06-300000318154amgn:NplateMember2022-04-012022-06-300000318154amgn:NplateMembercountry:US2021-04-012021-06-300000318154amgn:NplateMemberus-gaap:NonUsMember2021-04-012021-06-300000318154amgn:NplateMember2021-04-012021-06-300000318154country:USamgn:OtherProductsMember2022-04-012022-06-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2022-04-012022-06-300000318154amgn:OtherProductsMember2022-04-012022-06-300000318154country:USamgn:OtherProductsMember2021-04-012021-06-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2021-04-012021-06-300000318154amgn:OtherProductsMember2021-04-012021-06-300000318154country:USus-gaap:ProductMember2022-04-012022-06-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2022-04-012022-06-300000318154country:USus-gaap:ProductMember2021-04-012021-06-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2021-04-012021-06-300000318154amgn:EnbrelMembercountry:US2022-01-012022-06-300000318154amgn:EnbrelMemberus-gaap:NonUsMember2022-01-012022-06-300000318154amgn:EnbrelMember2022-01-012022-06-300000318154amgn:EnbrelMembercountry:US2021-01-012021-06-300000318154amgn:EnbrelMemberus-gaap:NonUsMember2021-01-012021-06-300000318154amgn:EnbrelMember2021-01-012021-06-300000318154country:USamgn:ProliaMember2022-01-012022-06-300000318154us-gaap:NonUsMemberamgn:ProliaMember2022-01-012022-06-300000318154amgn:ProliaMember2022-01-012022-06-300000318154country:USamgn:ProliaMember2021-01-012021-06-300000318154us-gaap:NonUsMemberamgn:ProliaMember2021-01-012021-06-300000318154amgn:ProliaMember2021-01-012021-06-300000318154country:USamgn:OtezlaMember2022-01-012022-06-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2022-01-012022-06-300000318154amgn:OtezlaMember2022-01-012022-06-300000318154country:USamgn:OtezlaMember2021-01-012021-06-300000318154amgn:OtezlaMemberus-gaap:NonUsMember2021-01-012021-06-300000318154amgn:OtezlaMember2021-01-012021-06-300000318154amgn:XgevaMembercountry:US2022-01-012022-06-300000318154amgn:XgevaMemberus-gaap:NonUsMember2022-01-012022-06-300000318154amgn:XgevaMember2022-01-012022-06-300000318154amgn:XgevaMembercountry:US2021-01-012021-06-300000318154amgn:XgevaMemberus-gaap:NonUsMember2021-01-012021-06-300000318154amgn:XgevaMember2021-01-012021-06-300000318154country:USamgn:AranespMember2022-01-012022-06-300000318154amgn:AranespMemberus-gaap:NonUsMember2022-01-012022-06-300000318154amgn:AranespMember2022-01-012022-06-300000318154country:USamgn:AranespMember2021-01-012021-06-300000318154amgn:AranespMemberus-gaap:NonUsMember2021-01-012021-06-300000318154amgn:AranespMember2021-01-012021-06-300000318154country:USamgn:NeulastaMember2022-01-012022-06-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2022-01-012022-06-300000318154amgn:NeulastaMember2022-01-012022-06-300000318154country:USamgn:NeulastaMember2021-01-012021-06-300000318154us-gaap:NonUsMemberamgn:NeulastaMember2021-01-012021-06-300000318154amgn:NeulastaMember2021-01-012021-06-300000318154amgn:RepathaevolocumabMembercountry:US2022-01-012022-06-300000318154amgn:RepathaevolocumabMemberus-gaap:NonUsMember2022-01-012022-06-300000318154amgn:RepathaevolocumabMember2022-01-012022-06-300000318154amgn:RepathaevolocumabMembercountry:US2021-01-012021-06-300000318154amgn:RepathaevolocumabMemberus-gaap:NonUsMember2021-01-012021-06-300000318154amgn:RepathaevolocumabMember2021-01-012021-06-300000318154amgn:KyprolisMembercountry:US2022-01-012022-06-300000318154amgn:KyprolisMemberus-gaap:NonUsMember2022-01-012022-06-300000318154amgn:KyprolisMember2022-01-012022-06-300000318154amgn:KyprolisMembercountry:US2021-01-012021-06-300000318154amgn:KyprolisMemberus-gaap:NonUsMember2021-01-012021-06-300000318154amgn:KyprolisMember2021-01-012021-06-300000318154amgn:NplateMembercountry:US2022-01-012022-06-300000318154amgn:NplateMemberus-gaap:NonUsMember2022-01-012022-06-300000318154amgn:NplateMember2022-01-012022-06-300000318154amgn:NplateMembercountry:US2021-01-012021-06-300000318154amgn:NplateMemberus-gaap:NonUsMember2021-01-012021-06-300000318154amgn:NplateMember2021-01-012021-06-300000318154country:USamgn:OtherProductsMember2022-01-012022-06-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2022-01-012022-06-300000318154amgn:OtherProductsMember2022-01-012022-06-300000318154country:USamgn:OtherProductsMember2021-01-012021-06-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2021-01-012021-06-300000318154amgn:OtherProductsMember2021-01-012021-06-300000318154country:USus-gaap:ProductMember2022-01-012022-06-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2022-01-012022-06-300000318154country:USus-gaap:ProductMember2021-01-012021-06-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2021-01-012021-06-30xbrli:pure0000318154us-gaap:DomesticCountryMember2021-05-310000318154us-gaap:DomesticCountryMember2022-04-280000318154us-gaap:USTreasurySecuritiesMember2022-06-300000318154us-gaap:USTreasuryBillSecuritiesMember2022-06-300000318154us-gaap:MoneyMarketFundsMember2022-06-300000318154amgn:OtherShortTermInterestBearingSecuritiesMember2022-06-300000318154us-gaap:USTreasurySecuritiesMember2021-12-310000318154us-gaap:USTreasuryBillSecuritiesMember2021-12-310000318154us-gaap:MoneyMarketFundsMember2021-12-310000318154amgn:OtherShortTermInterestBearingSecuritiesMember2021-12-310000318154amgn:AvailableForSalesInvestmentsMember2022-06-300000318154amgn:AvailableForSalesInvestmentsMember2021-12-310000318154us-gaap:FairValueInputsLevel1Member2022-06-300000318154us-gaap:FairValueInputsLevel1Member2021-12-310000318154amgn:BeiGeneMember2022-06-300000318154amgn:BeiGeneMember2021-12-310000318154amgn:BeiGeneMember2022-04-012022-06-300000318154amgn:BeiGeneMember2021-04-012021-06-300000318154amgn:BeiGeneMember2022-01-012022-06-300000318154amgn:BeiGeneMember2021-01-012021-06-300000318154amgn:NeumoraTherapeuticsIncMember2021-09-300000318154amgn:NeumoraTherapeuticsIncMember2021-09-302021-09-300000318154amgn:NeumoraTherapeuticsIncMember2022-06-300000318154amgn:NeumoraTherapeuticsIncMember2021-12-310000318154amgn:NeumoraTherapeuticsIncMember2022-04-012022-06-300000318154amgn:NeumoraTherapeuticsIncMember2022-01-012022-06-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-06-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-06-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-04-012022-06-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-04-012021-06-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-01-012022-06-300000318154srt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-01-012021-06-300000318154us-gaap:DevelopedTechnologyRightsMember2022-06-300000318154us-gaap:DevelopedTechnologyRightsMember2021-12-310000318154us-gaap:LicensingAgreementsMember2022-06-300000318154us-gaap:LicensingAgreementsMember2021-12-310000318154us-gaap:MarketingRelatedIntangibleAssetsMember2022-06-300000318154us-gaap:MarketingRelatedIntangibleAssetsMember2021-12-310000318154amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember2022-06-300000318154amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember2021-12-310000318154us-gaap:InProcessResearchAndDevelopmentMember2022-06-300000318154us-gaap:InProcessResearchAndDevelopmentMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2022-06-30iso4217:CHF0000318154us-gaap:NotesPayableToBanksMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2021-12-310000318154amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMemberus-gaap:NotesPayableToBanksMember2022-06-300000318154amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointSixTwoFivePercentNotesDue2024Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointSixTwoFivePercentNotesDue2024Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember2022-06-30iso4217:EUR0000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember2021-12-310000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember2022-06-300000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member2022-06-30iso4217:GBP0000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member2021-12-310000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2022-06-300000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointTwoZeroNotesDue2027Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointTwoZeroNotesDue2027Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:OnePointSixFivePercent2028NotesMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:OnePointSixFivePercent2028NotesMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3002029NotesMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:A3002029NotesMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FourPercentPoundSterlingNotesDue2029Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPercentPoundSterlingNotesDue2029Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointFourFivePercentNotesDue2030Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointFourFivePercentNotesDue2030Member2021-12-310000318154amgn:TwoPointThreeZeroPercentNotesDue2031Memberus-gaap:NotesPayableToBanksMember2022-06-300000318154amgn:TwoPointThreeZeroPercentNotesDue2031Memberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointZeroPercent2032NotesMemberMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointZeroPercent2032NotesMemberMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3352032NotesMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointThreeSevenFivePercentNotesDue2037Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointThreeSevenFivePercentNotesDue2037Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointNineZeroPercentNotesDue2038Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointNineZeroPercentNotesDue2038Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointFourZeroPercentNotesDue2039Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:SixPointFourZeroPercentNotesDue2039Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneFivePercentNotesDue2040Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointOneFivePercentNotesDue2040Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSevenFivePercentNotesDue2040Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSevenFivePercentNotesDue2040Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointEightZeroPercent2041NotesMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:TwoPointEightZeroPercent2041NotesMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointNineFivePercentNotesDue2041Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointNineFivePercentNotesDue2041Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointOneFivePercentNotesDue2041Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointOneFivePercentNotesDue2041Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSixFivePercentNotesDue2042Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointSixFivePercentNotesDue2042Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointThreeSevenFivePercentNotesDue2043Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:FivePointThreeSevenFivePercentNotesDue2043Member2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointThreeSevenFivePercentNotesDue2050Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:ThreePointThreeSevenFivePercentNotesDue2050Member2021-12-310000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember2022-06-300000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A300NotesDue20523002052NotesMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:A300NotesDue20523002052NotesMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A4202052NotesMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:A4202052NotesMember2021-12-310000318154amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMemberus-gaap:NotesPayableToBanksMember2022-06-300000318154amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMemberus-gaap:NotesPayableToBanksMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:A4402062NotesMember2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:A4402062NotesMember2021-12-310000318154us-gaap:NotesPayableToBanksMemberamgn:OtherNotesDue2097Member2022-06-300000318154us-gaap:NotesPayableToBanksMemberamgn:OtherNotesDue2097Member2021-12-310000318154us-gaap:NotesPayableToBanksMember2022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3002029NotesMember2022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3352032NotesMember2022-03-310000318154amgn:A4202052NotesMember2022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A4202052NotesMember2022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A4402062NotesMember2022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3352032NotesMember2022-01-012022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A3002029NotesMember2022-01-012022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A4402062NotesMember2022-01-012022-03-310000318154us-gaap:NotesPayableToBanksMemberamgn:A4202052NotesMember2022-01-012022-03-310000318154us-gaap:DebtSecuritiesPayableMembersrt:MinimumMember2022-01-012022-03-310000318154us-gaap:DebtSecuritiesPayableMembersrt:MaximumMember2022-01-012022-03-310000318154amgn:AcceleratedStockRepurchaseAgreementMember2022-02-24amgn:financial_institution0000318154amgn:AcceleratedStockRepurchaseAgreementMember2022-02-252022-02-250000318154us-gaap:RetainedEarningsMemberamgn:AcceleratedStockRepurchaseAgreementMember2022-02-252022-02-250000318154amgn:AcceleratedStockRepurchaseAgreementMemberus-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-02-252022-02-2500003181542021-12-012021-12-3100003181542022-03-012022-03-3100003181542022-06-012022-06-300000318154srt:ScenarioForecastMember2022-09-082022-09-080000318154us-gaap:SubsequentEventMember2022-08-032022-08-030000318154us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2021-12-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2022-01-012022-03-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2022-03-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2022-04-012022-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-04-012022-06-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-04-012022-06-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2022-04-012022-06-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300000318154us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-06-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2022-06-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2022-06-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-06-300000318154us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2022-06-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2022-06-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2022-06-300000318154us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-06-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-06-300000318154us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-06-300000318154us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember2022-06-300000318154us-gaap:FairValueInputsLevel2Memberamgn:OtherShortTermInterestBearingSecuritiesMember2022-06-300000318154us-gaap:FairValueInputsLevel3Memberamgn:OtherShortTermInterestBearingSecuritiesMember2022-06-300000318154us-gaap:FairValueInputsLevel2Member2022-06-300000318154us-gaap:FairValueInputsLevel3Member2022-06-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2022-06-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2022-06-300000318154us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2022-06-300000318154us-gaap:ForeignExchangeContractMember2022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel1Member2022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel2Member2022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel3Member2022-06-300000318154amgn:CrossCurrencySwapContractsMember2022-06-300000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2022-06-300000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2022-06-300000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2022-06-300000318154us-gaap:InterestRateSwapMember2022-06-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2021-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2021-12-310000318154us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2021-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2021-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2021-12-310000318154us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-12-310000318154us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember2021-12-310000318154us-gaap:FairValueInputsLevel2Memberamgn:OtherShortTermInterestBearingSecuritiesMember2021-12-310000318154us-gaap:FairValueInputsLevel3Memberamgn:OtherShortTermInterestBearingSecuritiesMember2021-12-310000318154us-gaap:FairValueInputsLevel2Member2021-12-310000318154us-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2021-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2021-12-310000318154us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2021-12-310000318154us-gaap:ForeignExchangeContractMember2021-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel2Member2021-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel3Member2021-12-310000318154amgn:CrossCurrencySwapContractsMember2021-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2021-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2021-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2021-12-310000318154us-gaap:InterestRateSwapMember2021-12-310000318154amgn:TeneobioIncMember2021-12-310000318154amgn:TeneobioIncMember2022-06-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMember2022-06-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMember2021-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2022-06-300000318154amgn:CrossCurrencySwapContractsMembercurrency:CHFus-gaap:CashFlowHedgingMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2022-06-300000318154currency:USDamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberamgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember2022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember2022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMembercurrency:EUR2022-06-300000318154currency:USDamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberamgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember2022-06-300000318154amgn:CrossCurrencySwapContractsMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberus-gaap:CashFlowHedgingMember2022-06-300000318154amgn:CrossCurrencySwapContractsMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberus-gaap:CashFlowHedgingMembercurrency:GBP2022-06-300000318154currency:USDamgn:CrossCurrencySwapContractsMemberamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberus-gaap:CashFlowHedgingMember2022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberamgn:FourPercentPoundSterlingNotesDue2029Member2022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMembercurrency:GBPamgn:FourPercentPoundSterlingNotesDue2029Member2022-06-300000318154currency:USDamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberamgn:FourPercentPoundSterlingNotesDue2029Member2022-06-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-04-012022-06-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-04-012021-06-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-012022-06-300000318154us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2022-04-012022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2021-04-012021-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2022-01-012022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2021-01-012021-06-300000318154us-gaap:CashFlowHedgingMember2022-04-012022-06-300000318154us-gaap:CashFlowHedgingMember2021-04-012021-06-300000318154us-gaap:CashFlowHedgingMember2022-01-012022-06-300000318154us-gaap:CashFlowHedgingMember2021-01-012021-06-300000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-06-300000318154amgn:LongTermDebtCurrentMaturitiesMember2022-06-300000318154amgn:LongTermDebtCurrentMaturitiesMember2021-12-310000318154us-gaap:LongTermDebtMember2022-06-300000318154us-gaap:LongTermDebtMember2021-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:ProductMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:ProductMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300000318154us-gaap:InterestRateSwapMember2022-04-012022-06-300000318154us-gaap:InterestRateSwapMember2022-01-012022-06-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:ProductMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:ProductMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300000318154us-gaap:InterestRateSwapMember2021-04-012021-06-300000318154us-gaap:InterestRateSwapMember2021-01-012021-06-300000318154us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2022-06-300000318154us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberamgn:OtherCurrentNoncurrentAssetsMember2022-06-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2022-06-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2022-06-300000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2022-06-300000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2022-06-300000318154us-gaap:DesignatedAsHedgingInstrumentMember2022-06-300000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberamgn:OtherCurrentNoncurrentAssetsMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2021-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2021-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2021-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2021-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2021-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMember2021-12-3100003181542022-05-272022-05-27amgn:argument

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-37702
Amgen Inc.
(Exact name of registrant as specified in its charter)
Delaware 95-3540776
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)
One Amgen Center Drive 91320-1799
Thousand Oaks
California
(Address of principal executive offices) (Zip Code)
(805) 447-1000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.0001 par valueAMGNThe Nasdaq Stock Market LLC
2.00% Senior Notes due 2026AMGN26The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filerNon-accelerated filer
Smaller reporting companyEmerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 
Yes No 
As of August 1, 2022, the registrant had 534,930,850 shares of common stock, $0.0001 par value, outstanding.



AMGEN INC.
INDEX
i


Defined Terms and Products
Defined terms
We use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related as well as names of other companies, which are given below.
TermDescription
2017 Tax ActTax Cuts and Jobs Act of 2017
ANDAAbbreviated New Drug Application
AOCIaccumulated other comprehensive income (loss)
ASRaccelerated share repurchase
BeiGeneBeiGene, Ltd.
BergamoLaboratorio Quimico Farmaceutico Bergamo Ltda
ChemoCentryxChemoCentryx, Inc.
CMSCenters for Medicare & Medicaid Services
COVID-19coronavirus disease 2019
EczacıbaşıEIS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş.
EMAEuropean Medicines Agency
EPSearnings per share
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
FitchFitch Ratings, Inc.
Five PrimeFive Prime Therapeutics, Inc.
FTCFederal Trade Commission
GAAPU.S. generally accepted accounting principles
GensentaGensenta İlaç Sanayi ve Ticaret A.Ş.
HHSU.S. Department of Health & Human Services
IPR&Din-process research and development
IRPinternational reference pricing
IRSInternal Revenue Service
LIBORLondon Interbank Offered Rate
Lp(a)lipoprotein(a)
MD&Amanagement’s discussion and analysis
MFNmost-favored nation
Moody’sMoody’s Investors Service, Inc.
NeumoraNeumora Therapeutics, Inc.
OECDOrganisation for Economic Co-operation and Development
PBMpharmacy benefit manager
PTABPatent Trial and Appeal Board
R&Dresearch and development
RARRevenue Agent Report
ROWrest of world
S&PStandard & Poor’s Financial Services LLC
SECU.S. Securities and Exchange Commission
SG&Aselling, general and administrative
TeneobioTeneobio, Inc.
U.S. TreasuryU.S. Department of Treasury
USPTOU.S. Patent and Trademark Office
UTBunrecognized tax benefit
ii



Products
The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are given below.
TermDescription
Aimovig
Aimovig® (erenumab-aooe)
AMGEVITA
AMGEVITA (adalimumab)
Aranesp
Aranesp® (darbepoetin alfa)
AVSOLA
AVSOLA® (infliximab-axxq)
BLINCYTO
BLINCYTO® (blinatumomab)
Corlanor
Corlanor® (ivabradine)
ENBREL
Enbrel® (etanercept)
EPOGEN
EPOGEN® (epoetin alfa)
EVENITY
EVENITY® (romosozumab-aqqg)
IMLYGIC
IMLYGIC® (talimogene laherparepvec)
KANJINTI
KANJINTI® (trastuzumab-anns)
KYPROLIS
KYPROLIS® (carfilzomib)
LUMAKRAS/LUMYKRAS
LUMAKRAS® / LUMYKRAS (sotorasib)
MVASI
MVASI® (bevacizumab-awwb)
Neulasta
Neulasta® (pegfilgrastim)
NEUPOGEN
NEUPOGEN® (filgrastim)
Nplate
Nplate® (romiplostim)
OlpasiranOlpasiran (formerly AMG 890)
Onpro
Onpro®
Otezla
Otezla® (apremilast)
Parsabiv
Parsabiv® (etelcalcetide)
Prolia
Prolia® (denosumab)
Repatha
Repatha® (evolocumab)
RIABNI
RIABNI (rituximab-arrx)
Sensipar/Mimpara
Sensipar®/Mimpara (cinacalcet)
TEZSPIRE
TEZSPIRE® (tezepelumab-ekko)
Vectibix
Vectibix® (panitumumab)
XGEVA
XGEVA® (denosumab)

iii


PART I — FINANCIAL INFORMATION 

Item 1.FINANCIAL STATEMENTS
AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per-share data)
(Unaudited)

 Three months ended
June 30,
Six months ended
June 30,
 2022202120222021
Revenues:
Product sales$6,281 $6,114 $12,012 $11,706 
Other revenues313 412 820 721 
Total revenues6,594 6,526 12,832 12,427 
Operating expenses:
Cost of sales1,510 1,637 3,071 3,127 
Research and development1,039 1,082 1,998 2,049 
Acquired in-process research and development 1,505  1,505 
Selling, general and administrative1,327 1,384 2,555 2,638 
Other542 90 532 151 
Total operating expenses4,418 5,698 8,156 9,470 
Operating income2,176 828 4,676 2,957 
Other income (expense):
Interest expense, net(328)(281)(623)(566)
Other (expense) income, net(317)11 (847)24 
Income before income taxes1,531 558 3,206 2,415 
Provision for income taxes214 94 413 305 
Net income$1,317 $464 $2,793 $2,110 
Earnings per share:
Basic$2.46 $0.81 $5.16 $3.67 
Diluted$2.45 $0.81 $5.13 $3.65 
Shares used in calculation of earnings per share:
Basic535 573 541 575 
Diluted537 576 544 578 

See accompanying notes.
1





AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)

Three months ended
June 30,
Six months ended
June 30,
 2022202120222021
Net income$1,317 $464 $2,793 $2,110 
Other comprehensive income (loss), net of reclassification adjustments and taxes:
Foreign currency translation(65)14 (116)(25)
Cash flow hedges156 (48)240 142 
Other (1)  
Other comprehensive income (loss), net of reclassification adjustments and taxes91 (35)124 117 
Comprehensive income$1,408 $429 $2,917 $2,227 

See accompanying notes.
2





AMGEN INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per-share data)

June 30, 2022December 31, 2021
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$5,203 $7,989 
Marketable securities1,980 48 
Trade receivables, net5,327 4,895 
Inventories4,554 4,086 
Other current assets2,258 2,367 
Total current assets19,322 19,385 
Property, plant and equipment, net5,158 5,184 
Intangible assets, net13,927 15,182 
Goodwill14,865 14,890 
Other noncurrent assets6,022 6,524 
Total assets$59,294 $61,165 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$1,256 $1,366 
Accrued liabilities10,545 10,731 
Current portion of long-term debt817 87 
Total current liabilities12,618 12,184 
Long-term debt35,705 33,222 
Long-term tax liabilities5,603 6,594 
Other noncurrent liabilities2,949 2,465 
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—534.9 shares in 2022 and 558.3 shares in 2021
31,343 32,096 
Accumulated deficit(28,252)(24,600)
Accumulated other comprehensive loss(672)(796)
Total stockholders’ equity2,419 6,700 
Total liabilities and stockholders’ equity$59,294 $61,165 

See accompanying notes.
3





AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In millions, except per-share data)
(Unaudited)

Number
of shares
of common
stock
Common
stock and
additional
paid-in capital
Accumulated
deficit
Accumulated
other
comprehensive
loss
Total
Balance as of December 31, 2021
558.3 $32,096 $(24,600)$(796)$6,700 
Net income— — 1,476 — 1,476 
Other comprehensive income, net of taxes— — — 33 33 
Dividends declared on common stock ($1.94 per share)
— — (1,034)— (1,034)
Issuance of common stock in connection with the Company’s equity award programs
0.5 18 — — 18 
Stock-based compensation expense— 78 — — 78 
Tax impact related to employee stock-based compensation expense
— (45)— — (45)
Repurchases of common stock (Note 10)(24.6)(900)(5,410)— (6,310)
Balance as of March 31, 2022
534.2 31,247 (29,568)(763)916 
Net income— — 1,317 — 1,317 
Other comprehensive income, net of taxes— — — 91 91 
Issuance of common stock in connection with the Company’s equity award programs
0.7 45 — — 45 
Stock-based compensation expense— 120 — — 120 
Tax impact related to employee stock-based compensation expense
— (69)— — (69)
Other— — (1)— (1)
Balance as of June 30, 2022
534.9 $31,343 $(28,252)$(672)$2,419 






























4





AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (continued)
(In millions, except per-share data)
(Unaudited)

Number
of shares
of common
stock
Common
stock and
additional
paid-in capital
Accumulated
deficit
Accumulated
other
comprehensive
loss
Total
Balance as of December 31, 2020
578.3 $31,802 $(21,408)$(985)$9,409 
Net income— — 1,646 — 1,646 
Other comprehensive income, net of taxes— — — 152 152 
Dividends declared on common stock ($1.76 per share)
— — (1,012)— (1,012)
Issuance of common stock in connection with the Company’s equity award programs
0.7 6 — — 6 
Stock-based compensation expense— 57 — — 57 
Tax impact related to employee stock-based compensation expense
— (59)— — (59)
Repurchases of common stock(3.7)— (865)— (865)
Balance as of March 31, 2021
575.3 31,806 (21,639)(833)9,334 
Net income— — 464 — 464 
Other comprehensive loss, net of taxes— — — (35)(35)
Issuance of common stock in connection with the Company’s equity award programs
0.8 47 — — 47 
Stock-based compensation expense— 100 — — 100 
Tax impact related to employee stock-based compensation expense
— (76)— — (76)
Repurchases of common stock(6.5)— (1,592)— (1,592)
Other— — 5 — 5 
Balance as of June 30, 2021
569.6 $31,877 $(22,762)$(868)$8,247 

See accompanying notes.

5





AMGEN INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)

 Six months ended
June 30,
 20222021
Cash flows from operating activities:
Net income$2,793 $2,110 
Depreciation, amortization and other1,669 1,696 
Deferred income taxes(514)(137)
Acquired in-process research and development 1,505 
Adjustments for equity method investments497 (36)
Loss on divestiture560  
Other items, net436 206 
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net(504)35 
Inventories(410)(167)
Other assets198 (258)
Accounts payable(98)(156)
Accrued income taxes, net(685)(930)
Long-term tax liabilities108 47 
Other liabilities44 120 
Net cash provided by operating activities4,094 4,035 
Cash flows from investing activities:
Purchases of marketable securities(1,976)(8,000)
Proceeds from sales of marketable securities 4,404 
Proceeds from maturities of marketable securities47 6,528 
Purchases of property, plant and equipment(436)(351)
Cash paid for acquisitions, net of cash acquired (1,626)
Other61 (65)
Net cash (used in) provided by investing activities(2,304)890 
Cash flows from financing activities:
Net proceeds from issuance of debt3,954  
Repurchases of common stock (Note 10)(6,360)(2,452)
Dividends paid(2,118)(2,024)
Other(52)(85)
Net cash used in financing activities(4,576)(4,561)
(Decrease) increase in cash and cash equivalents(2,786)364 
Cash and cash equivalents at beginning of period7,989 6,266 
Cash and cash equivalents at end of period$5,203 $6,630 

See accompanying notes.
6





AMGEN INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2022
(Unaudited)

1. Summary of significant accounting policies
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation
The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.0 billion and $8.8 billion as of June 30, 2022 and December 31, 2021, respectively.
Recent accounting pronouncements
In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.
7





In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.

2. Acquisitions and divestitures
Acquisition of Teneobio, Inc.
On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio’s proprietary bispecific and multispecific antibody technologies, which complement Amgen’s existing antibody capabilities and bispecific T-cell engager (BiTE®) platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen’s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our condensed consolidated financial statements commencing on the acquisition date.
Measurement period adjustments for the six months ended June 30, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $22 million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen’s results of operations during the six months ended June 30, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):
Amounts
Cash purchase price$993 
Contingent consideration299 
Total consideration$1,292 
Cash and cash equivalents$100 
In-process research and development991 
Finite-lived intangible asset – research and development technology rights115 
Finite-lived intangible assets – licensing rights41 
Goodwill273 
Other assets, net16 
Deferred tax liability(244)
Total assets acquired, net$1,292 
Consideration for this transaction comprised (i) an upfront cash payment of $993 million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio’s former equity holders of up to $1.6 billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $299 million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 11, Fair value measurement, for information regarding the estimated fair value of these obligations as of June 30, 2022.
8





The estimated fair values of acquired IPR&D assets totaled $991 million, of which $784 million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to four separate preclinical oncology programs. The R&D technology rights of $115 million relate to Teneobio’s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over 10 years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41 million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.
A deferred tax liability of $244 million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.
The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $273 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.
Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis of certain tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.
Acquisition of Five Prime Therapeutics, Inc.
On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $1.6 billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. Five Prime’s operations have been included in our condensed consolidated financial statements commencing after the acquisition date.
We allocated the consideration to acquire Five Prime to: the bemarituzumab IPR&D program of $1.5 billion, which was expensed immediately in Acquired IPR&D expense in the Condensed Consolidated Statements of Income; deferred tax assets of $177 million; and other net liabilities of $47 million. The Acquired IPR&D expense was not tax deductible.
Divestiture of Gensenta İlaç Sanayi ve Ticaret A.Ş.
On June 28, 2022, we entered into a share purchase agreement with Eczacıbaşı under which Eczacıbaşı will acquire all of our shares in Gensenta—a subsidiary in Turkey. Net assets related to Gensenta of $80 million met the criteria to be classified as held-for-sale and did not meet the criteria to be classified as discontinued operations. Upon closing of the transaction, we expect to receive $135 million in cash. The transaction is expected to close in the third quarter of 2022 upon approval by the Turkish Competition Authority.
As of June 30, 2022, held-for-sale assets and liabilities of $100 million and $20 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $560 million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuation allowances to Other current assets and Accrued liabilities in the Condensed Consolidated Balance Sheets.
9





3. Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.
Revenues were as follows (in millions):
Three months ended June 30,
20222021
U.S.ROWTotalU.S.ROWTotal
ENBREL$1,036 $15 $1,051 $1,113 $31 $1,144 
Prolia611 311 922 538 276 814 
Otezla487 107 594 423 111 534 
XGEVA391 142 533 355 133 488 
Aranesp132 225 357 135 232 367 
Neulasta263 47 310 434 52 486 
Repatha154 171 325 143 143 286 
KYPROLIS213 104 317 190 90 280 
Nplate156 128 284 136 109 245 
Other products1,003 585 1,588 907 563 1,470 
Total product sales(1)
$4,446 $1,835 6,281 $4,374 $1,740 6,114 
Other revenues313 412 
Total revenues$6,594 $6,526 
Six months ended June 30,
20222021
U.S.ROWTotalU.S.ROWTotal
ENBREL$1,879 $34 $1,913 $2,007 $61 $2,068 
Prolia1,193 581 1,774 1,039 533 1,572 
Otezla837 208 1,045 789 221 1,010 
XGEVA759 276 1,035 689 267 956 
Aranesp269 446 715 260 462 722 
Neulasta567 91 658 855 113 968 
Repatha319 335 654 282 290 572 
KYPROLIS409 195 604 349 182 531 
Nplate312 238 550 248 224 472 
Other products1,939 1,125 3,064 1,759 1,076 2,835 
Total product sales(1)
$8,483 $3,529 12,012 $8,277 $3,429 11,706 
Other revenues820 721 
Total revenues$12,832 $12,427 
____________
(1)    Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021.


10





4. Income taxes
The effective tax rates for the three and six months ended June 30, 2022, were 14.0% and 12.9%, respectively, compared with 16.8% and 12.6%, respectively, for the corresponding periods of the prior year.
The decrease in our effective tax rate for the three months ended June 30, 2022, was primarily due to the prior year nondeductible IPR&D expense arising from the acquisition of Five Prime, partially offset by current year unfavorable items including a loss on a nonstrategic divestiture. The increase in our effective tax rate for the six months ended June 30, 2022, was primarily due to current year unfavorable items compared to last year including a loss on a nonstrategic divestiture, partially offset by the prior year nondeductible IPR&D expense arising from the acquisition of Five Prime and changes in earnings mix. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States treated as a foreign jurisdiction for U.S. tax purposes, that are currently subject to a tax incentive grant through 2035. In addition, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. These foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. See Note 2, Acquisitions and divestitures.
The U.S. territory of Puerto Rico imposes a 4% excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We account for the excise tax as a manufacturing cost that is capitalized in Inventories and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes, in 2022, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.
One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters.
In 2017, we received an RAR and a modified RAR from the IRS for the years 2010–2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010–2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010–2012 by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed for the years 2010–2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings.
In 2020, we received an RAR and a modified RAR from the IRS for the years 2013–2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010–2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013–2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013–2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for the years 2013–2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued on our foreign earnings.
We firmly believe that the IRS positions set forth in the 2010–2012 and 2013–2015 Notices are without merit. We are contesting the 2010–2012 and 2013–2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court.
We are currently under examination by the IRS for the years 2016–2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we have examinations by a number of state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.
We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.
11





See Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations, Income Taxes, for further discussion and Part II, Item 1A, Risk Factors—The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.
During the three and six months ended June 30, 2022, the gross amounts of our UTBs increased by $50 million and $95 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of June 30, 2022, if recognized, would affect our effective tax rate.

5. Earnings per share
The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.
The computations for basic and diluted EPS were as follows (in millions, except per-share data):
 Three months ended
June 30,
Six months ended
June 30,
 2022202120222021
Income (Numerator):
Net income for basic and diluted EPS$1,317 $464 $2,793 $2,110 
Shares (Denominator):
Weighted-average shares for basic EPS535 573 541 575 
Effect of dilutive securities2 3 3 3 
Weighted-average shares for diluted EPS537 576 544 578 
Basic EPS$2.46 $0.81 $5.16 $3.67 
Diluted EPS$2.45 $0.81 $5.13 $3.65 
For the three and six months ended June 30, 2022 and 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

12





6. Investments
Available-for-sale investments
The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):
Types of securities as of June 30, 2022Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Fair
values
U.S. Treasury notes$ $ $ $ 
U.S. Treasury bills1,980   1,980 
Money market mutual funds4,433   4,433 
Other short-term interest-bearing securities    
Total interest-bearing securities$6,413 $ $ $6,413 

Types of securities as of December 31, 2021Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Fair
values
U.S. Treasury notes$47 $ $ $47 
U.S. Treasury bills1,400   1,400 
Money market mutual funds5,856   5,856 
Other short-term interest-bearing securities1   1 
Total interest-bearing securities$7,304 $ $ $7,304 
The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):
Condensed Consolidated Balance Sheets locationsJune 30, 2022December 31, 2021
Cash and cash equivalents$4,433 $7,256 
Marketable securities1,980 48 
Total interest-bearing securities$6,413 $7,304 
Cash and cash equivalents in the above table excludes bank account cash of $770 million and $733 million as of June 30, 2022 and December 31, 2021, respectively.
Total interest-bearing securities as of June 30, 2022 and December 31, 2021, mature in one year or less.
For the three and six months ended June 30, 2022 and 2021, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.
The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
Equity securities
We held investments in equity securities with readily determinable fair values (publicly traded securities) of $361 million and $611 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022 and 2021, net unrealized gains and losses on publicly traded securities were a $106 million net loss and a $25 million net gain, respectively. During the six months ended June 30, 2022 and 2021, net unrealized losses on publicly traded securities were $276 million and $31 million, respectively. Realized gains and losses on sales of publicly traded securities for the three and six months ended June 30, 2022 and 2021, were not material.
13





We held investments of $280 million and $262 million in equity securities without readily determinable fair values as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and six months ended June 30, 2022 and 2021, upward adjustments and downward adjustments on these securities were not material. Adjustments were based on observable price transactions.
Equity method investments
BeiGene, Ltd.
As of June 30, 2022 and December 31, 2021, we had an ownership interest in BeiGene of approximately 18.2% and 18.4%, respectively, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets and accounted for under the equity method of accounting. We amortize the difference between the fair value of equity securities acquired and our proportionate share of the carrying value of the underlying net assets of BeiGene over the useful lives of the assets that gave rise to this basis difference. This amortization and our share of the results of operations of BeiGene are included in Other (expense) income, net, in the Condensed Consolidated Statements of Income one quarter in arrears.
During the three months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene’s net loss of $80 million and net income of $14 million, respectively, and amortization of the basis difference of $48 million and $42 million, respectively. During the six months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene’s net losses of $188 million and $83 million, respectively, and amortization of the basis difference of $95 million and $84 million, respectively. As of June 30, 2022 and December 31, 2021, the carrying values of our investment in BeiGene totaled $2.5 billion and $2.8 billion, respectively, and the fair values of our investment totaled $3.1 billion and $5.1 billion, respectively. As of June 30, 2022, we believe the carrying value of our equity investment in BeiGene is fully recoverable.
Neumora Therapeutics, Inc.
On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257 million, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets, in exchange for a $100 million cash payment and $157 million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of June 30, 2022 and December 31, 2021, our ownership interest in Neumora was approximately 25.7% and 25.9%, respectively, and the fair values of our investment were $131 million and $220 million, respectively. Accordingly, for the reduction in fair value of our investment during the three and six months ended June 30, 2022, we recognized a loss of $39 million and $89 million, respectively, for the reduction in fair value of our investment in Other (expense) income, net, in the Condensed Consolidated Statements of Income. For information on determination of fair values, see Note 11, Fair value measurement.
Limited partnerships
We held limited partnership investments of $338 million and $573 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of June 30, 2022, unfunded additional commitments to be made for these investments during the next several years were $209 million. For the three months ended June 30, 2022 and 2021, net unrealized losses from our limited partnership investments were $60 million and $43 million, respectively. For the six months ended June 30, 2022 and 2021, net unrealized gains and losses from our limited partnership investments were a $220 million net loss and a $165 million net gain, respectively.

14





7. Inventories
Inventories consisted of the following (in millions):
June 30, 2022December 31, 2021
Raw materials$779 $647 
Work in process2,763 2,367 
Finished goods1,012 1,072 
Total inventories$4,554 $4,086 


8. Goodwill and other intangible assets
Goodwill
The change in the carrying amount of goodwill was as follows (in millions):
Six months ended
June 30, 2022
Beginning balance$14,890 
Adjustments to goodwill resulting from acquisitions and divestitures, net(1)
7 
Currency translation adjustment(32)
Ending balance$14,865 
____________
(1)    Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.

Other intangible assets
Other intangible assets consisted of the following (in millions):
 June 30, 2022December 31, 2021
 Gross
carrying
amounts
Accumulated
amortization
Other intangible
assets, net
Gross
carrying
amounts
Accumulated
amortization
Other intangible
assets, net
Finite-lived intangible assets:
Developed-product-technology rights$25,537 $(13,863)$11,674 $25,561 $(12,769)$12,792 
Licensing rights3,864 (3,050)814 3,807 (2,973)834 
Marketing-related rights1,326 (1,125)201 1,354 (1,112)242 
Research and development technology rights1,371 (1,153)218 1,377 (1,133)244 
Total finite-lived intangible assets32,098 (19,191)12,907 32,099 (17,987)14,112 
Indefinite-lived intangible assets:
In-process research and development1,020 — 1,020 1,070 — 1,070 
Total other intangible assets$33,118 $(19,191)$13,927 $33,169 $(17,987)$15,182 

Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses.
15





IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.
During the three months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $629 million and $652 million, respectively. During the six months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $1.3 billion in both periods. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining six months ending December 31, 2022, and the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $1.3 billion, $2.5 billion, $2.5 billion, $2.4 billion, $1.7 billion and $1.8 billion, respectively.


16





9. Financing arrangements
Our borrowings consisted of the following (in millions):
 June 30, 2022December 31, 2021
0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)
$733 $767 
2.25% notes due 2023 (2.25% 2023 Notes)
750 750 
3.625% notes due 2024 (3.625% 2024 Notes)
1,400 1,400 
1.90% notes due 2025 (1.90% 2025 Notes)
500 500 
3.125% notes due 2025 (3.125% 2025 Notes)
1,000 1,000 
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
786 853 
2.60% notes due 2026 (2.60% 2026 Notes)
1,250 1,250 
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)
579 643 
2.20% notes due 2027 (2.20% 2027 Notes)
1,750 1,750 
3.20% notes due 2027 (3.20% 2027 Notes)
1,000 1,000 
1.65% notes due 2028 (1.65% 2028 Notes)
1,250 1,250 
3.00% notes due 2029 (3.00% 2029 Notes)
750  
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)
853 947 
2.45% notes due 2030 (2.45% 2030 Notes)
1,250 1,250 
2.30% notes due 2031 (2.30% 2031 Notes)
1,250 1,250 
2.00% notes due 2032 (2.00% 2032 Notes)
1,250 1,250 
3.35% notes due 2032 (3.35% 2032 Notes)
1,000 — 
6.375% notes due 2037 (6.375% 2037 Notes)
478 478 
6.90% notes due 2038 (6.90% 2038 Notes)
254 254 
6.40% notes due 2039 (6.40% 2039 Notes)
333 333 
3.15% notes due 2040 (3.15% 2040 Notes)
2,000 2,000 
5.75% notes due 2040 (5.75% 2040 Notes)
373 373 
2.80% notes due 2041 (2.80% 2041 Notes)
1,150 1,150 
4.95% notes due 2041 (4.95% 2041 Notes)
600 600 
5.15% notes due 2041 (5.15% 2041 Notes)
729 729 
5.65% notes due 2042 (5.65% 2042 Notes)
415 415 
5.375% notes due 2043 (5.375% 2043 Notes)
185 185 
4.40% notes due 2045 (4.40% 2045 Notes)
2,250 2,250 
4.563% notes due 2048 (4.563% 2048 Notes)
1,415 1,415 
3.375% notes due 2050 (3.375% 2050 Notes)
2,250 2,250 
4.663% notes due 2051 (4.663% 2051 Notes)
3,541 3,541 
3.00% notes due 2052 (3.00% 2052 Notes)
1,350 1,350 
4.20% notes due 2052 (4.20% 2052 Notes)
1,000  
2.77% notes due 2053 (2.77% 2053 Notes)
940 940 
4.40% notes due 2062 (4.40% 2062 Notes)
1,250  
Other notes due 2097100 100 
Unamortized bond discounts, premiums and issuance costs, net(1,245)(1,213)
Fair value adjustments(210)284 
Other13 15 
Total carrying value of debt36,522 33,309 
Less current portion(817)(87)
Total long-term debt$35,705 $33,222 
There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.
17





During the three months ended March 31, 2022, we issued $4.0 billion of debt consisting of $750 million of the 3.00% 2029 Notes, $1.0 billion of the 3.35% 2032 Notes, $1.0 billion of the 4.20% 2052 Notes and $1.25 billion of the 4.40% 2062 Notes. The 3.00% 2029 Notes were issued to finance eligible projects that meet specified criteria to benefit the environment. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a make-whole amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during a specified period of time immediately prior to the maturing of the notes. Such time periods range from two months to six months prior to maturity.

10. Stockholders’ equity
Stock repurchase program
Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):
20222021
 SharesDollars SharesDollars
First quarter24.6 $5,410 3.7 $865 
Second quarter  6.5 1,592 
Total stock repurchases24.6 $5,410 10.2 $2,457 
On February 24, 2022, the Company entered into ASR agreements with three third-party financial institutions (Dealers). Under the ASR agreements, the Company made payments in an aggregate amount of $6.0 billion on February 25, 2022, to the Dealers and received and retired an initial 23.3 million shares of the Company’s common stock from the Dealers. The payments were recorded as reductions to shareholders’ equity, consisting of a $5.1 billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $0.9 billion decrease in additional paid-in capital, which reflects the value of the stock that remains to be delivered by the Dealers pending final settlement. The final number of shares to be repurchased by the Company will be based on the daily volume-weighted average stock price of the Company’s common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, under certain circumstances, one or more of the Dealers may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to a Dealer. The final settlement under the ASR agreements is scheduled to occur in the third quarter of 2022, subject to an earlier termination under certain limited circumstances, as set forth in the ASR agreements. In total, we repurchased 24.6 million shares of common stock in the first quarter of 2022, including shares received under the ASR agreements.
As of June 30, 2022, $4.6 billion of authorization remained available under our stock repurchase program.
Dividends
In March 2022 and December 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which were paid in June 2022 and March 2022, respectively. In August 2022, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which will be paid on September 8, 2022.
18





Accumulated other comprehensive income (loss)
The components of AOCI were as follows (in millions):
Foreign
currency
translation
Cash flow
hedges
Available-for-sale
securities
OtherAOCI
Balance as of December 31, 2021$(844)$61 $ $(13)$(796)
Foreign currency translation adjustments(51)— — — (51)
Unrealized gains— 56   56 
Reclassification adjustments to income— 51  — 51 
Income taxes (23) — (23)
Balance as of March 31, 2022
(895)145  (13)(763)
Foreign currency translation adjustments(65)— — — (65)
Unrealized gains— 67   67 
Reclassification adjustments to income— 132  — 132 
Income taxes (43) — (43)
Balance as of June 30, 2022
$(960)$301 $ $(13)$(672)
Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):
Three months ended June 30,
Components of AOCI20222021Condensed Consolidated
Statements of Income locations
Cash flow hedges:
Foreign currency contract gains (losses)$53 $(18)Product sales
Cross-currency swap contract (losses) gains(185)46 Other (expense) income, net
(132)28 Income before income taxes
28 (6)Provision for income taxes
$(104)$22 Net income
Six months ended June 30,
Components of AOCI20222021Condensed Consolidated
Statements of Income locations
Cash flow hedges:
Foreign currency contract gains (losses)$80 $(19)Product sales
Cross-currency swap contract losses(263)(86)Other (expense) income, net
(183)(105)Income before income taxes
39 22 Provision for income taxes
$(144)$(83)Net income


19





11. Fair value measurement
To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:
Level 1Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
Level 2Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs
Level 3Valuations based on inputs that are unobservable and significant to the overall fair value measurement
The availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.
The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
Quoted prices in
active markets for
identical assets
(Level 1)
Significant
other observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Fair value measurement as of June 30, 2022, using:Total
Assets:
Available-for-sale securities:
U.S. Treasury notes$ $ $ $ 
U.S. Treasury bills1,980   1,980 
Money market mutual funds4,433   4,433 
Other short-term interest-bearing securities    
Equity securities361  131 492 
Derivatives:
Foreign currency contracts 413  413 
Cross-currency swap contracts 29  29 
Interest rate swap contracts    
Total assets$6,774 $442 $131 $7,347 
Liabilities:
Derivatives:
Foreign currency contracts$ $30 $ $30 
Cross-currency swap contracts 503  503 
Interest rate swap contracts 591  591 
Contingent consideration obligations
  310 310 
Total liabilities$ $1,124 $310 $1,434 
20





Quoted prices in
active markets for
identical assets
(Level 1)
Significant
other observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Fair value measurement as of December 31, 2021, using:Total
Assets:
Available-for-sale securities:
U.S. Treasury notes$47 $ $ $47 
U.S. Treasury bills1,400   1,400 
Money market mutual funds5,856   5,856 
Other short-term interest-bearing securities 1  1 
Equity securities611  220 831 
Derivatives:
Foreign currency contracts 183  183 
Cross-currency swap contracts 66  66 
Interest rate swap contracts 16  16 
Total assets$7,914 $266 $220 $8,400 
Liabilities:
Derivatives:
Foreign currency contracts$ $39 $ $39 
Cross-currency swap contracts 339  339 
Interest rate swap contracts 156  156 
Contingent consideration obligations
  342 342 
Total liabilities$ $534 $342 $876 

Interest-bearing and equity securities
The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair value of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available market information for similar companies that have actively traded equity securities.
Derivatives
All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.
Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.
Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.
21





Contingent consideration obligations
As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.
Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):
Three months ended
June 30,
Six months ended
June 30,
2022202120222021
Beginning balance$330 $39 $342 $33 
Payments(1)(2)(3)(3)
Net changes in valuations(19)11 (29)18 
Ending balance$310 $48 $310 $48 
As of June 30, 2022 and December 31, 2021, our contingent consideration obligations are primarily the result of our acquisition of Teneobio in October 2021, which obligates us to pay the former shareholders up to $1.6 billion upon achieving separate development and regulatory milestones with regard to various R&D programs. See Note 2, Acquisitions and divestitures.
Summary of the fair values of other financial instruments
Cash equivalents
The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.
Borrowings
We estimated the fair values of our borrowings by using Level 2 inputs. As of June 30, 2022 and December 31, 2021, the aggregate fair values of our borrowings were $34.4 billion and $37.9 billion, respectively, and the carrying values were $36.5 billion and $33.3 billion, respectively.
Investment in BeiGene, Ltd.
We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of June 30, 2022 and December 31, 2021, the fair values were $3.1 billion and $5.1 billion, and the carrying values were $2.5 billion and $2.8 billion, respectively.
During the three and six months ended June 30, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis, except with respect to the impairment of net assets in connection with the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.


22





12. Derivative instruments
The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative- trading purposes.
Cash flow hedges
We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales are being hedged than in successive periods.
As of June 30, 2022 and December 31, 2021, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.6 billion and $5.7 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.
To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.
The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):
Foreign currencyU.S. dollars
Hedged notesNotional amountsInterest ratesNotional amountsInterest rates
0.41% 2023 Swiss franc BondsCHF700 0.4 %$704 3.4 %
2.00% 2026 euro Notes750 2.0 %$833 3.9 %
5.50% 2026 pound sterling Notes£475 5.5 %$747 6.0 %
4.00% 2029 pound sterling Notes£700 4.0 %$1,111 4.5 %
In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the six months ended June 30, 2022, and amounts expected to be recognized during the subsequent 12 months are not material.
23





The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):
 Three months ended
June 30,
Six months ended
June 30,
Derivatives in cash flow hedging relationships2022202120222021
Foreign currency contracts$252 $(46)$330 $137 
Cross-currency swap contracts(185)15 (207)(60)
Total unrealized gains (losses)$67 $(31)$123 $77 
Fair value hedges
To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of both June 30, 2022 and December 31, 2021, we had interest rate swap contracts with aggregate notional amounts of $6.7 billion that hedge certain portions of our long-term debt issuances.
For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.
The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):
Carrying amounts of hedged liabilities(1)
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)
Condensed Consolidated Balance Sheets locationsJune 30, 2022December 31, 2021June 30, 2022December 31, 2021
Current portion of long-term debt$82 $85 $82 $85 
Long-term debt$6,241 $6,729 $(292)$199 
____________
(1)     Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $399 million and $440 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.
(2)    Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $299 million and $340 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.

24





Impact of hedging transactions
The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):
Three months ended June 30, 2022Six months ended June 30, 2022
Product salesOther (expense) income, netInterest expense, netProduct salesOther (expense) income, netInterest expense, net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$6,281 $(317)$(328)$12,012 $(847)$(623)
The effects of cash flow and fair value hedging:
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
Foreign currency contracts$53 $— $— $80 $— $— 
Cross-currency swap contracts$— $(185)$— $— $(263)$— 
Gains (losses) on fair value hedging relationships—interest rate swap agreements:
Hedged items(1)
$— $— $157 $— $— $494 
Derivatives designated as hedging instruments$— $— $(135)$— $— $(450)

Three months ended June 30, 2021Six months ended June 30, 2021
Product salesOther (expense) income, netInterest expense, netProduct salesOther (expense) income, netInterest expense, net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$6,114 $11 $(281)$11,706 $24 $(566)
The effects of cash flow and fair value hedging:
(Losses) gains on cash flow hedging relationships reclassified out of AOCI:
Foreign currency contracts$(18)$— $— $(19)$— $— 
Cross-currency swap contracts$— $46 $— $— $(86)$— 
(Losses) gains on fair value hedging relationships—interest rate swap agreements:
Hedged items(1)
$— $— $(34)$— $— $141 
Derivatives designated as hedging instruments$— $— $55 $— $— $(97)
__________
(1)    Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.
No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of June 30, 2022, we expected to reclassify $179 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.
25





Derivatives not designated as hedges
To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of June 30, 2022 and December 31, 2021, the total notional amounts of these foreign currency forward contracts were $550 million and $680 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and six months ended June 30, 2022 and 2021.
The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
 Derivative assetsDerivative liabilities
June 30, 2022Condensed Consolidated
Balance Sheets locations
Fair valuesCondensed Consolidated
Balance Sheets locations
Fair values
Derivatives designated as hedging instruments:
Foreign currency contractsOther current assets/ Other noncurrent assets$413 
Accrued liabilities/ Other noncurrent liabilities
$30 
Cross-currency swap contractsOther current assets/ Other noncurrent assets29 
Accrued liabilities/ Other noncurrent liabilities
503 
Interest rate swap contractsOther current assets/ Other noncurrent assets 
Accrued liabilities/ Other noncurrent liabilities
591 
Total derivatives designated as hedging instruments
$442 $1,124 

 Derivative assetsDerivative liabilities
December 31, 2021Condensed Consolidated
Balance Sheets locations
Fair valuesCondensed Consolidated
Balance Sheets locations
Fair values
Derivatives designated as hedging instruments:
Foreign currency contractsOther current assets/ Other noncurrent assets$183 
Accrued liabilities/ Other noncurrent liabilities
$39 
Cross-currency swap contractsOther current assets/ Other noncurrent assets66 
Accrued liabilities/ Other noncurrent liabilities
339 
Interest rate swap contractsOther current assets/ Other noncurrent assets16 
Accrued liabilities/ Other noncurrent liabilities
156 
Total derivatives designated as hedging instruments
$265 $534 
Our derivative contracts that were in liability positions as of June 30, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.
The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.

26





13. Contingencies and commitments
Contingencies
In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2021, Part I, Item 1A. Risk Factors—Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.
We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. Although it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
Certain recent developments concerning our legal proceedings and other matters are discussed below:
ANDA Patent Litigation
Otezla ANDA Patent Litigation
Amgen Inc. v. Apotex Inc.
On June 14, 2022, Amgen filed a lawsuit in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Apotex Inc. (Apotex) for infringement of U.S. Patent Nos. 7,427,638, 9,872,854 and 10,092,541, which are listed in the Orange Book for Otezla. This lawsuit was based on Apotex’s submission of an ANDA seeking FDA approval to market a generic version of Otezla and seeks an order of the New Jersey District Court making any FDA approval of Apotex’s ANDA effective no earlier than the expiration of the applicable patents.
Repatha Patent Litigation
Patent Disputes in the International Region
On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP’004 Patent), seeking infringement damages and injunctive relief. The EP’004 Patent is currently in opposition proceedings, initiated by Amgen and an anonymous third party, before the European Patent Office (EPO). A hearing before the Opposition Division of the EPO was held on June 8 and 9, 2022, and the Opposition Division upheld the validity of the claims at issue with narrowing amendments. The parties are awaiting the Opposition Division’s written opinion. Amgen filed a Notice of Appeal on July 6, 2022.



27





Antitrust Actions
Sensipar Antitrust Class Actions
On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal of the U.S. District Court for the District of Delaware’s (the Delaware District Court’s) March 11, 2022 order denying Amgen’s Motion to Dismiss solely with respect to the reverse payment claim and the various state law claims. The plaintiffs did not oppose Amgen’s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs’ motion on June 10, 2022, and reply briefs were filed on June 24, 2022.
HUMIRA® Biosimilar Antitrust Actions
On August 1, 2022, the U.S. Court of Appeals for the Seventh Circuit issued an opinion affirming the June 30, 2020 dismissal with prejudice by the U.S. District Court for the Northern District of Illinois of a consolidated complaint against Amgen along with AbbVie Inc., AbbVie Biotechnology Ltd., Samsung Bioepis Co. and Sandoz Inc.
Regeneron Pharmaceuticals, Inc. Antitrust Action
On May 27, 2022, Regeneron Pharmaceuticals, Inc. (Regeneron) filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen’s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payors and PBMs have harmed the sales of its product PRALUENT® and focuses on two primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen’s initial responsive pleading was filed on August 1, 2022.
U.S. Tax Litigation
Amgen Inc. & Subsidiaries v. Commissioner of Internal Revenue
See Note 4, Income taxes, for discussion of the IRS tax dispute and the Company’s petition in the U.S. Tax Court.

28





Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following MD&A is intended to assist the reader in understanding Amgen’s business. MD&A is provided as a supplement to and should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2021, and our Quarterly Report on Form 10-Q for the period ended March 31, 2022. Our results of operations discussed in MD&A are presented in conformity with GAAP. Amgen operates in one business segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.
Forward-looking statements
This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management’s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as “expect,” “anticipate,” “outlook,” “could,” “target,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “should,” “may,” “assume” and “continue” as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Item 1A. Risk Factors in Part II herein and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021, and in Part II, Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the period ended March 31, 2022. We have based our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, EPS, liquidity and capital resources, trends, planned dividends, stock repurchases, collaborations and effects of pandemics. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.

Overview
Amgen is a biotechnology company committed to unlocking the potential of biology for patients suffering from serious illnesses. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Our principal products are ENBREL, Prolia, Otezla, XGEVA, Aranesp, Neulasta, Repatha, KYPROLIS and Nplate. We also market a number of other products, including MVASI, Vectibix, EVENITY, BLINCYTO, EPOGEN, AMGEVITA, Aimovig, Parsabiv, KANJINTI, LUMAKRAS/LUMYKRAS, NEUPOGEN, Sensipar/Mimpara and TEZSPIRE.
COVID-19 pandemic
Since the onset of the pandemic in 2020, we have been closely monitoring the pandemic’s effects on our global operations. We continue to take appropriate steps to minimize risks to our employees, a significant number of whom have continued to work virtually. To date, our remote working arrangements have not significantly affected our ability to maintain critical business operations, and we have not experienced disruptions to or shortages of our supply of medicines.
Over the course of the pandemic we have experienced changes in demand for some of our products as fluctuations in the frequency of patient visits to doctors’ offices have impacted the provision of treatments to existing patients and reduced diagnoses in new patients. During 2021, there was a gradual recovery in both patient visits and diagnosis rates that approached pre-pandemic levels. In 2022, the pandemic has continued to impact the healthcare sector, and our business, to varying degrees across our markets. To date in 2022, in most of our major markets, with the exception of the Asia Pacific region that has been affected by sustained lockdowns, we have seen greater stability in patient visits and demand patterns even in areas facing surges in the virus. Given the evolution of COVID-19 since its onset, including the proliferation of variants, we cannot predict the impact of future virus surges on our business and will continue to closely monitor the impact of COVID-19 on our business and on the healthcare sector more generally.
29


With respect to our drug development activities, we continue to work to mitigate COVID-19 effects on future study enrollment in our clinical trials around the world. We remain focused on effectively supporting the delivery of care and investigational drug supply to patients enrolled in our active clinical sites.
Despite the ongoing pandemic and business impacts noted above, we believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures and debt service requirements as well as to engage in capital-return and other business initiatives that we plan to pursue. For a discussion of risks the COVID-19 pandemic presents to our results, see Risk Factors in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021, and in Part II, Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the period ended March 31, 2022.

Significant developments
Following is a summary of selected significant developments affecting our business that occurred since the filing of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. For additional developments or for a more comprehensive discussion of certain developments discussed below, see our Annual Report on Form 10-K for the year ended December 31, 2021, and our Quarterly Report on Form 10-Q for the period ended March 31, 2022.
Products/Pipeline
General Medicine
Olpasiran
In May 2022, we announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in adult patients with lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA (siRNA) designed to lower the body’s production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events. In the double-blind placebo-controlled treatment period, olpasiran was administered up to 225 mg subcutaneously every 12 weeks to patients with a median baseline Lp(a) of approximately 260 nmol/L. These data demonstrated a significant reduction from baseline in Lp(a) of up to or greater than 90 percent at week 36 (primary endpoint) and week 48 (end of treatment period) for the majority of doses. No new safety concerns were identified during this treatment period.
Inflammation
TEZSPIRE
In July 2022, our partner AstraZeneca plc announced that the Committee for Medicinal Products for Human Use of the EMA has recommended TEZSPIRE for marketing authorization in the European Union as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Business development
Proposed acquisition of ChemoCentryx, Inc.
On August 4, 2022, Amgen announced its proposed acquisition of ChemoCentryx for $52.00 per share in cash, for a total transaction price of approximately $4.0 billion. ChemoCentryx is a biopharmaceutical company focused on orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. In the United States, ChemoCentryx markets TAVNEOS®, the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis). The transaction is expected to close in the fourth quarter of 2022.


30


Selected financial information
The following is an overview of our results of operations (in millions, except percentages and per-share data):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
Product sales
U.S.$4,446 $4,374 %$8,483 $8,277 %
ROW1,835 1,740 %3,529 3,429 %
Total product sales6,281 6,114 %12,012 11,706 %
Other revenues313 412 (24)%820 721 14 %
Total revenues$6,594 $6,526 %$12,832 $12,427 %
Operating expenses$4,418 $5,698 (22)%$8,156 $9,470 (14)%
Operating income$2,176 $828 *$4,676 $2,957 58 %
Net income$1,317 $464 *$2,793 $2,110 32 %
Diluted EPS$2.45 $0.81 *$5.13 $3.65 41 %
Diluted shares537 576 (7)%544 578 (6)%
* Change in excess of 100%
In the following discussion of changes in product sales, any reference to unit demand growth or decline refers to changes in purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies).
Total product sales increased for the three months ended June 30, 2022, primarily driven by higher unit demand for certain brands including Repatha, Prolia, EVENITY, LUMAKRAS/LUMYKRAS and KYPROLIS, partially offset by declines in the net selling prices of certain products and unfavorable changes in foreign currency exchange rates. Total product sales increased for the six months ended June 30, 2022, primarily driven by higher unit demand for certain brands, including Repatha, Prolia, EVENITY, LUMAKRAS/LUMYKRAS and KYPROLIS, and by favorable changes to estimated sales deductions, partially offset by declines in the net selling prices of certain products and unfavorable changes in foreign currency exchange rates. For the remainder of 2022, we expect that net selling prices will continue to decline at a portfolio level, driven by increased competition.
Over the course of the COVID-19 pandemic we experienced changes in demand for some of our products as fluctuations in the frequency of patient visits to doctors’ offices have impacted the provision of treatments to existing patients and reduced diagnoses in new patients. In general, declines in the sales of our products that were impacted by the dynamics of the pandemic were most significant in the early months of the pandemic, with product demand beginning to show some recovery in late 2020. During 2021, there was a gradual recovery in both patient visits and diagnosis rates that approached pre-pandemic levels; however, variants (including Omicron) began to impact the healthcare sector and our business in late 2021 and early 2022. This led to diminished capacity in the healthcare sector and reduced working days for our own sales force. For the second quarter 2022, we have seen the impact of these variants recede in most markets, with the exception of some markets in the Asia Pacific region, which has allowed us to engage in increased field-facing activities. Provider and patient activity has also increased, leading to improvements in demand for our products to pre-pandemic levels. However, the cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which continues to impact our business. Given the unpredictable nature of the pandemic, there could be intermittent disruptions in physician–patient interactions, and as a result, we may experience quarter-to-quarter variability. In addition, other changes in the healthcare ecosystem have the potential to introduce variability into product sales trends. For example, changes in U.S. employment have led to changes to the insured population. Growth in numbers of Medicaid enrollees and uninsured individuals may have a negative impact on product demand and sales. Overall, uncertainty remains around the timing and magnitude of our sales during the COVID-19 pandemic. See Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021, and in Part II, Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the period ended March 31, 2022.
31


Other revenues decreased for the three months ended June 30, 2022, driven by lower revenue from COVID-19 antibody material and increased for the six months ended June 30, 2022, primarily driven by higher revenue from COVID-19 antibody material.
Operating expenses decreased for the three and six months ended June 30, 2022, primarily due to the Acquired IPR&D expense related to the Five Prime acquisition in 2021, partially offset by a loss on a nonstrategic divestiture in 2022. See Note 2, Acquisitions and divestitures.
Although changes in foreign currency exchange rates result in increases or decreases in our reported international product sales, the benefit or detriment that such movements have on our international product sales is partially offset by corresponding increases or decreases in our international operating expenses and our related foreign currency hedging activities. Further, while not designed to completely address foreign currency changes, our hedging activities seek to offset, in part, the effects of foreign currency exchange rate changes, both favorable and unfavorable, on our net income by hedging our net foreign currency exposure, primarily with respect to product sales denominated in euros. The net impact from changes in foreign currency exchange rates was not material for the three and six months ended June 30, 2022 and 2021.

Results of operations
Product sales
Worldwide product sales were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
ENBREL$1,051 $1,144 (8)%$1,913 $2,068 (7)%
Prolia 922 814 13 %1,774 1,572 13 %
Otezla594 534 11 %1,045 1,010 %
XGEVA533 488 %1,035 956 %
Aranesp357 367 (3)%715 722 (1)%
Neulasta310 486 (36)%658 968 (32)%
Repatha325 286 14 %654 572 14 %
KYPROLIS317 280 13 %604 531 14 %
Nplate284 245 16 %550 472 17 %
Other products1,588 1,470 %3,064 2,835 %
Total product sales$6,281 $6,114 %$12,012 $11,706 %
Future sales of our products will depend in part on the factors discussed below and in the following sections of this report: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Selected Financial Information; and (ii) Part II, Item 1A. Risk Factors, and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2021: (i) Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products; (ii) Part I, Item 1A. Risk Factors; and (iii) Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales, as well as in our Quarterly Report on Form 10-Q for the period ended March 31, 2022: (i) Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Product Sales; and (ii) Part II, Item 1A. Risk Factors.
32


ENBREL
Total ENBREL sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
ENBREL — U.S.$1,036 $1,113 (7)%$1,879 $2,007 (6)%
ENBREL — Canada15 31 (52)%34 61 (44)%
Total ENBREL$1,051 $1,144 (8)%$1,913 $2,068 (7)%
The decrease in ENBREL sales for the three and six months ended June 30, 2022, was primarily driven by lower net selling price and lower unit demand.
For the remainder of 2022, we expect that net selling price will continue to decline driven by increased competition.
Prolia
Total Prolia sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
Prolia — U.S.$611 $538 14 %$1,193 $1,039 15 %
Prolia — ROW311 276 13 %581 533 %
Total Prolia$922 $814 13 %$1,774 $1,572 13 %
The increase in global Prolia sales for the three and six months ended June 30, 2022, was primarily driven by higher unit demand.
Otezla
Total Otezla sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
Otezla — U.S.$487 $423 15 %$837 $789 %
Otezla — ROW107 111 (4)%208 221 (6)%
Total Otezla$594 $534 11 %$1,045 $1,010 %
The increase in global Otezla sales for the three months ended June 30, 2022, was driven by higher unit demand and favorable changes to estimated sales deductions, partially offset by lower net selling price.
The increase in global Otezla sales for the six months ended June 30, 2022, was primarily driven by higher unit demand and favorable changes to estimated sales deductions, partially offset by lower net selling price and unfavorable changes to inventory.
For a discussion of litigation related to Otezla, see Part IV—Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021, and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in this Quarterly Report.
33


XGEVA
Total XGEVA sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
XGEVA — U.S.$391 $355 10 %$759 $689 10 %
XGEVA — ROW142 133 %276 267 %
Total XGEVA$533 $488 %$1,035 $956 %
The increase in global XGEVA sales for the three and six months ended June 30, 2022, was primarily driven by higher net selling price and favorable changes to estimated sales deductions.
Aranesp
Total Aranesp sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
Aranesp — U.S.$132 $135 (2)%$269 $260 %
Aranesp — ROW225 232 (3)%446 462 (3)%
Total Aranesp$357 $367 (3)%$715 $722 (1)%
The decrease in global Aranesp sales for the three months ended June 30, 2022, was primarily driven by lower net selling price.
The decrease in global Aranesp sales for the six months ended June 30, 2022, was driven by lower net selling price and unfavorable changes in foreign currency exchange rates, partially offset by favorable changes to estimated sales deductions and higher unit demand.
Aranesp continues to face competition from a long-acting erythropoiesis-stimulating agent (ESA) and also faces competition from biosimilar versions of EPOGEN, which will continue to impact sales in the future.
Neulasta
Total Neulasta sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
Neulasta — U.S.
$263 $434 (39)%$567 $855 (34)%
Neulasta — ROW
47 52 (10)%91 113 (19)%
Total Neulasta$310 $486 (36)%$658 $968 (32)%
The decrease in global Neulasta sales for the three and six months ended June 30, 2022, was primarily driven by lower net selling price and unit demand.
Increased competition as a result of biosimilar versions of Neulasta has had and will continue to have a significant adverse impact on brand sales, including accelerating net price erosion and lower unit demand. We also expect other biosimilar versions, including biosimilars that will use an on-body injector that would compete with our Onpro injector, to be approved in the future.
For a discussion of ongoing patent litigations related to these and other biosimilars, see Part IV—Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021, and Part I—Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.
34


Repatha
Total Repatha sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
Repatha — U.S.$154 $143 %$319 $282 13 %
Repatha — ROW171 143 20 %335 290 16 %
Total Repatha$325 $286 14 %$654 $572 14 %
The increase in global Repatha sales for the three and six months ended June 30, 2022, was driven by higher unit demand, partially offset by lower net selling price. Contracting changes to support and expand Medicare Part D and commercial patient access and the inclusion of Repatha on China’s National Reimbursement Drug List as of January 1, 2022, resulted in the decrease to net selling price in 2022.
For a discussion of ongoing litigation related to Repatha, see Part IV—Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; Part I—Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022; and Part I—Note 13, Contingencies and commitments, to the condensed consolidated financial statements in this Quarterly Report.
KYPROLIS
Total KYPROLIS sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
KYPROLIS — U.S.$213 $190 12 %$409 $349 17 %
KYPROLIS — ROW104 90 16 %195 182 %
Total KYPROLIS$317 $280 13 %$604 $531 14 %
The increase in global KYPROLIS sales for the three and six months ended June 30, 2022, was driven by higher unit demand, partially offset by lower net selling price.
The FDA has reported that it has granted tentative or final approval of ANDAs for generic carfilzomib products filed by a number of companies. The date of approval of those ANDAs for generic carfilzomib products is governed by the Hatch–Waxman Act and any applicable settlement agreements between us and certain companies that seek to develop generic carfilzomib products.
Nplate
Total Nplate sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
Nplate — U.S.$156 $136 15 %$312 $248 26 %
Nplate — ROW128 109 17 %238 224 %
Total Nplate$284 $245 16 %$550 $472 17 %
The increase in global Nplate sales for the three and six months ended June 30, 2022, was primarily driven by higher unit demand and net selling price.
35


Other products
Other product sales by geographic region were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
MVASI — U.S.
$161 $206 (22)%$329 $430 (23)%
MVASI — ROW
82 88 (7)%158 158 — %
Vectibix — U.S.
96 92 %181 171 %
Vectibix— ROW111 147 (24)%227 259 (12)%
EVENITY — U.S.130 79 65 %240 136 76 %
EVENITY— ROW61 52 17 %121 102 19 %
BLINCYTO — U.S.77 62 24 %156 127 23 %
BLINCYTO — ROW62 46 35 %121 88 38 %
EPOGEN — U.S.
136 130 %256 255 — %
AMGEVITA — ROW
116 107 %224 213 %
Aimovig — U.S.88 82 %186 148 26 %
Aimovig — ROW— NM— NM
Parsabiv — U.S.71 37 92 %128 83 54 %
Parsabiv — ROW32 34 (6)%61 67 (9)%
KANJINTI — U.S.
69 132 (48)%149 262 (43)%
KANJINTI — ROW
16 24 (33)%32 55 (42)%
LUMAKRAS — U.S.
51 *99 *
LUMYKRAS — ROW
26 — NM40 — NM
NEUPOGEN — U.S.
21 36 (42)%44 54 (19)%
NEUPOGEN — ROW
16 15 %31 31 — %
Sensipar — U.S.25 %*
Sensipar/Mimpara — ROW
15 20 (25)%31 43 (28)%
Other — U.S.(1)
98 38 *162 80 *
Other — ROW(1)
44 30 47 %72 60 20 %
Total other products$1,588 $1,470 %$3,064 $2,835 %
Total U.S. — other products$1,003 $907 11 %$1,939 $1,759 10 %
Total ROW — other products585 563 %1,125 1,076 %
Total other products$1,588 $1,470 %$3,064 $2,835 %
NM = not meaningful
* Change in excess of 100%
____________
(1) Other products include Corlanor, AVSOLA, TEZSPIRE, IMLYGIC and RIABNI as well as sales by Gensenta and Bergamo subsidiaries.

36


Operating expenses
Operating expenses were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 20222021Change20222021Change
Operating expenses:
Cost of sales$1,510 $1,637 (8)%$3,071 $3,127 (2)%
% of product sales24.0 %26.8 %25.6 %26.7 %
% of total revenues22.9 %25.1 %23.9 %25.2 %
Research and development$1,039 $1,082 (4)%$1,998 $2,049 (2)%
% of product sales16.5 %17.7 %16.6 %17.5 %
% of total revenues15.8 %16.6 %15.6 %16.5 %
Acquired in-process research and development$— $1,505 NM$— $1,505 NM
% of product sales— %24.6 %— %12.9 %
% of total revenues— %23.1 %— %12.1 %
Selling, general and administrative$1,327 $1,384 (4)%$2,555 $2,638 (3)%
% of product sales21.1 %22.6 %21.3 %22.5 %
% of total revenues20.1 %21.2 %19.9 %21.2 %
Other$542 $90 *$532 $151 *
Total operating expenses$4,418 $5,698 (22)%$8,156 $9,470 (14)%
NM = not meaningful
* Change in excess of 100%
Cost of sales
Cost of sales decreased to 22.9% and 23.9% of total revenues for the three and six months ended June 30, 2022, respectively, driven by lower COVID-19 antibody shipments, lower manufacturing costs and lower amortization expense from acquisition-related assets, partially offset by unfavorable product mix.
Research and development
The decrease in R&D expense for the three months ended June 30, 2022, was driven by lower marketed product support and lower expense resulting from acquisition-related activity, partially offset by higher spend in research and early pipeline.
The decrease in R&D expense for the six months ended June 30, 2022, was driven by lower marketed product support and lower expense resulting from acquisition-related activity, partially offset by higher late-stage development program spend and research and early pipeline spend.
Acquired in-process research and development
The decrease in Acquired IPR&D expense for the three and six months ended June 30, 2022, was due to the bemarituzumab program, which was acquired as part of the Five Prime acquisition in 2021. See Note 2, Acquisitions and divestitures.
Selling, general and administrative
The decrease in SG&A expense for the three and six months ended June 30, 2022, was primarily driven by lower spend for marketed products and lower expense resulting from acquisition-related activity.
Other
Other operating expenses for the three and six months ended June 30, 2022, consisted primarily of a loss on a nonstrategic divestiture. See Note 2, Acquisitions and divestitures. Other operating expenses for the three and six months ended June 30, 2021, consisted primarily of expenses related to cost saving initiatives.

37


Nonoperating expense/income and income taxes
Nonoperating expense/income and income taxes were as follows (dollar amounts in millions):
 Three months ended
June 30,
Six months ended
June 30,
 2022202120222021
Interest expense, net$(328)$(281)$(623)$(566)
Other (expense) income, net$(317)$11 $(847)$24 
Provision for income taxes$214 $94 $413 $305 
Effective tax rate14.0 %16.8 %12.9 %12.6 %
Interest expense, net
The increase in Interest expense, net, for the three and six months ended June 30, 2022, was primarily due to higher overall debt outstanding and higher LIBOR rates on debt for which we effectively pay a variable rate of interest through the use of interest rate swaps.
Other (expense) income, net
The change in Other (expense) income, net, for the three and six months ended June 30, 2022, was primarily due to net losses recognized on our strategic equity investments in the current year compared with net gains recognized in the prior year and higher current year losses in connection with our BeiGene investment.
Income taxes
The decrease in our effective tax rate for the three months ended June 30, 2022, was primarily due to the prior year nondeductible IPR&D expense arising from the acquisition of Five Prime, partially offset by current year unfavorable items, including a loss on a nonstrategic divestiture. The increase in our effective tax rate for the six months ended June 30, 2022, was primarily due to current year unfavorable items compared to last year including a loss on a nonstrategic divestiture, partially offset by the prior year nondeductible IPR&D expense arising from the acquisition of Five Prime and changes in earnings mix. See Note 2, Acquisitions and divestitures.
The Administration proposed and Congress is considering a variety of potentially significant changes to existing tax law. These changes, or others, could substantially increase taxes we pay to the U.S. government. Further, the OECD recently reached an agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, either by all OECD participants or unilaterally by individual countries, this agreement could result in tax increases in both the United States and foreign jurisdictions. The U.S. Treasury recently released final foreign tax credit regulations that eliminate U.S. creditability of the Puerto Rico Excise Tax beginning in 2023, which would increase our U.S. tax liability. However, the U.S. territory of Puerto Rico recently enacted Act 52-2022, which provides for an alternate fixed tax rate on industrial development income that is expected to be creditable under U.S. law. As part of this new law, eligible businesses would be subject to incremental income and withholding taxes in lieu of payment of the Puerto Rico Excise Tax. In order to qualify for the alternative fixed tax rate, we must amend our current tax grant with the Puerto Rico government by December 31, 2022. Once we qualify for this alternative fixed tax rate, which we expect to occur as of January 1, 2023, our tax expense will increase. While we expect these taxes to be partially offset by U.S. foreign tax credits, the U.S. Treasury has not yet issued guidance on whether the alternative fixed tax rate will be creditable under U.S. law.
In 2017, we received an RAR and a modified RAR from the IRS for the years 2010–2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010–2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010–2012 by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed for the years 2010–2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings.
38


In 2020, we received an RAR and a modified RAR from the IRS for the years 2013–2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010–2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013–2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013–2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for the years 2013–2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued on our foreign earnings.
We firmly believe that the IRS positions set forth in the 2010–2012 and 2013–2015 Notices are without merit. We are contesting the 2010–2012 and 2013–2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court.
We are currently under examination by the IRS for the years 2016–2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we have examinations by a number of state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.
We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.
See Part II, Item 1A, Risk Factors—The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability, and Note 4, Income taxes, to the condensed consolidated financial statements for further discussion.

Financial condition, liquidity and capital resources
Selected financial data were as follows (in millions):
June 30, 2022December 31, 2021
Cash, cash equivalents and marketable securities$7,183 $8,037 
Total assets$59,294 $61,165 
Current portion of long-term debt$817 $87 
Long-term debt$35,705 $33,222 
Stockholders’ equity$2,419 $6,700 
Cash, cash equivalents and marketable securities
Our balance of cash, cash equivalents and marketable securities was $7.2 billion as of June 30, 2022. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
Capital allocation
Consistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including investments in innovation, both internally and externally, strategic transactions (including those that expand our portfolio of products in areas of therapeutic interest), payment of dividends, stock repurchases and repayment of debt.
We intend to continue to invest in our business while returning capital to stockholders through the payment of cash dividends and stock repurchases, thereby reflecting our confidence in the future cash flows of our business and our desire to optimize our cost of capital. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, availability of financing on acceptable terms, debt service requirements, our credit rating, changes to applicable tax laws or corporate laws, changes to our business model and
39


periodic determination by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Company’s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include block purchases, tender offers, ASRs and market transactions.
In March 2022 and December 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share of common stock, which were paid on June 8, 2022 and March 8, 2022, respectively, an increase of 10% over quarterly cash dividend paid in each quarter in 2021. In August 2022, the Board of Directors declared a quarterly cash dividend of $1.94 per share of common stock, which will be paid on September 8, 2022 to all stockholders of record as of the close of business on August 18, 2022.
We also returned capital to stockholders through our stock repurchase program. During the six months ended June 30, 2022, we executed trades to repurchase $5.4 billion of common stock, including $5.1 billion of an initial purchase under the ASR agreements described below. As of June 30, 2022, $4.6 billion of authorization remained available under our stock repurchase program.
In February 2022, we entered into ASR agreements under which we paid an aggregate amount of $6.0 billion to the Dealers and retired an initial 23.3 million shares of common stock. Approximately $0.9 billion of stock remains to be delivered by the Dealers pending final settlement, which will be based on the daily volume-weighted average stock price of our common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, which is scheduled to occur in the third quarter of 2022, the Dealers may be required to deliver additional shares of common stock to us, or under certain circumstances, we may be required to deliver shares of common stock or to make a cash payment, at our election, to the Dealers.
As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of June 30, 2022 and December 31, 2021. Our accumulated deficit is not anticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our continuing profitability and strong financial position.
We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure and debt service requirements, our plans to pay dividends and repurchase stock and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, borrowings through commercial paper and/or syndicated credit facilities and access to other domestic and foreign debt markets and equity markets. See our Annual Report on Form 10-K for the year ended December 31, 2021, Part I, Item 1A. Risk Factors—Global economic conditions may negatively affect us and may magnify certain risks that affect our business.
Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) consolidated interest expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of June 30, 2022.
Cash flows
Our summarized cash flow activity was as follows (in millions):
 Six months ended
June 30,
 20222021
Net cash provided by operating activities$4,094 $4,035 
Net cash (used in) provided by investing activities$(2,304)$890 
Net cash used in financing activities$(4,576)$(4,561)
40


Operating
Cash provided by operating activities has been and is expected to continue to be our primary recurring source of funds. Cash provided by operating activities during the six months ended June 30, 2022, increased primarily due to higher net income, after adjustments for noncash items, partially offset by the impact of working capital items.
Investing
Cash used in investing activities during the six months ended June 30, 2022, was primarily due to net cash outflows related to marketable securities activity of $1.9 billion and capital expenditures of $436 million. Cash provided by investing activities during the six months ended June 30, 2021, was primarily due to net cash inflows related to marketable securities activity of $2.9 billion, partially offset by the acquisition of Five Prime for $1.6 billion and capital expenditures of $351 million. We currently estimate 2022 spending on capital projects to be approximately $950 million.
Financing
Cash used in financing activities during the six months ended June 30, 2022, was primarily due to payments to repurchase our common stock of $6.4 billion, including amounts paid under the ASR agreements discussed above, and the payment of dividends of $2.1 billion, partially offset by proceeds from the issuance of debt of $4.0 billion. Cash used in financing activities during the six months ended June 30, 2021, was primarily due to payments to repurchase our common stock of $2.5 billion and the payment of dividends of $2.0 billion. See Note 9, Financing arrangements, and Note 10, Stockholders’ equity, to the condensed consolidated financial statements for further discussion.

Critical Accounting Policies and Estimates
The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies and estimates is presented in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Information about our market risk is disclosed in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2021, and is incorporated herein by reference. There were no material changes during the six months ended June 30, 2022, to the information provided in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2021.

41


Item 4.CONTROLS AND PROCEDURES
We maintain “disclosure controls and procedures,” as such term is defined under the Securities Exchange Act Rule 13a-15(e) that are designed to ensure that information required to be disclosed in Amgen’s Exchange Act reports gets recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information gets accumulated and communicated to Amgen’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to facilitate timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgen’s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, Amgen’s management necessarily was required to apply its judgment in evaluating the cost–benefit relationship of possible controls and procedures. We carried out an evaluation under the supervision and with the participation of our management, including Amgen’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgen’s disclosure controls and procedures. Based on their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2022.
Management determined that as of June 30, 2022, no changes in our internal control over financial reporting had occurred during the fiscal quarter then ended that materially affected or are reasonably likely to materially affect our internal control over financial reporting.
42


PART II — OTHER INFORMATION

Item 1.LEGAL PROCEEDINGS
See Note 13, Contingencies and commitments, to the condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2022 and June 30, 2022, for discussions that are limited to certain recent developments concerning our legal proceedings. Those discussions should be read in conjunction with Part IV—Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 1A.RISK FACTORS
This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management’s assumptions. These statements are not guarantees of future performance, and they involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties our business faces. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price.
Below we provide in supplemental form the material changes to our risk factors that occurred during the past quarter. Our risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2021, provide additional disclosure for these supplemental risks and are incorporated herein by reference.
Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected and are likely to continue to affect our profitability.
Sales of our products depend on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers continue to pursue initiatives to manage drug utilization and contain costs. These payers are increasingly focused on costs, which have resulted, and are expected to continue to result, in lower reimbursement rates for our products or narrower populations for whom payers will reimburse. Continued intense public scrutiny of the price of drugs and other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which can have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced to attempt to lower drug prices. These include proposals that would enable the U.S. government to negotiate drug prices directly, limit drug reimbursement in Medicare and/or the commercial market based on reference prices, impose penalties if drug prices are increased at a rate faster than inflation or permit importation of drugs from Canada. Additional proposals would require a rebate to the government for any price increase in excess of the Consumer Price Index for All Urban Consumers and/or to shift some of the costs of these Medicare Part D reforms to manufacturers to offset the costs. Certain proposals focused on drug pricing have been adopted, and additional proposals are likely to be adopted and implemented in some form.
—Changing U.S. federal coverage and reimbursement policies and practices have affected and may continue to affect access to, pricing of and sales of our products
A substantial portion of our U.S. business relies on reimbursement from federal government healthcare programs and commercial insurance plans regulated by federal and state governments. See Part I, Item 1. Business—Reimbursement of our Annual Report on Form 10-K for the year ended December 31, 2021. Our business has been and will continue to be affected by legislative actions changing U.S. federal reimbursement policy. Congress has focused on drug pricing reforms and oversight since 2018, and this activity is still ongoing and has intensified. Since 2019, a number of Congressional committees debated drug pricing reform proposals, and in 2020, Amgen participated in House Oversight and Reform Committee hearings on drug pricing practices. In 2019, the Senate Finance Committee advanced a bill that would, among other things, penalize pharmaceutical manufacturers for raising prices on drugs covered by Medicare Parts B and/or D faster than the rate of inflation, cap out-of-pocket expenses for Medicare Part D beneficiaries and require higher or additional manufacturer discounts in Medicare Part D. Additionally, in late 2019, a drug-pricing bill, H.R. 3, passed the House of Representatives and included provisions that, among other things, enabled direct price negotiations by the federal government on certain drugs, (with the maximum price paid by Medicare capped by prices derived from an international index), penalized failures to reach agreement with the government and required that manufacturers offer these negotiated prices to other payers. Provisions from H.R. 3 have
43


been incorporated and adapted into other proposed legislation, including the most recent reconciliation bill released by the Senate in July 2022, which included penalties if drug price benchmarks rise faster than inflation, Medicare price setting for certain drugs paid for under Parts B and D (whereby manufacturers must accept a price established by the government or face penalties on all U.S. sales), and Part D redesign including a cap on beneficiary spending and a new manufacturer discount program. This framework remains in discussion with policymakers in Congress and the Administration. There are other outstanding proposals that, if enacted and implemented, in whole or in part, could also affect access to and sales of our products, including, but not limited to, federal and various state proposals to allow importation of prescription medications from Canada or other countries. See —Changing reimbursement and pricing actions in various states have negatively affected and may continue to negatively affect access to and have affected and may continue to affect sales of our products. In July 2021, the Administration issued an Executive Order designed to address anticompetitive behavior across multiple sectors, and for the healthcare sector, called for, among other things, the FDA to work with states and Indian tribes to develop prescription drug importation programs, more scrutiny of anticompetitive activity by the FTC, emphasized the need for actions to allow for greater competition from generics and biosimilars, and included a process and timeline for federal agencies to deliver to the Administration ideas that address drug pricing. Subsequently, in September 2021, HHS released a report that presented guiding principles for the Administration’s drug pricing proposals, including changes to promote competition throughout the prescription drug industry, highlighting potential legislative policies that Congress could pursue (including drug price negotiation in Medicare Parts B and D, making those negotiated prices available to commercial plans and legislation to speed the entry of biosimilar and generic drugs) and examples of potential administrative tools available to the HHS (including testing various models and enhanced focus of the FTC and the USPTO to address impediments to generic drug and biosimilar competition). Also, in response to the July 2021 Executive Order, the FDA sent a letter to the USPTO describing ways to strengthen coordination between the two agencies, offering training to help identify prior art and seeking USPTO’s views on practices that extend market exclusivities, whether pharmaceutical patent examiners need additional resources, and the effect of post-grant challenges at the PTAB on drug patents. In its reply to the FDA, on July 6, 2022, the USPTO affirmed its interest in coordinating with the FDA and outlined specific initiatives, including enhancing procedures for obtaining patents and easing the process for challenging issued patents before the PTAB.
Legislation enacted in 2021 also contained drug pricing reforms. For example, the Infrastructure Investment and Jobs Act includes a provision requiring manufacturers to provide refunds, beginning in 2023, to the government for discarded amounts of certain drugs (including certain Amgen products) from single use containers under Medicare Part B, and CMS recently released proposed regulations to implement this requirement. Also, the American Rescue Plan Act of 2021 includes a provision that increases the Medicaid rebate liability, beginning in 2024, by no longer capping Medicaid rebates at 100% of the Average Manufacturer Price for certain medicines that raise prices in excess of inflation. The implementation of a final rule issued by HHS that revises regulations under the federal antikickback statute to encourage PBMs to use rebates received from biopharmaceutical manufacturers to reduce patient cost-sharing at the point of sale under Medicare Part D has been delayed to January 1, 2027. However, the future of this rule remains uncertain because, among other issues, it is subject to litigation and because a permanent repeal is being considered in other legislation.
Our business has been, and is expected to continue to be, affected by changes in U.S. federal reimbursement policy resulting from federal regulations and federal demonstration projects. Over the past several years, federal agencies, including the CMS, announced a number of recommendations, policies, proposals and demonstration projects addressing drug pricing. The Administration has also developed and sought to advance a range of policy proposals that could affect U.S. federal reimbursement policy for drugs and biologics, including changes to Medicare Parts B and D. For example, in 2020, in response to an Executive Order, HHS released a rule to allow states to potentially enable the importation of certain drugs from Canada. This rule is in litigation, but should such litigation be unsuccessful, it could allow for the importation of Canadian versions of certain of Amgen’s products (including Otezla), that could have a material adverse effect on Amgen’s business. Also in response to an Executive Order, CMS released an interim final rule to implement the MFN pricing approach aimed at setting the reimbursement rate for 50 Medicare Part B drugs (including our products, such as Prolia, XGEVA, KYPROLIS, Neulasta, Nplate, EPOGEN and Aranesp) equal to the lowest adjusted price in 22 OECD nations for these drugs. In December 2021, subsequent to challenges, including procedural defects, CMS announced it was withdrawing the MFN rule. Notwithstanding the withdrawal of the rule, the MFN rule’s approach to drug pricing and other similar approaches remain of interest to policymakers. In connection with its withdrawal of the MFN rule, CMS noted that it will “… explore all options to incorporate value into payments for Medicare Part B drugs, improve beneficiaries’ access to evidence-based care, and reduce drug spending for consumers and throughout the health care system.” Further, we expect continued significant focus on healthcare and similar drug pricing proposals for the foreseeable future, including proposals under which the government would set drug prices or limit drug reimbursement. In the second quarter of 2022, several Medicare Administrative Contractors issued notice, in contravention of TEZSPIRE’s FDA approved labeling, that TEZSPIRE would be added to their “self-administered drug” exclusion lists. While the effective date for adding TEZSPIRE to the exclusion list has been deferred until further notice, this exclusion, if implemented, would result in Medicare beneficiaries with severe asthma losing access to TEZSPIRE coverage under Medicare Part B and potentially also under Medicare Advantage.
44


CMS policy changes and demonstration projects to test new care, delivery and payment models can also significantly affect how drugs, including our products, are covered and reimbursed. For example, we believe that CMS’s Oncology Care Model demonstration (which has, beginning in 2016, provided participating physician practices with performance-based financial incentives that aim to manage or reduce Medicare costs without negatively affecting the efficacy of care) reduced utilization of certain of our oncology products by participating physician practices. While the Oncology Care Model demonstration ended on June 30, 2022, CMS announced a new oncology model (the Enhancing Oncology Model) that will run for five years (from July 2023 through June 2028) that builds on this prior demonstration program. Further, HHS’s September 2021 comprehensive plan to address drug pricing included potential future mandatory models that link payment for prescription drugs and biologics to factors such as: improved patient outcomes, reductions in health disparities, patient affordability and lower overall costs; bundled payment models; total cost of care models; models in which Medicare Part B savings from utilization of biosimilars, generics, or other high-value products are shared between prescribing providers and the government; additional Medicare Part D cost-sharing support for biosimilars and generics; and potential expansion of the Part D Senior Savings Model to additional classes of drugs. CMS also recently finalized a national Medicare coverage determination for certain Alzheimer’s disease medications that received accelerated FDA approvals that limits coverage to only patients in qualifying clinical trials, thereby suggesting that accelerated regulatory approval does not necessarily result in full Medicare coverage. In this dynamic environment, particularly in light of the pressures on healthcare budgets as a result of the pandemic, we are unable to predict which or how many federal policy, legislative, regulatory, executive or administrative changes may ultimately be, or effectively estimate the consequences to our business if, enacted and implemented. However, to the extent that these or other federal government initiatives further decrease or modify the coverage or reimbursement available for our products, require that we pay increased rebates or shift other costs to us, limit or affect our decisions regarding the pricing of or otherwise reduce the use of our U.S. products, or limit our ability to offer co-pay assistance to commercial patients, such actions could have a material adverse effect on our business and results of operations.
We also face risks related to the reporting of pricing data that affects reimbursement of and discounts provided for our products. U.S. government price reporting regulations are complex and may require biopharmaceutical manufacturers to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we may be required to pay additional rebates and provide additional discounts. The prior Administration finalized a rule (the implementation of which has been delayed by the current Administration) mandating price and cost-sharing transparency for almost all health plans and insurers in the individual and group commercial markets. Further, the current Administration finalized transparency provisions required under the Consolidated Appropriations Act of 2021 for health plans and insurer reporting of certain drug pricing information by December 27, 2022, and each June thereafter, resulting in a biennial public report highlighting drug pricing trends and the impact of prescription drug costs on premiums and out-of-pocket costs. It is unclear how group health plans and health insurers may respond.
—Changing reimbursement and pricing actions in various states have negatively affected and may continue to negatively affect access to and have affected and may continue to affect sales of our products
At the state level, government actions or ballot initiatives can also affect how our products are covered and reimbursed and/or create additional pressure on our pricing decisions. A number of states have adopted, and many other states are considering, drug importation programs or other new pricing actions, including proposals designed to require biopharmaceutical manufacturers to publicly report proprietary pricing information, limit price increases or place a maximum price ceiling or cap on biopharmaceutical products. Existing and proposed state pricing laws have added complexity to the pricing of drugs and may already be affecting industry pricing decisions. For example, a California law, the constitutionality of which is currently being challenged, purports to require biopharmaceutical manufacturers to notify health insurers and government health plans at least 60 days before scheduled prescription drug price increases that exceed certain thresholds. Similar laws exist in Oregon and Washington. States are also seeking to change the way they pay for drugs for patients covered by state programs. California adopted a 2020–21 budget that incorporates international pricing into Medicaid supplemental rebate negotiations and allows its Medicaid program to seek federal approval to extend supplemental rebates to non-Medicaid populations. New York has established a Medicaid drug spending cap, and Massachusetts implemented a new review and supplemental rebate negotiation process. Other states may consider implementing similar policies and procedures as they face budget deficits from the effects of the COVID-19 pandemic. Additionally, Colorado, Florida, Maine, New Hampshire, New Mexico and Vermont have enacted laws, and several other states have proposed bills, to implement importation of drugs from Canada. The FDA recently met with representatives from Colorado, Florida, Maine and New Mexico to discuss those states’ proposed importation programs, and the FDA may be working towards approving such plans. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs. Ultimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.
45


—U.S. commercial payer actions have affected and may continue to affect access to and sales of our products
Payers, including healthcare insurers, PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, increasingly seek ways to reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient copay or coinsurance obligations and more significant limitations on patients’ use of manufacturer commercial copay assistance programs. Further, government regulation of payers may affect these trends. For example, CMS finalized a policy in May 2020 (for plan years starting on or after January 1, 2021, which remains standing policy for 2022) that has caused commercial payers to more widely adopt copay accumulator adjustment programs. Payers have sought, and continue to seek, price discounts or rebates in connection with the placement of our products on their formularies or those they manage, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable. Payers also control costs by imposing restrictions on access to or usage of our products, such as Step Therapy, or requiring that patients receive the payer’s prior authorization before covering the product or that patients use a mail-order pharmacy or a limited network of payer fully-owned mail-order or specialty pharmacies. Payers have also chosen to exclude certain indications for which our products are approved or chosen to exclude coverage entirely. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet payer utilization management criteria, and these requirements have served to limit and may continue to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers, including PBMs that administer Medicare Part D prescription drug plans. However, affordability of patient out-of-pocket co-pay cost has limited and may continue to limit patient use. For example, in late 2018 and early 2019, in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list price in an attempt to address affordability for patients, particularly those on Medicare, and on December 31, 2019, we discontinued the higher list price option for Repatha. Despite these net and list price reductions, some payers have restricted and may continue to restrict patient access, and have changed and may continue to change formulary coverage for Repatha, and they may seek further discounts or rebates or take other actions that could reduce our sales of Repatha. These factors have served to limit and may continue to limit patient affordability and use, and negatively affect Repatha sales.
Further, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in the United States, as of the beginning of 2021, the top five integrated health plans and PBMs controlled about 85% of all pharmacy prescriptions. The consolidation among insurers, PBMs and other payers, including through integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers, and has resulted in greater price discounts, rebates and service fees realized by those payers. In 2019, 2020 and 2021, CVS, Express Scripts and United Health Group, respectively, each created Rebate Management Organizations that further increase their respective leverage to negotiate deeper discounts. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse effect on our product sales, business and results of operations. Policy reforms advanced by Congress or the Administration that refine the role of PBMs in the U.S. marketplace could have downstream implications or consequences for our business and how we interact with these entities. For example, on June 7, 2022, the FTC launched an inquiry into the business practices of PBMs, and the results of such inquiry could have an effect on manufacturer interactions with PBMs, resulting in changes to access to certain medicines. See our Annual Report on Form 10-K for the year ended December 31, 2021, Part I, Item 1A. Risk Factors—Concentration of sales at certain of our wholesaler distributors and at one free-standing dialysis clinic business and consolidation of private payers may negatively affect our business.
—Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our products
Outside the United States, we expect countries will also continue to take actions to reduce their drug expenditures. See Part I, Item 1. Business—Reimbursement of our Annual Report on Form 10-K for the year ended December 31, 2021. IRP has been widely used by many countries outside the United States to control costs based on an external benchmark of a product’s price in other countries. IRP policies can change quickly and frequently and may not reflect differences in the burden of disease, indications, market structures, or affordability differences across countries or regions. Other expenditure control practices, including but not limited to the use of revenue clawbacks, rebates and percentage caps on price increases, are used in various foreign jurisdictions as well. In addition, countries may refuse to reimburse or may restrict the reimbursed population for a product when their national health technology assessments do not consider a medicine to demonstrate sufficient clinical benefit beyond existing therapies or to meet certain cost effectiveness thresholds. For example, despite the EMA’s approval of Repatha for the treatment of patients with established atherosclerotic disease, the reimbursement for Repatha in France prior to
46


2020 was limited to a narrower patient population (such as those with homozygous familial hypercholesterolemia (HoFH)) following a national health technology assessment, which had limited our efforts in France to expand Repatha access to the broader patient population covered by the approved label. Some countries decide on reimbursement between potentially competing products through national or regional tenders that often result in one product receiving most or all of the sales in that country or region. Failure to obtain coverage and reimbursement for our products, a deterioration in their existing coverage and reimbursement, or a decline in the timeliness or certainty of payment by payers to physicians and other providers has negatively affected, and may further negatively affect, the ability or willingness of healthcare providers to prescribe our products for their patients and otherwise negatively affect the use of our products or the prices we realize for them. Such changes have had, and could in the future have, a material adverse effect on our product sales, business and results of operations.
The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.
We are subject to income and other taxes in the United States and other jurisdictions in which we do business. As a result, our provision for income taxes is derived from a combination of applicable tax rates in the various places we operate. Significant judgment is required for determining our provision for income tax.
One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts, and such tax authorities (including the IRS) are becoming more aggressive in their audits and are particularly focused on such matters. In 2017, we received an RAR and a modified RAR from the IRS for the years 2010–2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS administrative appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Notices for the years 2010–2012 that we received in May and July 2021 which seek to increase our U.S. taxable income for the years 2010–2012.
In 2020, we received an RAR and a modified RAR from the IRS for the years 2013, 2014 and 2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010–2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013–2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013–2015 and asserts penalties.
We firmly believe that the IRS positions set forth in the 2010–2012 and 2013–2015 Notices are without merit. We are contesting the 2010–2012 and 2013–2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court.
We are currently also under examination by the IRS for the years 2016, 2017 and 2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse effect on the results of our operations.
See Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations, Income Taxes, and Part I—Note 4, Income taxes, to the condensed consolidated financial statements.
Our provision for income taxes and results of operations in the future could be adversely affected by changes to our operating structure, changes in the mix of income and expenses in countries with differing tax rates, changes in the valuation of deferred tax assets and liabilities and changes in applicable tax laws, regulations or administrative interpretations thereof. The 2017 Tax Act is complex and a large volume of regulations and guidance has been issued and could be subject to different interpretations. We could face audit challenges to our application of the 2017 Tax Act. The Administration proposed and Congress is considering a variety of potentially significant changes to existing tax law. These changes, or others, could substantially increase taxes we pay to the U.S. government. Further, the OECD recently reached an agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. If enacted, either by all OECD participants or unilaterally by individual countries, this agreement could result in tax increases in both the United States and
47


foreign jurisdictions.
The U.S. Treasury recently released final foreign tax credit regulations that eliminate U.S. creditability of the Puerto Rico Excise Tax beginning 2023, which would increase our U.S. tax liability. However, the U.S. territory of Puerto Rico recently enacted Act 52-2022, which provides for an alternate fixed tax rate on industrial development income that is expected to be creditable under U.S. law. As part of this new law, eligible businesses would be subject to incremental income and withholding taxes in lieu of payment of the Puerto Rico Excise Tax. In order to qualify for the alternative fixed tax rate, we must amend our current tax grant with the Puerto Rico government by December 31, 2022. Once we qualify for this alternative fixed tax rate, which we expect to occur as of January 1, 2023, our tax expense will increase. While we expect these taxes to be partially offset by U.S. foreign tax credits, the U.S. Treasury has not yet issued guidance on whether the alternative fixed tax rate will be creditable under U.S. law.
Changes to existing tax law in the United States, the U.S. territory of Puerto Rico, or other jurisdictions, including the changes and potential changes discussed above, could result in tax increases where we do business and could have a material adverse effect on the results of our operations.
Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions.
We seek innovation through significant investment in both internal R&D and external transactions, including collaborations, partnerships, alliances, licenses, joint ventures, mergers and acquisitions (collectively, acquisition activity). Acquisition activities may be subject to regulatory approvals or other requirements that are not within our control. There can be no assurance that such regulatory or other approvals will be obtained or that all closing conditions required in connection with our acquisition activities will be satisfied or waived, which could result in us being unable to complete the planned acquisition activities. In addition, antitrust scrutiny by regulatory agencies and changes to regulatory approval process in the U.S. and foreign jurisdictions may cause approvals to take longer than anticipated to obtain, not be obtained at all, or contain burdensome conditions, which may jeopardize, delay or reduce the anticipated benefits of acquisitions to us and could impede the execution of our business strategy.
Acquisition activities are complex, time consuming and expensive and may result in unanticipated costs, delays or other operational or financial problems related to integrating the acquired company and business with our company, which may divert our management’s attention from other business issues and opportunities and restrict the full realization of the anticipated benefits of such transactions within the expected timeframe or at all. We may pay substantial amounts of cash, incur debt or issue equity securities to pay for acquisition activities, which could adversely affect our liquidity or result in dilution to our stockholders, respectively. Further, failures or difficulties in integrating or retaining new personnel or in integrating the operations of the businesses, products or assets we acquire (including related technology, commercial operations, compliance programs, manufacturing, distribution and general business operations and procedures) may affect our ability to realize the benefits of the transaction and grow our business and may result in us incurring asset impairment or restructuring charges. These and other challenges may arise in connection with our proposed acquisition of ChemoCentryx, in addition to our acquisitions of Otezla, Five Prime, Teneobio and/or our collaborations with BeiGene and Kyowa Kirin Co., Ltd., or with other acquisition activities, which could have a material adverse effect on our business, results of operations and stock price.

48


Item 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During the three months ended June 30, 2022, we had one outstanding stock repurchase program, under which the repurchase activity was as follows:
Period
Total number
of shares
purchased (1)
Average
price paid
per share
Total number
of shares purchased
as part of publicly announced program
Maximum dollar
value that may
yet be purchased
under the program
April 1 - 30— — — 4,579,263,848 
May 1 - 31— — — 4,579,263,848 
June 1 - 30— — — 4,579,263,848 
Total— — 
___________
(1)    As part of the stock repurchase program, the Company entered into ASR agreements with three third-party financial institutions (Dealers) in February 2022. Under the ASR agreements, the Company made payments in an aggregate amount of $6.0 billion to the Dealers and received and retired an initial 23,258,997 shares of common stock. Approximately $0.9 billion of stock was held back by the Dealers pending final settlement of the ASR agreement, which will be based on the volume-weighted average stock price of the Company’s common stock during the term of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, which is scheduled to occur in the third quarter of 2022, the Dealers may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to the Dealers.

49



Item 6. EXHIBITS
Reference is made to the Index to Exhibits included herein.
50


INDEX TO EXHIBITS
Exhibit No.Description
2.1
Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation. (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)
2.2
Amendment No. 1 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation. (Filed as an exhibit to Form 8-K on October 17, 2019 and incorporated herein by reference.)
2.3
Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
2.4
Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgen’s acquisition of Otezla. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
2.5
Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company. (Filed as an exhibit to Form 8-K on August 26, 2019 and incorporated herein by reference.)
2.6
Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis Advisors LLC. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential)(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2021 on November 3, 2021 and incorporated herein by reference.)
3.1
Restated Certificate of Incorporation of Amgen Inc. (As Restated March 6, 2013.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 on May 3, 2013 and incorporated herein by reference.)
3.2
Amended and Restated Bylaws of Amgen Inc. (As Amended and Restated February 15, 2016.) (Filed as an exhibit to Form 8-K on February 17, 2016 and incorporated herein by reference.)
4.1
Form of stock certificate for the common stock, par value $.0001 of the Company. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1997 on May 14, 1997 and incorporated herein by reference.)
4.2Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.)
4.3
Agreement of Resignation, Appointment and Acceptance dated February 15, 2008. (Filed as an exhibit to Form 10-K for the year ended December 31, 2007 on February 28, 2008 and incorporated herein by reference.)
4.4
First Supplemental Indenture, dated February 26, 1997. (Filed as an exhibit to Form 8-K on March 14, 1997 and incorporated herein by reference.)
4.5
8-1/8% Debentures due April 1, 2097. (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)
4.6
4.7
Indenture, dated August 4, 2003. (Filed as an exhibit to Form S-3 Registration Statement on August 4, 2003 and incorporated herein by reference.)
4.8
Corporate Commercial Paper - Master Note between and among Amgen Inc., as Issuer, Cede & Co., as Nominee of The Depository Trust Company, and Citibank, N.A., as Paying Agent. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1998 on May 13, 1998 and incorporated herein by reference.)
4.9
Officers’ Certificate of Amgen Inc., dated May 30, 2007, including form of the Company’s 6.375% Senior Notes due 2037. (Filed as an exhibit to Form 8-K on May 30, 2007 and incorporated herein by reference.)
4.10
Officers’ Certificate of Amgen Inc., dated May 23, 2008, including form of the Company’s 6.90% Senior Notes due 2038. (Filed as exhibit to Form 8-K on May 23, 2008 and incorporated herein by reference.)
4.11
Officers’ Certificate of Amgen Inc., dated January 16, 2009, including form of the Company’s 6.40% Senior Notes due 2039. (Filed as exhibit to Form 8-K on January 16, 2009 and incorporated herein by reference.)
51


Exhibit No.Description
4.12
Officers’ Certificate of Amgen Inc., dated March 12, 2010, including form of the Company’s 5.75% Senior Notes due 2040. (Filed as exhibit to Form 8-K on March 12, 2010 and incorporated herein by reference.)
4.13
Officers’ Certificate of Amgen Inc., dated September 16, 2010, including form of the Company’s 4.95% Senior Notes due 2041. (Filed as an exhibit to Form 8-K on September 17, 2010 and incorporated herein by reference.)
4.14
Officers’ Certificate of Amgen Inc., dated June 30, 2011, including form of the Company’s 5.65% Senior Notes due 2042. (Filed as an exhibit to Form 8-K on June 30, 2011 and incorporated herein by reference.)
4.15
Officers’ Certificate of Amgen Inc., dated November 10, 2011, including form of the Company’s 5.15% Senior Notes due 2041. (Filed as an exhibit to Form 8-K on November 10, 2011 and incorporated herein by reference.)
4.16
Officers’ Certificate of Amgen Inc., dated December 5, 2011, including form of the Company’s 5.50% Senior Notes due 2026. (Filed as an exhibit to Form 8-K on December 5, 2011 and incorporated herein by reference.)
4.17
Officers’ Certificate of Amgen Inc., dated May 15, 2012, including form of the Company’s 5.375% Senior Notes due 2043. (Filed as an exhibit to Form 8-K on May 15, 2012 and incorporated herein by reference.)
4.18
Officers’ Certificate of Amgen Inc., dated September 13, 2012, including form of the Company’s 4.000% Senior Notes due 2029. (Filed as an exhibit to Form 8-K on September 13, 2012 and incorporated herein by reference.)
4.19
Indenture, dated May 22, 2014, between Amgen Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee. (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)
4.20
Officers’ Certificate of Amgen Inc., dated May 22, 2014, including form of the Company’s 3.625% Senior Notes due 2024. (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)
4.21
4.22
Officer’s Certificate of Amgen Inc., dated as of February 25, 2016, including form of the Company’s 2.000% Senior Notes due 2026. (Filed as an exhibit on Form 8-K on February 26, 2016 and incorporated herein by reference.)
4.23
Form of Permanent Global Certificate for the Company’s 0.410% bonds due 2023. (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)
4.24
Terms of the Bonds for the Company’s 0.410% bonds due 2023. (Filed as an exhibit on Form 8-K on March 8, 2016 and incorporated herein by reference.)
4.25
4.26
4.27
4.28
4.29
Officer’s Certificate of Amgen Inc., dated as of May 6, 2020, including form of the Company’s 2.300% Senior Notes due 2031. (Filed as an exhibit to Form 8-K on May 6, 2020 and incorporated herein by reference.)
52


Exhibit No.Description
4.30
Officer’s Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Company’s 2.770% Senior Notes due 2053. (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.)
4.31
4.32
4.33
10.1+
Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (Filed as Appendix C to the Definitive Proxy Statement on Schedule 14A on April 8, 2013 and incorporated herein by reference.)
10.2+
First Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 4, 2015. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2015 on April 27, 2015 and incorporated herein by reference.)
10.3+
Second Amendment to Amgen Inc. Amended and Restated 2009 Equity Incentive Plan, effective March 2, 2016. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2016 on May 2, 2016 and incorporated herein by reference.)
10.4+
Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended and Restated on December 2, 2021.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)
10.5+
Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended and Restated on December 2, 2021.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)
10.6+
Amgen Inc. 2009 Performance Award Program. (As Amended on December 12, 2017.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2017 on February 13, 2018 and incorporated herein by reference.)
10.7+
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended and Restated on December 2, 2021.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)
10.8+
Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on October 21, 2020.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.)
10.9+
Form of Grant of Non-Qualified Stock Option Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (Filed as an exhibit to Form 8-K on May 8, 2009 and incorporated herein by reference.)
10.10+
Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
10.11+
Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
10.12+
Amgen Inc. Supplemental Retirement Plan. (As Amended and Restated effective October 16, 2013.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)
10.13+
First Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 14, 2016. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)
53


Exhibit No.Description
10.14+
Second Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 23, 2019). (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
10.15+
Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021. (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)
10.16+
Amended and Restated Amgen Change of Control Severance Plan. (As Amended and Restated effective December 9, 2010 and subsequently amended effective March 2, 2011.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)
10.17+
Amgen Inc. Executive Incentive Plan. (As Amended and Restated effective January 1, 2022.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2022 on April 28, 2022 and incorporated herein by reference.)
10.18+
Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated effective October 16, 2013.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)
10.19+
First Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective October 14, 2016. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)
10.20+
Second Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2020. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
10.21+
Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022. (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)
10.22+
Agreement between Amgen Inc. and Peter Griffith, dated October 18, 2019. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.)
10.23+
Aircraft Time Sharing Agreement, dated December 3, 2021, by and between Amgen Inc. and Robert A. Bradway. (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)
10.24
10.25
10.26
10.27
10.28
Collaboration Agreement, dated April 22, 1994, by and between Bayer Corporation (formerly Miles, Inc.) and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 by Onyx Pharmaceuticals, Inc. on May 10, 2011 and incorporated herein by reference.)
10.29
Amendment to Collaboration Agreement, dated April 24, 1996, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)
54


Exhibit No.Description
10.30
Amendment to Collaboration Agreement, dated February 1, 1999, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2006 by Onyx Pharmaceuticals, Inc. on May 10, 2006 and incorporated herein by reference.)
10.31
Settlement Agreement and Release, dated October 11, 2011, by and between Bayer Corporation, Bayer AG, Bayer HealthCare LLC and Bayer Pharma AG and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)
10.32
Fourth Amendment to Collaboration Agreement, dated October 11, 2011, by and between Bayer Corporation and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 by Onyx Pharmaceuticals, Inc. on February 27, 2012 and incorporated herein by reference.)
10.33
Side Letter Regarding Collaboration Agreement, dated May 29, 2015, by and between Bayer HealthCare LLC and Onyx Pharmaceuticals, Inc. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2015 on August 5, 2015 and incorporated herein by reference.)
10.34
Side Letter Regarding Collaboration Agreement and Stivarga Agreement, dated February 13, 2020, by and between Onyx Pharmaceuticals, Inc. and Bayer HealthCare LLC. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2020 on May 1, 2020 and incorporated herein by reference.)
10.35
Sourcing and Supply Agreement, dated January 6, 2017, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc. (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2017 on April 27, 2017 and incorporated herein by reference.)
10.36
Exclusive License and Collaboration Agreement, dated August 28, 2015, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)
10.37
Amendment No. 1 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)
10.38
Amendment No. 2 to the Exclusive License and Collaboration Agreement, dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2017 on July 26, 2017 and incorporated herein by reference.)
10.39
Amendment No. 3 to the Exclusive License and Collaboration Agreement, dated January 31, 2022, by and between Amgen Inc. and Novartis Pharma AG (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential). (Filed as an exhibit to the Company’s Current Report on Form 8-K on January 31, 2022 and incorporated herein by reference.)
10.40
Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
10.41*
First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)
10.42
Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)
10.43
Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)
10.44
Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)
55


Exhibit No.Description
10.45
Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)
10.46*
Collaboration Agreement dated March 30, 2012 by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, a wholly owned subsidiary of AstraZeneca Pharmaceuticals LP (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)
10.47*
Amendment No. 1 to the Collaboration Agreement, dated October 1, 2014, by and among Amgen Inc., AstraZeneca Collaboration Ventures, LLC and AstraZeneca Pharmaceuticals LP (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)
10.48
Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.)
10.49
Amendment No. 7 to the Collaboration Agreement, dated December 17, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.)
10.50
Amendment No. 8 to the Collaboration Agreement, dated November 19, 2021, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)(Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)
10.51
License and Collaboration Agreement, dated June 1, 2021, by and between Amgen Inc. and Kyowa Kirin Co., Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2021 on August 4, 2021 and incorporated herein by reference.)
10.52
Form of ASR Agreement. (Filed as an exhibit to Form 8-K on February 24, 2022 and incorporated herein by
reference.)
31*
32**
101.INSInline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
____________________________
(* = filed herewith)
(** = furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended)
(+ = management contract or compensatory plan or arrangement)
56


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Amgen Inc.
(Registrant)
Date:August 4, 2022By:
/S/  PETER H. GRIFFITH
Peter H. Griffith
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
57
EX-10.41 2 exhibit1041-firstamendment.htm FIRST AMENDMENT TO COLLABORATION AGREEMENT BETWEEN AMGEN AND BEIGENE Document
EXHIBIT 10.41
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.


FIRST AMENDMENT TO COLLABORATION AGREEMENT
This Amendment to the Collaboration Agreement (“Amendment”) is entered into as of April 20, 2022 (the “Amendment Effective Date”) by and among Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), BeiGene Switzerland GmbH, a Swiss corporation with a principal place of business at Aeschengraben 27, 4051 Basel, Switzerland (“BeiGene”), and BeiGene, Ltd., a Cayman Islands exempted company incorporated with limited liability with its registered offices c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, P.O. Box 1348, Grand Cayman KY1-1108, Cayman Islands (“BeiGene Parent”). BeiGene and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” This Amendment amends that certain Collaboration Agreement (the “Agreement”), entered into as of October 31, 2019, by and between Amgen and BeiGene and, solely with respect to Section 13.6 thereof, BeiGene Parent. Capitalized terms used but not defined herein have the meanings given to them in the Agreement.
RECITALS
WHEREAS, the Agreement contains certain terms and conditions relating to the financial responsibilities of the Parties in connection with the development and commercialization of certain Amgen proprietary Products for the treatment of oncology-related diseases and conditions; and
WHEREAS, the Parties desire to amend the Agreement upon the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein, the Parties, intending to be legally bound hereby, do agree as follows:
AGREEMENT
1.Amendment to Section 1.48 of the Agreement. Section 1.48 of the Agreement is hereby amended and replaced in its entirety as follows:
“Section 1.48    “Costs” means both internal and external costs and expenses (including the cost of allocated FTEs at the FTE Rate and Sales Force FTEs at the Sales Force FTE Rate). [*]”
2.New Section 1.170. The following is hereby inserted as a new Section 1.170 of the Agreement:
“Section 1.170    “Hainan Bo Ao” shall mean Pilot Zone in the Hainan province where Bo Ao Product may be stored and then imported into the Collaboration Territory with a patient application prior to Regulatory Approval for the Bo Ao Product in the Collaboration Territory.”
3.New Section 1.171. The following is hereby inserted as a new Section 1.171 of the Agreement:
“Section 1.171    “Bo Ao Support Costs” means all actual and, if reasonably practicable, documented costs incurred by Amgen and/or its Affiliates and pre-approved pursuant to the Supply Agreement, if applicable, [*]”
4.New Section 1.172. The following is hereby inserted as a new Section 1.172 of the Agreement:
“Section 1.172    “Product Team” means, for any Product [*].”



5.New Section 1.173. The following is hereby inserted as a new Section 1.173 of the Agreement:
“Section 1.173    “Work Package Team” means, for any Product [*].”
6.Amendment to Section 7.1.2 of the Agreement. The following text is hereby inserted as a new Section 7.1.2(d), Section 7.1.2(e), Section 7.1.2(f), and Section 7.1.2(g), respectively, of the Agreement: [*]
7.Amendments to Section 7.2 of the Agreement.
a.The first paragraph of Section 7.2 (Profit Sharing) of the Agreement is hereby amended and replaced in its entirety as follows:
“Section 7.2    Profit Sharing.
(a)    Prior to the Transition Date designated by the Joint Steering Committee (generally the second Launch Readiness Review for a Product) for an In-Line Product (the “Transition Date”) pursuant to Section 3.1.1 (Transition and Development of Products) and Section 5.1.2(b) (Initial In-Line Product Transition), [*] set forth in the definition of “Commercialization and Related Costs.” The Joint Steering Committee has designated the Transition Date for each In-Line Product as follows: XGEVA®, [*]; BLINCYTO®, [*]; and Kyprolis®, [*].
For the avoidance of doubt, [*] from Amgen to BeiGene pursuant to Section 3.1.1 (Transition and Development of Products) and Section 5.1.2(b) (Initial In-Line Product Transition).
(b)    [*] set forth in the definition of “Commercialization and Related Costs” for each Pipeline Product until [*] prior to the anticipated launch date for such Pipeline Product (such date to be designated for each Pipeline Product by the Joint Alliance Committee and subject to adjustment by the Joint Alliance Committee in the event the anticipated launch date changes) (such date, the “Initiation Date”).
(c)    The Parties will share in Profits generated by Products in the Collaboration Scope: (i) with respect to In-Line Products, beginning on [*] and ending upon [*] for such In-Line Product; (ii) with respect to Pipeline Products, beginning on [*] and ending upon [*] for such Pipeline Product; and (iii) for such longer period as set forth in Section 5.1 for each Retained In-Line Product and each Retained Pipeline Product (i.e., for so long as such Retained In-Line Product or Retained Pipeline Product, as applicable, is sold in the Collaboration Territory); in each case as follows:”
b.Section 7.2.3 (FTE Rate) of the Agreement is hereby amended and restated in its entirety as follows:
“Section 7.2.3. FTE Rate.
(a)    The FTE Rate used for calculation of Costs pursuant to this Article VII (Financial Consideration) with respect to any activity will be the relevant FTE Rate for [*] in which such activity was undertaken.
(b)    Effective as of [*], the Parties agree that the Costs (calculated using the development FTE Rate (as defined in Section 1.72(i)) or commercial FTE Rate (as defined in Section 1.72(ii)), as applicable) of FTEs performing Product Team/Work Package Team strategy activities (i.e. Support to advise
2


on the China specific aspects of the Global Development Plan) for Pipeline Products incurred by the Parties or their respective Affiliates: (i) prior to Regulatory Approval, in accordance with the Development Plan and Development Budget will be deemed Amgen Pipeline Product Global Development Costs and subject to Global Development Cost-Share Payments in accordance with Section 7.1.2 (Global Development Cost Share) and (ii) after Regulatory Approval (including strategy activities for new indications or label expansion after Regulatory Approval), in accordance with the Commercialization Plan and Commercialization Budget, will be deemed to be Commercialization and Related Costs and included in the collaboration profit sharing pursuant to Section 7.2 (Profit Sharing). The Product Team and Work Package Team FTEs will be initially set, and shall in no event exceed, [*] to support the Pipeline Products. The table below sets out the 2021 baseline budget for Product Team/Work Package Team strategy FTEs based on the Pipeline Product portfolio as of the Amendment Effective Date. [*]
(c)    The Product Team and Work Package Team FTE allocation for Pipeline Products will be adjusted by Amgen [*] based on relevant factors, [*].”
c.The following is hereby inserted as a new Section 7.2.8 of the Agreement:
“Section 7.2.8    Hainan Bo Ao Cost-Share Matters. Notwithstanding anything to the contrary in this Agreement, with respect to the AMG 510 (also known as sotorasib or LUMAKRAS®) Product (the “Bo Ao Product”), the Parties desire to initiate the Profit-sharing arrangement set forth in Section 7.2 prior to applicable Initiation Date, subject to the following terms and conditions:
(a)    Commercialization and Related Costs. Prior to the applicable Initiation Date, costs (including Costs for outside services and expenses (e.g., consultants, agency fees, etc.)) for the following activities shall be considered “Commercialization and Related Costs” for purposes of determining “Amgen Costs” or “BeiGene Costs,” as applicable:
(i)    [*];
(ii)    Medical Affairs Activities Costs incurred in connection with Hainan Bo Ao in or for the Collaboration Territory prior to commercialization and during commercialization;
(iii)    all Costs incurred by the Parties or their respective Affiliates associated with any recalls of the Bo Ao Product in the Collaboration Scope and in or for the Collaboration Territory;
(iv)    all Costs incurred by the Parties or their respective Affiliates with respect to product liability claims for the Bo Ao Product in the Collaboration Scope in the Collaboration Territory;
(v)    all Costs incurred by the Parties or their respective Affiliates associated with any returns and withdrawals of the Bo Ao Product in the Collaboration Scope in the Collaboration Territory;
(vi)    any Third Party IP Payments to the extent not already included in Manufacturing Actual Costs; and
(viii)    all unrecovered Indirect taxes, including, for the avoidance of doubt, unrecovered VAT surcharge, incurred by either Party arising with respect to payments to be made under Section 7.2.7 (Calculation of Collaboration Profits). [*]
3


Commercialization and Related Costs for purposes of this Section 7.2.8 shall not include [*] or any Cost subject to an indemnification obligation under Article XIII.
(b)    Manufacturing Actual Costs. The Manufacturing Actual Costs incurred with respect to the Bo Ao Product in connection with Hainan Bo Ao shall be deemed “Amgen Costs” for purposes of the calculations set forth under Section 7.2 (Profit Sharing).
(c)    Net Revenues. Net Revenues from the sale or transfer for value of the Bo Ao Product in Hainan Bo Ao shall be considered “Net Revenues” for purpose of Section 7.2 (Profit Sharing).
(d)    Support Costs. Bo Ao Support Costs incurred with respect to Bo Ao Product in connection with Hainan Bo Ao shall be deemed “Amgen Costs” for purposes of the calculations set forth under Section 7.2 (Profit Sharing).”
8.Amendment to Section 7.9 of the Agreement. Section 7.9 (Overruns) of the Agreement is hereby supplemented and amended by adding the following at the end of the existing Section 7.9:
“Without limiting the foregoing, the Parties further agree as follows:
(a)    While the final overrun calculation is based on annual amounts, the Parties agree to perform quarterly assessments of cost variances for the Overrun Categories shown below, recognizing that both Parties have quarterly reporting requirements.
(b)    In any given calendar quarter, the quarterly profit share and development cost share calculations will reflect up to a maximum of [*] of the planned amounts of the “Overrun Categories” (with an exception for materiality described in Section 7.9(e) below).
(c)    To the extent costs exceed [*] of the budgeted amount in a given calendar quarter, the following shall apply: The Parties agree that they will track variances above [*] of the planned amount into subsequent calendar quarters, to comply with the annual nature of the cost overage calculation in this Section 7.9. [*] If, at a later time, joint approval is obtained from each Party’s finance representative to the JAC for additional activities and related spending beyond the [*] cap, an adjustment will be made in the subsequent period.
(d)    To the extent costs are below budget in a given calendar quarter, actual variances resulting in underspend will be reimbursable in a subsequent period to the extent costs are for a pre-agreed upon activity that had a timing difference and the rationale for the variance is communicated, along with the rationale for why the activity/spend will be performed in a subsequent period. The Parties may agree to a new activity to take the place of the activity that did not occur and the costs of such activity will be reimbursed if under the [*] expense cap, unless otherwise agreed. Agreement will be obtained by each Party’s finance representatives to the JAC.
(e)    The Parties have agreed to a US$[*] dollar threshold for calendar quarter reconciliation of cost overruns, to eliminate the inefficient analysis of greater than [*] variance for smaller dollar amount categories. [*]
(f)    Costs will be evaluated for overrun in the following manner: [*]
(g)    The baseline for the overrun calculation pursuant to this Section 7.9 will be the most recently approved Global Development Budget or Commercialization Budget, as applicable.”
9.New Section 7.12 of the Agreement. The following is hereby inserted as a new Section 7.12 of the Agreement:
4


“Section 7.12    Additional Cost-Share Matters. The Parties expect that from time-to-time one Party may perform activities that are the responsibility of the other Party or a Party may request that the other Party provide services or conduct activities that are not contemplated by the Agreement. In these instances, if the JAC approves such activities and the budget for such activities, the Party performing the activity for the benefit of the other Party shall be reimbursed for the reasonable costs of providing such services or conducting such activities. Such costs shall be documented in writing and the Party providing such service shall be reimbursed quarterly to the Party performing such service concurrently with the Compensating Payment made pursuant to Section 7.2.7 (Calculation of Collaboration Profits). As of the Effective Date, the Parties have agreed that Amgen shall be reimbursed for the following activities as set forth below: [*]”
10.Supply Price Schedule. The Supply Price Schedule is hereby amended to include the following as a new row:
[*][*]

11.Miscellaneous.
d.Except as specifically amended above, the Agreement shall continue to be in full force and effect.
e.This Amendment and its effect are subject to and shall be construed and enforced in accordance with the laws of the State of New York, U.S.A.
f.This Amendment may be executed in counterparts with the same effect as if both Parties had signed the same document. All such counterparts will be deemed an original, will be construed together and will constitute one and the same instrument. Signature pages of this Amendment may be exchanged by facsimile or other electronic means without affecting the validity thereof.

5


IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Effective Date.


AMGEN INC.

/s/ Rachna Khosla
Name: Rachna Khosla
Title: SVP Business Development



BEIGENE SWITZERLAND GMBH

/s/ Beatriz Martinez-Lahuerta
Name: Beatriz Martinez-Lahuerta
Title: Assistant General Counsel, Head of Legal, Europe & New Markets



BEIGENE, LTD.

/s/ Angus Grant
Name: Angus Grant
Title: Senior Vice President, Chief Business Executive


6
EX-10.46 3 exhibit1046-collaborationa.htm COLLABORATION AGREEMENT BETWEEN AMGEN AND ASTRAZENECA Document

EXHIBIT 10.46

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.














Collaboration Agreement

by and between

Amgen Inc.

and

AstraZeneca Collaboration Ventures, LLC




Table of Contents

    i


ii



iii






iv



Schedules
AMG827 Territory
Amgen Distribution Countries
Commercial Allocation
Completed Clinical Trials
[*] Designated Endpoints [*]
Development/Commercial Lead
Distracting Product
Invoice
Press Release
Products
Profit (Loss) Example
Quality Agreement
Stage 1 Clinical Trial
v



Collaboration Agreement
    This Collaboration Agreement (this “Agreement”) is entered into as of the 30th day of March, 2012 (the “Effective Date”) by and between Amgen Inc., a Delaware corporation with a place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and AstraZeneca Collaboration Ventures, LLC, a Delaware limited liability company with a place of business at 1800 Concord Pike, Wilmington, Delaware 19850 (“Partner”). Amgen and Partner are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. AstraZeneca Pharmaceuticals LP, the parent corporation of Partner (“AstraZeneca”), [*] is a party to this Agreement [*].
Recitals
    WHEREAS, Amgen is a global biopharmaceutical company that researches, develops, manufactures and commercializes novel therapeutics to treat grievous illness;
    WHEREAS, Amgen has developed certain proprietary Products (as defined below) for the treatment of certain diseases and conditions; and
    WHEREAS, Amgen and Partner desire to collaborate, and share certain expenses and revenues, with respect to the development, manufacture and commercialization of the Products as set forth in more detail herein.
    NOW, THEREFORE, in consideration of the premises and the mutual promises set forth herein, and intending to be legally bound, the Parties agree as follows:
1.DEFINITIONS
1.1.“Access and Pricing Plan” means the country specific plan for a Product approved by the JSC that sets forth the proposed price, target population and reimbursement target.
1.2.“Affiliate” means, with respect to a Party, any Person which controls, is controlled by or is under common control with such Party. For purposes of this definition only, “control” means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the securities entitled to be voted generally or in the election of directors of such Person, or by contract or otherwise. For clarity, Kirin-Amgen, Inc. shall not be considered an Affiliate of Amgen. Notwithstanding the foregoing, for the purposes of Article 9 (Distracting Products) and Section 1.51 (“Distracting Transaction”) only, [*].
1.3.“Agreement” has the meaning set forth in the Preamble.
1.4.“Alliance Manager” has the meaning set forth in Section 2.9 (Alliance Managers).
1.5.“AMG157 Data Package” has the meaning set forth in Section 14.2 (Termination for Convenience).
1.6.“AMG157 Termination Event” has the meaning set forth in Section 14.2 (Termination for Convenience).
1.7.“AMG827 Territory” means Australia, Canada, Mexico, New Zealand, the United States (its territories and possessions), all European countries, including those listed in Column 1 of the AMG827 Territory Schedule attached hereto, all Central and South American countries, including those listed in Column 2 of AMG827 Territory Schedule attached hereto, and those certain African and Middle East countries listed in Column 3 of AMG827 Territory Schedule attached hereto.
1.8.“Amgen” has the meaning set forth in the Preamble.
1.9.“Amgen Costs” has the meaning set forth in Section 7.2.2 (Amgen Costs).
    1


1.10.“Amgen Distribution Countries” means those countries listed on the Amgen Distribution Countries Schedule.
1.11.“Amgen Housemarks” means (i) the corporate logo of Amgen, (ii) the trademark “Amgen”, (iii) any other trademark, trade name or service mark (whether registered or unregistered) containing the word “Amgen”, and (iv) any other trademark or service mark associated with goods or services of Amgen or its Affiliates, but excluding the Product Trademarks and trademarks, trade names or service marks associated with goods or services outside the scope of this Agreement; and all intellectual property rights residing in any of the foregoing.
1.12.“Amgen Indemnitees” has the meaning set forth in Section 13.1 (Indemnity by Partner).
1.13.“Amgen Intellectual Property” means any Know-How, Patent, electronic media registrations (including domain names, usernames, websites, blogs and the like), or Copyright controlled by Amgen or its Affiliates that (i) as of the Effective Date is being used in connection with the research and development of any of the Products, or (ii) is used (but is not generated or conceived) during the Term by either Party or its Affiliates in the performance of this Agreement. Amgen Intellectual Property specifically excludes Program Intellectual Property.
1.14.“Amgen Sales Force Costs” means the allocable share of Amgen’s or its Affiliates’ sales force costs for sales representatives that Detail Products in the Collaboration Scope in accordance with this Agreement, calculated in accordance with Section 7.2.11 (Calculation of Sales Force Costs).
1.15.“Anti-Corruption Laws” means the US Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism.
1.16.“Applicable Laws” means, individually and collectively, any federal, state, local, national and supra-national laws, treaties, statutes, ordinances, rules and regulations, including any rules, regulations, guidance, guidelines or requirements having the binding effect of law of national securities exchanges, automated quotation systems or securities listing organizations, Governmental Authorities, courts, tribunals, agencies other than Governmental Authorities, legislative bodies and commissions that are in effect from time to time during the Term and applicable to a particular activity hereunder.
1.17.“Assisting Party” has the meaning set forth in Section 13.4 (Defense of Third Party Claims).
1.18.“AstraZeneca” has the meaning set forth in the Preamble.
1.19.“Audited Party” has the meaning set forth in Section 8.4 (Audits).
1.20.“Auditing Party” has the meaning set forth in Section 8.4 (Audits).
1.21.“Brand Plan” means the global, cross-functional commercialization plan for a Product approved by the JSC, including any applicable Global Payer Plan and country specific Access and Pricing Plan.
1.22.“Bundle” means any Product sold together with another pharmaceutical compound for a single price, including combination products or more than one product sold together.
1.23.“cGMP” has the meaning set forth in the applicable Quality Agreement.
1.24.“Collaboration Review Committee” or “CRC” means the review committee established pursuant to Article 2 (Scope and Governance).
2



1.25.“Collaboration Profit (Loss)” has the meaning set forth in Section 7.2.8 (Calculation of Profit (or Loss)).
1.26.“Collaboration Scope” means, with respect to a particular Product, any and all uses of such Product in the applicable Collaboration Territory.
1.27.“Collaboration Territory” means the world, except for the Excluded Territory for AMG557 and AMG827.
1.28.“Commercialization Budget” has the meaning set forth in Section 2.4.1.3. An initial Commercialization Budget for each Product will be approved by the JSC not later than three (3) months after initiation of the first Phase 3 Trial for such Product.
1.29.“Commercial Lead” has the meaning set forth in Section 5.2 (Commercial Lead).
1.30.“Commercially Reasonable Efforts” means, with respect to activities of a Party related to a Product under this Agreement, the efforts and resources typically used by that Party in the conduct of such activities with respect to products of comparable market potential, taking into account all relevant factors including, as applicable, stage of development, efficacy and safety relative to competitive products in the marketplace, actual or anticipated Governmental Authority approved labeling, the nature and extent of market exclusivity (including patent coverage and regulatory exclusivity), and cost and likelihood of obtaining Regulatory Approval. For purposes of clarity, Commercially Reasonable Efforts will be determined on a country-by-country basis within the Collaboration Territory, and it is anticipated that the level of effort may be different for different countries and may change over time, reflecting changes in the status of a Product and the country(ies) involved.
1.31.“Competing Product” has the meaning set forth in Section 5.9 (Competing Products).
1.32.“Confidential Information” has the meaning set forth in Section 11.1 (Confidentiality; Exceptions).
1.33.“Continued Development Meeting” means on a Product-by-Product basis, a meeting of the JSC to be held promptly following the completion of the Stage 1 Clinical Trial(s) for such Product, in which the JSC will discuss plans for the next phase of development of each such Product.
1.34.“Contract Interest Rate” means [*], plus the thirty (30) day U.S. Dollar LIBOR rate effective for the date that payment was due, as published by The Wall Street Journal, Eastern U.S. Edition, on the date such payment was due (or, if unavailable on such date, the first date thereafter on which such rate is available), or, if lower, the maximum rate permitted by Applicable Law.
1.35.“Copyright” means all right, title, and interest in and to all copyrightable works and any copyright registration or corresponding legal right.
1.36.“Costs” means both internal and external costs and expenses (including the cost of allocated FTEs at the FTE Rate).
1.37.“Country Plans” has the meaning set forth in Section 5.1 (Allocation of Commercial Responsibility).
1.38.“Critical Matters” means (A) all decisions made by the CRC, JSC and JPTs that, in the reasonable opinion of either Party, are likely to have any of the following impacts: (i) [*] under a Development Plan or Brand Plan; (ii) a change to a Development Plan or Brand Plan that results in the lesser of (a) an increase of [*] or more (provided, that such amount is at least [*]) and (b) [*] or more, in each case, to the then-current budgeted amount of Development Costs and/or General Costs for any specific calendar year under the applicable Development Budget, Operations Budget or Commercialization Budget or the amounts estimated under Sections 7.2.1 (Partner Costs) and 7.2.2 (Amgen Costs); (iii) a change to a Development Plan or Brand Plan
3



that results in a decrease of [*] (provided, that such amount is at least [*]) or more to the then-current budgeted amount of Development Costs and/or General Costs for any specific calendar year under the applicable Development Budget, Operations Budget or Commercialization Budget or the amounts estimated under Sections 7.2.1 (Partner Costs) and 7.2.2 (Amgen Costs); or (iv) a change to a Development Plan (including any plans with respect to a contemplated Regulatory Approval set forth therein) or Brand Plan that would, based upon [*], result in [*] of a Product for any specific calendar year under the applicable Development Plan or Brand Plan; (B) agreement of the initial Commercialization Budget for each Product; (C) agreement of the initial Brand Plan (or material updates thereto reflecting the launch of a new indication), Global Payer Plan and any Access and Pricing Plan for each Product; and (D) deadlocks with respect to the approval of an annual Development Budget, Operations Budget or Commercialization Budget as provided for under Section 7.7 (Budget Deadlocks).
1.39.“Defending Party” has the meaning set forth in Section 13.4 (Defense of Third Party Claims).
1.40.“Designated Amgen Activities” means those development, regulatory, manufacturing, access and commercial activities for which Amgen is responsible pursuant to this Agreement, including such activities allocated to it by any of the committees and teams established under this Agreement.
1.41.“Designated Partner Activities” means those development, regulatory, manufacturing, access and commercial activities for which Partner is responsible pursuant to this Agreement, including such activities allocated to it by any of the committees and teams established under this Agreement.
1.42.“Designated Regulatory Party” has the meaning set forth in Section 3.2.1 (Designated Regulatory Party).
1.43.“Detail” means an interactive face-to-face visit by a sales representative with a medical professional having prescribing authority or who is able to influence prescribing decisions, within the target audience during which approved uses, safety, effectiveness, contraindications, side effects, warnings or other relevant characteristics of a pharmaceutical product are discussed in an effort to increase prescribing preferences of a pharmaceutical product for its approved uses. Detail includes First Position Details, Second Position Details and Other Details. Details will not include (i) activities conducted by medical support staff (such as medical science liaisons) or (ii) E-details, activities conducted at conventions or similar gatherings and activities performed by market development specialists, managed care account directors and other personnel not performing face-to-face sales calls or not specifically trained with respect to a pharmaceutical product. “Detailing” means the act of performing Details and to “Detail” means to perform Details.
1.44.“Development Budget” has the meaning set forth in Section 2.4.1.1. The initial Development Budgets will be agreed in writing by the Parties as soon as reasonably practicable on or after the Effective Date.
1.45.“Development Costs” means with respect to all Products:
1.45.1.all Costs associated with obtaining, maintaining and renewing Regulatory Filings and Regulatory Approvals pertaining to a Product in accordance with the applicable Development Plan;
1.45.2.all Costs incurred by the Parties or their respective Affiliates in performing activities designated to the Parties under the applicable Development Plan, as applicable (including the Costs of clinical trials and related support to obtain marketing approval for a Product and other lifecycle management activities as well as Phase 4 Trials, development of related devices, observational research
4



and any economic value evidence generation in support of reimbursement activities such as health technology assessment submissions);
1.45.3.all manufacturing Costs not otherwise included in Manufacturing Standard Cost or Manufacturing Actual Costs, including stability testing and other CMC support costs for such Products, Costs relating to the development of manufacturing processes, scale-ups, validations and technology transfers for Products;
1.45.4.for any clinical supply of Products, (i) the Manufacturing Standard Cost, if it is manufactured in the Manufacturing Lead’s (or its designee’s) clinical manufacturing facility, or (ii) all Manufacturing Actual Costs, if it is manufactured in the Manufacturing Lead’s (or its designee’s) non-clinical (i.e., commercial) manufacturing facility;
1.45.5.all Costs for other materials (such as non-Party comparator drugs and placebo) obtained for use in clinical trials of or related to a Product; and
1.45.6.all Costs associated with engineering, conformance, or other manufacturing activities required to achieve commercial scale production of a Product, CMC filing requirements, and the like not otherwise included in Manufacturing Actual Costs for such Product.
All to the extent incurred after the Effective Date. For clarity, Development Costs are exclusive of and do not include General Costs. Except to the extent already included in overhead, Development Costs shall not include either Party’s Costs to the extent they solely relate to legal, accounting, finance or alliance management activities associated with overseeing execution of and compliance with this Agreement.
1.46.“Development Lead” has the meaning set forth in Section 3.1.2 (Development Lead).
1.47.“Development Plan” means the plan approved by the JSC for each Product (which plan will be updated annually and will cover a period of at least [*] years) covering: (i) the research and development (including Phase 4 Trials) of the Products in the Collaboration Scope, including observational research and payer evidence generation including economic value; (ii) the preparation and submission of Regulatory Filings; and (iii) the obtaining, maintenance or expansion of Regulatory Approvals of the Products in the Collaboration Scope. The initial Development Plans covering calendar years [*] will be agreed in writing by the Parties as soon as reasonably practicable on or after the Effective Date.
1.48.“Distracting Product” means, with respect to a given Product, any product, [*], directed at [*] the Product Target or any Distracting Target [*]. For clarity, a [*] antibody that binds to [*] shall be a Distracting Product unless the Parties agree otherwise.
1.49.“Distracting Program” means the clinical development, manufacture or commercialization (including Detailing, selling, promoting or distributing) of any Distracting Product.
1.50.“Distracting Target” has the meaning set forth on the Distracting Product Schedule.
1.51.“Distracting Transaction” means any transaction entered into by a Party or its Affiliates on or after the Effective Date whereby a Third Party that is engaged in a Distracting Program becomes an Affiliate of a Party or any of its Affiliates.
1.52.“Distracting Transaction Party” has the meaning set forth in Section 9.3.3 (Inclusion).
1.53.“Distribution Party” has the meaning set forth in Section 4.4 (All Sales by Distribution Party).
5



1.54.“Divest” means, with respect to any Distracting Program, the sale, exclusive license or other transfer of all right, title and interest in and to such Distracting Program, including technology, intellectual property and other assets materially relating thereto, to a Third Party, without the retention or reservation of any rights or interest (other than an economic interest, reversion rights or other similar rights typical of a licensor in an exclusive license agreement) in such Distracting Program by such Party or its Affiliates.
1.55.“Early Stage Programs” has the meaning set forth in Section 4.1 (Allocation of Manufacturing Responsibility).
1.56.“Effective Date” has the meaning set forth in the Preamble.
1.57.“Europe” means those countries, nations, states or other territories under the jurisdiction of the European Medicines Agency (or any successor agency thereto), as such jurisdiction may change from time to time, and Iceland, Liechtenstein, Norway and Switzerland.
1.58.“Excluded Territory” means (i) with respect to AMG557, Japan, and (ii) with respect to AMG827, all countries not included within the AMG827 Territory.
1.59.“Excluded Territory Agreement” means (i) in relation to AMG827, the AMG827 Technology Transfer Agreement by and among Kyowa Hakko Kirin Co., Ltd., Amgen and Kirin-Amgen, Inc., the Research, Development and Technology Disclosure Agreement: AMG827 by and among Kyowa Hakko Kirin Co., Ltd., Amgen and Kirin-Amgen, Inc., and the AMG827 License Agreement between Kirin-Amgen, Inc., all dated October 29, 2010 and (ii) in relation to AMG557, means the License Agreement by and between Amgen and Takeda Pharmaceutical Company Limited dated February 1, 2008, in each case as the same have been amended and may be amended from time to time hereafter in accordance with terms of this Agreement.
1.60.“First Position Detail” means a Detail in which the applicable pharmaceutical product is Detailed before any other product and/or the predominant portion of time is devoted to the Detailing of such pharmaceutical product.
1.61.“Force Majeure” has the meaning set forth in Section 15.7 (Force Majeure).
1.62.“FTE” means, with respect to a person (other than an employee that Details a Product), the equivalent of the work of one (1) employee full time for one (1) year (consisting of at least a total of [*] weeks or [*] hours per year (excluding vacations and holidays)).  Overtime, and work on weekends, holidays and the like [*] be counted [*] toward the number of hours that are used to calculate the FTE contribution. For an employee that Details a Product, FTEs will be calculated as set forth in Section 7.2.11 (Calculation of Sales Force Costs).
1.63.“FTE Rate” means, for the period commencing on the Effective Date until such time as the Parties agree otherwise, (i) [*] for activities conducted in the U.S., and (ii) for all other geographic locations [*] multiplied by a cost of living adjustment between the U.S. and such other geographic location as set forth in the then most current edition of [*] (or in the event such geographic location is not listed, the nearest listed geographic location that is most comparable to such non-listed geographic location). The FTE Rate will be increased by [*]. The FTE Rate shall include costs of salaries, benefits, supplies, other employee costs, facility costs, depreciation and supporting general and administration allocations.
1.64.“GAAP” means the then-current generally accepted accounting principles in the United States as established by the Financial Accounting Standards Board or any successor entity or other entity generally recognized as having the right to establish such principles in the United States, in each case consistently applied.
6




1.65.“General Costs” means with respect to all Products:
1.65.1.all Costs, other than Amgen Sales Force Costs and Partner Sales Force Costs, associated with activities related to the commercialization of Products, including: sales, pricing, access, coverage (including risk sharing arrangements), reimbursement, presentation, purchase of ancillary items or devices, contracting, launch timing, distribution, marketing messaging, product positioning, development of training materials, sales tracking and auditing, market research and product usage surveys, provision of medical affairs support staff, and scientific and medical advisory boards (including any global medical conferences);
1.65.2.all Amgen Sales Force Costs and Partner Sales Force Costs incurred in accordance with the Brand Plan and calculated in accordance with Section 7.2.11 (Calculation of Sales Force Costs);
1.65.3.all training Costs incurred in accordance with Section 5.5 (Training);
1.65.4.all defense, enforcement and cooperation Costs incurred within or materially related to the Collaboration Scope in accordance with Section 10.7 (Defense and Settlement of Third Party Claims), Section 13.4 (Defense of Third Party Claims) and Section 10.8 (Enforcement) ([*]);
1.65.5.all Costs with respect to product liability claims for Products in the Collaboration Scope [*];
1.65.6.all Costs associated with any recalls, returns and withdrawals of a Product in the Collaboration Scope ([*]);
1.65.7.all Costs incurred in connection with Prosecution and Maintenance of Amgen Intellectual Property and Program Intellectual Property in accordance with Section 10.6 (Prosecution and Maintenance) within or materially related to the Collaboration Scope;
1.65.8.all Manufacturing Actual Costs for any samples of Products provided in the Collaboration Scope;
1.65.9.for any commercial supply of Products, all Manufacturing Actual Costs for Products sold;
1.65.10.all manufacturing Costs not otherwise included in Manufacturing Actual Costs, including stability testing and other CMC support costs for such Products, but only to the extent such costs are not included in Development Costs under Section 1.45.3; and
1.65.11.any amounts paid by either Party to Third Parties for rights to manufacture, use or sell a Product in or for the Collaboration Scope to the extent not already included in Manufacturing Actual Costs; provided, that [*].
All to the extent incurred after the Effective Date. For clarity, General Costs are exclusive of and do not include Development Costs. Except to the extent already included in overhead, General Costs shall not include either Party’s Costs to the extent they solely relate to legal, accounting, finance or alliance management activities associated with overseeing execution of and compliance with this Agreement.
1.66.“Global Payer Plan” means the global plan for a Product approved by the JSC that sets forth the strategic direction, positioning, value proposition and reimbursement for such Product.
7



1.67.“Governmental Authority” means any government or supranational administrative agency, commission or other governmental or supranational authority, body or instrumentality, or any federal, state, local, domestic or foreign governmental or supranational regulatory body.
1.68.“Government Official” means (i) any Person employed by or acting on behalf of a Governmental Authority; (ii) any political party, party official or candidate; (iii) any Person who holds or performs the duties of an appointment, office or position created by custom or convention; and (iv) any Person who holds himself out to be the authorized intermediary of any of the foregoing.
1.69.“Housemarks” means the Amgen Housemarks or the Partner Housemarks, as the case may be.
1.70.“IFRS” means the then-current International Financial Reporting Standards, consistently applied.
1.71.“Indemnified Party” has the meaning set forth in Section 13.3 (Claim for Indemnification).
1.72.“Indemnifying Party” has the meaning set forth in Section 13.3 (Claim for Indemnification).
1.73.“Indirect Taxes” means VAT, sales taxes, consumption taxes and other similar taxes.
1.74.“Infringement Claim” has the meaning set forth in Section 10.7 (Defense and Settlement of Third Party Claims of Infringement).
1.75.“Invention” means any idea, concept, discovery, invention, improvement or trade secret.
1.76.“Inventorship Margin” has the meaning set forth in Section 7.2.8.2 (Profit).
1.77.“Joint Claim” has the meaning set forth in Section 13.4 (Defense of Third Party Claims).
1.78.“Joint Product Team” or “JPT” means the individual Product teams established pursuant to Article 2 (Scope and Governance).
1.79.“Joint Steering Committee” or “JSC” means the steering committee established pursuant to Article 2 (Scope and Governance).

1.80.“Key Regulatory Filings” means any (i) Investigational New Drug Application (or similar filing outside the United States); (ii) Biologic Licensing Application (or similar filing outside the United States); (iii) briefing books; and (iv) any other Regulatory Filing designated a Key Regulatory Filing by written agreement of the Parties. 
1.81.“Know-How” means all tangible and intangible techniques, information, technology, practices, trade secrets, Inventions (whether patentable or not), methods, processes, knowledge, know-how, conclusions, skill, experience, test data and results (including pharmacological, toxicological, manufacturing, and clinical test data and results), regulatory documentation, analytical and quality control data, results or descriptions, software and algorithms, including works of authorship and Copyrights, and materials, including biological materials, compositions and the like. Know-How does not include Patents, Product Trademarks, Amgen Housemarks, Partner Housemarks, or Program Patents and Trademarks.
1.82.“Losses” has the meaning set forth in Section 13.1 (Indemnity by Partner).
1.83.“Manufacturing Actual Costs” means (i) [*]. Manufacturing Actual Costs will be calculated consistently with other products manufactured by the Manufacturing Lead
8



and in accordance with GAAP or IFRS, as applicable. For clarity, in the event that the Manufacturing Lead uses a contract manufacturer to perform any manufacturing activities under this Agreement, Manufacturing Actual Costs for such activities will be the price the Manufacturing Lead pays such contract manufacturer for such activities, plus the Costs to manage and to process materials obtained from such contract manufacturer.
1.84.“Manufacturing Lead” has the meaning set forth in Section 4.2 (Manufacturing Lead).
1.85.“Manufacturing Standard Costs” means, with respect to a Product, [*]. For clarity, (i) where Amgen is the Manufacturing Lead, Amgen’s internal clinical standard cost methodology for clinical product [*], and (ii) in the event that the Manufacturing Lead uses a contract manufacturer to perform any manufacturing activities under this Agreement, Manufacturing Standard Cost for such activities will be the price the Manufacturing Lead pays such contract manufacturer for such activities, plus the Costs to manage and to process materials obtained from such contract manufacturer.
1.86.“Material Anti-Corruption Law Violation” means a violation of an Anti-Corruption Law relating to the subject matter of this Agreement which would if it were publicly known, in the reasonable view of a Party, have a material adverse effect on it or on its reputation because of its relationship with the other Party.
1.87.“Medarex Agreement” means that certain Research and Commercialization Agreement by and among Medarex, Inc., GenPharm International, Inc. and Amgen dated as of December 23, 2002.
1.88.“[*]” means Partner’s proprietary antibody [*] that is currently in clinical development.
1.89.“Net Revenues” means: (i) the aggregate of the gross invoiced sales prices for Products that are sold or transferred for value by either Party or their respective Affiliates to Third Parties in the Collaboration Territory, minus the following amounts incurred or paid (each as recognized by GAAP or IFRS, as applicable, and each to the extent not already deducted when calculating Manufacturing Actual Costs) by such selling Party or its Affiliates with respect to such sales or transfers for value (regardless of the period in which such amounts are incurred or paid):
1.89.1.trade, cash, prompt payment or quantity discounts;
1.89.2.payments to Governmental Authorities, returns, refunds, allowances, rebates and chargebacks;
1.89.3.retroactive price reductions applicable to sales of such Product;
1.89.4.fees paid to distributors, wholesalers, selling agents (excluding any sales representatives of a Party or any of its Affiliates), group purchasing organizations and managed care entities;
1.89.5.the standard inventory cost (actual acquisition or manufacture cost) of devices used for dispensing or administering such Product that are shipped with such Product and included in the gross invoiced sales prices;
1.89.6.credits or allowances for product replacement, whether cash or trade;
1.89.7.any tax, tariff, duty or governmental charge levied on the sales, transfer, transportation or delivery of such Product (including any tax such as a value added or similar tax or government charge), other than franchise or income tax of any kind whatsoever;
1.89.8.[*];
9



1.89.9.[*]; and
1.89.10.any import or export duties or their equivalent borne by the relevant seller;
plus (ii) any Recoveries made pursuant to Section 10.8 (Enforcement).
1.90.“Non-Suspending Party” has the meaning set forth in Section 7.8 (Program Recommitment).
1.91.“North America” means the United States and Canada.
1.92.“[*]” has the meaning set forth in Section 7.2.8.1.2 (Quarterly Cap).
1.93.“Operations Budget” has the meaning set forth in Section 2.4.1.2. The initial Operations Budgets will be agreed in writing by the Parties as soon as reasonably practicable on or after the Effective Date.
1.94.“Other Detail” means any Detail other than a First Position Detail or a Second Position Detail.
1.95.“Out-License Election” has the meaning set forth in Section 7.8.2.4 (Out-License).
1.96.“Partner” has the meaning set forth in the Preamble.
1.97.“Partner Costs” has the meaning set forth in Section 7.2.1 (Partner Costs).
1.98.“Partner Housemarks” means (i) the corporate logo of Partner, (ii) the trademark “AstraZeneca” and “MedImmune”, (iii) any other trademark, trade name or service mark (whether registered or unregistered) containing the word “AstraZeneca” or “MedImmune”, and (iv) any other trademark or service mark associated with goods or services of Partner or its Affiliates, but excluding the Product Trademarks and trademarks, trade names or service marks associated with goods or services outside the scope of this Agreement; and all intellectual property rights residing in any of the foregoing.
1.99.“Partner Indemnitees” has the meaning set forth in Section 13.2 (Indemnity by Amgen).
1.100.“Partner Intellectual Property” means any Know-How, Patents, electronic media registrations (including domain names, usernames, websites, blogs and the like), or Copyright controlled by Partner or its Affiliates that is used (but is not generated or conceived) during the Term by either Party or its Affiliates in the performance of this Agreement. Partner Intellectual Property specifically excludes Program Intellectual Property.
1.101.“Partner Sales Force Costs” means the allocable share of Partner’s (or its Affiliates’) costs for sales representatives that Detail Products in the Collaboration Scope in accordance with this Agreement, calculated in accordance with Section 7.2.11 (Calculation of Sales Force Costs).
1.102.“Party” or “Parties” has the meaning set forth in the Preamble.
1.103.“Party Representatives” has the meaning set forth in Section 12.3.3.
1.104.“Patent Coordinator” means those employees of each of the Parties appointed pursuant to Section 2.10 (Patent Coordinators) to serve as each such Party’s primary liaison with the other Party on matters relating to intellectual property as described in this Agreement.
1.105.“Patent Extensions” has the meaning set forth in Section 10.9 (Patent Term Extensions).
10



1.106.“Patents” means the issued patents and pending patent applications (including certificates of invention, applications for certificates of invention and priority rights) in any country or region, including all provisional applications, refilings, substitutions, continuations, continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues, re-examinations and patent term extensions thereof, and all international or foreign counterparts of any of the foregoing (including supplemental protection certificates, patents of addition and the like).

1.107.“Person” means an individual, corporation, partnership, limited liability company, limited partnership, trust, business trust, association, joint stock company, joint venture, pool, syndicate, “group” as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically listed herein.
1.108.“Phase 1 Trial” means a clinical trial of a pharmaceutical product that meets the definition of a Phase 1 study for the United States as described in 21 C.F.R. §312.21(a), or its successor regulation, or the equivalent regulation in any other country, including the Phase 1 part of any clinical trial that is a combination Phase 1 Trial and Phase 2 Trial. A “Phase 1(b) Trial” means a Phase 1 Trial that is designed to demonstrate evidence of clinical impact.
1.109.“Phase 2 Trial” means a clinical trial of a pharmaceutical product that meets the definition of a Phase 2 study for the United States as described in 21 C.F.R. §312.21(b), or its successor regulation, or the equivalent regulation in any other country.
1.110.“Phase 3 Trial” means a clinical trial of a pharmaceutical product that meets the definition of a Phase 3 study for the United States as described in 21 C.F.R. §312.21(c), or its successor regulation, or the equivalent regulation in any other country.
1.111.“Phase 4 Trial” means any clinical study initiated in the Collaboration Territory for a Product following the first Regulatory Approval for the sale of such Product in the Collaboration Scope for the indication being studied. Phase 4 Trials may include epidemiological studies, modeling and pharmacoeconomic studies, and post-marketing surveillance studies, as well as any clinical study or research study sponsored and conducted by an individual not employed by or on behalf of either Party.
1.112.“Product” means any pharmaceutical product containing one of the pharmaceutical compounds listed on the Products Schedule [*].
1.113.“Product Intellectual Property” means Amgen Intellectual Property, Partner Intellectual Property, and Program Intellectual Property.
1.114.“Product Target” has the meaning set forth on the Distracting Product Schedule.
1.115.“Product Trademarks” means any trademark, trade name or service mark (whether registered or unregistered) selected by the JPT for use on, with, or to refer to a Product (other than Amgen Housemarks and Partner Housemarks, as applicable) or used with patient support or other information or services or Promotional Materials associated with a Product in the Collaboration Territory during the Term, and all intellectual property rights residing in the foregoing.
1.116.“Program Intellectual Property” means any Know-How, Patents, Product Trademark, trademark application, electronic media registrations (including domain names, usernames, websites, blogs and the like), or Copyright generated or conceived by Amgen, Partner or their respective Affiliates, whether solely or jointly (or together with a Third Party), during the Term as a result of carrying out the Designated Amgen Activities or the Designated Partner Activities, as applicable.

11



1.117.“Program Notice” has the meaning set forth in Section 9.4 (Pre-Clinical Research and Development Programs).
1.118.“Program Patents and Trademarks” has the meaning set forth in Section 10.6.3 (Program Intellectual Property).
1.119.“Promotional Materials” has the meaning set forth in Section 5.7 (Promotional Materials).
1.120.“Prosecution and Maintenance” means the preparation, filing, and prosecution of patent applications and maintenance of patents, as well as re-examinations and reissues with respect to such patents, together with the conduct of interferences, post–grant proceedings (including without limitation post-grant review, inter-partes review, and derivation proceedings in the U.S.) and the defense of oppositions with respect to such patent application or patent; and “Prosecute and Maintain” has the correlative meaning.
1.121.“Quarterly Cap” has the meaning set forth in Section 7.2.8.1.2 (Quarterly Cap).
1.122.“Quality Agreement” means that certain Quality Agreement dated as of the date hereof between the Parties (and substantially in the form attached hereto as the Quality Agreement Schedule) regarding the clinical use of Products manufactured by Amgen, and any subsequent quality agreements between the Parties related to Products supplied pursuant to this Agreement.
1.123.“Recoveries” means all monies received by either Party from a Third Party in connection with the final, non-appealable judgment (or judgment with respect to which the time period for appeal has expired), award or settlement of any enforcement with respect to any Product Intellectual Property, to the extent such judgment, award or settlement pertains to activities within the Collaboration Scope.
1.124.“Re-Entry Notice” has the meaning set forth in Section 7.8.2.1 (Re-Entry Period).
1.125.“Re-Entry Period” has the meaning set forth in Section 7.8.2.1 (Re-Entry Period).
1.126.“Regulatory Approval” means an approval for a Product from a Governmental Authority necessary for the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of such Product.
1.127.“Regulatory Filing” means any filing with any Governmental Authority with respect to the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of a Product.
1.128.“Reimbursed Development Costs” means any Development Costs incurred by either Party for which Amgen is entitled to reimbursement from a Third Party pursuant to the Excluded Territory Agreements; provided, that [*] shall not be a Reimbursed Development Cost.
1.129.“Researching Party” has the meaning set forth in Section 9.4 (Pre-Clinical Research and Development Programs).

1.130.“Safety Agreement” means that certain Safety Agreement to be entered into between the Parties within ninety (90) days of the Effective Date regarding adverse event reporting with respect to Products manufactured by Amgen, and any subsequent safety agreements between the Parties related to Products supplied pursuant to this Agreement.
1.131.“Second Position Detail” means a Detail in which the applicable pharmaceutical product is Detailed in the second position (i.e., no more than one (1) other product is presented to or discussed with the healthcare professional before such Product) and/or
12



the second most predominant portion of time is devoted to the Detailing of such pharmaceutical product.
1.132.“Segregate” means, with respect to two (2) programs: (i) to restrict and prevent all program-related contacts and communications between personnel (whether employees, consultants, Third Party contractors or otherwise and whether or not located within the Collaboration Territory (for the purposes of this definition, “Personnel”)) working on or involved with the development or commercialization of the first program and Personnel working on or involved with the development or commercialization of the second program; (ii) to ensure that Personnel that are working on the first program will not simultaneously work on the second program and vice versa; (iii) to ensure that confidential information relating to the first program is not shared with or accessed by Personnel that are working on the second program and vice versa; and (iv) from time-to-time, upon the reasonable request of the other Party, to provide information requested relating to the foregoing items (i) through (iii), and to reasonably cooperate to enable the other Party to verify that such restrictions are in place and sufficient to achieve the foregoing. For clarity, [*] as set forth herein.
1.133.“Specifications” has the meaning set forth in the applicable Quality Agreement.
1.134.“Stage 1 Clinical Trial” means, with respect to each Product, the trial or trials set forth in the Stage 1 Clinical Trial Schedule.
1.135.“Stage 2 Clinical Trial” means, with respect to each Product, the trial or trials mutually agreed upon by the Parties at such time either Party provides a Suspension Election with respect to such Product under Section 7.8.1.1 (Suspension Election) (provided, that if the Parties are unable to agree upon such trial or trials, then Stage 2 Clinical Trial shall be deemed to be first study in the next phase of development (i.e., the first Phase 3 Trial if the Stage 1 Clinical Trial was a Phase 2b Trial, the first Phase 2b Trial if it were a Phase 2a Trial, the first Phase 2a Trial if it were a Phase 1b Trial, etc.).
1.136.“Sublicensing Revenue” means with respect to any Terminated Products, all cash payments (and the fair market value of all non-cash consideration) received by the Continuing Party and/or any of its Affiliates from any Third Party in consideration for a transaction, series of transactions or other arrangement in which such Third Party obtains a license (or sublicense) of the Product Intellectual Property (or any option or other right to obtain a license of the Product Intellectual Property), including, without limitation, up-front payments, milestones, royalties, and research funding (provided, that with respect to research funding payments, only the amounts in excess of the Continuing Party’s external costs and internal costs directly related to such research activities will be included).
1.137.“Suspending Party” has the meaning set forth in Section 7.8 (Program Recommitment).
1.138.“Suspension Election” has the meaning set forth in Section 7.8.1.1 (Suspension Election).
1.139.“Taxes” means any tax, excise or duty, other than taxes and withholdings upon income.
1.140.“Technical Feasibility” means, with respect to any Product manufactured, the first date on which, in the good-faith determination of the Manufacturing Lead, there is a high probability that (i) such related Product candidates will obtain Regulatory Approval for the sale of such Product candidate and (ii) the related costs will be recoverable through the commercialization of such manufactured Product.
1.141.“Term” means the period commencing on the Effective Date and continuing in perpetuity, unless and until earlier terminated pursuant to any provision of this Agreement.
13



1.142.“Termination Election” has the meaning set forth in Section 7.8.1.4 (Subsequent Termination).
1.143.“Third Party” means any Person that is not a Party, or an Affiliate of a Party.
1.144.“Third Party Claim” means any claim, action, lawsuit, or other proceeding brought by any Third Party. Third Party Claim includes any Infringement Claim.
1.145.“Total Costs” means all General Costs, Unreimbursed Development Costs and Reimbursed Development Costs.
1.146.“United States” or “U.S.” means the United States of America and its territories and possessions.
1.147.“Unreimbursed Development Costs” means any Development Costs incurred by either Party for which Amgen is not entitled to reimbursement from a Third Party pursuant to the Excluded Territory Agreements; provided, that [*] shall be an Unreimbursed Development Cost.
1.148.“VAT” means the tax imposed by Council Directive 2006/112/EC of the European Community and any national legislation implementing that directive together with legislation supplemental thereto and in particular, in relation to the United Kingdom, the tax imposed by the Value Added Tax Act of 1994 or other tax of a similar nature imposed in other countries in the Collaboration Territory.
1.149.“Withholding Party” has the meaning set forth in Section 8.6.1 (Withholding).

14



2.SCOPE AND GOVERNANCE
2.1.Purpose of the Collaboration. The purpose of the collaboration is for the Parties to collaborate in the development, manufacture and commercialization of the Products and for the Parties to share in certain costs and revenues related to the Products, all as described in more detail herein.
2.2.Ex-Territory Activities.
2.2.1.No Rights in Excluded Territory. The Parties acknowledge that no rights are granted hereunder to Partner with respect to the applicable Product in any country in the Excluded Territory, and that Partner will have no authority with respect to the research, development, manufacture or commercialization of such applicable Products in the Excluded Territory. As between the Parties, Amgen or its licensees will have the sole right to research, develop, manufacture and commercialize such Products in the Excluded Territory. Partner hereby acknowledges that (i) Amgen has previously licensed rights for AMG557 in Japan to Takeda Pharmaceutical Company Limited, and (ii) Amgen obtained its rights for AMG827 under license from Kirin-Amgen, Inc. and its right to develop, manufacture and commercialize AMG827 is subject to certain agreements between Amgen and Kirin-Amgen, Inc.
2.2.2.License Grant by Partner. To the extent Amgen is required under any Excluded Territory Agreement to grant rights to a Third Party under any intellectual property rights, Know-How, Regulatory Filings or Regulatory Approvals with respect to a Product in the Excluded Territory, Partner hereby grants Amgen a license (with the right to sublicense) in and to any Partner Intellectual Property, Program Intellectual Property, Know-How, Regulatory Filings or Regulatory Approvals as necessary for Amgen to comply with its obligations under any such Excluded Territory Agreement.
2.2.3.Kirin-Amgen Royalty Payments. Additionally, any royalties payable to Kirin-Amgen, Inc. with respect to AMG827 under an Excluded Territory Agreement shall be paid directly by Amgen and shared by the Parties in a manner consistent with Section 7.2.8.2 (Profit).
2.2.4.Subsequent Rights in Excluded Territory. If Amgen obtains the right to develop and commercialize Products in all or part of the Excluded Territory, then, upon the request of Partner (made no later than sixty (60) days following receipt of written notice from Amgen regarding such Excluded Territory rights), Amgen and Partner will enter into good faith discussions for the inclusion of such rights under this Agreement on terms to be agreed by Parties (provided, that if the Parties are unable to agree upon such terms within [*] of the initiation of such discussions, Amgen shall be free to develop and commercialize Products in such Excluded Territory itself or with a Third Party).
2.2.5.Prior Consultation. Amgen will consult with Partner in advance with respect to: (i) [*]; (ii)  [*]; and (iii) [*].
2.1.Committees and Teams.
2.3.1.Formation. Promptly but not later than sixty (60) days following the Effective Date, the Parties will establish (i) a single, cross-functional Collaboration Review Committee; (ii) a single, cross-functional Joint Steering Committee; and (iii) a cross-functional Joint Product Team for each Product. The JSC and each JPT will each have the right to establish subcommittees or working teams with respect to issues within its area of responsibility as it sees fit (e.g., development, regulatory, pricing, access, manufacturing, commercial or operations), including
15



local or regional commercialization/operations teams to facilitate the performance of its responsibilities or a finance team to facilitate the implementation of the cost allocations provided in this Agreement.
2.3.2.Membership. The CRC will be comprised of three (3) members appointed by each of the Parties or such other number of members as agreed by the Parties (with representatives from each Party for each of development, manufacturing and commercialization). The JSC will be comprised of five (5) members appointed by each of the Parties or such other number of members as agreed by the Parties. The CRC and JSC will each be led by two (2) co-chairs, one (1) appointed by each of the Parties. Each Party will designate such number of members to each JPT as it deems appropriate in order to accomplish the activities for which it is responsible. Each Party will ensure that the CRC, JSC and JPT members appointed by it have (i) the appropriate level of seniority and decision-making authority commensurate with the responsibilities of the committee or team to which they are appointed, and (ii) a range of expertise in the development, manufacture and commercialization of therapeutic products to enable an efficient cross-functional committee or team structure. Each Party will have the right to replace its committee or team members by written notice to the other Party. In the event any committee or team member becomes unwilling or unable to fulfill his or her duties hereunder, the Party that appointed such member will promptly appoint a replacement by written notice to the other Party.
2.3.3.Meetings. The CRC will meet semi-annually, via teleconference or videoconference or otherwise (with at least one (1) meeting per calendar year being in person), or as otherwise agreed by the Parties. Additionally, either Party may request a meeting of the CRC to resolve any Critical Matters requiring resolution. The JSC will meet quarterly, via teleconference or videoconference or otherwise (with at least one (1) meeting per calendar year being in person and with at least one (1) meeting per calendar year being scheduled as appropriate to approve [*]), or as otherwise agreed by the Parties. Each JPT and each subcommittee and working team established hereunder will establish a meeting frequency and meeting protocol necessary to coordinate and conduct the activities for which it is responsible, as agreed by the Parties. Any in-person meetings of the CRC or JSC will be held on an alternating basis between Partner’s and Amgen’s headquarters, unless otherwise agreed by the Parties. Each Party will be responsible for its own expenses relating to such meetings. As appropriate, other employee representatives of the Parties may attend such meetings as non-voting participants, but no Third Party personnel may attend unless otherwise agreed by the Parties. Either Party may also call for special meetings of the CRC and JSC as reasonably required to resolve a Critical Matter escalated to the CRC or JSC pursuant to Section 2.4.2 (JPT Deadlocks) or 2.5.2 (JSC Deadlocks) below; provided, that the requesting Party provides at least ten (10) business days’ prior written notice to the co-chair of such committee appointed by the other Party and such notice includes a proposed agenda for such meeting. All committee and team meetings must have at least two (2) members appointed by each Party in attendance. All committee and team meetings will be conducted in English, and all documents (including Development Plans, Development Budgets, clinical trial protocols for the Products, Operations Budgets, Brand Plans and Commercialization Budgets) will be in English.
2.3.4.Decision-Making. Subject to the terms of this Agreement (including Sections 2.4.2 (JPT Deadlocks) and 2.5.2 (JSC Deadlocks) below), the decisions of the
16



CRC, JSC, JPTs and any subcommittees and working teams established hereunder will be made by consensus of the members thereof, with each Party having one (1) vote.
2.2.Joint Product Teams.
2.4.1.Responsibilities. Except for decisions expressly reserved to the JSC or CRC pursuant to Section 2.5 (Joint Steering Committee) or 2.6 (Collaboration Review Committee), respectively, each JPT will (i) establish subcommittees and working teams as necessary to coordinate and conduct its activities hereunder; (ii) coordinate with and oversee the activities of any such subcommittees and working teams; and (iii) be responsible for all operational matters regarding the development, manufacture and commercialization of the Products, including:
2.4.1.1.the following development matters: (i) developing the Development Plan for the applicable Product in the Collaboration Territory and annual updates (or any other updates) thereto; (ii) developing the [*] expense budget for development activities to be undertaken pursuant to the collaboration (the “Development Budget”) for such Product in the Collaboration Territory and annual updates (or any other updates) thereto; (iii) preparing all clinical trial protocols for such Product; (iv) providing for communication and discussion between the Parties to optimize the efficacy and safety of the development of such Product in the Collaboration Territory; (v) reviewing and monitoring the activities and progress against the Development Plan, including regulatory matters, site enrollment, patient enrollment, progress of trials, data received and data analysis; (vi) developing observational research and any payer and economic value evidence generation plans for inclusion in the Development Plan; (vii) communicating with the Parties regarding all of the foregoing; and (viii) making such decisions as are specified in Article 3 (Development and Regulatory) to be made by the JPT;
2.4.1.2.the following operations matters: (i) overseeing supply of the applicable Product (in accordance with the applicable Quality Agreement); (ii) reviewing cost of goods of such Product, including yields, success rates and other relevant production statistics; (iii) preparing a draft supply forecast for such Product; (iv) developing the [*] expense budget for manufacturing activities to be undertaken pursuant to the collaboration, including CMC, process development and device-related activities (the “Operations Budget”) for such Product in the Collaboration Territory and annual updates (or any other updates) thereto; (v) reviewing other operational issues relating to the manufacture or supply of such Product and any related devices; and (vi) making such decisions as are specified in Article 4 (Manufacturing) to be made by the JPT; and
2.4.1.3.the following commercialization matters: (i) preparing the Brand Plan for the applicable Product and annual updates (or any other updates) thereto; (ii) developing the [*] expense budget for commercialization activities to be undertaken pursuant to the Brand Plans and Country Plans (the “Commercialization Budget”) for such Product in the Collaboration Territory and annual updates (or any other updates) thereto; (iii) preparing on an annual basis a three year sales forecast for such Product; (iv) conducting consolidation of expense and sales forecasts from the country or regional level for such Product; (v) reviewing the tactical alignment of commercialization activities with expense budget allocations; (vi) monitoring and reporting on the competitive landscape
17



for such Product in the Collaboration Territory; (vii) establishing a process for reviewing and approving Promotional Materials and training materials and programs for such Product; (viii) developing a global pricing policy for the applicable Product; and (ix) making such decisions as are specified in Article 5 (Commercialization) to be made by the JPT.
2.4.2.JPT Deadlocks. If a JPT is unable to reach consensus on a non-Critical Matter, the decision will be made by the members of such JPT appointed by: (i) the applicable Development Lead, in the case of matters under Section 2.4.1.1; (ii) the applicable Manufacturing Lead, in the case of matters under Section 2.4.1.2; and (iii) the applicable Commercialization Lead, in the case of matters under Section 2.4.1.3. If a JPT is unable to reach consensus on a Critical Matter, the members of such JPT appointed by either Party will have the right to require that such issue be escalated to the JSC for determination; provided, that if, in the good faith determination of the Development Lead, the Manufacturing Lead or the Commercialization Lead, as applicable, resolution of such Critical Matter requires exigent action pursuant to Applicable Law or to prevent a material adverse effect on a Product or a Party, the members of such JPT appointed by the Development Lead, the Manufacturing Lead or the Commercialization Lead, as applicable, will have the right to make an interim decision pending JSC determination.
2.3.Joint Steering Committee.
2.5.1.Responsibilities. The JSC will (i) oversee the activities of the Parties hereunder generally, each Joint Product Team and any subcommittees or working teams established hereunder, (ii) establish subcommittees and working teams as necessary to coordinate and conduct its activities hereunder, and (iii) be responsible for:
2.5.1.1.the following development matters: (i) approving the Development Plan for each Product in the Collaboration Territory and annual updates thereto; (ii) approving the Development Budget for each Product in the Collaboration Territory and [*] updates thereto; (iii) reviewing and approving all clinical trial protocols for the Products; and (iv) making such decisions as are specified in Article 3 (Development and Regulatory) to be made by the JSC;
2.5.1.2.the following operations matters: (i) approving the Operations Budget for each Product in the Collaboration Territory; (ii) approving the draft supply forecast for each Product; and (iii) making such decisions as are specified in Article 4 (Manufacturing) to be made by the JSC; and
2.5.1.3.the following commercialization matters: (i) approving the Brand Plans and integrating such plans with the Development Plans; (ii) approving a global pricing policy for the applicable Product; (iii) reviewing sales forecasts for each Product; (iv) approving the Commercialization Budget for each Product in the Collaboration Territory; and (v) making such decisions as are specified in Article 5 (Commercialization) to be made by the JSC.
2.5.2.JSC Deadlocks. If the JSC is unable to reach consensus on a non-Critical Matter, the decision will be made by the members of the JSC appointed by (i) the applicable Development Lead, in the case of matters under Section 2.5.1.1; (ii) the applicable Manufacturing Lead, in the case of matters under Section 2.5.1.2; and (iii) the applicable Commercialization Lead, in the case of matters under Section 2.5.1.3. If the JSC is unable to reach consensus on a
18



Critical Matter, the members of the JSC appointed by either Party will have the right to require that such issue be escalated to the CRC for determination; provided, that if, in the good faith determination of the Development Lead, the Manufacturing Lead or the Commercialization Lead, as applicable, resolution of such Critical Matter requires exigent action pursuant to Applicable Law or to prevent a material adverse effect on a Product or a Party, the members of the JSC appointed by the Development Lead, the Manufacturing Lead or the Commercialization Lead, as applicable, will have the right to make an interim decision pending CRC determination.
2.4.Collaboration Review Committee. The CRC will be responsible for (i) providing general oversight of the collaboration; (ii) resolving any matters specifically designated to it under this Agreement; and (iii) resolving any Critical Matters escalated to it from the JSC. For clarity, all decisions of the CRC will be made by consensus of the members of the CRC, with each Party having one (1) vote, unless expressly set forth in this Agreement to the contrary.
2.5.Reporting. Each Party will keep the applicable committee or team fully and promptly informed of progress and results of activities for which it is responsible or that it is permitted to conduct hereunder through its members on such committee or team and as otherwise provided herein.
2.6.No Authority to Amend or Modify. Notwithstanding anything herein to the contrary, no committee or team will have any authority to amend, modify or waive compliance with this Agreement.
2.7.Alliance Managers. Promptly after the Effective Date, each Party will appoint a person who will oversee interactions between the Parties between meetings of the committees and teams established hereunder (each, an “Alliance Manager”). The Alliance Mangers will have the right to attend all meetings of the CRC, the JSC, the JPTs and any subcommittees and working teams established hereunder, as non-voting participants at such meetings. Each Party may in its sole discretion replace its Alliance Manager at any time by notice in writing to the other Party.
2.8.Patent Coordinators. The Parties will each appoint a Patent Coordinator for each Product promptly after the Effective Date. The Patent Coordinators will serve as the primary contacts and forum for discussion between the Parties with respect to intellectual property matters involving each Product worldwide, and will cooperate with respect to the activities set forth in Article 10 (Intellectual Property). For each Product, the associated Patent Coordinators will discuss a strategy with regard to Prosecution and Maintenance, defense and enforcement of Product Intellectual Property, and defense against allegations that the activities hereunder infringe, or obtaining or amending licenses to, Third Party Patents or Know-How. The Patent Coordinators will meet as often as agreed by them (and at least semi-annually if requested), via teleconference or videoconference or as otherwise agreed, to discuss matters arising out of the activities set forth in Article 10 (Intellectual Property). Each Party may in its sole discretion replace any of its Patent Coordinators at any time by notice in writing to the other Party.
3.DEVELOPMENT AND REGULATORY
3.1.Development Matters.
3.1.1.Allocation of Development and Regulatory Responsibility. The JSC will (i) allocate development and regulatory activities to Amgen or Partner on a country-specific or activity-specific basis, taking into consideration all relevant factors (including the strategic objectives and capabilities of each Party) and
19



(ii) determine whether operational responsibility for any such activity should be transferred from Partner to Amgen or vice versa. Unless and until determined otherwise by the JSC in accordance with the foregoing, the initial allocation of operational responsibility for development and regulatory activities for each Product will be as set forth in the applicable Development Plan.
3.1.2.Development Lead. On a Product-by-Product basis, one Party will oversee development and regulatory activities for such Product in the Collaboration Scope (the “Development Lead”). The Development Lead for each Product is set forth in the Development/Commercial Lead Schedule. Absent agreement by the JSC to the contrary (as indicated in the applicable Development Plan), it is the expectation of the Parties that the Development Lead will have primary responsibility for day-to-day development activities relating to the relevant Product, including generating protocols, conducting clinical trials, and data collection, verification and analysis. Following the Effective Date, the Parties will promptly meet to coordinate the transition of development and regulatory activities from Amgen to Partner with respect to Products for which Partner is the designated Development Lead in a manner so as to not unduly delay or hamper the development of the relevant Products. The Parties will amend the applicable Development Budgets and Operations Budgets to reflect the reasonable costs to be incurred by each Party in connection with such transfer.
3.1.3.[*] Updates. The JSC will review and approve updates to the Development Plans and Development Budgets prior to [*].
3.1.4.Conduct of Development. The Parties will cooperate in the conduct of the activities set forth in the applicable Development Plan, including the preparation of protocols and the development of documents therefor. Both Parties will collaborate to achieve globally aligned regulatory documents and interactions for each Product.
3.1.5.Sharing of Materials. In the event that it becomes necessary for one Party to provide the other Party with tangible research or biological materials (other than a Product for clinical or commercial use), the Parties will enter into an appropriate material transfer agreement related thereto, which agreement will be subject to this Agreement and will be interpreted consistent with the terms hereof.
3.1.6.Ownership of Development and Safety Data. Each Party will solely own all data generated by it or its designee in its development activities conducted hereunder, and such data will be subject to the license from Partner to Amgen under Section 10.5 (License Grant by Partner) or from Amgen to Partner under Section 10.4 (License Grant by Amgen), as applicable. Notwithstanding the foregoing, the Development Lead will own the global safety database, the developmental core safety information (DCSI), and core data sheet for each Product.
3.2.Regulatory Matters.
3.2.1.Designated Regulatory Party. Except as set forth in Section 3.2.4 (Manufacturing Matters), the JSC will allocate, on a Product-by-Product and country-specific basis, operational responsibility for regulatory activities to a Party (the “Designated Regulatory Party”) although there will be a presumption that the Development Lead will also be the Designated Regulatory Party.
3.2.2.Regulatory Communications and Filings. The Designated Regulatory Party will prepare, submit and maintain all Regulatory Filings and obtain all Regulatory
20



Approvals for which it is responsible in accordance with the applicable Development Plan. The other Party will cooperate with the Designated Regulatory Party, at its reasonable request, with respect to any regulatory matters for which the Designated Regulatory Party is responsible. Unless exigent action is required with respect to such Regulatory Filing or material communication, the Designated Regulatory Party will provide the other Party with copies of Key Regulatory Filings prior to submission within a reasonable amount of time (but not less than five (5) business days) to allow such Party to review and comment on such Key Regulatory Filings, and the Designated Regulatory Party will consider all comments and proposed revisions from the other Party in good faith prior to submission (but in the event of a disagreement between the Parties with respect to such comments and proposed revisions, (i) if the Development Lead’s determination is consistent with the then-current Development Plan, then the Development Lead’s determination shall prevail, and (ii) if the Development Lead’s determination is not consistent with the then-current Development Plan, then such matter shall be escalated to the JSC for review (and if a Critical Matter, further escalated to the CRC)). The Designated Regulatory Party will consult with the other Party regarding, and keep the other Party informed of, the status of the preparation of all Regulatory Filings it submits, Governmental Authority review of any such Regulatory Filings, and all Regulatory Approvals that it obtains with respect to a Product. Upon request of the other Party, the Designated Regulatory Party will provide to the other Party copies of all final Regulatory Filings it submits.
3.2.3.Regulatory Meetings. The Designated Regulatory Party will consult with the other Party reasonably in advance of the date of any anticipated meeting with a Governmental Authority and will consider any timely recommendations made by the other Party in preparation for such meeting. Upon the request of the other Party, the Designated Regulatory Party will permit the other Party to attend particular meetings between the Designated Regulatory Party and the applicable Governmental Authority. The Designated Regulatory Party will request that the applicable Governmental Authority allow at least one (1) representative of the other Party to attend, solely as an observer, such meetings; provided, that the foregoing will not apply to informal meetings or unscheduled teleconferences or meetings or teleconferences otherwise intended by the Governmental Authority to be between it and the Designated Regulatory Party’s representatives only. The other Party will strictly follow the Designated Regulatory Party’s instructions with respect to any meeting which it attends, and will not discuss the contents of any such meeting with any Governmental Authority except as required by Applicable Law or authorized by the Designated Regulatory Party in writing.
3.2.4.Manufacturing Matters. In order to assist the Designated Regulatory Party, the Manufacturing Lead will prepare [*] in English for the relevant Product, and the Designated Regulatory Party will modify as appropriate such module for use in Regulatory Filings in the Collaboration Territory. The Manufacturing Lead will have the option, in order to protect proprietary manufacturing information, to take over operational responsibility from the Designated Regulatory Party for some or all correspondence and for specified official communications, including the preparation and submission of all Regulatory Filings required to be filed with any Governmental Authority in the Collaboration Territory with respect to the manufacture of a Product (except to the extent such transfer of operational responsibility is prohibited by Applicable Law or a Governmental Authority). With respect to any such correspondence and communication, each Party will
21



promptly provide the other with copies of material written correspondence as reasonably necessary to permit each Party to comply with its relevant regulatory obligations or as otherwise reasonably requested; provided, that the Manufacturing Lead will not be required to disclose proprietary or competitively sensitive information unless such disclosure is required by Applicable Law.
3.2.5.Ownership of Regulatory Filings and Regulatory Approvals. The Development Lead for a Product will own all right, title and interest in and to any and all Regulatory Filings and Regulatory Approvals directed to such Product and all such Regulatory Filings and Regulatory Approvals will be held in the name of the Development Lead, and the other Party will execute all documents and take all actions as are reasonably requested by the Development Lead to vest such title in the Development Lead, subject to Section 3.1.6 (Ownership of Development and Safety Data) and Section 3.2.4 (Manufacturing Matters). The Development Lead hereby grants to the other Party a non-exclusive, non-transferable (except in connection with a permitted assignment, sublicense or subcontract) “right of reference” (as defined in 21 C.F.R. §314.3(b)) with respect to such Regulatory Filings and Regulatory Approvals solely as necessary for the other Party, if such other Party is the Designated Regulatory Party, to prepare, submit and maintain Regulatory Filings for which it is responsible or as otherwise necessary to perform its obligations hereunder or to comply with Applicable Law.
3.3.Brand Security and Anti-Counterfeiting. The Parties will establish contacts for communication regarding brand security issues and will each reasonably cooperate with the other with respect thereto.

3.4.Product Complaints, Recalls and Returns. The Parties’ rights and obligations with respect to nonconformance, recalls and returns of Products will be governed by the applicable Quality Agreement.
3.5.Clinical Trial Register. The Development Lead will, in accordance with Applicable Law and its internal policies, publish the results or summaries of clinical trials relating to a Product on a clinical trial register maintained by it and the protocols of clinical trials relating to such Product on www.ClinicalTrials.gov (or an equivalent register, or as otherwise required by Applicable Law or such Party’s policies). The other Party will have the right to publish results or summaries (in the identical form as published by the Development Lead) if the Development Lead has already published in accordance with the foregoing sentence, or the applicable JPT approves such publication. The Parties will cooperate to establish timelines and procedures for JPT review of publications and presentations.
3.6.Sharing of Data and Know-How.
3.6.1.Generally. Each Party shall (and shall cause its Affiliates to) reasonably cooperate with the other Party to promptly share and provide access to (i) all clinical trial data and results within the Program Intellectual Property, and (ii) such other Know-How within the Product Intellectual Property as is reasonably necessary for the other Party to exercise its rights or fulfill its obligations under this Agreement. The JSC may establish reasonable policies to effectuate such exchange of data and Know-How between the Parties.
3.6.2.Manufacturing Know-How. For clarity, except as provided in Section 3.2.4 (Manufacturing Matters) above, the Manufacturing Lead shall not be obligated
22



to share with the other Party or provide the other Party access to Know-How related to the manufacture of a Product unless and until such Party becomes the Manufacturing Lead with respect to such aspect of manufacturing of such Product, in which case the Manufacturing Lead shall promptly provide the other Party with access to such manufacturing Know-How within the Product Intellectual Property as is reasonably necessary for such Party to fulfill its obligations as Manufacturing Lead with respect to such Product. All such transfer of manufacturing Know-How shall be overseen and facilitated by the JPT for the applicable Product.
4.MANUFACTURING
4.1.Allocation of Manufacturing Responsibility. Amgen will be responsible for the supply of clinical and commercial product for AMG827. Amgen will be responsible for the initial supply of clinical product for all other Products (the “Early Stage Programs”). Amgen will elect at least [*] days prior to the initiation of the first [*] for each Early Stage Program whether or not to continue supplying later stage clinical material and commercial material for such Early Stage Program itself or through a contract manufacturing organization. If Amgen elects not to do so, then Partner will have [*] days to elect to manufacture such later stage clinical material and commercial material for such Early Stage Program (including conducting any process development work related thereto). If neither Party elects to manufacture later stage clinical material and commercial material for such Early Stage Program, then the Parties will mutually agree upon a Third Party manufacturer to conduct process development and clinical and commercial manufacturing. In any event, Amgen will continue to supply clinical material (in the form that exists prior to such election) until such time as Partner or such Third Party manufacturer completes commercial process development and begins to supply such later stage clinical material; provided, that, if Partner elects to manufacture later stage clinical material and commercial material, then Partner will promptly and diligently undertake such efforts as are necessary to assume responsibility for such activities.
4.2.Manufacturing Lead. The Party that actually manufactures (itself or through a designee) a specific Product will be the “Manufacturing Lead” for such manufactured Product. For clarity, one Party may be the Manufacturing Lead for drug substance and the other Party may be the Manufacturing Lead for drug product. Subject to Section 4.6 (Shortage; Allocation), the Manufacturing Lead will use Commercially Reasonable Efforts to supply Product in a manner sufficient to fulfill demand for the Product in the Collaboration Territory. Additionally, if Partner elects to become the Manufacturing Lead for a Product in accordance with Section 4.1 (Allocation of Manufacturing Responsibility) or is otherwise appointed the Manufacturing Lead by the CRC, the Parties will, with respect to Products manufactured by Partner, negotiate in good faith supplements to the definitions of Manufacturing Standard Costs and Manufacturing Actual Costs in order to make such definitions consistent, on a GAAP or IFRS basis (as applicable), with the manner in which Partner accounts for its other products.
4.3.[*] Updates. The JSC will review and approve updates to the Operations Budgets prior to [*]. Additionally, after Technical Feasibility has been achieved with respect to a Product, on a quarterly basis the Manufacturing Lead will inform the JSC of any expected decrease in [*] that is expected to result in [*]. At the request of the other Party, the Manufacturing Lead will inform the other Party of [*] and will discuss with the other Party [*] with respect thereto. The Manufacturing Lead will have the sole right to determine which of its manufacturing sites will be used to manufacture a Product and may transfer the manufacturing of such Product from one site to another,
23



so long as such transfer would not reasonably be likely to have a material adverse effect on the continued supply of such Product.
4.4.Distribution. Amgen will be solely responsible for the distribution of Products in the Amgen Distribution Countries. Partner will be solely responsible for the distribution of Products in all other countries in the Collaboration Territory. The Party that actually distributes Products in a particular country will be deemed the “Distribution Party” for such country. The Manufacturing Lead of drug product will supply Products for commercial use in labeled, finished form (unless otherwise agreed to by the JSC) to the other Party for distribution in the countries for which the non-Manufacturing Lead for drug product has been allocated distribution responsibility. The non-Manufacturing Lead will reimburse the Manufacturing Lead for such Product at the Manufacturing Lead’s Manufacturing Actual Cost upon delivery of such Product to the non-Manufacturing Lead. Such reimbursement will not be included in the calculation of Collaboration Profit (Loss) under Section 7.2 (Profit/Expense Sharing), but rather the non-Manufacturing Lead will be entitled to include such payment as part of Amgen Costs or Partner Costs, as applicable, upon sale of such Product to a Third Party.
4.5.Quality and Safety Agreements. Concurrently with the execution of this Agreement, the Parties have entered into the Quality Agreement with respect to the supply of Products by Amgen to Partner for clinical use. Within ninety (90) days of the Effective Date, the Parties will enter into the Safety Agreement with respect to the supply of Products by Amgen to Partner for clinical use. One year prior to the anticipated first commercial launch of a Product, the Parties will enter into a Quality Agreement with respect to the supply of Products by Amgen to Partner for commercial use and will work in good faith to revise the existing Safety Agreement as necessary. In the event that Partner becomes a Manufacturing Lead for a Product, the Parties will enter into a Quality Agreement with respect thereto and will work in good faith to revise the existing Safety Agreement as necessary.
4.6.Shortage; Allocation. In the event that the Manufacturing Lead reasonably believes that it will not be able to supply requirements for a Product in accordance with a mutually agreed upon supply forecast, the Manufacturing Lead shall provide prompt written notice to the other Party thereof. If the Manufacturing Lead actually cannot supply a Product in accordance with such mutually agreed upon supply requirements, then the Manufacturing Lead will undertake to allocate the manufacturing of Products with its other products so as to not [*]. For clarity, if the Manufacturing Lead cannot actually supply requirements for a Product in accordance with a mutually agreed upon supply forecast, the Manufacturing Lead will reasonably allocate its manufacturing capacity over all its products in the following order of prioritization: (a) to [*]; (b) to [*]; (c) to [*]; and (d) to [*].
5.COMMERCIALIZATION
5.1.Allocation of Commercial Responsibility. The JSC will (i) allocate commercial activities to Amgen or Partner on a Product-by-Product basis and country-specific or activity-specific basis, and (ii) determine whether operational responsibility for any such activity should be transferred from Partner to Amgen or vice versa. Allocations of commercial operational responsibility for countries and regions may be set forth in country plans developed by the applicable JPT that are consistent with the allocation of responsibility established by the JSC and the Brand Plan, taking into account the planned launch timing for the relevant country (as such plans may be updated or modified from time-to-time by the applicable JPT, the “Country Plans”). The initial allocation of commercial activities, as well as the guidelines for allocating commercial activities in the future, is as set forth in the Commercial Allocation Schedule.
24



5.2.Commercial Lead. For each Product, one Party will oversee commercialization activities with respect to all indications for such Product in the Collaboration Scope (the “Commercial Lead”). The Commercial Lead for each Product will be as set forth on the Development/Commercial Lead Schedule.
5.3.Initial Plans; [*] Updates. An initial Brand Plan for each Product will be approved by the JSC not later than three (3) months after initiation of the first Phase 3 Trial for such Product; provided, that the initial Global Payer Plan and each initial Access and Pricing Plan will be approved by the JSC at such times as the JSC so determines. The JSC will review and approve updates to the Brand Plans and Commercialization Budgets prior to [*].
5.4.All Sales by Distribution Party. Only the Distribution Party with respect to a particular Product in a particular country is authorized to sell such Product in such country. The Distribution Party will have the sole right, in such Party’s discretion, to take orders for and returns of, issue credits for, sell, and book sales for, such Product. The non-Distribution Party will promptly forward to the Distribution Party all orders for, and requests to order, such Product. The Distribution Party will have the right to refuse or cancel any order for such Product without liability to the other Party. The non-Distribution Party will not interfere with any agreement of the Distribution Party or any of its Affiliates related to such Product, including contracting for the sale of such Product.
5.5.Training. The JPT will establish a process by which the Parties will review, comment on and approve training materials and programs, and training of the Parties’ sales forces for commercialization of the Products will be conducted using only training materials and programs approved in accordance with such process. Each Party will train its respective sales representatives with respect to the promotion of a Product (and update such training from time to time as appropriate) which training will include compliance training as appropriate, all in accordance with the applicable Brand Plan. The Commercial Lead for a Product will own all right, title and interest in the training materials developed hereunder for such Product (except with respect to any Housemarks of the other Party contained therein), and the non-Commercial Lead will execute all documents and take all actions as are reasonably requested by the Commercial Lead to vest title to such training materials in the Commercial Lead.
5.6.Information Concerning Products. Each Party will ensure that no claims or representations in respect of a Product or the characteristics thereof are made by or on behalf of it or its Affiliates (by sales force members or otherwise) that have not been approved by the JPT and neither Party will make any claim or representation that does not represent an accurate summary or explanation of the labeling of such Product.
5.7.Promotional Materials. The JPT will establish a process by which the Parties will review, comment on and approve all written sales, promotion and advertising materials relating to a Product, and other media and materials used to promote the Products or educate the public regarding an indication treated with a Product (collectively and including translations, “Promotional Materials”). All Promotional Materials will be produced by the applicable Commercial Lead in accordance with the Brand Plan and such process and any use thereof by the non-Commercial Lead will be subject to prior approval of the Commercial Lead. All Promotional Materials will include, to the extent permitted by Applicable Law, the Amgen Housemarks and the Partner Housemarks. Unless otherwise determined by the applicable JPT, the Commercial Lead will be responsible for the printing and delivery to the other Party of Promotional Materials for use in such other Party’s Detailing obligations hereunder. Other than a Party’s use and distribution of Promotional Materials that are approved in accordance with the foregoing process and used and distributed in connection with a Party’s Detailing of a
25



Product, neither Party will produce or modify (other than as concepts for consideration by the other Party), or distribute or otherwise use any Promotional Material relating to a Product. If so instructed by the applicable JPT, a Party will immediately cease to use any Promotional Materials and will collect and destroy any such materials from its sales representatives (and record and document such collection and destruction (and provide a copy of such documentation to the other Party upon request)). The Commercial Lead for a Product will own all right, title and interest in and to any and all Promotional Materials for such Product (except with respect to any Housemarks of the other Party included in any Promotional Materials), and the non-Commercial Lead will execute all documents and take all actions as are reasonably requested by the Commercial Lead to vest title to such Promotional Materials in the Commercial Lead.
5.8.Detailing Reports and Audit Rights.
5.8.1.Reporting. Each Party will provide the other Party with a report, in such form and manner as determined by the JSC, within forty-five (45) calendar days after the end of each calendar month, setting forth the following information regarding the efforts of the reporting Party’s sales force in Detailing each Product during the preceding month: (i) the total number of Details made by such sales force, including a breakdown of First Position Details, Second Position Details and Other Details by target and frequency of Detail by customer priority; and (ii) such other information as may be specified by the JSC. In any country in the Collaboration Territory where the Parties are co-Detailing a Product, each Party will provide the foregoing information with respect to such Product [*]. In any country in the Collaboration Territory where the Parties are not co-Detailing a Product, each Party will provide the foregoing information with respect to such Product [*].
5.8.2.Audits. Each Party will keep complete and accurate records of its Detailing of Products in sufficient detail to permit the other Party to audit its performance of Details hereunder. During regular business hours, with not less than ten (10) business days’ advance written notice and under reasonable obligations of confidentiality, a Party will permit the other Party or its authorized representatives to: (i) have access to the records of Detailing activities maintained by such Party for purposes of verifying the accuracy of reports described in Section 5.8.1 (Reporting); and (ii) audit such records; provided, that such audits may not be performed by a Party more than once per calendar year, such records will be open (in such form as may be available or reasonably requested) to inspection for at least three (3) years following the end of the period to which they pertain, and such records for any particular calendar year will only be subject to one (1) audit. Any and all audits undertaken pursuant to this Section 5.8.2 (Audits) will be performed at the sole and exclusive expense of the auditing Party and will not be included in Amgen Costs or Partner Costs, as the case may be, for purposes of calculating Collaboration Profit (Loss). If an audit reveals an overstatement of Details of greater than [*] of the correct amount for the audited period, then the audited Party will pay the reasonable out-of-pocket cost of such inspection.
5.9.Competing Products. If either Party or its Affiliates has sales representatives Detailing both a Product and a non-Product that is approved by a Governmental Authority for use in the same indication as such Product (a “Competing Product”), then, in addition to the reporting obligations contained in Section 5.8.1 (Reporting), such Party will provide to specified employees of the other Party (as specified by such Party’s JSC members) with a report within thirty (30) calendar days after the end of each calendar month, setting forth [*]. The purpose of such report shall be solely to substantiate the calculation of Sales Force Costs. It shall only be used by the specified employees and it
26



shall not be used by either Party in violation of any Applicable Law. If the JSC or CRC authorizes a sales representative to Detail a Product in the First Position Detail, then [*].
5.10.Sales Force [*]. On a country-by-country and Product-by-Product basis, during the period of time beginning [*] of such Product in such country, if either Party intends to [*] in such country that are expected to [*] such Product, then such Party shall provide the other Party with at least sixty (60) days’ prior written notice. In such event, at the request of either Party, the JSC shall meet to [*] in such country (with escalation to the CRC if the JSC is unable to agree on such [*]). The Party that has [*] during the applicable period (but not to exceed [*] that are in excess of its [*].

6.PERFORMANCE STANDARDS
6.1.Collaborative Activities. Activities to be undertaken by the Parties hereunder will be conducted in a collaborative manner as determined by the committee or team overseeing such activities, and in accordance with the terms and conditions of this Agreement, as applicable.
6.2.Diligence and Performance Standards. Subject to the decisions made by and oversight of the committees and teams established hereunder, each Party will use, and will assure that each of its Affiliates uses, Commercially Reasonable Efforts in the performance of its and their activities hereunder. Each Party will conduct, and ensure that each of its Affiliates conducts, all of its and their activities with respect to the development, registration, manufacture, distribution, promotion and commercialization of a Product in accordance with this Agreement, the applicable Development Plan, the applicable Brand Plan, applicable Global Payer Plan, applicable Access and Pricing Plan, applicable Country Plans, accepted national and international pharmaceutical industry codes of practices in and for the Collaboration Territory (including the Pharmaceutical Research and Manufacturers of America (PhRMA) Code of Pharmaceutical Marketing Practices and the American Medical Association (AMA) Guidelines on Gifts to Physicians from Industry, as the same may be amended from time to time), and all Applicable Law. The Parties will provide each other with all reasonably requested cooperation to enable each of them to comply with Applicable Law and accepted national and international pharmaceutical industry standards, including permitting each Party to verify the other Party’s compliance therewith.
6.3.Violation of Laws. Each Party will promptly notify the other Party of any violation of Applicable Law by its personnel with respect to the conduct of activities under this Agreement. In the event of any such violation, the Parties will promptly confer regarding any such violation and will promptly take remedial or preventative action as may be reasonably required by the applicable JPT with respect thereto. The Parties will have the right to require that any personnel that materially violates Applicable Law or applicable national or international pharmaceutical industry codes of practices cease to perform activities under this Agreement.
6.4.Use of Affiliates and Third Party Contractors. Each Party will perform the activities designated to it itself or through any of its Affiliates, and any proposed use of a Third Party to conduct such activities will be subject to the other Party’s prior written consent, such consent not to be unreasonably withheld; provided, that (i) Partner’s consent will not be required for activities Amgen has, prior to the Effective Date, arranged to have performed by Third Parties and which have been disclosed to Partner prior to the Effective Date, and (ii) either Party will be permitted to, upon thirty (30) days’ prior written notice to the other Party, engage a Third Party contract manufacturer, contract research organization, contract sales organization, distributor or wholesaler without the other Party’s consent. Cost overruns resulting from either
27



Party’s use of a Third Party to conduct any such activities will be subject to Section 7.2.6 (Overruns). Each Party will be responsible for compliance by its respective Affiliates and Third Party contractors with this Agreement and will be responsible for all acts and omissions of such Affiliates and Third Party contractors as if committed or omitted by the applicable Party.
6.5.Management of Personnel. Each Party will have sole authority and responsibility for recruiting, hiring, managing, compensating (including paying for all benefits, wages, special incentives, workers’ compensation and employment taxes), disciplining, firing and otherwise controlling the personnel provided by such Party for performance of its obligations hereunder; provided, that each Party will require its personnel to be subject to a confidentiality agreement and Invention assignment commitment prior to, and as a condition of, such personnel performing any such activities hereunder. Each Party will provide the day-to-day management of its sales representatives and other personnel, including furnishing administrative support, financial resources, equipment and supplies.
7.UP-FRONT PAYMENT AND PROFIT/EXPENSE SHARING
7.1.Up-front Payment. As partial consideration for the rights granted to Partner by Amgen pursuant to the terms of this Agreement, Partner will pay to Amgen a non-refundable, non-creditable payment equal to Fifty Million Dollars ($50,000,000.00) within fifteen (15) days after the Effective Date, payable by wire transfer of immediately available funds in accordance with wire transfer instructions of Amgen that will be provided in writing to Partner prior to the Effective Date.
7.2.Profit/Expense Sharing. The Parties will share in profits and losses generated by Products in the Collaboration Scope as follows:
7.2.1.Partner Costs. Within forty-five (45) days after the end of each calendar quarter Partner will provide to Amgen a detailed, itemized report of its Development Costs and General Costs, on a Product-by-Product basis, incurred by Partner or its Affiliates in accordance with this Agreement (collectively, “Partner Costs”) in such quarter in the format set forth in the Invoice Schedule attached hereto. In addition to the annual JSC approval of the relevant budgets for each Product, prior to the end of each calendar year, Partner will provide Amgen with a non-binding estimate of its Development Costs and General Costs for each Product for the [*] period (detailed on a calendar year basis) following the [*] covered by such approved budget; provided, that the Parties will review and discuss such estimated costs at the JSC.
7.2.2.Amgen Costs. Within forty-five (45) days after the end of each calendar quarter Amgen will provide to Partner a detailed, itemized report of its Development Costs and General Costs, on a Product-by-Product basis, incurred by Amgen or its Affiliates in accordance with this Agreement (collectively, “Amgen Costs”) in such quarter in the format set forth in the Invoice Schedule attached hereto. In addition to the annual JSC approval of the relevant budgets for each Product, prior to the end of each calendar year, Amgen will provide Partner with a non-binding estimate of its Development Costs and General Costs for each Product for the [*] period (detailed on a calendar year basis) following the [*] covered by such approved budget; provided, that the Parties will review and discuss such estimated costs at the JSC. For clarity, any costs incurred by or on behalf of Amgen in connection with the research and development of AMG557 for the sole benefit of Japan or the research and development of AMG827 for the sole benefit of the applicable Excluded Territory will not be included in Amgen Costs.
28



7.2.3.FTE Rate. The FTE Rate used for calculation of Costs pursuant to this Article 7 (Profit/Expense Sharing) with respect to any activity will be the relevant FTE Rate for the calendar year in which such activity was undertaken.
7.2.4.Income Taxes. For the avoidance of doubt, income and withholding taxes imposed on either of the Parties hereunder will not be included in cost sharing hereunder.
7.2.5.Exchange Rate. For purposes of calculating quarterly balancing payments as set forth in Section 7.2.9 (True-Up), Net Revenues, Amgen Costs and Partner Costs will be converted from local currency (if different from U.S. Dollars) to U.S. Dollars in accordance with Section 8.3.2 (Conversions).
7.2.6.Overruns. Each Party will promptly notify the other Party upon becoming aware that the anticipated Costs to be incurred by such Party for a given calendar year will be in excess of the applicable Development Budget, Operations Budget or Commercialization Budget. Unless otherwise agreed by the Parties in advance, in writing, Costs reported by a Party pursuant to Section 7.2.1 (Partner Costs) or 7.2.2 (Amgen Costs) incurred with respect to a Product in excess of [*] percent ([*]%) of the aggregate amounts budgeted to be incurred by or on behalf of such Party for its activities for such Product in such calendar year in the then-current applicable Development Budget, Operations Budget or Commercialization Budget, respectively, will not be included in the calculation of profit (or loss) pursuant to Section 7.2.8 (Calculation of Profit (or Loss)); provided, that such Partner Costs and Amgen Costs in excess of such amount will be included in the calculation of profit (or loss) pursuant to Section 7.2.8 (Calculation of Profit (or Loss)) (A) to the extent such Costs were attributable to: (i) a change in Applicable Law; (ii) a Force Majeure event; [*].
7.2.7.Net Revenues. Within five (5) business days prior to the end of each calendar quarter, each Party will provide the other Party with a reasonably detailed estimate of Net Revenues for such calendar quarter in the countries for which it is the Distribution Party. Within thirty (30) days after the end of each calendar quarter, each Party will provide the other Party with a report of Net Revenues for such calendar quarter in the countries for which it is the Distribution Party, which report will contain a detailed and itemized calculation of Net Revenues for each Product in such countries during such calendar quarter.
7.2.8.Calculation of Profit (or Loss).
7.2.8.1.Costs.
7.2.8.1.1.Allocation. On a calendar quarter-by-calendar quarter basis, Partner will be responsible for one hundred percent (100%) of the following cost items, in the order set forth below, up to the Quarterly Cap for such calendar quarter. Thereafter, Amgen shall be responsible for one hundred percent (100%) of such costs for such calendar quarter.
7.2.8.1.1.1.Unreimbursed Development Costs and General Costs. First, Partner will be responsible for one hundred percent (100%) of Unreimbursed Development Costs and General Costs up to the Quarterly Cap.
7.2.8.1.1.2.Reimbursed Development Costs. If, following reimbursement for Unreimbursed Development Costs and General Costs, the Quarterly Cap has not yet been met, then Partner will be responsible for one hundred percent (100%) of Reimbursed Development Costs up to the Quarterly Cap.
29



7.2.8.1.2.Quarterly Cap. The “Quarterly Cap” for a given calendar quarter shall, during the applicable calendar year set forth below, be as follows:
Calendar YearQuarterly Cap
201265% of Total Costs for the applicable calendar quarter - [*]
201365% of Total Costs for the applicable calendar quarter + [*]
201465% of Total Costs for the applicable calendar quarter
2015 and each year thereafter50% of Total Costs for the applicable calendar quarter

The Development Costs and General Costs for any calendar quarter will only include [*] of Development Costs and General Costs incurred in the conduct of the [*] set forth in the Development Plan for [*]. In the event either (i) the designated endpoints set forth on the [*] Designated Endpoints [*] Schedule for the [*] are met, or (ii) the Parties agree to initiate a [*], then Amgen shall have the right to allocate an amount equal to [*] of the Development Costs and General Costs incurred after the Effective Date in the conduct of the [*] between: (a) a one-time success milestone payment from Partner to Amgen (payable within forty-five (45) days of notice from Amgen of the allocation between (a) and (b) provided below) and (b) an immediate increase (applied evenly) to the Quarterly Cap for the subsequent four (4) calendar quarters. Amgen shall notify Partner in writing as to the allocation, which must total one hundred percent (100%) between (a) and (b). Additionally as of the Effective Date, the Parties agree that the [*] set forth in the Development Plan for [*] is optional for the [*]. The Parties will evaluate whether or not it is beneficial to conduct the [*] as part of such trial. If the Parties disagree, then Amgen shall have the right, [*], to conduct the [*].) If the [*] meets the designated endpoints set forth on the [*], then Partner will reimburse Amgen [*] of the Costs associated with the [*] (to be allocated between a milestone or increase to the Quarterly Cap as set forth in the forgoing sentence at Amgen’s option) and any Costs associated with the [*] incurred after such endpoints have been met will be included in Amgen Costs and shared in accordance with Section 7.2.8.1 (Costs).
1.1.1.1.Profit. The total profit for a calendar quarter will be calculated by Amgen by first deducting from aggregate Net Revenues for each Product for such quarter a percentage of such Net Revenues equal to the applicable “Inventorship Margin” set forth below, which will be paid to Amgen to reflect Amgen’s inventorship of the Products:

30



Inventorship Margin
AMG827Other Products
[*][*]

Additionally, [*]. After deduction of the Inventorship Margin [*], the remaining Net Revenues will be shared by the Parties equally.
7.2.9.True-up. Within sixty (60) days after the end of each calendar quarter, Amgen will calculate and provide to Partner a report of the amount each Party is responsible for under Section 7.2.8.1 (Costs) for such quarter, and a report of the amount each Party is entitled to under Section 7.2.8.2 (Profit). The resulting amounts under Sections 7.2.8.1 (Costs) and 7.2.8.2 (Profit) will be the “Collaboration Profit (Loss)” for such calendar quarter. A balancing payment will be made between the Parties in order to effect the profit and loss sharing allocation set forth in Section 7.2.8 (Calculation of Profit (or Loss)). The net paying Party will make a payment pursuant to this Section 7.2.9 (True-up) within thirty (30) days after delivery of such report of Collaboration Profit (Loss).
7.2.10.Payments. Payments pursuant to this Article 7 (Profit/Expense Sharing) will be made in accordance with the provisions of Article 8 (Payments).
7.2.11.Calculation of Sales Force Costs. Sales force FTE costs for each of the Parties will be determined by including in Partner Costs or Amgen Costs, as the case may be, a pro rata portion of each Party’s sales representative’s FTE Rate as follows: (i) [*] if such sales representative Details only a single Product (and no other products) with the approval of the CRC; (ii) [*] if such sales representative Details two (2) products with a Product as the First Position Detail or Details only a Product without the approval of the CRC; (iii) [*] if such sales representative Details three (3) or more products with a Product as the First Position Detail; (iv) [*] if such sales representative Details two (2) products with a Product as the Second Position Detail; (v) [*] if such sales representative Details three (3) or more products with a Product as the Second Position Detail; and (vi) [*] if such sales representative Details three (3) or more products with a Product as the Other Detail. If a sales representative Details more than one (1) Product, then the foregoing percentages will be aggregated for each such Product. For the avoidance of doubt, if a sales representative Details a Product in more than one (1) position, then a pro rata share of the foregoing percentages, to be calculated based on the time spent by such sales representative on Detailing such Product in each such position, will be included in Partner Costs or Amgen Costs, as the case may be. For periods in which sales representatives are performing activities in support of the collaboration but are not Detailing Products (e.g., during launch preparation or training), FTE costs will be calculated based upon percent of effort, resource utilization or other reasonable measure, in each case calculated and allocated in accordance with the applicable Party’s accounting procedures, consistently applied.
7.2.12.Kirin-Amgen and Takeda Payments. For clarity, the Parties agree and acknowledge that any payments received by Amgen from (i) in the case of
31



AMG827, Kirin-Amgen, Inc. or Kyowa Hakko Kirin Co., Ltd and (ii) in the case of AMG557, Takeda Pharmaceutical Company Limited, in each case pursuant to the related Excluded Territory Agreement with such Third Party, shall be excluded from the calculation of Collaboration Profit (Loss). Any such payments shall not, in any way (in part or in full), reduce Amgen Costs hereunder, and Amgen shall be entitled to retain any such payments in full without compensation to, or any separate accounting or audit right undertaken by, Partner.
7.3.Example. The Profit (Loss) Example Schedule sets forth an example of calculation and true-up of the Collaboration Profit (Loss).
7.4.Calculation of Net Revenues. In calculating Net Revenues for the purposes of this Article 7 (Profit/Expense Sharing):
7.4.1.Free Products. Any disposal of a Product at no charge for, or use of a Product without charge in, clinical or pre-clinical trials, given as free samples, or distributed at no charge to patients unable to purchase the same will not be included in Net Revenues.
7.4.2.Bundled Products. Where a Product is sold in a Bundle, then for the purposes of calculating Net Revenues under this Agreement, such Product will be deemed to be sold for an amount equal to [X ÷ (X + Y)] × Z, where: X is the average sales price during the applicable reporting period generally achieved for such dosage form of such Product in the Collaboration Scope; Y is the sum of the average sales price during the applicable reporting period generally achieved in the Collaboration Territory, when sold alone, by each pharmaceutical product in the relevant dosage form included in the Bundle (excluding such Product); and Z equals the price at which the Bundle was actually sold. In the event that such Product or one or more of the other pharmaceutical products in the Bundle are not sold separately in the relevant dosage form, Net Revenues from the sale of such Bundle will be reasonably allocated between such Product and the other product(s) in such Bundle based upon their relative values and the Parties will determine the equitable fair market prices to apply to such Bundle; provided, that in the event of a disagreement with respect to such relative values, the Parties will engage a mutually agreed upon independent expert to make the final determination with respect thereto. Notwithstanding the foregoing, no Product will be sold in a Bundle if such sale would violate Applicable Law.
7.5.Excluded Losses. The following losses will not be charged to the Collaboration Profit (Loss): (i) losses of a Party to the extent attributable to a breach of this Agreement by such Party, or (ii) losses subject to indemnification pursuant to Section 13.1 (Indemnity by Partner) or Section 13.2 (Indemnity by Amgen).

7.6.Manufacturing Costs Calculation and True-Up. Manufacturing Standard Costs for a Product, calculated as part of Development Costs, will be included in Amgen Costs and Partner Costs, as applicable, at the time of manufacture of such Product. Prior to Technical Feasibility, Manufacturing Actual Costs for a Product intended for use in a clinical trial, calculated as part of Development Costs, will be included in Amgen Costs and Partner Costs, as applicable, at the time of manufacture of such Product. After Technical Feasibility, Manufacturing Actual Costs for a Product intended for use in a clinical trial, calculated as part of Development Costs, will be included in Amgen Costs and Partner Costs, as applicable, at the time such Product is shipped to a site for use of such Product in a clinical trial. Subject to Section 4.4 (Distribution), Manufacturing Actual Costs for a Product for commercial use, calculated as part of General Costs, will be included in Amgen Costs and Partner Costs, as applicable, at the time of sale of such
32



Product. In addition, due to the fact that Manufacturing Actual Costs may not be known at the time such costs are to be included within the Collaboration Profit (Loss), for the purposes of determining Development Costs or General Costs for a particular calendar quarter, the Manufacturing Lead will, to the extent any manufacturing costs are to be calculated using Manufacturing Actual Costs, use the then-current estimated Manufacturing Actual Costs for such calendar quarter. By March 31 of each calendar year, the Manufacturing Lead will reconcile the estimated Manufacturing Actual Costs included in Development Costs and General Costs in the prior calendar year with the final Manufacturing Actual Costs for such Product and provide such reconciliation to the other Party. If such reconciliation leads to an over or under payment by either Party, a balancing payment will be made between the Parties in order to maintain the intended profit and loss sharing allocation set forth in this Agreement within thirty (30) days after delivery of such reconciliation report by the Manufacturing Lead and agreement thereon by the Parties.
7.7.Budget Deadlocks. In the event that the JSC is unable to approve [*] Development Budget, Operations Budget or Commercialization Budget prior to the expiration of any such budget, then, until approval of such budget by the CRC, each Party will be entitled to continue the Designated Amgen Activities and Designated Partner Activities, as applicable, and include its Development Costs and General Costs, as applicable, in the calculation of Collaboration Profit (Loss) for any calendar quarter not covered by an approved budget, until such time as the aggregate Development Costs and General Costs of such Party included in the calculation of Collaboration Profit (Loss) for [*] equal the amount of such Party’s Development Costs and General Costs included in the then most recent estimate provided under Sections 7.2.1 (Partner Costs) and 7.2.2 (Amgen Costs), as applicable, plus [*] of such estimate.
7.8.Program Recommitment. [*], after the applicable Continued Development Meeting for a Product has been held and upon consultation at the CRC, in the event either (or both) Party(ies) do not wish to continue to participate in the continued development and commercialization of such Product, each Party will have the right to suspend its participation by providing the other Party with a written notice thereof on or prior to [*] days following the applicable Continued Development Meeting. A Party so suspending its commitment will be referred to as a “Suspending Party” and a Party not doing so a “Non-Suspending Party”.
7.8.1.Suspension.
7.8.1.1.Suspension Election. If only one Party delivers a notice of suspension with respect to a Product (a “Suspension Election”), then the remaining provisions of this Section 7.8 (Program Recommitment) shall apply. If both Parties deliver a notice of suspension with respect to a Product, then the Agreement shall be deemed to be terminated with respect to such Product in accordance with Section 14.2 (Termination for Convenience) and Section 14.6.1 (Product by Product Termination) and Amgen shall be the Continuing Party with respect to such Product.
7.8.1.2.Transition. Upon making a Suspension Election, the Suspending Party will, at the Non-Suspending Party’s cost, undertake all reasonable efforts to effect a smooth and orderly transition of its development, regulatory and commercial activities and responsibilities under this Agreement with respect to such Product to the Non-Suspending Party. If the Suspending Party is the Manufacturing Lead for such Product, then, at the Non-Suspending Party’s cost, the Suspending Party will use all reasonable efforts to continue to supply Product for clinical use and complete any commercial process development activities initiated prior to the effective
33



date of such Suspension Election; provided, that, the Manufacturing Lead will have the right to transition such manufacturing to a contract manufacturer or, if agreed to by the Non-Suspending Party, to the Non-Suspending Party. For clarity, from and after the effective date of any Suspension Notice, the Suspending Party shall not be liable for any Development Costs or General Costs for such Product committed before the effective date of the Suspension Notice but not yet incurred at that date or otherwise incurred after such date.
7.8.1.3.Committee Participation. Upon making a Suspension Election and until such time as the Suspending Party elects to resume funding its share of Development Costs and General Costs with respect to such Product pursuant to Section 7.8.2 (Re-Entry Right) below, the Suspending Party’s right to participate on the CRC, the JSC, any JPT and any subcommittee or subteam thereunder will be limited to a right to participate in any meetings brought before such committee or team without any right to vote on any matter that specifically relates to such Product (for clarity the Suspending Party will retain the right to vote on any matter that relates to any other Product). Additionally, if the Suspending Party was the Development Lead and Commercial Lead for such Product, then the Non-Suspending Party shall be the Development Lead and Commercial Lead going forth, and the Suspending Party shall not be entitled to resume such role even if such Party elects to resume funding its share of Development Costs and General Costs with respect to such Product pursuant to Section 7.8.2 (Re-Entry Right) below. Additionally, the Non-Suspending Party shall promptly share with, and provide access to, the Suspending Party (i) all clinical trial data and results within the Program Intellectual Property, (ii) such other Know-How within the Product Intellectual Property generated before the date of the Suspension Election; and (iii) any other information reasonably requested by the Suspending Party related to such Product.
7.8.1.4.Subsequent Termination. If the Non-Suspending Party subsequently decides that it is no longer willing to continue further development and commercialization of the Product, then the Non-Suspending Party may elect to terminate further development and commercialization by providing the Suspending Party with [*] prior written notice (a “Termination Election”). If the Suspending Party is Partner and Amgen delivers a Termination Election during the Re-Entry Period, then upon receipt of such Termination Election from Amgen, Partner shall have the right upon prior written notice, delivered by no later than [*] following receipt of Amgen’s Termination Election, to elect to continue with the further development and commercialization of the Product, in which case, Partner shall thereafter be deemed to be the Non-Suspending Party and Amgen shall be deemed to be the Suspending Party. If Partner does not elect within such [*] period to continue with such development or commercialization or if Partner is the Non-Suspending Party, then upon the effective date of a Termination Election, the Agreement shall be deemed to be terminated with respect to such Product in accordance with Section 14.2 (Termination for Convenience) and Section 14.6.1 (Product by Product Termination) and Amgen shall be the Continuing Party with respect to such Product.
7.8.2.Re-Entry Rights.
34



7.8.2.1.Re-Entry Period. With respect to any non-terminated Product subject to a Suspension Election, at any time beginning upon receipt of the Suspension Election until [*] following the receipt of the flash memo for the applicable Stage 2 Clinical Trial for such Product and receipt of any information requested by the Suspending Party that is reasonably necessary to determine whether to re-enter the program (the “Re-Entry Period”), the Suspending Party will have the right to re-enter the program by written notice (a “Re-Entry Notice”) to the Non-Suspending Party, effective as of the date of receipt of such notice by the Non-Suspending Party.
7.8.2.2.Re-Entry Payment. In the event of such re-entry, the Suspending Party will pay the Non-Suspending Party an amount equal to [*].
7.8.2.3.Lapse. If the Suspending Party fails to provide the Re-Entry Notice with respect to a Product during the applicable Re-Entry Period, then the Suspending Party shall be deemed to have terminated the Agreement with respect to such Product in accordance with Section 14.2 (Termination for Convenience) and Section 14.6.1 (Product by Product Termination).
7.8.2.4.Out-license. If, during the Re-Entry Period for a Product, the Non-Suspending Party elects to grant to a bona fide Third Party the exclusive right to develop or commercialize such Product in any country within the Collaboration Territory, then the Non-Suspending Party will provide the Suspending Party with [*] prior written notice (the “Out-License Election”). If the Suspending Party fails to provide a Re-Entry Notice within [*] of receipt of the Out-License Election and the Out-License Election relates to only certain countries within the Collaboration Territory, then the Suspending Party’s right to re-enter the program shall exclude such countries. If the Suspending Party fails to provide a Re-Entry Notice within [*] of receipt of the Out-License Election and the Out-License Election relates to all countries within the Collaboration Territory, then, then the Suspending Party’s right to provide a Re-Entry Notice with respect to such Product shall terminate.
8.PAYMENTS
8.1.Appropriate Measure of Value. Each of the Parties acknowledges that the value provided by the other hereunder is comprised of many related items, including performance of various services, access to development, regulatory, manufacturing and commercial expertise, clinical data and other financial and non-financial consideration and that the amount of the Inventorship Margin, and the ratio of profit and expense sharing set forth herein are intended to capture such value as an aggregate. Therefore, the increase, decrease or lapse of any particular items or rights (including Patents), including allocation of operational responsibilities between the Parties, will not affect the amount of such payment, or the ratio of profit and expense sharing and the Parties agree that both the amount and duration of such payment and the ratio of profit and expense sharing are reasonable.
8.2.No Other Compensation. Other than as explicitly set forth in this Agreement, neither Party will be obligated to pay any additional fees, milestone payments, royalties or other payments of any kind to the other hereunder.
8.3.Currency.
35



8.3.1.Payments. All payments made hereunder between the Parties will be made in U.S. Dollars except as set forth in Section 8.5 (Blocked Currency) or as otherwise agreed by the Parties. Each Party will pay all sums due hereunder by wire transfer, or electronic funds transfer (EFT) in immediately available funds. If the EFT option is chosen by Amgen or Partner, a completed electronic funds transfer form will be provided in a timeframe that facilitates timely payment. Each Party will promptly notify the other Party of the appropriate account information to facilitate any such payments. All amounts set forth in any budget established under this Agreement will be expressed in U.S. Dollars except as otherwise agreed by the Parties.
8.3.2.Conversions. With respect to amounts required to be converted into another currency for calculation or payment, hereunder, such amounts will be converted using a rate of exchange which corresponds to the rate used for conversion between the relative currencies by whichever Party recorded the relevant receipt or expenditure, for the respective reporting period in its books and records that are maintained in accordance with GAAP or IFRS, as the case may be. If a Party is not required to perform such a currency conversion for its GAAP or IFRS reporting with respect to the applicable period, then for such period such Party will make such conversion using the rate of exchange which corresponds to the noon buying rate as published in the Wall Street Journal, Eastern U.S. Edition on the second to last business day of the calendar quarter (or such other publication as agreed-upon by the Parties) in which such receipt or expenditure was incurred.
8.4.Audits. Each Party will keep complete and accurate records pertaining to the activities to be conducted hereunder in sufficient detail to permit the other Party (the “Auditing Party”) to confirm the accuracy of all payments due hereunder, and such records will be open (in such form as may be available or reasonably requested) to inspection for [*] following the end of the period to which they pertain. The Auditing Party will have the right, at its own expense to have an independent, certified public accountant, selected by it, perform a review of the records of the other Party (the “Audited Party”) applicable to amounts payable hereunder (including any records kept in the ordinary course of the Audited Party’s business) during regular business hours, with not less than ten (10) business days’ advance written notice and under reasonable obligations of confidentiality. The report of such accountant will be made available to both Parties simultaneously, promptly upon its completion. The Auditing Party’s right to perform an audit pertaining to any calendar year will expire [*] after the end of such year and the books and records for any particular calendar year will only be subject to one (1) audit. Should an inspection pursuant to this Section 8.4 (Audits) lead to the discovery of a payment discrepancy, then the appropriate Party will pay to the other the amount of the discrepancy (plus, if the error was in favor of the Auditing Party, interest accrued at the Contract Interest Rate, compounded annually from the day the relevant payment(s) were due). If a payment discrepancy was greater than [*] of the correct amount for the audited period and the discrepancy was in favor of the Audited Party, then the Audited Party will pay the reasonable out-of-pocket cost of such inspection, but in no case will the costs of an audit pursuant to this Section 8.4 (Audits) be included in Partner Costs or Amgen Costs or otherwise included in the calculation of Collaboration Profit (Loss). This Section 8.4 (Audits) does not apply to or include manufacturing audits or regulatory inspections.
8.5.Blocked Currency. If Applicable Law in the Collaboration Territory prevents the prompt remittance of any payments with respect to sales therein, the paying Party will have the right and option to make such payments by depositing the amount thereof in local currency to the other Party’s account in a bank or depository in such country.
36



8.6.Taxes.
8.6.1.Withholding. If Applicable Law requires a Party to pay or withhold Taxes with respect to any payment to be made pursuant to this Agreement, the paying Party will notify the other in writing of such payment or withholding requirements prior to making the payment and provide such assistance to the receiving Party, including the provision of such documentation as may be required by a tax authority, as may be reasonably necessary in such Party’s efforts to claim an exemption from or reduction of such Taxes. Each Party will withhold any Taxes required by law to be withheld from the amount due, remit such Taxes to the appropriate tax authority, and furnish the other Party with proof of payment of such Taxes promptly following payment thereof. If Taxes are paid to a tax authority, each Party will provide the other such assistance as is reasonably required to obtain a refund of Taxes withheld, or obtain a credit with respect to Taxes paid. In the event that the governing tax authority retroactively determines that a payment made by a Party to the other pursuant to this Agreement should have been subject to withholding (or to additional withholding) for Taxes, and such Party (the “Withholding Party”) remits such withholding Taxes to the tax authority, the Withholding Party will have the right to offset such amount, including any interest and penalties that may be imposed thereon (except to the extent any such interest or penalties result from the negligence of the Withholding Party), against future payment obligations of the Withholding Party under this Agreement (or, at the option of the Withholding Party, the Withholding Party will have the right to invoice the other Party for such amount, and the other Party will pay such amount within sixty (60) days of the receipt of such invoice); provided, that the Withholding Party may also pursue reimbursement by any other available remedy.
8.6.2.Indirect Taxes. All payments are exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any payments, the paying Party shall pay such Indirect Taxes at the applicable rate in respect of such payments following receipt, where applicable, of an Indirect Taxes invoice in the appropriate form issued by the receiving Party in respect of those payments. The Parties shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement purposes. If such amounts of Indirect Taxes are refunded by the applicable Governmental Authority or other fiscal authority subsequent to payment, the Party receiving such refund will transfer such amount to the paying Party within forty-five (45) days of receipt.
8.6.3.Employee Taxes. Each Party shall be responsible for taxes based on, imposed on or calculated by reference to any employees employed by that Party.
8.6.4.Imports.  For the avoidance of doubt, the Parties acknowledge and agree that none of the upfront payment or royalties payable under this Agreement are related to the license (or right) to import or any import of Products.  The Parties shall cooperate in accordance with Applicable Laws to ensure where permissible no import duties are paid on imported Product.  The Parties shall cooperate to ensure that the Party responsible for shipping values clinical Product in accordance with Applicable Laws and minimises where permissible any such duties and any related import taxes that are not reclaimable from the relevant authorities.  The receiving Party shall be responsible for any import clearance, including payment of any import duties and similar charges, in connection with any Products transferred to such Party under this Agreement.
37



8.6.5.Payment Flows. The Parties recognize that this Agreement is global in nature and does not set out in detail how the financial flows will be implemented at a legal entity level in order to achieve the economic sharing of profits and losses generated by the Products as set forth in this Agreement. At least eighteen (18) months prior to first commercial launch of a Product, the Parties will discuss and agree upon the principles for such profit and loss sharing at a legal entity level. The Parties will use reasonable efforts to minimize the impact on both Parties of irrecoverable and/or non-creditable Indirect Taxes, including, where appropriate, causing their local Affiliates to enter into a “Marketing Services Agreement” with one another or otherwise discussing how to address the issue. For clarity, the provisions of this Section 8.6.5 (Payment Flows) will in no way change the allocation between the Parties of Development Costs and General Costs set forth in Section 7.2.8.1 (Costs) or of Net Revenues set forth in Section 7.2.8.2 (Profits).
8.7.Late Payment. Any payments or portions thereof due hereunder which are not paid when due will bear interest at the Contract Interest Rate, compounded annually, calculated on the number of days such payment is delinquent. This Section 8.7 (Late Payment) will in no way limit any other remedies available to either Party.
8.8.Change in Accounting Periods. From time to time, either of the Parties may change its accounting and financial reporting practices from calendar quarters and calendar years to fiscal quarters and fiscal years or vice versa. If a Party notifies the other in writing of a change in its accounting and financial reporting practices from calendar quarters and calendar years to fiscal quarters and fiscal years or vice versa, then thereafter, beginning with the period specified in the notice, the Parties will cooperate to determine a way to report and reconcile each Party’s accounting periods so as to facilitate payments to be made hereunder.
9.DISTRACTING PRODUCTS
9.1.Distracting Program. Except as set forth in Sections 9.2 (Post-Effective Date Affiliates), 9.3 (Termination, Divestiture or Inclusion) and 9.4 (Pre-Clinical Research and Development Programs):
9.1.1.Partner will not, during the Term and, other than in the event of termination by Partner pursuant to Section 14.3 (Termination for Breach), for [*] thereafter, itself or through its Affiliates, conduct or participate in, or advise, assist or intentionally enable any Third Party to conduct or participate in, any Distracting Program anywhere in the world; provided, that [*];
9.1.2.Amgen will not, during the Term, itself or through its Affiliates, conduct or participate in, or advise, assist or intentionally enable any Third Party to conduct or participate in, any Distracting Program in the Collaboration Territory; and
9.1.3.[*].
9.2.Post-Effective Date Affiliates. If a Party enters into a Distracting Transaction then it will provide notice to the other Party, within [*] business days after the closing of the Distracting Transaction, describing in reasonable detail, to the extent permitted by Applicable Law and without disclosing any proprietary information, the Distracting Program. During the pendency of any potential Distracting Transaction, and until the provisions of Section 9.3 (Termination, Divestiture or Inclusion) are fully implemented, the Party entering into the Distracting Transaction will Segregate the Distracting Program from programs for the Products.
38



9.3.Termination, Divestiture or Inclusion. The notice provided pursuant to Section 9.2 (Post-Effective Date Affiliates) will include a notification as to whether the Party entering into the Distracting Transaction intends to Divest, terminate or include in the collaboration the Distracting Program in accordance with this Section 9.3 (Termination, Divestiture or Inclusion):
9.3.1.Divestiture. If a Party elects to Divest the Distracting Program, then it will Segregate such Distracting Program from the programs for the Products and Divest such Distracting Program within [*] months of the closing of the Distracting Transaction. The divesting Party and its Affiliates (including the Affiliate with the Distracting Program) will not directly or indirectly assert any intellectual property or proprietary right embodied in the Distracting Program and under the control of the divesting Party or its Affiliates as a result of the Distracting Transaction, against or with respect to Products or otherwise obstruct the Parties’ (or their Affiliates, sublicensees’, contractors’ or agents’) efforts under this Agreement or, if Partner is the divesting Party, Amgen’s (or its Affiliates, sublicensees’, contractors’ or agents’) efforts with respect to Products in the Excluded Territory. If the divesting Party fails to complete a divestiture of the Distracting Program within [*] months of the closing of the Distracting Transaction, then such Party will be deemed to have chosen to terminate the Distracting Program, effective as of such [*] month anniversary, and will promptly comply with the requirements of Section 9.3.2 (Termination); provided, that if at the expiration of such [*] month period, the divesting Party has agreed terms with a Third Party to Divest the Distracting Program then such [*] month period will be extended as required for the divesting Party and such Third Party to consummate the transaction, but in no event will such extension exceed an additional [*] days.
9.3.2.Termination. If a Party elects to terminate such Distracting Program, it will terminate all activities of such Distracting Program within [*] days after the closing of the Distracting Transaction, during which period it will Segregate such Distracting Program from the programs for the Products. The terminating Party and its Affiliates will not directly or indirectly assert any intellectual property or proprietary right of the Distracting Program against or with respect to Products or otherwise to obstruct the Parties’ (or their Affiliates, sublicensees’, contractors’ or agents’) efforts under this Agreement or if Partner is the terminating Party, Amgen’s (or its Affiliates, sublicensees’, contractors’ or agents’) efforts with respect to Products in the Excluded Territory during such termination period or thereafter.
9.3.3.Inclusion. If a Party elects to include the Distracting Program in the collaboration, then such Party (the “Distracting Transaction Party”) will provide written notice within [*] days after the closing of the Distracting Transaction of such election to the other Party, together with a non-confidential summary of the related Distracting Program. If the non-Distracting Transaction Party desires to evaluate such Distracting Program, then the non-Distracting Transaction Party will notify the Distracting Transaction Party within [*] days of its receipt of such notice. Promptly after the Distracting Transaction Party’s receipt of such evaluation notice, the Distracting Transaction Party will provide the non-Distracting Transaction Party with a confidential summary of the Distracting Program, including material pre-clinical and clinical data and proposed development plan and budget (as well as such other information that the non-Distracting Transaction may reasonably request), which summary will be deemed to be Confidential Information of the Distracting Transaction Party under this Agreement (and the non-Distracting Transaction Party shall be
39



entitled to use such information solely for the purpose of evaluating whether to include such Distracting Program in the collaboration). Within [*] days of its receipt of such summary, the non-Distracting Transaction Party will notify the Distracting Transaction Party of its election to either (i) include the Distracting Program in the collaboration or (ii) decline to include such Distracting Program in the collaboration. If the non-Distracting Transaction Party agrees in writing to include such Distracting Program in the collaboration, then (a) the Distracting Program will be included under the terms of this Agreement and all the technology, intellectual property and tangible materials (including biological compounds, chemical compounds, intermediates, assays, screens, animal models and reagents) of such Distracting Program will be considered within the Product Intellectual Property; (b) the Distracting Products included in the Distracting Program will be deemed Products hereunder; (c) a JPT will be formed for each such Distracting Product and each such JPT will develop a Development Plan and Development Budget for each Distracting Product, for review and approval by the JSC; (d) all Development Costs, General Costs and profits with respect to each such Distracting Product [*]; and (e) the Parties will enter into an amendment or supplement to this Agreement to the extent necessary to specify which Party will be the Development Lead, Manufacturing Lead, and Commercial Lead, plus such other changes, modifications and assignments as are reasonably necessary to effectuate the addition of such Distracting Product. If the non-Distracting Transaction Party does not agree to include such Distracting Program in the collaboration, then (i) from and after the date of such election, the obligations of the Distracting Transaction Party set forth in Section 9.1 (Distracting Program) will no longer apply with respect to such Distracting Program, and (ii) the non-Distracting Party shall destroy the confidential summary of the Distracting Program provided to it by the Distracting Transaction Party (provided, that the non-Distracting Party shall be entitled to retain one (1) copy of such information for its record-keeping purposes).
9.4.Pre-Clinical Research and Development Programs. Notwithstanding anything in this Article 9 (Distracting Products), either Party will have the right, either itself or through its Affiliates, to conduct non-clinical research and non-clinical development on any Distracting Product, subject to this Section 9.4 (Pre-Clinical Research and Development). At least [*] days prior to the anticipated initiation of the first [*] for such Distracting Product, the Party conducting such activities (the “Researching Party”) will notify the non-Researching Party and provide a non-confidential summary of the related Distracting Program to the non-Researching Party (“Program Notice”). If the non-Researching Party desires to evaluate such Distracting Program, then the non-Researching Party will notify the Researching Party within thirty (30) days of its receipt of the Program Notice. Promptly after the Researching Party’s receipt of such evaluation notice, the Researching Party will provide the non-Researching Party with a confidential summary of the Distracting Program, including material pre-clinical data and proposed development plan and budget (as well as such other information that the non-Researching Party may reasonably request), which summary will be deemed to be Confidential Information of the Researching Party under this Agreement (and the non-Researching Party shall be entitled to use such information solely for the purpose of evaluating whether to include such Distracting Program in the collaboration). Within [*] days of its receipt of such summary, the non-Researching Party will notify the Researching Party of its election to either (i) include the Distracting Program in the collaboration, in which case the terms of Section 9.3.3 (Inclusion) will apply with respect to such Distracting Program (provided, that the Researching Party will be entitled to receive a [*]) or (ii) decline to include such Distracting Program in the
40



collaboration. If the non-Researching Party declines to include such Distracting Program in the collaboration, then (i) from and after the date of such election, the obligations of the Researching Party set forth in Section 9.1 (Distracting Program) will no longer apply with respect to such Distracting Program, and (ii) the non-Researching Party shall destroy the confidential summary of the Distracting Program provided to it by the Researching Party (provided, that the non-Research Party shall be entitled to retain one (1) copy of such information for its record-keeping purposes).
9.5.Reasonable Restrictions. Each of the Parties acknowledges the provisions of this Article 9 (Distracting Products) are reasonable and necessary to protect the legitimate interests of the other Party and to encourage the free sharing of information between the Parties with respect to Products, and each of the Parties agrees not to contest such limitations in any proceeding. Each Party acknowledges that the other Party would not have entered into this Agreement absent the restrictions set forth in this Article 9 (Distracting Products) and that a breach or threatened breach of this Article 9 (Distracting Products) would be likely to result in irreparable harm to such Party for which there is no adequate remedy at law. Therefore, the Parties will be entitled to obtain from any court of competent jurisdiction injunctive relief, specific performance, and an equitable accounting of any earnings, profits or benefits arising out of any such breach without the requirement to post a bond or to demonstrate irreparable harm, balancing of harms, consideration of the public interest or inadequacy of monetary damages as a remedy. Nothing in this Section 9.5 (Reasonable Restrictions) is intended or will be construed to limit in any way either Party’s right to equitable relief or any other remedy for breach of this or any other provision of this Agreement.
10.INTELLECTUAL PROPERTY
10.1.Invention Ownership. Each Party will own all right, title, and interest in and to all Inventions that are made by or on behalf of such Party, solely or independent of the other Party, and all intellectual property rights related thereto, and any Invention that is jointly made will be owned jointly by the Parties. Inventorship will be determined according to United States Patent Law (without reference to any conflict of law principles).
10.2.Copyright Ownership; Certain Confidential Information. Each Party will own all right, title, and interest in and to all Copyrights created pursuant to this Agreement that are authored by or on behalf of such Party, solely or independent of the other Party, and all intellectual property rights related thereto. The Parties will jointly own all right, title, and interest in and to all Copyrights created pursuant to this Agreement that are authored by or on the behalf of the Parties jointly, and all intellectual property rights related thereto. Notwithstanding the foregoing, any Copyrights pertaining to Promotional Materials or training materials for a Product will be owned solely by the Commercial Lead for such Product.
10.3.Joint Ownership. Except as expressly provided in this Agreement, it is understood that neither Party will have any obligation to obtain any approval or consent of, nor pay a share of the proceeds to or account to, the other Party to practice, enforce, license, assign or otherwise exploit Inventions or intellectual property (including Copyrights and Product Trademarks) owned jointly by the Parties hereunder, and each Party hereby waives any right it may have under the laws of any jurisdiction to require such approval, consent or accounting. Each Party agrees to cooperate with the other Party, as reasonably requested, and to take such actions as may be required to give effect to this Section 10.3 (Joint Ownership) in a particular country within the Collaboration Territory.

41



10.4.License Grant by Amgen. Amgen hereby grants and causes its Affiliates to grant to Partner during the Term a [*], fully-paid, royalty-free license to Amgen Intellectual Property and Program Intellectual Property solely (i) to the extent necessary to conduct the Designated Partner Activities and (ii) to exercise and perform Partner’s other rights and obligations under the terms of this Agreement. Such license is sublicensable by Partner or its Affiliates solely in accordance with Section 6.4 (Use of Affiliates and Third Party Contractors).
10.5.License Grant by Partner. Partner hereby grants and causes its Affiliates to grant to Amgen and its Affiliates a [*], fully-paid, royalty-free license to Partner Intellectual Property and Program Intellectual Property solely (i) to the extent necessary to conduct the Designated Amgen Activities and (ii) to exercise and perform Amgen’s other rights and obligations under the terms of this Agreement. The foregoing license is sublicensable by Amgen or its Affiliates in accordance with Section 6.4 (Use of Affiliates and Third Party Contractors). Additionally, Partner hereby grants and causes its Affiliates to grant to Amgen and its Affiliates a [*], irrevocable, fully-paid, royalty-free, world-wide license to Partner Intellectual Property and Program Intellectual Property solely to use, make, have made, sell, offer for sale and import Products for all uses in the Excluded Territory (which license is sublicensable by Amgen or its Affiliates to Third Parties to whom Amgen or its Affiliates also grant a license in the Excluded Territory to Know-How or Patents owned or controlled by Amgen with respect to Product(s) , or the manufacture, formulation or use thereof; [*]).
10.6.Prosecution and Maintenance.
10.6.1.Amgen Intellectual Property. Subject to the provisions of Section 2.10 (Patent Coordinators), Amgen will control, itself or through outside counsel, and have final decision making authority (after consultation with Partner in accordance with the terms and conditions of this Agreement) with respect to the Prosecution and Maintenance of the Patents within the Amgen Intellectual Property in the Collaboration Territory that claim a Product, and with respect to preparation and filing for any Patent Extensions.
10.6.2.Partner Intellectual Property. Subject to the provisions of Section 2.10 (Patent Coordinators), Partner will control, itself or through outside counsel, and have final decision making authority (after consultation with Amgen in accordance with the terms and conditions of this Agreement) with respect to the Prosecution and Maintenance of the Patents within the Partner Intellectual Property in the Collaboration Territory that claim a Product, and with respect to preparation and filing for any Patent Extensions.
10.6.3.Program Intellectual Property. Subject to the provisions of Section 2.10 (Patent Coordinators), Amgen will have the first right (but not the obligation) to control, through outside counsel, and have final decision making authority (after consultation with Partner in accordance with the terms and conditions of this Agreement) with respect to the Prosecution and Maintenance of the Patents and Product Trademarks within the Program Intellectual Property (the “Program Patents and Trademarks”), and with respect to preparation and filing for any Patent Extensions. If Amgen desires to abandon the prosecution of a Program Patent or Trademark, then it will inform Partner thereof in writing with sufficient advance notice to reasonably enable Partner to assume the filing or prosecution of such Program Patent or Trademark (but in no event later than [*] days prior to the next deadline for any action that may be taken with respect such Program Patent or Trademark with the U.S. Patent and Trademark Office or any non-U.S. patent office) at Partner’s non-reimbursable cost.
42



10.6.4.Review and Comment Rights - Patents. Through the Patent Coordinators: (i) the filing Party will provide the non-filing Party with copies of and an opportunity to review and comment upon the text of the applications relating to the applicable Patents at least [*] days before filing; provided, that if it is not reasonably practicable to provide such application in such [*] day period, then the filing Party will provide either a draft copy of such application or a statement of intent to file such application in such [*] day period; (ii) the filing Party will provide the non-filing Party with a copy of each submission made to and document received from a patent authority, court or other tribunal regarding any Patent reasonably promptly after making such filing or receiving such document, including a copy of each application for each Patent as filed together with notice of its filing date and application number; (iii) the filing Party will keep the non-filing Party advised of the status of all material communications, and actual and prospective filings or submissions regarding the Patents, and will give the non-filing Party copies of and an opportunity to review and comment on any such material communications, filings and submissions proposed to be sent to any patent authority or judicial body; and (iv) the filing Party will consider in good faith the non-filing Party’s comments on such communications, filings and submissions for the Patents. With respect to any filings or other materials provided to the non-filing Party under this Section 10.6 (Prosecution and Maintenance), the filing Party will have the right to redact any manufacturing information and any information relating to any product other than Products from any such filings and materials. Either Patent Coordinator may escalate to the JSC whether to obtain any license to Third Party Patents or Know-How; provided, that in the event of a disagreement at the JSC with respect to such decision, Amgen will make the final decision with respect thereto.
10.6.5.Review and Comment Rights - Product Trademarks. Through the Patent Coordinators: (i) the filing Party will provide the non-filing Party with copies of and an opportunity to review and comment upon the text of each application relating to registration of a Product Trademark at least [*] business days before filing; (ii) the filing Party will provide the non-filing Party with a copy of each submission made to and document received from a trademark registration authority, court or other tribunal regarding any Product Trademark reasonably promptly after making such filing or receiving such document, including a copy of each application for registration of each Product Trademark as filed together with notice of its filing date and application number; (iii) the filing Party will keep the non-filing Party advised of the status of all material communications, and actual and prospective filings or submissions regarding the application for registration of Product Trademarks, and will give the non-filing Party copies of and an opportunity to review and comment on any such material communications, filings and submissions proposed to be sent to any trademark registration authority or judicial body; and (iv) the filing Party will consider in good faith the non-filing Party’s comments on such communications, filings and submissions for the Product Trademarks.
10.7.Defense and Settlement of Third Party Claims of Infringement. If a Third Party asserts that Patents, Know-How or other rights owned or controlled by it are infringed by the activities hereunder of either of the Parties, then defense of such claim (an “Infringement Claim”) will be managed in accordance with the provisions of Section 13.4 (Defense of Third Party Claims), with coordination and cooperation between the Defending Party and Assisting Party occurring via the Patent Coordinators. If either Party seeks to initiate a nullification, declaratory judgment, revocation, or opposition proceeding against any such Patents, Know-How or other rights in response to
43



prospective or actual Third Party Claims of Infringement, the Parties will coordinate and cooperate in regard to such proceedings in accordance with the procedures set forth in Section 13.4 (Defense of Third Party Claims), with coordination and cooperation between the Defending Party and Assisting Party occurring via the Patent Coordinators.
10.8.Enforcement. Except as expressly set forth in this Section 10.8 (Enforcement), each Party will retain all its rights to control the enforcement of its own intellectual property. Amgen will have the first right (but not the obligation) to enforce the Program Intellectual Property against any Third Party that is developing, manufacturing, selling, or importing a product or service that competes with a Product; provided, that Partner will have the right to approve in writing any settlement of any claim, suit or action involving its intellectual property that admits the invalidity or unenforceability of its intellectual property or imposes on Partner restrictions or obligations. If Amgen fails to bring any such action or proceeding within forty-five (45) days (or twenty-five (25) days in the case of an action brought under the Biologics Price Competition and Innovation Act of 2009 (or any amendment or successor statute thereto) or within the time frame of any other relevant regulatory or statutory framework that may govern) of a request by Partner to do so (or, if sooner, five (5) days before the time limit, if any, set forth in the relevant laws and regulations for the filing of such actions), or earlier notifies Partner in writing of its intent not to bring such action or proceeding, then Partner will have the right (but not the obligation) to bring any such action or proceeding by counsel of its own choice; provided, that Amgen will have the right to approve in writing any settlement of any claim, suit or action involving its intellectual property that admits the invalidity or unenforceability of its intellectual property or imposes on Amgen restrictions or obligations. The non-enforcing Party will reasonably assist the enforcing Party with respect to any such enforcement in the Collaboration Territory, including, in the event that it is determined that the non-enforcing Party is an indispensable Party to such action, by being named as a Party in such action, and cooperate in any such action at the enforcing Party’s request. Without limiting the foregoing, the enforcing Party will keep the non-enforcing Party advised of all material communications, actual and prospective filings or submissions regarding such action, and will provide the non-enforcing Party copies of and an opportunity to review and comment on any such material communications, filings and submissions (provided, that the enforcing Party will have the right to redact any manufacturing information and any information relating to any product other than Products from any such materials). All Recoveries will be retained by or paid to Amgen (whether Amgen is the enforcing Party or not), but to the extent such Recoveries were obtained with respect to a Product or a product that competes directly with a Product, the same shall be included in Net Revenues for the period in which such Recovery is made.
10.9.Patent Term Extensions. Each non-filing Party will provide reasonable assistance to the filing Party in connection with obtaining supplementary protection certificates, patent term extensions or similar protection for Patents (“Patent Extensions”) within the Product Intellectual Property or otherwise licensed or assigned hereunder as determined by the Patent Coordinators. To the extent reasonably and legally required to obtain any such Patent Extensions in a particular country, the non-filing Party will make available to the filing Party copies of all necessary documentation to enable the filing Party to use the same for the purpose of obtaining Patent Extensions in such country. Notwithstanding Section 10.6 (Prosecution and Maintenance) above, the Patent Coordinator for the Commercial Lead will have the right to make the final decision as to which Patents within the Amgen Intellectual Property, Partner Intellectual Property or Program Intellectual Property will be extended with respect to the Product(s) for which such Party is the Commercial Lead.
10.10.Trademarks.
44



10.10.1.Title. The Parties will jointly own all right, title and interest in and to the Product Trademarks unless the local laws of any country prohibit joint ownership in which case Amgen shall own the Product Trademarks in those countries. Neither Party will, and will ensure that its Affiliates do not: (i) challenge any Product Trademark or the registration thereof in any country; (ii) file, register or maintain any registrations for any trademarks or trade names that are confusingly similar to any Product Trademark (other than for a Product), in any country without the express prior written consent of the other Party; or (iii) authorize or assist any Third Party to do the foregoing.
10.10.2.Required Use and Compliance.
10.10.2.1.Promotional Materials and all packaging and package inserts for Products in the Collaboration Scope will display the Amgen Housemarks and the Partner Housemarks to the extent allowed by Applicable Law and in accordance with the Brand Plan. Except for the use of the Amgen Housemarks and the Partner Housemarks as may be expressly set forth in the Brand Plan, each Party will promote Products in the Collaboration Scope only under the Product Trademarks.
10.10.2.2.Each Party agrees that it and its Affiliates will: (i) ensure that each use of the Product Trademarks and the other Party’s Housemarks by such Party is accompanied by an acknowledgement that such Product Trademarks are jointly owned and such Housemarks are owned by the other Party; (ii) not use such Product Trademarks or the other Party’s Housemarks in a way that might materially prejudice their distinctiveness or validity or the goodwill of the other Party therein; and (iii) not use any trademarks or trade names so resembling any of such Product Trademarks or the other Party’s Housemarks as to be likely to cause confusion or deception.
10.10.3.Housemark Licenses.
10.10.3.1.To Partner. Amgen hereby grants to Partner a [*], royalty-free license to use the Amgen Housemarks solely as set forth in the Promotional Materials and other materials provided to it by Amgen, and solely to develop, manufacture and commercialize Products in the Collaboration Scope in accordance with the Brand Plan, Country Plans and this Agreement.
10.10.3.2.To Amgen. Partner hereby grants to Amgen a [*], royalty-free license to use the Partner Housemarks solely as set forth in the Promotional Materials and other materials provided to it by Partner, and solely to develop, manufacture and commercialize Products in the Collaboration Scope in accordance with the Brand Plan, Country Plans and this Agreement.
10.10.1.Respect of Trademarks. Partner will not have, assert or acquire any right, title or interest in or to any Amgen Housemarks or the goodwill pertaining thereto, and Amgen will not have, assert or acquire any right, title or interest in or to any Partner Housemarks or the goodwill pertaining thereto, in each case by means of entering into or performing under this Agreement, except in each case for the limited licenses explicitly provided in this Agreement.
10.10.2.Infringement. Each Party will monitor the Product Trademarks against infringing uses within the Collaboration Scope and will promptly notify the other Party of any infringement or threatened infringement of any of the Product Trademarks of which it becomes aware. The Patent Coordinators will
45



determine what action, if any, to take in response to any such infringement or threatened infringement of any Product Trademark.
11.CONFIDENTIALITY, PUBLICATIONS AND PRESS RELEASES
11.1.Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, during the Term and for [*] years thereafter, the receiving Party will keep confidential and will not publish or otherwise disclose or use for any purpose any and all information or materials related to the activities contemplated hereunder that is furnished to it by the other Party pursuant to this Agreement and is identified by the disclosing Party as confidential, proprietary or the like or that the receiving Party has reason to believe is confidential based upon its own similar information (collectively, “Confidential Information”). For clarity, except for rights expressly granted herein, both Parties will have no right to and will not utilize any Confidential Information of the other Party for activities outside the Collaboration Scope or for activities related to products other than the Products. Notwithstanding the foregoing, Confidential Information will not include any information to the extent that it can be established by written documentation by the receiving Party that such information:
11.1.1.was obtained or was already known by the receiving Party or its Affiliates without obligation of confidentiality as a result of disclosure from a Third Party that the receiving Party did not know was under an obligation of confidentiality to the disclosing Party with respect to such information;
11.1.2.was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party through no act or omission of the receiving Party or its Affiliates in breach of this Agreement;
11.1.3.became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement; or
11.1.4.was independently discovered or developed by the receiving Party or its Affiliates (without reference to or use of Confidential Information of the disclosing Party).
11.2.Authorized Disclosure. Except as expressly provided otherwise in this Agreement, each Party may use and disclose Confidential Information of the other Party solely as follows: (i) as reasonably necessary in conducting the activities contemplated under this Agreement; (ii) with respect to Confidential Information generated in the course of the activities conducted hereunder, to the extent pertaining specifically to a Product, for use by Amgen in connection with a Product in the Excluded Territory or disclosure by Amgen to a partner or licensee for use with respect to a Product in the Excluded Territory; (iii) to the extent such disclosure is to a Governmental Authority, as reasonably necessary in filing or prosecuting patent, copyright and trademark applications in accordance with this Agreement, prosecuting or defending litigation in accordance with this Agreement, complying with applicable governmental regulations with respect to performance under this Agreement, filing Regulatory Filings, obtaining Regulatory Approval or fulfilling post-approval regulatory obligations for a Product, or otherwise required by Applicable Law, provided, that if a Party is required by Applicable Law to make any such disclosure of the other Party’s Confidential Information it will, except where impracticable for necessary disclosures (for example, in the event of medical emergency), give reasonable advance notice to the other Party of such disclosure requirement and, in the case of each of the foregoing exceptions pursuant to this subsection (iii), will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed; (iv) to advisors
46



(including lawyers and accountants) on a need to know basis in support of the purposes of this Agreement, in each case under appropriate confidentiality provisions or professional standards of confidentiality substantially equivalent to those of this Agreement; and (v) to the extent mutually agreed to by the Parties. Neither Party will disclose Confidential Information of the other Party to its personnel or to an Affiliate except to the extent such personnel or Affiliate needs to know such information for the performance of such Party’s activities hereunder.

11.3.Confidential Treatment of Terms and Conditions. The Parties agree that the terms and conditions of this Agreement will be Confidential Information of each Party, and such material terms and conditions will not be disclosed, except (i) as otherwise permitted under Section 11.2 (Authorized Disclosure) and (ii) if required by Applicable Law (including disclosure of a redacted version of this Agreement in a relevant SEC filing). Notwithstanding the foregoing, with respect to complying with the disclosure requirements of any Governmental Authority in connection with any required filing of this Agreement, the Parties will consult with one another concerning which terms of this Agreement will be requested to be redacted in any public disclosure of this Agreement, and in any event each Party will seek reasonable confidential treatment for any public disclosure by any such Governmental Authority.
11.4.Press Releases. Notwithstanding Section 11.3 (Confidential Treatment of Terms and Conditions), the Parties will issue a joint press release to announce the execution of this Agreement, which is attached hereto as the Press Release Schedule (or such other joint press release as may be mutually agreed upon in writing by the Parties) and is for use in responding to inquiries about this Agreement. Thereafter, Partner and Amgen may each disclose to Third Parties (including media interviews and disclosures to financial analysts) the information contained in such press release (but only such information) without the need for further approval by the other; provided, that such information is still accurate. Each Party will have the right to issue additional press releases and disclosures in regards to the terms of this Agreement only with the prior written consent of the other Party, such consent not to be unreasonably withheld (or as required to comply with Applicable Law). For any such proposed press release or disclosure, the disclosing Party will provide [*] business days’ notice to the other Party and will reasonably consider the other Party’s comments that are provided within [*] business days after such notice, or such shorter notice and comment periods as are reasonably required under the circumstances but not less than [*] business days.
11.5.Prior Agreement. This Agreement supersedes the Confidential Disclosure Agreement between Amgen and MedImmune, LLC (an Affiliate of AstraZeneca) dated September 14, 2011, as amended and supplemented, including any written requests thereunder with respect to information disclosed thereunder relating to the Products and activities related thereto. All confidential information exchanged between the Parties and their respective Affiliates under such agreement will be deemed Confidential Information of the disclosing Party disclosed hereunder and will be subject to the terms of this Agreement.
11.6.Publications and Program Information. Except as permitted pursuant to Section 3.5 (Clinical Trial Register), the Development Lead for a Product will have the sole right to publish and make scientific presentations with respect to such Product, and to issue press releases (except with respect to the terms of this Agreement, which is governed by Section 11.4 (Press Releases)) or make other public disclosures regarding any such Product (including with respect to its development, commercialization and regulatory matters), and the other Party will not do so without the Development Lead’s prior written consent, except as required by Applicable Law; provided, that any publication or presentation to be made by the Development Lead that names the other Party will
47



require the prior consent of the other Party. The Development Lead will keep the relevant committee or team informed of its general publication strategy and presentation calendar. The Development Lead will consider any reasonable comments regarding such strategy from the other Party. In addition, the Development Lead will deliver to the other Party a copy of any proposed written publication or outline of presentation to be made by the Development Lead with respect to any scientific data pertaining to a Product in the Collaboration Scope in advance of submission for publication or presentation at least [*] days in advance of submission (or, where a copy of such publication or presentation is not available at such time, a draft or outline of such publication or a description of such presentation), and the other Party will have the right to: (i) require a delay in submission of not more than [*] days to enable patent applications protecting the other Party’s rights in Inventions owned by such Party; and (ii) prohibit disclosure of any of its Confidential Information in any such proposed publication or presentation. Publications and presentations will be subject to policies mutually agreed by the Patent Coordinators to ensure appropriate protection of intellectual property rights. If there is any dispute between the Parties with regard to a proposed publication, presentation or other communication regarding this Agreement, such dispute shall be referred to the JSC for resolution (with the Development Lead for the Product having the final decision).
12.REPRESENTATIONS AND WARRANTIES
12.1.Mutual Representations and Warranties. Each of the Parties hereby represents and warrants, as of the Effective Date to the other Party as follows:
12.1.1.It is duly organized and validly existing under the Applicable Law of its jurisdiction of incorporation and it has full corporate power and authority and has taken all corporate action necessary to enter into and perform this Agreement;
12.1.2.This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement, and compliance with its terms and provisions, and the consummation of the transaction contemplated hereby, by such Party will not materially conflict, interfere or be inconsistent with, result in any material breach of or constitute a material default under, any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor to its knowledge violate any Applicable Law. The person or persons executing this Agreement on such Party’s behalf have been duly authorized to do so by all requisite corporate action;
12.1.3.It has not been debarred or the subject of debarment proceedings by any Governmental Authority;

12.1.4.To its knowledge, it and its Affiliates have not violated any Anti-Corruption Law; and
12.1.5.It has not granted any right to any Third Party relating to any intellectual property or proprietary right licensed, granted or assigned by it to the other Party hereunder that conflicts with the rights licensed, granted or assigned to the other Party hereunder.
12.2.Amgen Representations and Warranties. In addition to the representations and warranties set forth in Section 12.1 (Mutual Representations and Warranties), Amgen hereby represents and warrants to Partner that, as of the Effective Date:
48



12.2.1.Amgen has not received written notice from any Third Party that any issued and enforceable Patent of such Third Party would be infringed by the importation, manufacture, distribution, marketing or sale of a Product (except, in each case, where Amgen may have since such time obtained a license to the relevant Patent);
12.2.2.Amgen is the sole owner of all right, title and interest in the Patents included within Amgen Intellectual Property or otherwise has the right to grant to Partner the rights to such Patents, and the Amgen Intellectual Property is not subject to any lien or other encumbrance in favor of any Third Party that conflicts with the rights or licenses of Partner hereunder;
12.2.3.No patent application or registration within the Amgen Intellectual Property is the subject of any pending interference, opposition, cancellation, or patent protest pursuant to 37 C.F.R. §1.291;
12.2.4.To Amgen’s knowledge, no Third Party is [*] in the Collaboration Scope;
12.2.5.To Amgen’s knowledge, the development of the Products in the Collaboration Scope by or on behalf of Amgen [*];
12.2.6.To Amgen’s knowledge, there is no [*]. For the purposes of this Section 12.2.6, “[*]” does not include claims for [*] for the [*] related to [*];
12.2.7.Amgen has made available to Partner true and correct copies of the following: (i) all material Regulatory Filings for the Collaboration Territory; (ii) all material correspondence with Governmental Authorities with respect to such Regulatory Filings; (iii) all minutes of any material meetings, telephone conferences or discussions with Governmental Authorities with respect to such Regulatory Filings; and (iv) all final clinical trial reports, in each case with respect to the Products and to the extent in existence as of the Effective Date;
12.2.8.Amgen is the owner of [*] Regulatory Filings for the Products in the Collaboration Scope;
12.2.9.Except as would not be reasonably expected to have a material adverse effect on the development, manufacture or commercialization of Products, Amgen has filed with the relevant Governmental Authorities all required notices, amendments and annual reports, as well as adverse event reports, with respect to the Regulatory Filings for the Products in the Collaboration Scope in existence as of the Effective Date;
12.2.10.To Amgen’s knowledge, there is no pending action or action threatened in writing by relevant Governmental Authorities to place a clinical hold order on, or otherwise terminate or suspend, any of the Regulatory Filings for a Product in existence as of the Effective Date;
12.2.11.The Completed Clinical Trials Schedule contains a complete list of all clinical trials carried out by or on behalf of Amgen or its Affiliates in relation to the Products for which dosing of patients was completed before the Effective Date;
12.2.12.Amgen has provided Partner with true and correct copies of [*];
12.2.13.No written notice has been given or received by Amgen that [*] prior to the Effective Date; and
12.2.14.Amgen has [*].
12.3.Mutual Covenants. Each Party hereby covenants to the other Party that, during the Term:
49



12.3.1.it will not grant any right to any Third Party relating to any intellectual property or proprietary right licensed or assigned by it to the other Party hereunder that conflicts with the rights granted to the other Party hereunder;
12.3.2.it will not knowingly use in connection with the research, development, manufacture or commercialization to take place pursuant to this Agreement any employee, consultant or investigator that has been debarred or the subject of debarment proceedings by any regulatory agency; and
12.3.3.Each Party agrees, on behalf of itself, its officers, directors and employees and on behalf of its Affiliates, agents, representatives, consultants and subcontractors hired in connection with the subject matter of his Agreement (together with the Party, the “Party Representatives”) that in connection with any Designated Partner Activities or Designated Amgen Activities, as applicable:
12.3.3.1.Each Party’s respective Party Representatives shall not directly or indirectly pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to:
(i)    any Government Official in order to influence official action;
(ii)    any Person (whether or not a Government Official) (a) to influence such Person to act in breach of a duty of good faith, impartiality or trust (“acting improperly”), (b) to reward such Person for acting improperly, or (c) where such Person would be acting improperly by receiving the money or other thing of value;
(iii)    any other Person while knowing or having reason to know that all or any portion of the money or other thing of value will be paid, offered, promised or given to, or will otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement; or
(iv)    any Person to reward that Person for acting improperly or to induce that Person to act improperly.
12.3.3.2.Each Party’s Party Representatives shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti-Corruption Laws.
12.3.3.3.Each Party, on behalf of itself and its other Party Representatives, represents and warrants to the other Party that for the term of this Agreement and [*] thereafter each Party shall maintain accurate books and reasonably detailed records in connection with the performance of its obligation under this Agreement including all records required to establish compliance with Sections 12.3.3.1 and 12.3.3.2 above.
12.3.3.4.Each Party shall promptly provide the other Party with written notice of the following events:
(a)    Upon becoming aware of any breach or violation by a Party or its Party Representative of any representation, warranty or undertaking set forth in Sections 12.3.3.1 and 12.3.3.2.
50



(b)    Upon receiving a formal notification that it is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation or upon receipt of information from any of its Party Representatives connected with this Agreement that any of them is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation.
12.4.Amgen Covenant. Except as would not be reasonably expected to have a material adverse effect on the development, manufacture or commercialization of Products, Amgen and its Affiliates will [*]. Amgen will notify Partner in writing of any [*].
12.5.AstraZeneca Covenant. [*].
12.6.Disclaimer of Warranties. EXCEPT AS SET FORTH IN THIS ARTICLE 12 (REPRESENTATIONS AND WARRANTIES), PARTNER AND AMGEN EXPRESSLY DISCLAIM ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE COLLABORATION, PRODUCT INTELLECTUAL PROPERTY, AMGEN HOUSEMARKS, PARTNER HOUSEMARKS, PRODUCT TRADEMARKS, THIS AGREEMENT, OR ANY OTHER SUBJECT MATTER RELATING TO THIS AGREEMENT, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OR NONINFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS.
12.7.Limitation of Liability. NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN, OTHER THAN TO THE EXTENT RESULTING FROM A PARTY’S BREACH OF ARTICLE 9 (DISTRACTING PRODUCTS) OR SECTION 11.1 (CONFIDENTIALITY; EXCEPTIONS), IN NO EVENT WILL PARTNER OR AMGEN BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT. THE FOREGOING SENTENCE WILL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST SUCH DAMAGES AS ARE AWARDED TO A THIRD PARTY WITH RESPECT TO THIRD PARTY CLAIMS UNDER SECTION 13.1 (INDEMNITY BY PARTNER) OR SECTION 13.2 (INDEMNITY BY AMGEN).
13.INDEMNIFICATION AND INSURANCE
13.1.Indemnity by Partner. Partner will defend, indemnify, and hold harmless Amgen, its Affiliates, and their respective directors, officers, employees, agents and representatives (collectively, “Amgen Indemnitees”), at Partner’s cost and expense, from and against any and all liabilities, losses, costs, damages, fees or expenses (including reasonable legal expenses and attorneys’ fees) (collectively, “Losses”) arising out of any Third Party Claims brought against any Amgen Indemnitee to the extent such Losses result from: [*]. The indemnification obligations under this Section 13.1 (Indemnity by Partner) exclude Losses to the extent they arise from [*] below in Section 13.2 (Indemnity by Amgen).
13.2.Indemnity by Amgen. Amgen will defend, indemnify, and hold harmless Partner, its Affiliates, and their respective directors, officers, employees, agents and representatives (collectively, “Partner Indemnitees”), at Amgen’s cost and expense, from and against any and all Losses arising out of any Third Party Claims brought against any Partner
51



Indemnitee to the extent such Losses result from: [*]. The indemnification obligations under this Section 13.2 (Indemnity by Amgen) exclude Losses to the extent they arise from [*] above in Section 13.1 (Indemnity by Partner).
13.3.Claim for Indemnification. Whenever any Third Party Claim or Loss arises for which a Partner Indemnitee or an Amgen Indemnitee (the “Indemnified Party”) may seek indemnification under this Article 13 (Indemnification and Insurance), the Indemnified Party will promptly notify the other Party (the “Indemnifying Party”) of the Third Party Claim or Loss; provided, that the failure by an Indemnified Party to give such notice will not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that the Indemnifying Party is actually prejudiced as a result of such failure. The Indemnifying Party will have exclusive control of the defense and settlement of all Third Party Claims for which it is responsible for indemnification and will assume defense thereof at its own expense promptly upon notice of such Third Party Claim. In no event will the Indemnifying Party settle any Third Party Claim without the prior written consent of the Indemnified Party if such settlement (x) does not include a complete release from liability on such Third Party Claim, or (y) includes any admission of wrongdoing by the Indemnified Party or that any intellectual property or proprietary right of the Indemnified Party is invalid or unenforceable. The Indemnified Party will have the right to employ separate counsel at the Indemnifying Party’s expense and to control its own defense of the applicable Third Party Claim if: (i) there are or may be legal defenses available to the Indemnified Party that are different from or additional to those available to the Indemnifying Party; or (ii) in the reasonable opinion of counsel to the Indemnified Party, a conflict or potential conflict exists between the Indemnified Party and Indemnifying Party that would make such separate representation advisable.
13.4.Defense of Third Party Claims. Except as otherwise provided in Section 13.3 (Claim for Indemnification), each Party (such Party referred to as the “Defending Party”) will have the sole right, but not the obligation, to defend against any Third Party Claims made against it with respect to its activities hereunder; provided, that any Third Party Claims relating to a nullification, declaratory judgment, opposition or revocation proceeding against any Product Intellectual Property will be governed by the provisions of Section 10.8 (Enforcement). Each Party will notify the other Party (the “Assisting Party”) as promptly as practicable if any such Third Party Claim is commenced or threatened against it, including any Infringement Claim. The Assisting Party will reasonably assist the Defending Party and cooperate in any such litigation at Defending Party’s reasonable request. Without limiting the foregoing, the Defending Party will keep the Assisting Party advised of all material communications, actual and prospective filings or submissions regarding such action, and will provide the Assisting Party copies of and an opportunity to review and comment on any such communications, filings and submissions; provided, that each Party will have the right to redact from any information disclosed to the other hereunder any information relating to a product other than a Product or relating to the manufacture of a Product. The Defending Party will control the defense and settlement of Third Party Claims, with the costs thereof being included in General Costs, to the extent provided in Section 1.65.4. The Defending Party will not settle such Third Party Claim without the prior written consent of the other Party (such consent not to be unreasonably withheld), unless such settlement: [*]. In the event that a Third Party Claim is brought against both of the Parties (a “Joint Claim”), then the Parties will determine whether to defend against such Joint Claim, which of the Parties should be the Defending Party or whether the Parties should jointly control such defense and the strategy for such defense. In the case of an Infringement Claim, the coordination and cooperation set forth in this Section 13.4 (Defense of Third Party Claims) will be accomplished via the Patent Coordinators. This Section 13.4
52



(Defense of Third Party Claims) will not apply to employment or similar personnel-related claims.
13.5.Insurance. Each of the Parties will, at their own respective expense (and not subject to cost sharing hereunder) procure and maintain during the Term, insurance policies adequate to cover their obligations hereunder and consistent with the normal business practices of prudent pharmaceutical companies of similar size and scope (or reasonable self-insurance sufficient to provide materially the same level and type of protection). Such insurance will not create a limit to either Party’s liability hereunder.
14.TERM AND TERMINATION
14.1.Term. This Agreement will become effective on the Effective Date and will continue during the Term.
14.2.Termination for Convenience.
14.2.1.Either Party will have the right to terminate this Agreement, either in whole or on a Product-by-Product basis, by providing the other Party with [*] prior written notice (or, after First Commercial Sale of a Product, [*] prior written notice with respect to such Product); provided, that a notice of termination with respect to a particular Product may only be provided after the Continued Development Meeting for such Product has occurred and a notice of termination with respect to the Agreement in whole may only be provided after the Continued Development Meetings for all Products have occurred.
14.2.2.[*].
14.3.Termination for Breach. In the event of a material breach of this Agreement, the non-breaching Party will have the right to terminate this Agreement, either in whole or (if such breach solely applies to a specific Product(s)) with respect to the applicable Product(s). The non-breaching Party may terminate this Agreement, whether in its entirety or on a Product-by-Product basis (as applicable), by written notice to the breaching Party, which notice will specify the nature of such breach in reasonable detail. Such termination will become effective on the date that is [*] days after the delivery thereof to the breaching Party (or, in the case of a failure to pay amounts due hereunder, [*] days) unless, during the [*] day (or [*] day) period after delivery of such notice to the breaching Party, the breaching Party has cured such breach to the reasonable satisfaction of the non-breaching Party. Notwithstanding the foregoing, in the event of a good faith dispute as to whether performance has been made by either Party pursuant to this Agreement, including any good faith dispute as to payments due under this Agreement, the relevant cure period with respect thereto will be tolled pending resolution of such dispute in accordance with the applicable provisions of this Agreement; provided, that if such dispute relates to payment, the cure period will only apply with respect to payment of disputed amounts, and not with respect to undisputed amounts.
14.4.Termination for Insolvency. Either Party will have the right to terminate this Agreement immediately upon written notice, if: (i) the other Party becomes insolvent; (ii) the other Party files a petition in bankruptcy, or if an involuntary petition in bankruptcy is filed against the other Party and such involuntary petition is not dismissed within seventy-five (75) days and the other Party (a) fails to assume this Agreement in any such bankruptcy proceeding within thirty (30) days after filing or (b) assumes and assigns this Agreement to a Third Party; or (iii) a receiver or guardian has been appointed for the other Party who is not discharged within seventy-five (75) days after appointment.
53



14.5.Termination for Challenge. Either Party will have the right to terminate this Agreement on a Product-by-Product basis by written notice to the other Party, if such other Party, its Affiliates or licensees bring or join any challenge to the validity or enforceability of (i) if Amgen is the challenging Party, any Partner Intellectual Property or any Program Intellectual Property, in each case as and to the extent such Partner Intellectual Property or Program Intellectual Property applies to the Product in the Collaboration Scope that is the subject of the termination notice; and (ii) if Partner is the challenging Party, any Amgen Intellectual Property (or any intellectual property corresponding to any such Amgen Intellectual Property in the Excluded Territory) or any Program Intellectual Property, in each case as and to the extent such Amgen Intellectual Property or Program Intellectual Property applies to a Product in the Collaboration Scope that is the subject of the termination notice. Notwithstanding the foregoing, nothing in this Section 14.5 (Termination for Challenge) will either: (a) prevent either Party from asserting any defense or counterclaim in an action for infringement of intellectual property, brought against such Party or its Affiliates, or any Third Party that such Party or any of its Affiliates is obligated to indemnify, or responding in any other manner to such an action for infringement; or (b) allow a Party to terminate this Agreement in the event the other Party asserts any such defense or counterclaim or otherwise responds in any such action for infringement.
14.6.Effects of Termination.
14.6.1.Product by Product Termination. Upon the termination of this Agreement by a Party with respect to one or more Products (each, a “Terminated Product”), the following will apply:
14.6.1.1.Termination of Product. Each Terminated Product will thereafter cease to be a Product for all purposes of this Agreement; and accordingly, for purposes of this Section 14.6 (Effects of Termination):
(i)    “Continuing Party” means the Party that is not the Terminating Party;
(ii)    “Continuing Scope” means with respect to a particular Terminated Product, the uses, countries and territories within the Collaboration Scope for such Terminated Product immediately prior to the Termination Effective Date;
(iii)    “Termination Effective Date” means, with respect to a particular Terminated Product, the effective date of such termination with respect to such Terminated Product;
(iv)    “Terminated Product Intellectual Property Rights” means (a) the Terminating Party’s rights in and to the Program Intellectual Property and (b) (1) to the extent the Terminating Party is Amgen, the Amgen Terminated Product IP or (2) to the extent the Terminating Party is Partner, the Partner Terminated Product IP. For such purposes, “Amgen Terminated Product IP” and “Partner Terminated Product IP” mean, respectively, Amgen Intellectual Property and Partner Intellectual Property, but substituting for each reference to “Product” and “Product Trademark” therein, “Terminated Product” and “Terminated Product Trademark,” respectively; and
(v)    “Terminated Product Promotional Materials” and “Terminated Product Trademarks” mean, respectively, Promotional Materials and Product Trademarks with respect to the Terminated Product (i.e., for such purposes, substituting in the definition of Promotional Materials and
54



Product Trademark a reference to “Terminated Product” for each reference to “Product”).
(vi)    “Terminating Party” means (a) the Party terminating the Agreement in the case of termination pursuant to Section 14.2 (Termination for Convenience); (b) the non-breaching Party in the case of termination pursuant to Section 14.3 (Termination for Breach); (c) the non-insolvent Party in the case of termination pursuant to Section 14.4 (Termination for Insolvency); and (d) the non-challenging Party in the case of termination pursuant to Section 14.5 (Termination for Challenge).
14.6.1.2.Accrued Obligations. Termination of this Agreement with respect to a Terminated Product will not release either Party from any liability (including any payment obligations) with respect to such Terminated Product that, at the time of such termination, has already accrued to the other Party or which is attributable to activities prior to such termination.
14.6.1.3.Continuing Party’s Rights. The Continuing Party will have the sole right, as between the Parties, to develop, manufacture and commercialize the Terminated Product within the Continuing Scope. Accordingly, upon the Termination Effective Date for such Terminated Product, or such earlier time as specified below, and in each case subject to Section 14.6.1.5 (Amgen’s Rights Outside Continuing Scope) below:
(i)    Terminated Product Intellectual Property Rights. The Terminating Party will grant, and hereby grants, to the Continuing Party an exclusive, royalty-free license, including the right to grant and authorized sublicenses, under the Terminated Product Intellectual Property Rights to make, have made, use, sell, offer for sale and import the Terminated Product within the Continuing Scope. The Terminating Party will, subject to clause (vii) of this Section 14.6.1.3, immediately cease all of its development, manufacturing and commercialization activities for the Terminated Product.
(ii)    Assignment of Trademarks. The Terminating Party will assign, and hereby assigns, to the Continuing Party all of the Terminating Party’s rights, title and interest in and to the Terminated Product Trademarks for such Terminated Product (including any goodwill associated therewith), including all registrations therefore. Accordingly, the Terminating Party will cease all use of such Terminated Product Trademark.
(iii)    Terminated Product Data. The Terminating Party will promptly transfer to the Continuing Party, at no cost, copies of all data, reports, records, materials and other Know-How in its possession or control that relate to the Terminated Product (“Terminated Product Data”), with such data to the extent they relate specifically to the Terminated Product becoming the Continuing Party’s Confidential Information and shall cease to be the Terminating Party’s Confidential Information. The Terminated Product Data will be provided in electronic form reasonably usable by the Continuing Party and, if reasonably necessary or useful in connection with the Continuing Party’s (or its designee’s) further commercialization, development or exploitation of the Terminated Product within the Continuing Scope, will include original hardcopies or duplicate copies thereof, as required.
55



(iv)    Return of Confidential Information. The Terminating Party will promptly return to the Continuing Party, or destroy at the Continuing Party’s request (and certify such destruction to the Continuing Party), all relevant records and materials in the Terminating Party’s possession or control containing Confidential Information of the Continuing Party that is: (a) related to the Terminated Product within the Continuing Scope and (b) not reasonably necessary for the Terminating Party to exercise any remaining rights or fulfill any remaining obligations it has under this Agreement after such termination; provided, that the Terminating Party (1) may keep one copy of such Confidential Information of the Terminating Party for archival purposes or as otherwise required under Applicable Law; and (2) ensures such copies are Segregated from any Distracting Program).
(v)    Return of Samples and Materials. The Terminating Party will promptly transfer to the Continuing Party, or destroy at the Continuing Party’s request (and certify such destruction to the Continuing Party), all samples, Terminated Product Promotional Materials, sales training materials and any other documents, or materials primarily intended for use in commercialization of the Terminated Product within the Continuing Scope.
(vi)    Assignment of Regulatory Filings and Approvals; Copyrights; Domain Names. The Terminating Party will, at its own expense (other than with respect to any fee payable to the relevant Governmental Authority in connection with the relevant assignment, which will be borne by the Continuing Party), assign, and hereby assigns, to the Continuing Party all Regulatory Filings and Regulatory Approvals related to the Terminated Product within the Continuing Scope, and all copyrights, copyright registrations, domain names and domain name registrations related to the Terminated Product (or to the Terminated Product Promotional Materials) within the Continuing Scope. The Terminating Party will promptly submit any necessary notices to Governmental Authorities to effect such assignments. If Applicable Laws prevent or delay the transfer of ownership of any such Regulatory Filing or Regulatory Approval to the Continuing Party, the Terminating Party will grant, and does hereby grant, to the Continuing Party an exclusive and irrevocable right of access and reference to such Regulatory Filing and Regulatory Approvals for purposes of developing and commercializing the Terminated Product within the Continuing Scope, and will cooperate fully to make the benefits of such Regulatory Filings and Regulatory Approvals available to the Continuing Party or its designee(s) for purposes within the Continuing Scope for such Terminated Product. Promptly upon request following the notice of termination, the Terminating Party will provide to the Continuing Party copies of all such Regulatory Filings and Regulatory Approvals. For purposes of this Section 14.6.1 (Product by Product Termination), references to Product in the defined terms Regulatory Filings and Regulatory Approvals shall be replaced with references to Terminated Product.
(vii)    Transition. During the applicable notice period prior to the Termination Effective Date, the Terminating Party will continue to meet its obligations to develop, manufacture, and commercialize Products within the Collaboration Scope, in accordance with the applicable
56



Development Plan, Brand Plan and Country Plan and this Agreement and bear its proportionate share of expenses with respect thereto, unless otherwise agreed by the Parties or specified in this Section 14.6 (Effects of Termination). Upon request by the Continuing Party, the Terminating Party will undertake reasonable efforts to effect a smooth and orderly transition of all development, manufacturing and commercial activities and responsibilities under this Agreement with respect to the Terminated Product to the Continuing Party (or, in the case of manufacturing activities, to a mutually agreed upon Third Party contract manufacturer), as soon as reasonably possible, to enable the Continuing Party to continue the development, manufacturing and commercialization of the Terminated Product in the Continuing Scope. Without limiting the foregoing:
A.    Continued Supply. The Terminating Party will transfer to the Continuing Party all quantities of the Terminated Product in its possession for which the manufacturing costs were shared by the Parties under Article 7 (Profit/Expense Sharing). In addition, the Terminating Party will, at the Continuing Party’s cost and expense, reasonably cooperate, as requested by the Continuing Party, to ensure uninterrupted supply of the Terminated Product. To the extent the Terminating Party was responsible for manufacturing the Terminated Product as of the Termination Effective Date, then the Terminating Party will continue to provide for manufacturing of such Terminated Product for the Continuing Party, at the fully-burdened manufacturing cost therefore, from the date of notice of such termination with respect to such Terminated Product, until the sooner to occur of such time as the Continuing Party is able, using Commercially Reasonable Efforts to do so, to secure an acceptable alternative manufacturing source from which sufficient quantities of Terminated Product may be procured or [*] months from the Termination Effective Date.
B.    Contracts. If the Terminating Party is, as of the Termination Effective Date, party to any Third Party contracts that pertain solely to the Continuing Scope with respect to a Terminated Product, then it will provide the Continuing Party notice and (to the extent permitted to do so) copies thereof; and the Terminating Party will assign to the Continuing Party any such contracts requested by the Continuing Party, to the extent it has the right under such contract(s) to do so (and will use Commercially Reasonable Efforts to obtain any required consents).
14.6.1.4.Distracting Products. Notwithstanding anything herein to the contrary, if Amgen is terminating this Agreement pursuant to Section 14.2 (Termination for Convenience), Article 9 (Distracting Products) will continue to apply with respect to the Terminated Product for [*] thereafter. In addition, for any termination hereunder, with respect to Article 9 (Distracting Product), each reference to “Product” or “Product Target” in the definitions of Distracting Product and Distracting Target will be deemed to a reference to include the Terminated Product and the Product Target corresponding to such Terminated Product.
14.6.1.5.Amgen’s Rights outside Continuing Scope. Notwithstanding the foregoing provisions of this Section 14.6.1 (Product by Product Termination):
57



(i)    Terminated Product Intellectual Property Rights. Partner will grant, and hereby grants (effective upon the Termination Effective Date), to Amgen an [*], royalty-free, [*] license, including the right to grant and authorize sublicenses, under the Partner Terminated Product IP and Partner’s rights in and to the Program Intellectual Property to use, sell, offer for sale and import Terminated Products in the Excluded Territory, and to make and have made the Terminated Product for use and sale in the Excluded Territory, and the last sentence of Section 2.2 (Ex-Territory Activities) shall continue to apply with respect to the Terminated Product. In addition, Amgen will retain, and not assign to Partner, Amgen’s right, title or interest in the Terminated Product Trademarks in the Excluded Territory.
(ii)    Terminated Product Data. If Amgen is the Terminating Party with respect to a Terminated Product, upon request by Amgen from time to time, Partner will promptly provide to Amgen at no cost, copies of Terminated Product Data then in Partner’s possession or control that relate to such Terminated Product, for use in the Excluded Territory in relation to the Terminated Product. Such Terminated Product Data will be provided in electronic form reasonably usable by Amgen and, if reasonably necessary or useful in connection with Amgen’s (or its designee’s) further commercialization, development or exploitation of Terminated Products in the Excluded Territory, will include original hardcopies or duplicate copies thereof, as required.
(iii)    Regulatory Filings; Regulatory Approvals. Partner will grant, and does hereby grant (effective upon the Termination Effective Date), to Amgen an exclusive and irrevocable right of access and reference to any and all Regulatory Filings and Regulatory Approvals for the Terminated Product for purposes in the Excluded Territory, and will cooperate fully to make the benefits of such Regulatory Filings and Regulatory Approvals available to Amgen or its designee(s) for purposes in the Excluded Territory. Promptly upon request by Amgen from time to time, Partner will provide to Amgen copies of all Regulatory Filings and Regulatory Approvals (and all underlying data) with respect to such Terminated Product held by or on behalf of Partner.
(iv)    Excluded Territory Agreements. In the event that Amgen is the Terminating Party for either AMG827 or AMG557, Partner, at the request of Amgen, will enter into good faith negotiations for the purpose of establishing direct communications and engagement between Partner and (i) Kirin-Amgen, Inc., in the case of AMG827, and (ii) Takeda Pharmaceutical Company Limited, in the case of AMG557, as necessary to fulfill Amgen’s obligations under the applicable Excluded Territory Agreement.
14.6.1.6.Royalty Payment. On a Terminated Product-by-Terminated Product basis, other than with respect to the AMG157 Termination Event, the Continuing Party will pay to the Terminating Party a tiered royalty on aggregate Terminated Product Net Revenues for such Terminated Product by the Continuing Party and its Affiliates (but not by its licensees or sublicensees) as follows:
58



Calendar Year Net Revenues for Terminated ProductRoyalty Rate
Less than or equal to [*][*]
Greater than [*] and less than or equal to [*][*]
Greater than [*][*]
Additionally, [*], the Continuing Party will pay to the Terminating Party [*] of any and all Sublicensing Revenues received by the Continuing Party and/or its Affiliates.
Additionally, if Partner is the Continuing Party, Partner will pay to Amgen an additional royalty equal to the applicable Terminated Product Inventorship Margin on Terminated Product Net Revenues by Partner, its Affiliates and sublicensees.
Such royalty will be payable quarterly within thirty (30) days of the end of the calendar quarter for which such royalties are owed. Each royalty payment will be accompanied by a report setting forth Partner’s calculation of Net Revenues and royalties owed for the applicable quarter. For such purposes, “Terminated Product Net Revenues” means “Net Revenues,” and “Terminated Product Inventorship Margin” will mean the “Inventorship Margin,” but for such purposes substituting in such definitions (including in each definition referenced in such definitions) a reference to “Terminated Product” for each reference to “Product;” and Sections 7.4 (Calculation of Net Revenues) and 8.3 (Currency) through 8.7 (Late Payment) (inclusive) will apply with respect to such royalty payments, mutatis mutandis.
14.6.2.Termination of Agreement in Entirety. In the event (i) this Agreement is terminated by Partner in its entirety under Section 14.2 (Termination for Convenience) or is terminated in its entirety under Sections 14.3 (Termination for Breach) through 14.5 (Termination for Challenge) (inclusive), or (ii) if as of the Termination Effective Date with respect to a Terminated Product, there are no other Products then being developed or commercialized under this Agreement, and Partner is not then developing or commercializing a Terminated Product as the Continuing Party under Section 14.6.1 (Product by Product Termination) above; then in either such case, the Agreement will terminate in whole, and all provisions of this Agreement will terminate as of the effective date of such termination, except as expressly set forth in Sections 14.6.1 (Product by Product Termination) and 14.6.3 (Survival) below.
14.6.3.Survival. Articles 1 (Definitions), 7 (Profit/Expense Sharing) (with respect to periods prior to termination), 8 (Payments) (with respect to periods prior to termination), 9 (Distracting Products) (only with respect to such continuing periods as expressly referenced in such Article), 13 (Indemnification and Insurance) (with respect to periods prior to termination), and 15 (Miscellaneous) and Sections 2.2 (Ex-Territory Activities), 3.4 (Product Complaints, Recalls and Returns), 5.8 (Detailing Reports and Audit Rights) (with respect to periods prior
59



to termination), 5.9 (Competing Products) (with respect to periods prior to termination), 10.1 (Invention Ownership), 10.3 (Joint Ownership), 10.4 (License Grant by Amgen) (only with respect to the transition period referenced in clause (vii) of Section 14.6.1.3 (Transition)), 10.5 (License Grant by Partner), 10.8 (Enforcement) (with respect to enforcement against activities that took place prior to or termination), 10.9 (Patent Term Extensions) (with respect to periods prior to termination), 10.10.3 (Housemark Licenses) (with respect to the transition period referenced in clause (vii) of Section 14.6.1.3 (Transition) and the sell-off period referenced therein), 11.1 (Confidentiality; Exceptions), 11.2 (Authorized Disclosure), 11.3 (Confidential Treatment of Terms and Conditions), 11.5 (Prior Agreement), and this 14.6 (Effects of Termination) (with all Products deemed Terminated Products and Amgen being the Continuing Party for all Terminated Products) will survive termination of this Agreement for any reason. Except as otherwise provided in this Section 14.6 (Effects of Termination), all rights and obligations of the Parties under this Agreement will terminate upon termination of this Agreement for any reason.
14.6.4.No Limitation of Rights. The rights provided in this Article 14 (Term and Termination) will be in addition and without prejudice to any other rights which the Parties may have with respect to any default or breach of the provisions of this Agreement. Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies at equity or law will remain available to the Parties except as expressly agreed otherwise herein.
15.MISCELLANEOUS
14.1.Affiliates. Each Party will have the right to exercise its rights and perform its obligations hereunder through its Affiliates (including by licensing rights hereunder where such rights are held in the name of any such Affiliate); provided, that such Party will be responsible for its Affiliates’ performance hereunder.
14.2.Assignment. Neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred (whether by operation of Applicable Law, general succession or otherwise) by either Party without the prior written consent of the other Party; provided, that either Party may assign this Agreement, or rights and obligations hereunder, without prior written consent to any Affiliate (as long as such entity remains an Affiliate of the relevant Party), or in connection with the transfer or sale of all or substantially all of the business to which this Agreement relates. Any assignment not in accordance with this Agreement will be void ab initio. Subject to the foregoing, the rights and obligations of the Parties under this Agreement will be binding upon and inure to the benefit of the successors and permitted assigns of the Parties.
14.3.Choice of Law; Jurisdiction. This Agreement will be governed by, and enforced and construed in accordance with, the laws of the State of New York without regard to its conflicts of law provisions, except as to any issue which depends upon the validity, scope or enforceability of any Patent, which issue will be determined in accordance with the laws of the country in which such patent was issued. Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the state and federal courts of the State of New York for any matter arising out of or relating to this Agreement and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts. Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Agreement or the transactions contemplated hereby in the state and federal courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum. The
60



Parties agree that a final judgment in any such matter will be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law. Any proceeding brought by either Party under this Agreement will be exclusively conducted in the English language. The United Nations Convention for the International Sale of Goods will not apply to the transactions contemplated herein.
14.4.Construction. The definitions of the terms herein will apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun will include the corresponding masculine, feminine and neuter forms. The words “include”, “includes” and “including” will be deemed to be followed by the phrase “without limitation”. The word “or” is used in the inclusive sense (and/or). The Parties each acknowledge that they have had the advice of counsel with respect to this Agreement, that this Agreement has been jointly drafted, and that no rule of strict construction will be applied in the interpretation hereof. Unless the context requires otherwise: (i) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein); (ii) any reference to any Applicable Law herein will be construed as referring to such Applicable Law as from time to time enacted, repealed or amended; (iii) any reference herein to any person will be construed to include the person’s permitted successors and assigns; (iv) the words “herein”, “hereof” and “hereunder”, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof; and (v) all references herein to Articles, Sections, or Schedules, unless otherwise specifically provided, will be construed to refer to Articles, Sections or Schedules of this Agreement. This Agreement has been executed in English, and the English version of this Agreement will control.
14.5.Counterparts. This Agreement may be executed in counterparts with the same effect as if both Parties had signed the same document. All such counterparts will be deemed an original, will be construed together and will constitute one and the same instrument. Signature pages of this Agreement may be exchanged by facsimile or other electronic means without affecting the validity thereof.
14.6.Entire Agreement. This Agreement, including the attached Schedules, constitutes the entire agreement between the Parties as to the subject matter of this Agreement, and supersedes and merges all prior or contemporaneous negotiations, representations, agreements and understandings regarding the same.
14.7.Force Majeure. Neither Party will be liable for delay or failure in the performance of any of its obligations hereunder (other than the payment of money) to the extent such delay or failure is due to causes beyond its reasonable control, including acts of God, fires, floods, pandemics, earthquakes, labor strikes, acts of war, terrorism or civil unrest (“Force Majeure”); provided, that the affected Party promptly notifies the other Party in writing (and continues to provide monthly status updates to the other Party for the duration of the effect); and provided, further that the affected Party uses its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and will continue performance with reasonable dispatch whenever such causes are removed.
14.8.Further Assurances. Each Party agrees to do and perform all such further acts and things and will execute and deliver such other agreements, certificates, instruments and documents necessary or that the other Party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and to evidence, perfect or otherwise confirm its rights hereunder.
61



14.9.Headings. Headings and captions are for convenience only and are not to be used in the interpretation of this Agreement.
14.10.No Set-Off. Except as expressly set forth in Section 7.2.9 (True-Up), Section 8.6.1 (Withholding) or Section 8.6.2 (Indirect Taxes), no Party will have the right to deduct from amounts otherwise payable hereunder any amounts payable to such Party (or its Affiliates) from the other Party (or its Affiliates), whether pursuant to this Agreement or otherwise.
14.11.Notices. Any notice required or permitted to be given by this Agreement will be in writing, in English, and will be delivered by hand or overnight courier with tracking capabilities or mailed postage prepaid by registered or certified mail addressed as set forth below unless changed by notice so given:
If to Amgen:    Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799
Attention: Corporate Secretary
Telephone: 805-447-1000
Facsimile: [*]

If to Partner:     AstraZeneca Collaboration Ventures, LLC
One MedImmune Way
Gaithersburg, Maryland 20878
Attention: President
Telephone: [*]
Facsimile: [*]

With a copy to the Secretary of AstraZeneca Collaboration Ventures, LLC at the above address.
Any such notice will be deemed given on the date delivered. A Party may add, delete (so long as at least one person is remaining), or change the person or address to which notices should be sent at any time upon written notice delivered to the other Party in accordance with this Section 15.11 (Notices).
14.12.Relationship of the Parties.  Each Party is an independent contractor under this Agreement.  Nothing contained herein will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party.  The Parties will operate their own businesses separately and independently and they will hold themselves out as, act as, and constitute independent contractors in all respects and not as principal and agent, partners or joint venturers. Neither party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. 
14.13.Severability. To the fullest extent permitted by Applicable Law, the Parties waive any provision of Applicable Law that would render any provision in this Agreement invalid, illegal or unenforceable in any respect. If any provision of this Agreement is held to be invalid, illegal or unenforceable, in any respect or to any extent, then in such respect and to such extent such provision will be given no effect by the Parties and will not form part of this Agreement. To the fullest extent permitted by Applicable Law, all other provisions of this Agreement will remain in full force and effect and the Parties will use their commercially reasonable efforts to negotiate a provision in replacement
62



of the provision held invalid, illegal or unenforceable that is consistent with Applicable Law and achieves, as nearly as possible, the original intention of the Parties.
14.14.Third Party Beneficiaries. Except as expressly provided with respect to Amgen Indemnitees or Partner Indemnities in Article 13 (Indemnification and Insurance), there are no Third Party beneficiaries intended hereunder and no Third Party will have any right or obligation hereunder.
14.15.Waivers and Modifications. The failure of any Party to insist on the performance of any obligation hereunder will not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof will not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any other occasion. No waiver, modification, release or amendment of any right or obligation under or provision of this Agreement will be valid or effective unless in writing and signed by all Parties hereto.
14.16.[*].
*********
(Signature page follows)
63



IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

ASTRAZENECA COLLABORATION        AMGEN INC.
VENTURES, LLC
By:     /s/ Peter Greenleaf        By:     /s/ David J. Scott    
Name: Peter Greenleaf        Name: David J. Scott    
Title: President        Title: SVP, General Counsel & Secretary    


ASTRAZENECA PHARMACEUTICALS LP        
By:     /s/ Ann Booth Barbarin        
Name: Ann Booth Barbarin        
Title: Assistant Secretary        

    S-1


Schedule
AMG827 Territory

Column 1Column 2Column 3
European CountriesCentral and South American CountriesAfrican and Middle East Countries
AlbaniaAntigua and BarbudaAlgeria
AndorraArgentinaAngola
ArmeniaBahamasBahrain
AustriaBarbadosAngola
AzerbaijanBelizeBenin
BelarusBoliviaBotswana
BelgiumBrazilBurkina Faso
Bosnia-Herzg.ChileCameroon
BulgariaColombiaCentral African Republic
CroatiaCosta RicaCongo (Democratic Republic of)
Czech RepublicCubaCongo (Republic of the)
DenmarkDominicaCote D’Ivoire/Ivory Coast
EstoniaDominican RepublicCyprus
FinlandEcuadorDjibouti
FranceEl SalvadorEgypt
GeorgiaFrench GuianaEritrea
GermanyGrenadaEthiopia
GreeceGuatemalaGabon
HungaryGuyanaGambia
IcelandHondurasGhana
IrelandJamaicaGibraltar
ItalyNicaraguaGreenland
LatviaPanamaIran
LithuaniaParaguayIraq
LiechtensteinPeruIsrael
LuxembourgSaint Kitts and NevisJordan
MacedoniaSaint LuciaKazakhstan
MaltaSaint Vincent and the GrenadinesKenya
MoldovaSurinameKuwait
MonacoTrinidad and TobagoKyrgyzstan
NetherlandsUruguayLesotho
NorwayVenezuelaLebanon
PolandLiberia
PortugalLibya
RomaniaMadagascar
RussiaMalawi
San MarinoMauritania
Serbia and MontenegroMauritius
    


Column 1Column 2Column 3
SlovakiaMorocco
SloveniaMozambique
SwedenNamibia
SwitzerlandNiger
SpainNigeria
Oman
Qatar
Rwanda
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sudan
Swaziland
Syria
Tajikistan
Tanzania
Tunisia
Turkey
Turkmenistan
Uganda
United Arab Emirates
Uzbekistan
Yemen
Zambia
Zimbabwe








Schedule
Amgen Distribution Countries

[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*]
[*][*]

    


Schedule
Commercial Allocation

AMG827-
Respiratory-
Partner will have the sole right to Detail Products in the Respiratory market in the Collaboration Territory.
Rheumatology-
Amgen will have the sole right to Detail Products in the Rheumatology market in North America, Europe, Australia and New Zealand.
For the Rheumatology market in all other countries in the Collaboration Territory, the Parties shall enter into discussions regarding the allocation of Details beginning [*] prior to the anticipated first commercial launch of AMG827 for a Rheumatology indication. The JSC shall agree upon the allocation of Details between the Parties taking into account all relevant factors [*]; provided, that if the JSC is unable to agree upon the allocation of Details in any country, then such matter shall be escalated to the CRC; provided, further, that if the CRC is unable to agree upon the allocation of Details in any country, [*]. To the extent less than one hundred percent (100%) of the Details in any such country have been allocated to the Parties, the Parties shall [*]. If the Parties in the aggregate elect to Detail in excess of one hundred percent (100%) of the Details in any such country, then each Party will be entitled to only [*].
Dermatology-
Amgen will have the sole right to Detail Products in the Dermatology market in North America.
For the Dermatology market in all other countries in the Collaboration Territory, Partner will have the sole right to Detail Products, provided, that, to the extent Amgen has or develops a commercial capability to Detail Products consistent with the Brand Plan in the Dermatology market in any such country, so that in such country Amgen would have the capability to provide [*] percent ([*]%) of the Details in that country, Amgen will have the right to provide [*] percent ([*]%) of such Details in such country, provided that Amgen shall not have the right to provide Details in countries which collectively represent in excess of [*] percent ([*]%) of [*] of all countries in the Collaboration Territory [*]. If Amgen determines that it wishes to build a commercial capability in a country (without necessarily having sufficient capability to provide [*] percent ([*]%) of the Details in that country) the Parties will discuss in good faith allocation of Details in such country to determine what is in the best interests of the Product in that country according to the then current Brand Plan.

    


Additional Indications-
For all market segments other than Respiratory, Rheumatology and Dermatology, the Parties shall enter into discussions regarding the allocation of Details beginning [*] prior to the anticipated first commercial launch of AMG827 for such market segment. The JSC shall agree upon the allocation of Details between the Parties taking into account all relevant factors [*]; provided, that if the JSC is unable to agree upon the allocation of Details in any country, then such matter shall be escalated to the CRC; provided, further, that if the CRC is unable to agree upon the allocation of Details in any country, [*]. To the extent less than one hundred percent (100%) of the Details in any such country have been allocated to the Parties, the Parties shall [*]. If the Parties in the aggregate elect to Detail in excess of one hundred percent (100%) of the Details in any such country, then each Party will be entitled to only [*].

Definitions-
“Dermatology” means the branch of medicine dealing with the skin and its diseases or disorders, including psoriasis and atopic dermatitis.
“Respiratory” means the branch of medicine dealing with inflammatory respiratory diseases or disorders and obstructive respiratory diseases or disorders, including asthma and chronic obstructive pulmonary disease (COPD).
“Rheumatology” means the branch of medicine dealing with rheumatic diseases or disorders, including rheumatoid arthritis, systemic lupus erythematosus (SCE), psoriatic arthritis, and ankylosing spondylitis.
All Other Products-
For all other Products, the Parties shall, on a market segment basis, enter into discussions regarding the allocation of Details for a Product beginning [*] prior to the anticipated first commercial launch of such Product for such market segment. The JSC shall agree upon the allocation of Details between for such Product in such market segment the Parties taking into account all relevant factors ([*]); provided, that if the JSC is unable to agree upon the allocation of Details in any country, then such matter shall be escalated to the CRC; provided, further, that if the CRC is unable to agree upon the allocation of Details in any country, [*]. To the extent less than one hundred percent (100%) of the Details in any such country have been allocated to the Parties, the Parties shall [*]. If the Parties in the aggregate elect to Detail in excess of one hundred percent (100%) of the Details in any such country, then each Party will be entitled to only [*].




Schedule
Completed Clinical Trials


AMG 139
Ph 1a FIH single ascending dose study (20080767)

AMG 157
Ph 1a FIH single ascending dose study (20070620)
Ph 1b multiple ascending dose study (20080390)

AMG 557
Ph 1a FIH single ascending dose study in SLE subjects (2006132)
Ph 1b MAD in SLE subjects (2007169)

AMG 827
Ph1 device preference study in HV (20110106)
Ph 1a FIH single ascending dose study (20060279)
Ph 1b multiple ascending dose study in RA (20070264)
Ph 2 multiple dose, dose ranging study in RA (20090061)
Ph 2 open label extension study in RA (20090402)
Ph 2 multiple dose, dose ranging study in psoriasis (20090062)
Ph 2 multiple dose, dose ranging study in CD (20090072)
Ph 2 open label extension study in CD (201000008)
Ph 2 multiple dose, dose ranging study in asthma (20090203)





    


Schedule
[*] Designated Endpoints [*]

All of the following criteria must be met for a go decision to commence a [*] Trial.

·[*]: A statistically significant [*] and clinically significant ([*]) change in [*] from [*] at [*] for [*] and the [*] performs similarly to or better than the [*].
·[*]: A trend in [*] of [*] from [*] for [*] and the [*]. [*] are defined as [*] leading to [*] for [*]. The [*] in [*] will be [*] with the [*]. If the [*], then [*] and the [*].
·[*]: There are no [*] that [*].








Schedule
Development/Commercial Lead


AmgenPartner
AMG827AMG139
AMG557AMG157
AMG181


[*] -

1Specifically with regard to AMG827 at the global level, the Parties will work closely through the JPT on the commercial strategy for the Respiratory market for AMG827 with Amgen taking the primary responsibility for [*].
2[*].
3The Parties will cooperate to ensure that [*] is made available to the JPT at both the global and regional level.
4This arrangement will be noted in the press release and other approved communications as “[*]” or with words of similar import.



Schedule
Distracting Product



ProductProduct Target
Distracting Target*
AMG 139[*][*]
AMG 157[*][*]
AMG 181[*][*]
AMG 557[*][*]
AMG 827[*][*]

*Distracting Target includes (i) any [*]; (ii) any [*]; (iii) any [*]; (iv) any [*]; and (v) any [*]. For avoidance of doubt, the Distracting Product Schedule lists [*].

    


Schedule
Invoice

    


Amgen Inc.
Invoice Template
2nd Quarter 2012 - Example Period
 
  A  B  C = A + B    D  E  F = D + E    G = A - F  <<< Amount Billed or Reimbursed to Partner
  
 Total Quarterly Spend*    Amgen’s Share of...**    Amount due  
Product Amgen  Partner  Total    Amgen’s Spend  Partner’s Spend  Total Spend    (From)/To Amgen  
AMG 139  
 $-     $-     $-      $-     $-     $-      $-     
AMG 157  
 $-     $-     $-      $-     $-     $-      $-     
AMG 181  
 $-     $-     $-      $-     $-     $-      $-     
AMG 557  
 $-     $-     $-      $-     $-     $-      $-     
AMG 827  
 $-     $-     $-      $-     $-     $-      $-     
Total
 $-     $-     $-      $-     $-     $-      $-     
Notes
* Total spend derived from Column K on Page 2 and Column C on Page 3
** Amgen’s Share of Total Spend derived from Column L on Page 2 and Column D on Page 3






Amgen Inc.
Invoice Template
2nd Quarter 2012 - Example Period
Step 1: Calculation of Total AMGEN Cost less Amount Reimbursed by 3rd Party
 
    A  B  C = A + B  D = C x 35%  E = C - D    F  G  H = F + G  I = H x 70%  J = H - I  K = C + H  L = D + I  M = E + J 
  
 
  
 Total Costs Excluding AMG827 Ph2b
Asthma Study
   Costs for AMG827 Ph2b Asthma
Study
  Total Amgen Costs 
  
 
  
 Gross Spend 
Amgen
Share
  
Partner
Share
    Gross Spend  
Amgen
Share
  
Partner
Share
          
Function Product OSE  FTE  Total  35%  65%    OSE  FTE  Total  70%  30%  Total  
Amgen
Share
  
Partner
Share
 
R&D
 AMG 139   $-     $-     $-              $-     $-     $-    
 AMG 157   $-     $-     $-              $-     $-     $-    
 AMG 181   $-     $-     $-              $-     $-     $-    
 AMG 557   $-     $-     $-              $-     $-     $-    
 AMG 827         $-     $-     $-              $-     $-     $-     $-     $-     $-    
 Sub-Total R&D $-     $-     $-     $-     $-      $-     $-     $-     $-     $-     $-     $-     $-    
Operations
 AMG 139   $-     $-     $-              $-     $-     $-    
 AMG 157   $-     $-     $-              $-     $-     $-    
 AMG 181   $-     $-     $-              $-     $-     $-    
 AMG 557   $-     $-     $-              $-     $-     $-    
 AMG 827         $-     $-     $-              $-     $-     $-     $-     $-     $-    
 Sub-Total Ops $-     $-     $-     $-     $-      $-     $-     $-     $-     $-     $-     $-     $-    
Commercial
 AMG 139   $-     $-     $-              $-     $-     $-    
 AMG 157   $-     $-     $-              $-     $-     $-    
 AMG 181   $-     $-     $-              $-     $-     $-    
 AMG 557   $-     $-     $-              $-     $-     $-    
 AMG 827         $-     $-     $-                          $-     $-     $-    
 Sub-Total Comm’l   $-     $-     $-     $-     $-      $-     $-     $-     $-     $-     $-     $-     $-    
Total
 AMG 139 $-     $-     $-     $-     $-              $-     $-     $-    
 AMG 157 $-     $-     $-     $-     $-              $-     $-     $-    
 AMG 181 $-     $-     $-     $-     $-              $-     $-     $-    
 AMG 557 $-     $-     $-     $-     $-              $-     $-     $-    
 AMG 827 $-     $-     $-     $-     $-      $-     $-     $-     $-     $-     $-     $-     $-    
 Grand Total $-     $-     $-     $-     $-      $-     $-     $-     $-     $-     $-     $-     $-    
Notes
1. Page reflects Total Costs Incurred by/Reimbursed to AMGEN only
2. The values in the “Total” Row will be used for the following purposes on Page 1
- Determine the combined (Amgen + Partner) Total Cost of all programs in a quarter
- Deduct the actual expenses incurred/paid by Amgen from Amgen’s share of quarterly expenses




Amgen Inc.
Invoice Template
2nd Quarter 2012 - Example Period

Costs Incurred by Partner
 
  
  
ABC = B+AD = 35% x CE = C-D
       
     Amgen
Share
Partner Share
FunctionProduct    FTE        OSE        Total 
Costs    
35%65%
R&DAMG 139$                -$                      -  $                -  
 AMG 157$                -$                      -  $                -  
 AMG 181$                -$                      -  $                -  
 AMG 557$                -$                      -  $                -  
 AMG 827  $                -$                      -   $                -  
 Total$          -    $          -    $                -$                       -  $                -  
OperationsAMG 139$                -$                      -  $                -  
 AMG 157$                -$                      -  $                -  
 AMG 181$                -$                      -  $                -  
 AMG 557$                -$                      -  $                -  
 AMG 827  $                -$                      -   $                -  
 Total$          -    $          -    $                -$                       -  $                -  
Commercial    AMG 139$                -$                      -  $                -  
 AMG 157$                -$                      -  $                -  
 AMG 181$                -$                      -  $                -  
 AMG 557$                -$                      -  $                -  
 AMG 827  $                -$                      -   $                -  
 Total$          -    $          -    $                -$                       -  $                -  
TotalAMG 139$          -    $          -    $                -$                      -  $                -  
 AMG 157$          -    $          -    $                -$                      -  $                -  
 AMG 181$          -    $          -    $                -$                      -  $                -  
 AMG 557$          -    $          -    $                -$                      -  $                -  
 AMG 827$          -    $          -    $                -$                      -   $                -  
 Total$          -    $          -    $                 -$                       -  $                 -  
Notes
1. On this tab, Amgen will capture the quarterly spend incurred by partner for aggregation purposes
2. Table above is a placeholder/stand-in which will be replaced by the quarterly actual cost summary provided by partner
3. The values in the “Total” Row will be used for the following purposes on Page 1
- Determine the combined (Amgen + Partner) Total Cost of all programs in a quarter
- Deduct the actual expenses incurred/paid by partner from the partner’s share of quarterly expenses








Schedule
Press Release

 

News Release
 
AMGEN AND ASTRAZENECA ANNOUNCE COLLABORATION
TO JOINTLY DEVELOP AND COMMERCIALIZE CLINICAL-
STAGE INFLAMMATION PORTFOLIO
Collaboration Comprises Five Monoclonal Antibodies
Brodalumab (AMG 827) Phase 3 Trial Planned in 2012
THOUSAND OAKS, Calif. and LONDON (April 2, 2012)—Amgen (NASDAQ:AMGN) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen’s clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).
The companies believe all the molecules have novel profiles and offer the potential to deliver important treatments across multiple indications in inflammatory diseases. The collaboration will provide Amgen with additional resources to optimally progress its portfolio, and Amgen will benefit from the strong respiratory, inflammation and asthma development expertise of MedImmune, AstraZeneca’s biologics arm. The collaboration will also capitalize on AstraZeneca’s global commercial reach in respiratory and gastrointestinal diseases. The agreement does not include certain territories previously partnered by Amgen for brodalumab with Kyowa Hakko Kirin and AMG 557 with Takeda.
Under the terms of the agreement, AstraZeneca will make a one-time $50 million upfront payment and the companies will share both costs and profits. Based on current plans, approximately 65 percent of costs for the 2012-2014 period will be funded by AstraZeneca. Thereafter, the companies will split costs equally. Amgen will book sales globally and will retain a low single-digit royalty for brodalumab and a mid single-digit royalty for the rest of the portfolio, after which the companies will share profits equally.
AstraZeneca will lead the development and commercialization strategy of AMG 139, AMG 157 and AMG 181, while Amgen will lead the development and commercialization strategy of brodalumab and AMG 557. Each development and commercialization lead will be under the oversight of joint governing bodies. For brodalumab, commercial promotion will be split. Amgen will promote in dermatology indications in the United States (U.S.) and Canada, and in rheumatology indications in U.S., Canada and Europe. AstraZeneca will promote in respiratory and, initially, in dermatology indications of brodalumab across all territories outside the U.S., Canada and those markets where Amgen has existing partnerships. Allocation of promotional rights for other territories, indications and molecules will be agreed later between the companies.
“We are delighted to join forces with Amgen in developing and commercializing these novel clinical-stage assets that add value to our pipeline and build on our expertise in biologics. This creative collaboration will make the most of both companies’ respective capabilities, including AstraZeneca’s extensive global reach, to help bring these potentially innovative treatment options for a variety of respiratory and inflammatory diseases to patients around the world,” said David Brennan, Chief Executive Officer, AstraZeneca.
“We are very excited at the prospect of collaborating with a well-respected organization like AstraZeneca to advance our inflammation pipeline,” said Kevin Sharer, Chairman and CEO at Amgen. “We believe this collaboration has the potential to bring more therapies to patients sooner, across more geographic areas. We are impressed with AstraZeneca’s



extensive experience in developing and launching products in the respiratory and gastroenterology areas, and believe this collaboration is an opportunity to work with a partner that has leading regulatory and commercial expertise in inflammation indications.”
-ENDS-


NOTES TO EDITORS
About the inflammation portfolio included in the agreement
Under the agreement, the companies will jointly develop and commercialize the following five assets from Amgen’s clinical-stage portfolio:
 
  
Brodalumab (AMG 827) is a human monoclonal antibody that binds to and blocks signaling via the IL-17 receptor. Brodalumab is being investigated for psoriasis (completed Phase 2 and planned Phase 3), psoriatic arthritis (Phase 2) and asthma (Phase 2).
 
  
AMG 139 is a human monoclonal antibody. AMG 139 is being investigated in Phase 1b for Crohn’s disease.
 
  
AMG 181 is a human monoclonal antibody. AMG 181 is being investigated in Phase 1a and Phase 1b for ulcerative colitis and Crohn’s disease.
 
  
AMG 557 is a human monoclonal antibody that binds to B7-related protein 1 (B7RP-1). AMG 557 is being investigated in Phase 1b for autoimmune diseases such as systemic lupus erythematosus.
 
  
AMG 157 is a human monoclonal antibody that blocks interaction of thymic stromal lymphopoietin (TSLP) with the TSLP receptor. AMG 157 is being investigated in Phase 1b for asthma.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
Amgen Forward Looking Statements
This news release contains forward-looking statements that are based on Amgen’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-



looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen’s most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen’s most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen’s business. Unless otherwise noted, Amgen is providing this information as of April 2, 2012 and expressly disclaims any duty to update information contained in this news release.
No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with Amgen’s products after they are on the market. Amgen’s business may be impacted by government investigations, litigation and products liability claims. Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development.
In addition, sales of Amgen’s products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others’ regulations and reimbursement policies may affect the development, usage and pricing of Amgen’s products. In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products. Amgen believes that some of its newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen’s products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products. In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen’s ability to obtain or maintain patent protection for its products or product candidates. Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products. Amgen’s stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of significant problems with a product similar to one of Amgen’s products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen’s business and results of operations.
The scientific information discussed in this news release related to Amgen’s product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.



CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)
 
ASTRA ZENECA CONTACTS
 
 
Media Enquiries    
Esra Erkal-Paler  +44 20 7604 8030  
Sarah Lindgreen  +44 20 7604 8033  
Investor Enquiries UK  

James Ward-Lilley  +44 20 7604 8122 mob: +44 7785 432613  
Karl Hård  +44 20 7604 8123 mob: +44 7789 654364  
Nicklas Westerholm  +44 20 7604 8124 mob: +44 7585 404950  
Investor Enquiries US  
Ed Seage  +1 302 886 4065 mob: +1 302 373 1361  
Jorgen Winroth  +1 212 579 0506 mob: +1 917 612 4043  








Schedule
Products


Product
AMG 139
AMG 157
AMG 181
AMG 557
AMG 827


    


Schedule
Profit (Loss) Example

This schedule provides examples of the calculation of the Inventorship Margin and the calculation of the Profit (Loss) True-Up pursuant to Section 7.2.8 (Calculation of Profit (or Loss)).
I.    Inventorship Margin. Assume for purposes of this example that Net Revenues are as follows:
 Q1 2017Q2 2017Q3 2017Q4 2017
Net Revenues (excluding AMG827):[*][*][*][*]

Net Revenues (AMG827 only):
[*][*][*][*]
Taking the third quarter as a representative example, the Inventorship Margin would be calculated as follows:
In Q3 2017, quarterly Net Revenues (excluding AMG827) are [*] and quarterly Net Revenues (AMG827 only) are [*]. The [*]% rate is applied to the [*] in Q3 2017 Net Revenues (excluding AMG827) and the [*]% rate is applied to the [*] in Q3 2017 Net Revenues (AMG827 only). The Inventorship Margin for the quarter is therefore [*] ([*] x [*] + [*] x [*] = [*]).


II.    Collaboration Profit (Loss). To determine the Collaboration Profit (Loss) in accordance with Section 7.2.8 (Calculation of Profit (or Loss)), each Party’s share of Net Revenues must be determined pursuant to Section 7.2.8.2 (Profits) and Total Costs pursuant to Section 7.2.8.1 (Costs) for the quarter.
Assume for purposes of this example that Net Revenues for Q3 2017 are [*] and the Inventorship Margin is [*] (consistent with the example above). Further assume the following for Q3 2017:

TotalAmgenPartner
Net Revenues[*][*][*]
Inventorship Margin[*][*][*]
Share of Net Revenues[*][*][*]
Collaboration Costs[*][*][*]
True-Up Payment[*][*]

    


In such a case, each Party’s share of Net Revenues for Q3 2017 would be [*] ([*]-[*] = [*] / [*] = [*]).
Each Party’s share of the Total Costs for Q3 2017 would be [*], representing Total Costs of [*] multiplied by the Quarterly Cap of 50% for Q3 2017. In this example, each Party incurred [*] of costs in such quarter, thus no netting would be required.
In this example, Partner would be entitled to a true-up payment from Amgen of [*], representing Partner’s share of the Net Revenues less the amount of Net Revenues collected by Partner in Q3 2017 ([*]-[*] = [*]).
If, however, the Total Costs that had been incurred by each Party in the quarter differed, then each Party’s share of the Collaboration Profit (Loss) for Q3 2017 for the quarter would need to be adjusted. For this example, assume the following:
TotalAmgenPartner
Net Revenues[*][*][*]
Inventorship Margin[*][*][*]
Share of Net Revenues[*][*][*]
Collaboration Costs[*][*][*]
True-Up Payment[*][*]
In such a case, each Party’s share of Net Revenues for Q3 2017 would still be [*], ([*]-[*] = [*] / [*] = [*]).
Additionally, each Party’s share of the Total Costs for Q3 2017 would still be [*], representing Total Costs of [*] multiplied by the Quarterly Cap of 50% for Q3 2017. However, Partner would owe [*] to Amgen as reimbursement for its share of Total Costs (([*] x [*]) - [*] = [*]).
In this example, Partner would be entitled to a true-up payment of [*], representing Partner’s share of the Net Revenues, less (i) the amount of Net Revenues collected by Partner in Q3 2017 and (ii) the amount owed to Amgen to cover Partner’s share of Total Costs ([*]-[*] - [*] = [*]).








Schedule
Quality Agreement





Finished Drug Product and Placebo
QUALITY AGREEMENT
Between
AstraZeneca Collaboration Ventures, LLC
Hereafter referred to as “PARTNER”
and
Amgen Inc.
Hereafter referred to as “AMGEN”
This Quality Agreement is intended by the Parties to set forth a plan for the quality assurance groups of AMGEN and PARTNER to work in relation to the manufacture, labeling, packaging, testing, release, shipment and storage of the clinical drug product supply of AMG 139, AMG 157, AMG 181, AMG 557, AMG 827, and the placebo form of the clinical drug products for PARTNER’s use in the Collaboration Territory. The specific details for each molecule will be outlined in addendums to the Quality Agreement. By signing below, the respective quality assurance representatives acknowledge and agree to the provisions of this Quality Agreement.
 
Agreed and accepted for:  Agreed and accepted for:
Partner  Amgen Inc.
By:  
                                                       
  By:  
                                                       
Printed  Printed
Name:    Michael Kinley  Name:    Astrid McLean
Title:    Sr. Director, Quality Assurance  Title:    Director, Quality Assurance
Date:  
                                                       
  Date:  
                                                       
Effective Date:     March 30, 2012
 





Table of contents
 
1.
    BACKGROUND INFORMATION3
2.
    SCOPE3
3.
    DEFINITIONS4
4.
    RESPONSIBILITIES6
5.
    COMMUNICATION6
6.
    BATCH DISPOSITION (PRODUCT RELEASE)7
7.
    LABEL APPROVAL8
8.
    QUALITY CONTROL8
9.
    REFERENCE SAMPLES9
10.
    RETENTION SAMPLES9
11.
    RECEIVING, SHIPPING, STORAGE AND DESTRUCTION9
12.
    CHANGE CONTROL10
13.
    INVESTIGATIONS OF NONCONFORMANCES, DISCREPANCIES (POST DISTRIBUTION NC’S)11
14.
    AUDITS AND INSPECTIONS11
15.
    DISPUTE RESOLUTION13
16.
    CUSTOMER COMPLAINTS13
17.
    STOCK RECOVERY13
18.
    RESPONSIBLE PERSONS: CONTACT INFORMATION14
EXHIBIT A
15
 
 
2




1.BACKGROUND INFORMATION
 
 1.1Amgen Inc. (hereinafter referred to as “AMGEN”) and Partner (hereinafter referred to as “PARTNER”) (hereinafter referred to individually as “Party” or collectively as “Parties”) have entered into that certain Collaboration Agreement dated as of March 30, 2012 (the “Collaboration Agreement”), pursuant to which AMGEN supplies PARTNER with Drug Product and Placebo.
 
2.SCOPE
 
 2.1This Quality Agreement defines the quality obligations of the Parties and their respective affiliates or approved contractors, with respect to the manufacture, labeling, packaging, testing, release, shipment and storage of Product in accordance with the Collaboration Agreement.
 
 2.2The provisions of this Quality Agreement supplement the provisions of the Collaboration Agreement. The terms of the Collaboration Agreement shall remain in full force and effect. In the event of any conflict between the Collaboration Agreement and this Quality Agreement, the Collaboration Agreement shall govern over the conflict.
 
 2.3This Quality Agreement may be amended only by mutual written agreement of the Parties.
 
 2.4Exhibits to this Quality Agreement are intended to provide additional definition to the applicable topic and, as such, should be updated to reflect the current information and business process, as applicable. Amendment of the Exhibits does not require re-approval of the Quality Agreement unless the Quality Agreement itself is affected. Exhibits and all amendments of Exhibits shall be approved by mutually written agreement by the Parties.
 
 2.5All activities under this Quality Agreement shall be performed in compliance with standard industry practices, regulatory agency guidelines, AMGEN specifications, and all applicable federal, state, and local laws and regulations, including, without limitations, cGMPs.
 
 2.6This Quality Agreement shall expire at the termination, cancellation, or expiration, as the case may be, of AMGEN’s obligation to supply Drug Product and Placebo for PARTNER’s clinical use.
 
 2.7PARTNER’s use of Product shall be limited to use in clinical trials approved by the Joint Steering Committee (JSC) as defined in the Collaboration Agreement and where PARTNER has been allocated responsibility to conduct such clinical trials.
 
3





3.DEFINITIONS
 
 3.1All capitalized terms not otherwise defined in this Quality Agreement shall have the definition set forth in the Collaboration Agreement.
 
 3.2As used in this Quality Agreement, the following terms shall have the following meanings:
 
CoA  Certificate of Analysis prepared by AMGEN for the Product representing the analytical results of the Product.
CoC  Certificate of Compliance or Quality Assurance Disposition (QAD), prepared by AMGEN for the Product representing that the Product was manufactured according to cGMP requirements.
Disposition
Manager
  AMGEN Quality Assurance staff member qualified to perform the comprehensive quality assessment and make the disposition decision.
Disposition
Package
  Documentation set provided to PARTNER representing AMGEN batch disposition of the Product.
Drug Product  AMG 139, AMG 157, AMG 181, AMG 557, AMG 827 Drug Product in finished form as manufactured by AMGEN under the terms of the Collaboration Agreement.
Final Release  Release of Product by AMGEN or PARTNER in accordance with standard operating procedures (“SOPs”).
cGMP  All applicable laws and regulations relating to current Good Manufacturing Practices, as promulgated by the United States Food and Drug Administration (FDA) and ‘Good Manufacturing Practices as defined in EC Volume IV of The Rules Governing Medical Products in the European Community’.
Manufacturer’s
Release
  Release of Product by AMGEN, according to its SOPs. Manufacturer’s Release signifies that Product has been produced using approved processes, in compliance with applicable cGMP regulations, and meets the specifications established for the Product, as determined by review of all appropriate documentation.
Material Change  A change which materially modifies the regulatory filing for the Product or is determined by AMGEN to have significant potential to materially affect the Safety, Quality, Identity, Potency, or Purity of the Product.
 
4



Nonconformance  Deviations incurred during the manufacture, labeling, packaging, testing, storage or shipment of the Product, which AMGEN determined to have the potential to impact the Safety, Quality, Identity, Potency, or Purity of the Product, upon preliminary evaluation and required performing an investigation according to AMGEN SOPs.
OOS Result  An examination, measurement or test result that does not conform with pre-established specification requirements established by the relevant Party.
Placebo  A mock treatment or drug that has no effect on the illness, given in a clinical trial to the control group to help differentiate the specific versus non-specific effects of an experimental treatment.
Product  The Drug Product and finished Placebo as manufactured by AMGEN for PARTNER under the terms of the Collaboration Agreement.
Regulatory Agency  A public authority or government agency responsible for protecting and promoting public health through regulation or rulemaking (codifying and enforcing rules and regulations and imposing supervision or oversight for the benefit of the public at large).
Reference Sample    Sample collected from the manufacture of Product for the purpose of being analyzed, should the need arise, to support significant investigations.
Retention Samples    A fully packaged unit from a batch of finished Product stored for identification purposes.
AMGEN Quality Specifications  AMGEN approved set of analytical methods, requirements, and limits as used to judge the identity, purity and potency of all source materials, raw materials, and finished filled, labeled and packaged Product which comprises the Product.
Stock Recovery  The removal or correction of a non-marketed product used in a clinical trial for reasons related to product Safety, Quality, Identity, Potency, or Purity, that has not been marketed or that has not left the direct control of PARTNER.
 
5




4.RESPONSIBILITIES
 
 4.1Without limiting any other provision of this Quality Agreement, the Parties agree that this Quality Agreement is intended to carry out the following guiding principles:
 
 4.1.1The Parties’ quality obligations with respect to the manufacture, labeling, packaging, testing, release, shipment and storage of Product are as set forth in this Quality Agreement and the Collaboration Agreement.
 
 4.1.2The Parties shall comply with all Applicable Laws in the conduct of activities under this Quality Agreement.
 
 4.1.3The Parties acknowledge that AMGEN and PARTNER shall each have the right to perform responsibilities hereunder through their Affiliates and contractors.
 
 4.1.4The Parties shall collaborate to address any disagreements.
 
5.COMMUNICATION
 
 5.1AMGEN and PARTNER agree to provide verbal communication to one another, in a timely manner, as necessary or appropriate for a given issue. Both Parties also agree to follow-up and clarify promptly in writing those important verbal communications to ensure clarity of issues. All official communications and documentation between AMGEN and PARTNER will be conducted in English.
 
 5.1.1The forwarding by PARTNER of any written communication from any global Regulatory Agency concerning the Product outlined in this document shall be done within 3 business days in the original language in which it was received by PARTNER with supplementary comments in English. An English translated version will also be forwarded.
 
 5.1.2The forwarding of any oral communication from any global Regulatory Agency concerning the Product outlined in this document shall be done within 3 business days in the original language in which the notes concerning the correspondence were taken by PARTNER with supplementary comments in English. An English translated version will also be forwarded.
 
 5.2Routine verbal and written communications required herein shall be delivered to the individuals indicated in EXHIBIT A or their delegates.
 
6





6.BATCH DISPOSITION (PRODUCT RELEASE)
 
 6.1AMGEN Quality Responsibility
 
 6.1.1AMGEN shall be responsible for the Manufacturer’s Release of the Product to PARTNER.
 
 6.1.2AMGEN shall provide to PARTNER the Disposition Package for each batch of Product supplied to PARTNER, upon shipment. The documents to be included in the Disposition Package will be outlined in amendments which are specific to the Product.
 
 6.1.3The Disposition Package for the batch will include a list of Nonconformance(s) incurred during the manufacture, labeling, packaging, testing, or storage of the Product. The list of Nonconformance(s) will include a summary of only lot-specific Nonconformances determined by AMGEN to have significant potential to adversely impact the Safety, Quality, Identity, Potency, or Purity of the Product, according to AMGEN procedures or regulatory filing. Such list will be sent to PARTNER upon shipment of the Product by AMGEN to PARTNER.
 
 6.1.4AMGEN shall use commercially reasonable efforts to mitigate the risk of Transmissible Spongiform Encephalopathy (TSE) for raw materials and components used during perform of Services per current requirements of Regulatory Agencies and current compendial requirements.
 
 6.2PARTNER Quality Responsibility
 
 6.2.1PARTNER shall be responsible for the Final Release of the Product for clinical distribution after reviewing the Disposition Package provided by AMGEN and any shipping records and, if applicable, results of acceptance testing as conducted by a PARTNER qualified laboratory.
 
 6.2.2In the event PARTNER provides AMGEN with notice of Nonconformance of the Product within 60 days from the date of delivery of Product, AMGEN and PARTNER agree to collaborate to investigate the Nonconformance prior to the disposition of the lot by PARTNER according to each Party’s respective failure investigation policies and procedures in accordance with the Quality Agreement.
 
7




 6.2.3In the event PARTNER is responsible for a specific European clinical trial, a PARTNER QP or one authorized by PARTNER, will be responsible for certification of Product according to the requirements set out in the European cGMPs.
 
7.LABEL APPROVAL
 
 7.1Physical Label Creation and Approval
 
 7.1.1Physical labels for Product will be generated and approved according to established procedures of AMGEN, for any such activities performed by such Party.
 
 7.1.2Label Application
 
 7.1.2.1AMGEN is responsible for labeling and bulk packaging of the clinical supplies.
 
 7.1.2.2AMGEN shall apply physical labels to Product prior to supply to PARTNER.
 
8.QUALITY CONTROL
 
 8.1AMGEN Quality Control Laboratory Testing Responsibility
 
 8.1.1AMGEN will conduct testing of Product according to AMGEN Quality Specifications and its methods, policies and procedures.
 
 8.2PARTNER Importation and Testing Responsibility
 
 8.2.1PARTNER shall be responsible for preparing all documents required for import clearance and entry of shipment with reasonable cooperation from AMGEN. Product batches will be evaluated by PARTNER upon receipt for conformance to applicable import and transport requirements, such as temperature monitoring, damage and documentation requirements.
 
 8.2.2PARTNER is responsible for sampling upon receipt and conducting testing, as required. Such testing will be conducted by PARTNER (or if AMGEN expressly consent in writing, by appropriately qualified laboratories) by appropriately qualified personnel according to testing procedures mutually agreed by the Parties.
 
 8.2.3If AMGEN expressly consents to PARTNER using a contract laboratory for import testing, then PARTNER is responsible for shipping Product to its contract laboratory to perform import testing, if necessary.
 
8






 
 8.2.4In the case of OOS, an investigation will be performed per Section 13 (INVESTIGATION OF NONCONFORMANCES, DISCREPANCIES) of this Quality Agreement and PARTNER should notify and obtain consent from AMGEN prior to conducting testing using any other analytical method during the investigation.
 
 8.3Stability Tesing
 
 8.3.1AMGEN will conduct routine stability testing of the Product according to AMGEN’s clinical stability program requirements.
 
 8.3.2AMGEN will communicate the expiration of each lot in the Disposition Package.
 
 8.3.3AMGEN shall notify PARTNER within two (2) business days of any confirmed stability failure of the Product and provide periodic updates on the OOS investigation.
 
 8.3.4PARTNER will not conduct any stability testing on the Product unless authorized to do so by AMGEN.
 
 8.3.5AMGEN will provide PARTNER the current Stability Summary Report, including trending, upon request.
 
9.REFERENCE SAMPLES
 
 9.1AMGEN shall retain Reference Samples for each manufactured lot of Product released to PARTNER for a minimum of five (5) years after the expiration period. This period may be shortened if the period of stability of the material, as indicated in its specification, is shorter.
 
10.RETENTION SAMPLES
 
 10.1PARTNER shall retain Retention Samples for each packaged lot of Product released for clinical distribution per established PARTNER procedure.
 
11.RECEIVING, SHIPPING, STORAGE and DESTRUCTION
 
9





 11.1Unless otherwise agreed by the Parties, AMGEN shall ship Product EXW (Incoterms 2010) AMGEN’s facility.
 
 11.2PARTNER is responsible for reviewing temperature recording data upon receipt of Product shipment.
 
 11.3PARTNER is responsible for adequate storage of the Product upon receipt according to the storage requirements specified in the product specification.
 
 11.4Shipping excursions will be investigated per Section 13 (INVESTIGATIONS OF NONCONFORMANCES, DISCREPANCIES) of this Quality Agreement.
 
 11.5PARTNER is responsible for reviewing temperature recording data of the Product according to the storage requirements if a temperature excursion is identified at a clinical investigation site.
 
 11.5.1PARTNER notifies AMGEN of any shipping Nonconformances, such as temperature excursions, upon receiving shipping records.
 
 11.5.2AMGEN shall provide PARTNER adequate training and relevant stability data to support temperature excursions obtained at clinical investigation sites, provided that, AMGEN shall not have any obligation to conduct new tests to support assessment of temperature excursions. If a temperature excursion exceeds any of the limits supported by the stability data, AMGEN shall provide reasonable support to properly assess the product impact, if requested by PARTNER.
 
 11.6PARTNER shall be responsible for the destruction of any unused and partially used Product in accordance with Applicable Laws and regulations.
 
12.CHANGE CONTROL
 
 12.1AMGEN shall notify PARTNER of AMGEN’s intention to implement such Material Change and the details of such Material Change for the material changes of manufacturing of the Product, specifically impacting the following documents, if applicable: (1) Analytical Methods, (2) Master Batch/Labeling/Packaging Records, (3) Primary Packaging Components Specifications, (4) Product Specifications, and (5) Raw Material/Component Specifications.
 
 12.2Within fourteen (14) calendar days after the receipt of such notification, to the extent such Material Change impacts a Regulatory Filing for which PARTNER is the Designated Regulatory Party, PARTNER shall provide to AMGEN a writtenassessment of whether the Material Change constitutes a change which is reportable to Governmental Authorities.
 



 12.3If a Material Change requires the approval of a Governmental Authority in the Collaboration Territory, then, where PARTNER is the Designated Regulatory Party, PARTNER shall use reasonable efforts to file for such approval within sixty (60) days of receipt of the necessary documentation from AMGEN and obtain necessary regulatory approvals.
 
 12.4PARTNER shall provide updates to AMGEN of any regulatory submissions relating to said changes.
 
 12.5PARTNER shall inform AMGEN of any required regulatory change and reporting category in writing within two (2) business days after PARTNER first becomes aware of such information. PARTNER must inform AMGEN of the request in writing, at a minimum the request should describe the proposed change and rationale.
 
 13.INVESTIGATIONS OF NONCONFORMANCES, DISCREPANCIES (POST DISTRIBUTION NC’S)
 
 13.1If a Nonconformance is identified after a Product batch has been shipped to PARTNER, AMGEN shall inform PARTNER within two (2) business days of such Nonconformance.
 
 13.2AMGEN will provide support, as necessary and reasonable, to enable PARTNER to comply with applicable regulatory reporting requirements that may result from the occurrence of a post-distribution Nonconformance.
 
 13.3Each Party shall inform the other Party as soon as reasonably possible of issues which may adversely impact Product quality, safety, efficacy or adverse events relating to the batch of Product received by PARTNER.
 
 14.AUDITS AND INSPECTIONS
 
 14.1PARTNER Audits
 
 14.1.1All audits of AMGEN are limited to the facilities where the Products are manufactured, Quality Systems and documentation directly related to the Products, and Batch Records related to lots provided to PARTNER, The scope, agenda, and timeline must be approved by AMGEN prior to each audit.
 
11





 14.1.2All audits of AMGEN facilities will be conducted during regular business hours in the presence of AMGEN representatives. Audits shall be conducted by not more than two (2) PARTNER representatives at each AMGEN facility, and, unless otherwise agreed upon by AMGEN, for not more than two (2) business days at each site. PARTNER shall provide AMGEN written notification of such audit no less than one hundred twenty days (120) days in advance. The written notification must clearly state the scope of the audit and regulatory standards to be used to conduct the audit. PARTNER may conduct an audit once in a twelve (12) month period, upon AMGEN’s approval of the audit request.
 
 14.1.3In addition to the annual audit described in Section 14.1.2 above, PARTNER is permitted to request an unplanned “For Cause” audit during the case of a quality or regulatory event. AMGEN will consider any such request in good faith, but will have sole discretion whether or not to grant such request.
 
 14.1.3.1Such “For Cause” audits require prior written notice by PARTNER to AMGEN and shall be conducted during AMGEN’s normal business hours. Each party must approve the audit scope, agenda and timeline prior to conducting the audit. For Cause audits shall be conducted by not more than two (2) PARTNER representatives at each AMGEN facility, and, unless otherwise agreed upon by AMGEN, for not more than two (2) business days.
 
 14.2Audit Findings
 
 14.2.1PARTNER shall provide AMGEN a copy of the audit report within thirty (30) calendar days of completion of an audit. After delivery of the audit report, AMGEN shall provide PARTNER with a written response to such report within thirty (30) calendar days from AMGEN’s receipt of the report from PARTNER. All information contained in the audit report shall be deemed the confidential information of AMGEN under the Collaboration Agreement.
 
 14.3Regulatory Agency Inspections
 
 14.3.1PARTNER shall notify AMGEN immediately upon notification by any Regulatory Agency or other Government Authority of any intended inspection of AMGEN’s facilities or records relating to the manufacturing, testing, packaging, labeling, and storage of the Product.
 
12





 14.3.2PARTNER shall have the right to have a maximum of one (1) representative present during a regulatory inspection of AMGEN’s facilities that perform manufacturing or testing of Product. Presence of PARTNER during an inspection at an AMGEN facility will be according to the direction of AMGEN. PARTNER representative shall not have direct participation during inspection discussions with Regulatory Agency inspector(s).
 
 14.3.3AMGEN shall provide PARTNER with a copy of the final response immediately after submission to the Regulatory Agency.
 
 14.3.4PARTNER is responsible for the arrangement of interpreters and translation of documents which may be required by the Regulatory Agency during inspection of AMGEN facilities. AMGEN shall have the right to arrange interpreter and document translation services upon agreement with PARTNER or if PARTNER fails to do so.
 
 15.DISPUTE RESOLUTION
 
 15.1Disputes relating to non-compliance or nonconformance of Product with the product specifications shall be governed by the terms set forth in the Collaboration Agreement. The provisions of Section 15.3 (choice of law; jurisdiction) of the Collaboration Agreement are deemed incorporated into this Quality Agreement.
 
 16.CUSTOMER COMPLAINTS
 
 16.1Any information related to customer complaints (i.e., communication that alleges deficiencies relating to the identity, quality, durability, reliability, safety, effectiveness, or performance of a drug, condition of labeling, or packaging, after it is released by PARTNER for clinical studies) shall be forwarded to AMGEN within one (1) business day after PARTNER first becomes aware of such information.
 
 16.2AMGEN shall investigate according to AMGEN’s applicable policy and procedures customer complaints submitted by PARTNER. Complaints which require an AMGEN investigation will be sent to this e-mail address: XXXXXXXXX@amgen.com
 
 16.3AMGEN shall provide PARTNER with an Interim Report within 30 days and an investigation closure Final Report within forty-five (45) days of receipt of the customer complaint.
 
17.STOCK RECOVERY
 
13





 17.1If any problems are discovered and identified as recall/stock recovery issues related to the Product, the discovering Party shall notify the other immediately.
 
 17.2PARTNER and AMGEN shall each notify the other Party within three (3) business days if it becomes aware that any Product is alleged or proven to be the subject of a recall or stock recovery in the Collaboration Territory.
 
 17.3The Parties shall meet to discuss the circumstances that merit the Product recall or stock recovery and to determine the appropriate course of action. Such course of action shall be consistent with the internal SOP of the Party having the right to control such recall pursuant to this section.
 
 17.4If either Party proposes to initiate a Stock Recovery or other corrective action with respect to the Product in the Collaboration Territory, the Parties will promptly discuss such proposed action. Any decisions by the Parties shall be governed by the terms of the Collaboration Agreement. The Parties shall cooperate, as reasonably necessary, in the implementation of such actions.
 
 17.5The Parties shall cooperate and promptly perform investigations into the root causes leading up to the Product Stock Recovery, when appropriate. Investigation reports regarding the defect or cause for such regulatory reporting shall be provided to the corresponding Party within an appropriate timeframe dependent on regulatory reporting requirements.
 
 17.6The Parties shall each maintain complete and accurate records of any Stock Recovery it has the right to control pursuant to this section of the Quality Agreement for such periods as may be required by legal requirements, but in any event for no less than three (3) years from the date of Stock Recovery.
 
 17.7Each Party maintains the responsibility for Product distributed within the Collaboration Territory for its own clinical studies.
 
 
18.RESPONSIBLE PERSONS: CONTACT INFORMATION
 
 18.1The individuals listed in EXHIBIT A shall be the key points of contact between AMGEN and PARTNER relating to the rights and obligations of the Parties in this Quality Agreement. The responsible individuals, or their respective delegates, must be notified in official communications as required by this Quality Agreement.
 
14





EXHIBIT A
Responsible Persons and Contact Information
 
 
 
AMGEN
 
 
Name
 
 Email Address Contact Number Responsibility
 
XXXXXXXXX
 
 
XXXXXXXXX
 
 
XXXXXXXXX
 
 
Manager,
International Quality
 
XXXXXXXXX
 
 
 
XXXXXXXXX
 
 
 
XXXXXXXXX
 
 
Director,
International Quality
 
 
 
PARTNER
 
 
Name
 
 
Email Address
 
 
Contact Number
 
 
Responsibility
 
 
XXXXXXXXX
 
 
 
XXXXXXXXX
 
 
 
XXXXXXXXX
 
 
Director of QA and EU QP
 
 
XXXXXXXXX
 
 
 
XXXXXXXXX
 
 
 
XXXXXXXXX
 
 
Senior Director,
 
Quality Assurance
 
Exhibit A Version Date:    March 30, 2012
 
Agreed and accepted for:
 
Partner
 
Agreed and accepted for:
 
Amgen Inc.
 
By:   By:   
Printed
 
Name:
   Michael Kinley 
Printed
 
Name:
   Astrid McLean 
Title:   Sr. Director, Quality Assurance Title:   Director, Quality Assurance 
Date:   Date:   
 
15





Schedule
Stage 1 Clinical Trial

ProductStage 1 Clinical Trial
AMG139[*]
AMG157[*]
AMG181[*]
AMG557[*]
AMG827[*]




EX-10.47 4 exhibit1047-amendmentno1to.htm FIRST AMENDMENT TO COLLABORATION AGREEMENT BETWEEN AMGEN AND ASTRAZENECA Document

EXHIBIT 10.47
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.


AMENDMENT NO. 1
TO THE
COLLABORATION AGREEMENT


This Amendment No. 1 to the Collaboration Agreement (this “Amendment”) is entered into as of the 1st day of October, 2014 (the “Amendment Effective Date”) by and between Amgen Inc., a Delaware corporation with a place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and AstraZeneca Collaboration Ventures, LLC, a Delaware limited liability company with a place of business at 1800 Concord Pike, Wilmington, Delaware 19850 (“Partner”). Amgen and Partner are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. AstraZeneca Pharmaceuticals LP, the parent corporation of Partner (“AstraZeneca”), [*] of the Agreement (as defined below) is a party to this Amendment [*].

WHEREAS, Amgen and Partner entered into that certain Collaboration Agreement, dated as of March 30, 2012 (the “Agreement”);

WHEREAS, Amgen and Partner wish to update certain portions of the Agreement.

NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Parties hereto agree to amend the Agreement as follows:
ARTICLE 1 - AMENDMENT

Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

1.1    Amendment to Certain Definitions. The Parties hereby agree that the following defintions in the Agreement are hereby deleted in their entirety and replaced with the following:
“Excluded Territory” means (i) with respect to AMG557 and AMG570, Japan, and (ii) with respect to AMG827, all countries not included within the AMG827 Territory.
“Excluded Territory Agreement” means (i) in relation to AMG827, the AMG827 Technology Transfer Agreement by and among Kyowa Hakko Kirin Co., Ltd., Amgen and Kirin-Amgen, Inc., the Research, Development and Technology Disclosure Agreement: AMG827 by and among Kyowa Hakko Kirin Co., Ltd., Amgen and Kirin-Amgen, Inc., and the AMG827 License Agreement between Kirin-Amgen, Inc., all dated October 29, 2010 and (ii) in relation to AMG557 and AMG570, means the License Agreement by and between Amgen and Takeda Pharmaceutical Company Limited dated February 1, 2008, in each case as the same have been amended and may be amended from time to time hereafter in accordance with terms of this Agreement.
        1


Amendment to Certain Schedules. The Parties hereby agree that the following schedules to the Agreement are hereby deleted in their entirety and replaced with the schedules set forth in Appendix I attached hereto:
Development/Commercial Lead Schedule;
Distracting Product Schedule;
Products Schedule; and
Stage 1 Clinical Trial Schedule.
1.2Acknowledgement. The Parties hereby acknowledge that (a) in accordance with Section 9.4 (Pre-Clinical Research and Development Programs) of the Agreement, the Inventorship Margin for AMG570 shall be [*] percent ([*]%), and (b) in accordance with Section 9.3.3 (Inclusion) of the Agreement, (i) all Development Costs and General Costs for AMG570 shall be shared on a [*] basis, and (ii) all Net Revenues for AMG570 shall, after the deduction of the Inventorship Margin for AMG570, be shared on a [*] basis.
1.3Manufacturing Lead. The Parties hereby agree that, notwithstanding the provisions of Section 4.1 (Allocation of Manufacturing Responsibility) of the Agreement to the contrary, Amgen shall not be required to elect whether or not to continue as the Manufacturing Lead for AMG570 and AMG557 until [*].
ARTICLE 2 – REFERENCE TO AND EFFECT ON THE AGREEMENT
2.1    Reference to Agreement. Upon and after the effectiveness of this Amendment, each reference in the Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Agreement shall mean and be a reference to the Agreement as modified and amended hereby.
2.2    Effectiveness of Amendment. Upon execution and delivery of this Amendment by both Parties, the amendments set forth above shall be effective as of the Amendment Effective Date. Except as specifically amended above, the Agreement is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed and shall constitute the legal, valid, binding and enforceable obligations of the Parties.
2.3    No Waiver. The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of either Party under the Agreement, nor constitute a waiver of any provision of the Agreement.
ARTICLE 3 – MISCELLANEOUS
3.1    Governing Law. This Amendment will be governed by, and enforced and construed in accordance with, the laws of the State of New York without regard to its conflicts of law provisions. Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the state and federal courts of the State of New York for any matter arising out of or relating to this Amendment and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts. Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Amendment or the transactions contemplated hereby in the state and federal courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum. The Parties agree that a final judgment in any such matter will be conclusive and may be enforced in other jurisdictions by suits on the judgment or in
        2


any other manner provided by law. Any proceeding brought by either Party under this Amendment will be exclusively conducted in the English language. The United Nations Convention for the International Sale of Goods will not apply to the transactions contemplated herein.
3.2    Headings. The heading for each article and section in this Amendment has been inserted for convenience of reference only and is not intended to limit or expand on the meaning of the language contained in the particular article or section.
3.3    Counterparts. This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
[Signature page follows]


        3


IN WITNESS THEREOF, duly authorized representatives of the Parties hereto have executed this Amendment as of the date first set forth above.


ASTRAZENECA COLLABORATION VENTURES, LLCAMGEN INC.
By:/s/ Pascal SoriotBy:/s/ Robert A. Bradway
Name:Pascal SoriotName:Robert A. Bradway
Title:CEOTitle:Chairman and Chief Executive Officer
ASTRAZENECA PHARMACEUTICALS LP
By:/s/ Pascal Soriot
Name:Pascal Soriot
Title:CEO





Appendix I
Schedules





Schedule
Development/Commercial Lead


AmgenPartner
AMG827AMG139
AMG557AMG157
AMG570AMG181


AMG827 Respiratory-

1Specifically with regard to AMG827 at the global level, the Parties will work closely through the JPT on the commercial strategy for the Respiratory market for AMG827 with Amgen taking the primary responsibility for [*].
2The Parties will [*].
3The Parties will cooperate to ensure that [*] is made available to the JPT at both the global and regional level.
4This arrangement will be noted in the press release and other approved communications as “[*],” or with words of similar import.

AMG570-
The Parties hereby agree that Amgen shall be the initial Development Lead and Commercial Lead for AMG570. The Parties shall [*], provided that, in the event that the Parties are unable to [*] if it elects to do so.






Schedule
Distracting Product



ProductProduct Target
Distracting Target*
AMG 139[*][*]
AMG 157[*][*]
AMG 181[*][*]
AMG 557[*][*]
AMG 570[*][*]
AMG 827[*][*]

*Distracting Target includes (i) any [*]; (ii) any [*]; (iii) any [*]; (iv) any [*]; and (v) any [*]. For avoidance of doubt, the Distracting Product Schedule lists without limitation [*].

**Notwithstanding anything contained in the Agreement to the contrary, Amgen’s [*] program referred to internally at Amgen as [*] shall not be a Distracting Product so long as such molecule is the subject of that certain License Agreement dated as of [*] by and between Amgen and [*], as amended.





Schedule
Products


Product
AMG 139
AMG 157
AMG 181
AMG 557
AMG 827
AMG 570


























Schedule
Stage 1 Clinical Trial

ProductStage 1 Clinical Trial
AMG139[*]
AMG157[*]
AMG181[*]
AMG557[*]
AMG827[*]
AMG570[*]




EX-31 5 amgn-ex31_2022630xq2.htm RULE 13A-14(A) CERTIFICATIONS Document
Exhibit 31
CERTIFICATIONS
I, Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President of Amgen Inc., certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.;
2.Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
(d)Disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
August 4, 2022/s/ ROBERT A. BRADWAY
Robert A. Bradway
Chairman of the Board,
Chief Executive Officer and President
1


CERTIFICATIONS
I, Peter H. Griffith, Executive Vice President and Chief Financial Officer of Amgen Inc., certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.;
2.Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
(d)Disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
August 4, 2022/s/ PETER H. GRIFFITH
Peter H. Griffith
Executive Vice President and Chief Financial Officer
2
EX-32 6 amgn-ex32_2022630xq2.htm SECTION 1350 CERTIFICATIONS Document
Exhibit 32
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
(i)the accompanying Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii)information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
August 4, 2022/s/ ROBERT A. BRADWAY
Robert A. Bradway
Chairman of the Board,
Chief Executive Officer and President

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
1


Certification of Chief Financial Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
(i)the accompanying Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii)information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
August 4, 2022/s/ PETER H. GRIFFITH
Peter H. Griffith
Executive Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
2
EX-101.SCH 7 amgn-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Summary of significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2111104 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2113105 - Disclosure - Earnings per share link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Earnings per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 2116106 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2317304 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2418407 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2419408 - Disclosure - Investments (Fair Values by Classification) (Details) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Investments (Available-for-sale Investments) (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2421410 - Disclosure - Investments (Fair Values by Contractual Maturity) (Details) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Investments (Equity Securities) (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Investments (BeiGene) (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Investments (Neumora Therapeutics, Inc.) (Details) link:presentationLink link:calculationLink link:definitionLink 2425414 - Disclosure - Investments Investments (Limited Partnership Investments) (Details) link:presentationLink link:calculationLink link:definitionLink 2126107 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2327305 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2428415 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2129108 - Disclosure - Goodwill and other intangible assets link:presentationLink link:calculationLink link:definitionLink 2330306 - Disclosure - Goodwill and other intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - Goodwill and other intangible assets (Goodwill Roll Forward) (Details) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2433418 - Disclosure - Goodwill and other intangible assets (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2134109 - Disclosure - Financing arrangements link:presentationLink link:calculationLink link:definitionLink 2335307 - Disclosure - Financing arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2436419 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) link:presentationLink link:calculationLink link:definitionLink 2437420 - Disclosure - Financing arrangements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2138110 - Disclosure - Stockholders' equity link:presentationLink link:calculationLink link:definitionLink 2339308 - Disclosure - Stockholders' equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2440421 - Disclosure - Stockholders' equity (Share Repurchase Program) (Details) link:presentationLink link:calculationLink link:definitionLink 2441422 - Disclosure - Stockholders' equity (Details Textual) (Details) link:presentationLink link:calculationLink link:definitionLink 2442423 - Disclosure - Stockholders' equity (Components of AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2443424 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2144111 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 2345309 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2446425 - Disclosure - Fair value measurement (Details) link:presentationLink link:calculationLink link:definitionLink 2447426 - Disclosure - Fair value measurement (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2448427 - Disclosure - Fair value measurement (Contingent Consideration Obligations) (Details) link:presentationLink link:calculationLink link:definitionLink 2149112 - Disclosure - Derivative instruments link:presentationLink link:calculationLink link:definitionLink 2350310 - Disclosure - Derivative instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2451428 - Disclosure - Derivative instruments (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2452429 - Disclosure - Derivative instruments (Cross-currency Swaps) (Details) link:presentationLink link:calculationLink link:definitionLink 2453430 - Disclosure - Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2454431 - Disclosure - Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) link:presentationLink link:calculationLink link:definitionLink 2455432 - Disclosure - Derivative instruments (Summary of Income and Expense Line Items) (Details) link:presentationLink link:calculationLink link:definitionLink 2456433 - Disclosure - Derivative instruments (Fair Value of Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 2157113 - Disclosure - Contingencies and commitments link:presentationLink link:calculationLink link:definitionLink 2458434 - Disclosure - Contingencies and commitments (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 amgn-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 amgn-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 amgn-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Business Acquisition [Axis] Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in AOCI [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Loss Contingency, Pending Claims, Number Loss Contingency, Pending Claims, Number Other Other Comprehensive Income (Loss), Other Adjustment, before Tax Other Comprehensive Income (Loss), Other Adjustment, before Tax United Kingdom, Pounds United Kingdom, Pounds Long-term debt, gross Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Disposal Group, Including Discontinued Operation, Other Assets, Current Disposal Group, Including Discontinued Operation, Other Assets, Current Gains on available-for-sale securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Current portion of long-term debt [Member] Long-Term Debt, Current Maturities [Member] Long-Term Debt, Current Maturities [Member] 3.375% notes due 2050 (3.375% 2050 Notes) [Member] Three Point Three Seven Five Percent Notes Due 2050 [Member] Three Point Three Seven Five Percent Notes Due 2050 [Member] Debt Instrument [Axis] Debt Instrument [Axis] Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Dividends paid Payments of Ordinary Dividends, Common Stock Contingent consideration obligation for acquisition Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract] Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets. Foreign currency contract [Member] Foreign currency contracts [Member] Foreign Exchange Contract [Member] The NASDAQ Global Select Market [Member] NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] Other Other General Expense (Income), Other Adjustments Other General Expense (Income), Other Adjustments Amount awarded from settlement Litigation Settlement, Damages Sought, Value Litigation Settlement, Damages Sought, Value Carrying value with discontinued hedging relationships Hedged Liability, Discontinued Fair Value Hedge Hedged Liability, Discontinued Fair Value Hedge Financial Instruments [Domain] Financial Instruments [Domain] Litigation Settlement, Number Of Primary Arguments Litigation Settlement, Number Of Primary Arguments Litigation Settlement, Number Of Primary Arguments Number of plaintiffs Loss Contingency, Number of Plaintiffs Other Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Schedule of Business Acquisitions by Acquisition, Contingent Consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Other current assets [Member] Other Current Assets [Member] Gross carrying amount Identifiable Intangible Assets Gross Identifiable intangible assets gross. Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Domestic Tax Authority Domestic Tax Authority [Member] 5.65% notes due 2042 (5.65% 2042 Notes) [Member] Five Point Six Five Percent Notes Due 2042 [Member] Five Point Six Five Percent Notes Due 2042 [Member] Other items, net Other Noncash Income (Expense) Foreign currency and cross-currency swap contracts Foreign Currency Contracts, Liability, Fair Value Disclosure 4.95% notes due 2041 (4.95% 2041 Notes) [Member] Four Point Nine Five Percent Notes Due 2041 [Member] Four Point Nine Five Percent Notes Due 2041 [Member] Net income Net income Net income for basic and diluted EPS Net income Net Income (Loss) Attributable to Parent 3.45% notes due 2020 (3.45% 2020 Notes) [Member] Three Point Four Five Percent Notes Due 2020 [Member] Three Point Four Five Percent Notes Due 2020 [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Equity Component [Domain] Equity Component [Domain] 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member] 5.50% 2026 pound sterling Notes [Member] Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member] Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member] 6.90% notes due 2038 (6.90% 2038 Notes) [Member] Six Point Nine Zero Percent Notes Due 2038 [Member] Six Point Nine Zero Percent Notes Due 2038 [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Scenario [Axis] Scenario [Axis] Total assets Assets, Fair Value Disclosure Other Operating Income (Expense) Other Operating Income (Expense) [Member] Increase in unrecognized tax benefits resulting from tax positions taken during the current period Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions XGEVA® (denosumab) [Member] XGEVA [Member] XGEVA. Fair values Total interest-bearing securities Interest-bearing securities Debt Securities, Available-for-Sale Hedging Designation [Domain] Hedging Designation [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Gensenta Ilac Sanayi vs Ticaret Gensenta Ilac Sanayi vs Ticaret [Member] Gensenta Ilac Sanayi vs Ticaret Number of operating segments Number of Operating Segments Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Fair Value, Inputs, Level 1 [Member] Quoted prices in active markets for identical assets (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Interest rate swap contracts Interest Rate Fair Value Hedge Liability at Fair Value Schedule of long-term instruments exchanged Schedule of Long-term Debt Instruments Exchanged [Table Text Block] Schedule of Long-term Debt Instruments Exchanged [Table] Repatriation tax on proposed additional tax 2013-2015 Repatriation tax on proposed additional tax 2013-2015 Repatriation tax on proposed additional tax 2013-2015 Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—534.9 shares in 2022 and 558.3 shares in 2021 Common Stocks, Including Additional Paid in Capital Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security Debt Securities, Available-for-Sale [Table Text Block] In-process Research and Development In Process Research and Development [Member] All Currencies [Domain] All Currencies [Domain] Cross-currency swap contract [Member] Cross-currency swap contracts [Member] Cross-currency swap contracts [Member] Cross Currency Swap Contracts [Member] Cross currency swap contracts. Operating expenses: Costs and Expenses [Abstract] 2.70% notes due 2022 (2.70% 2022 Notes) [Member] Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member] Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member] 2.00% Senior Notes Due 2026 [Member] 2.00% Senior Notes Due 2026 [Member] 2.00% Senior Notes Due 2026 [Member] Liability Class [Axis] Liability Class [Axis] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Geographical [Axis] Geographical [Axis] Net increase in goodwill Goodwill, Purchase Accounting Adjustments Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Fair value of assets acquired, cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Reclassifications out of accumulated other comprehensive income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] 4.20% 2052 Notes [Member] 4.20% 2052 Notes [Member] 4.20% 2052 Notes Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] 2.00% notes due 2032 (2.00% 2032 Notes) [Member] Two point zero percent 2032 Notes Member [Member] Two point zero percent 2032 Notes Member Repatha (evolocumab) [Member] Repatha (evolocumab) [Member] Repatha (evolocumab) [Member] Marketable securities Debt Securities, Available-for-Sale, Current Available-for-sale securities [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Document Type Document Type Schedule of notional amounts and interest rates for cross-currency swaps Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block] Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps 2.30% notes due 2031 (2.30% 2031 Notes) [Member] Two Point Three Zero Percent Notes Due 2031 [Member] Two Point Three Zero Percent Notes Due 2031 Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Assets: Assets, Fair Value Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Financing arrangements Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Number of asserted patents expired Loss Contingency, Patents Expired, Number Loss Contingency, Patents Expired, Number Marketing-Related Rights [Member] Marketing-Related Intangible Assets [Member] Net Investment Income [Line Items] Net Investment Income [Line Items] Equity Method Investments,Quoted Market Price Equity Method Investment, Quoted Market Value Developed-Product-Technology Rights [Member] Developed Technology Rights [Member] Financial Instrument [Axis] Financial Instrument [Axis] Summary of activity under our stock repurchase program Stock Repurchase Program [Table Text Block] Stock Repurchase Program [Table Text Block] Subsequent Event [Member] Subsequent Event [Member] Corporate debt securities - Industrial [Member] Corporate Debt Securities Industrial [Member] Corporate debt securities industrial Member. Document Period End Date Document Period End Date Income Tax Examination [Table] Income Tax Examination [Table] Accelerated stock repurchase agreement Accelerated stock repurchase agreement [Member] Accelerated stock repurchase agreement Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Available-for-sale investments [Member] Available For Sales Investments [Member] Available for sales investments. Long-term tax liabilities Increase (Decrease) In Noncurrent Tax Liability Increase (Decrease) In Noncurrent Tax Liability Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Components of accumulated other comprehensive income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Amount received from settlement Litigation Settlement, Amount Awarded from Other Party Income Statement Location [Axis] Income Statement Location [Axis] Business Nature Of Operations [Policy Text Block] Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description". debt exchange additional cash consideration Debt exchange additional cash consideration Debt exchange additional cash consideration paid Equity securities Equity Securities, FV-NI, Current Interest rate swap contracts [Member] Interest Rate Swap [Member] Interest rate swap agreements [Member] Interest Rate Swap [Member] Accrued liabilities Accrued Liabilities, Current Income taxes Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent 3.875% notes due 2021 (3.875% 2021 Notes) [Member] Three Point Eight Seven Five Percent Notes Due 2021 [Member] Three Point Eight Seven Five Percent Notes Due 2021 [Member] Current portion of long-term debt Less current portion Long-Term Debt, Current Maturities Value of intangible assets acquired Finite-Lived Intangible Assets Acquired Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Stock repurchase program, additional authorized amount Stock Repurchase Program, Authorized Amount Interest expense, net Interest Expense, Debt Other mortgage- and asset-backed securities [Member] Asset-Backed Securities [Member] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Derivatives in fair value hedging relationships Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Deferred income taxes Deferred Income Taxes and Tax Credits Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Earnings per share Earnings Per Share [Text Block] Forward Contracts [Member] Forward Contracts [Member] Corporate debt securities - Other [Member] Corporate Debt Securities Other [Member] Corporate debt securities other. Loss Contingency, Claims Settled, Number Loss Contingency, Claims Settled, Number Humira Biosimilar Antitrust Class Actions [Member] Humira Biosimilar Antitrust Class Actions [Member] Humira Biosimilar Antitrust Class Actions [Member] Fair values of derivatives included in the Condensed Consolidated Balance Sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Residential mortgage-backed securities [Member] Residential Mortgage-Backed Securities [Member] 4.40% notes due 2045 (4.40% 2045 Notes) [Member] Four Point Four Zero Percent Notes Due Two Zero Four Five [Member] Four Point Four Zero Percent Notes Due Two Zero Four Five [Member] Summary of amounts of income and expense line items Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Cash paid Payments to Acquire Businesses, Gross Derivative Contract [Domain] Derivative Contract [Domain] Teneobio Teneobio [Member] Teneobio Entity Registrant Name Entity Registrant Name Investment Company, Financial Support to Investee Contractually Required, Amount Investment Company, Financial Support to Investee Contractually Required, Amount Currency translation adjustment Goodwill, Foreign Currency Translation Gain (Loss) Foreign currency translation [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] 1.90% notes due 2025 (1.90% 2025 Notes) [Member] One Point Nine Zero Percent Notes Due Two Zero Two Five [Member] One Point Nine Zero Percent Notes Due Two Zero Two Five [Member] Entity Address, City or Town Entity Address, City or Town Total assets acquired, net Business acquired asset acquisition, Assets acquired and Liabilities assumed, net Business acquired asset acquisition, Assets acquired and Liabilities assumed, net Cash flow hedges [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Debt Instrument, Redemption Period without Payment of Make Whole Amount Debt Instrument, Redemption Period without Payment of Make Whole Amount Debt Instrument, Redemption Period without Payment of Make Whole Amount Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value Disposal Group, Including Discontinued Operation, Accrued Liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities Principles of consolidation Consolidation, Policy [Policy Text Block] Minimum [Member] Minimum [Member] Equity method investment, change in carrying value Equity method investment, change in carrying value Equity method investment, change in carrying value 4.10% notes due 2021 (4.10% 2021 Notes) [Member] Four Point One Zero Percent Notes Due 2021 [Member] Four Point One Zero Percent Notes Due 2021 [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock and additional paid-in capital, par value (in usd per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves 3.35% 2032 Notes [Member] 3.35% 2032 Notes [Member] 3.35% 2032 Notes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Income Tax Examination [Line Items] Income Tax Examination [Line Items] Fair value measurement Fair Value Disclosures [Text Block] Noncash or Part Noncash Acquisition, Investments Acquired Noncash or Part Noncash Acquisition, Investments Acquired Trading Symbol Trading Symbol Entity File Number Entity File Number 6.40% notes due 2039 (6.40% 2039 Notes) [Member] Six Point Four Zero Percent Notes Due 2039 [Member] Six Point Four Zero Percent Notes Due 2039 [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Total estimated amortization of finite-lived intangible assets for 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract] Fair Value Measured at Net Asset Value Per Share [Member] Fair Value Measured at Net Asset Value Per Share [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Investment Income [Table] Investment Income [Table] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Entity Information [Line Items] Entity Information [Line Items] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Other Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent Two Point Seven Seven Percent Notes Due Two Zero Five Three Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member] Two Point Seven Seven Percent Notes Due Two Zero Five Three KANJINTI Patent Litigation [Member] KANJINTI Patent Litigation [Member] KANJINTI Patent Litigation [Member] Molecule, Type [Axis] Molecule, Type [Axis] Molecule, Type Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract] Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets. Use of estimates Use of Estimates, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Acquisitions Business Combination Disclosure [Text Block] Other comprehensive income (loss), net of reclassification adjustments and taxes: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Fair value adjustments Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income taxes Income Tax Disclosure [Text Block] Other Mortgage and asset backed Other Mortgage and asset backed [Member] Other Mortgage and asset backed Finished goods Inventory, Finished Goods, Net of Reserves Amortization charges associated with finite-lived intangible assets Amortization of Intangible Assets Schedule of goodwill Schedule of Goodwill [Table Text Block] Basic (in usd per share) Basic EPS (in usd per share) Earnings Per Share, Basic Number Of Asserted Patents Number Of Asserted Patents Number Of Asserted Patents Total unrealized gains (losses) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc. [Member] Five Prime Therapeutics, Inc. Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total stockholders’ equity Balance as of beginning of period Balance as of end of period Stockholders' Equity Attributable to Parent Derivative instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Changes in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Total estimated amortization of finite-lived intangible assets for 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Income (Numerator): Net Income (Loss) Attributable to Parent [Abstract] Length of time hedged in foreign currency contracts (or less) Maximum Length of Time, Foreign Currency Cash Flow Hedge Money market mutual funds [Member] Money Market Funds [Member] Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Accumulated deficit [Member] Retained Earnings [Member] Dividends declared on common stock Dividends, Common Stock, Cash Enbrel® (etanercept) [Member] ENBREL [Member] ENBREL. Common Stock [Member] Number of shares of common stock [Member] Common Stock [Member] Limited Partnership [Member] Partnership Interest [Member] Other comprehensive income (loss), net of reclassification adjustments and taxes Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuance of common stock in connection with the Company’s equity award programs Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture 5.15% notes due 2041 (5.15% 2041 Notes) [Member] Five Point One Five Percent Notes Due 2041 [Member] Five Point One Five Percent Notes Due 2041 [Member] Repurchases of common stock (Note 10) Payments for Repurchase of Common Stock Contingent consideration obligations Beginning balance Ending balance Business Combination, Contingent Consideration, Liability Class of Stock [Axis] Class of Stock [Axis] Statement [Table] Statement [Table] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Acquired in-process research and development Research and Development Asset Acquired Other than Through Business Combination, Written-off Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Accumulated deficit Retained Earnings (Accumulated Deficit) Disposal Group Name [Axis] Disposal Group Name [Axis] Trade receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Purchases of marketable securities Payments to Acquire Marketable Securities Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Litigation Case [Domain] Litigation Case [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] 3.20% notes due 2027 (3.20% 2027 Notes) [Member] Three Point Two Zero Notes Due 2027 [Member] Three Point Two Zero Notes Due 2027 [Member] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Collaborative arrangement with BeiGene, Ltd. [Member] BeiGene [Member] BeiGene [Member] Other (expense) income, net Nonoperating Income (Expense) Gross carrying amounts Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense Repatriation tax on proposed additional tax Repatriation tax on proposed additional tax Repatriation tax on proposed additional tax Novartis Pharma AG Novartis Pharma AG [Member] Novartis Pharma AG Loss Contingencies [Table] Loss Contingencies [Table] Net changes in valuations Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Product sales [Member] Product [Member] Stock repurchased Stock Repurchased During Period, Value 2.20% notes due 2027 (2.20% 2027 Notes) [Member] Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member] Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member] U.S. Treasury bills [Member] US Treasury Bill Securities [Member] Accumulated other comprehensive loss [Member] AOCI [Member] AOCI Attributable to Parent [Member] Reclassification adjustments to income Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Document Transition Report Document Transition Report Local Phone Number Local Phone Number 2.80% notes due 2041 (2.80% 2041 Notes) [Member] Two point eight zero percent 2041 Notes [Member] Two point eight zero percent 2041 Notes Accumulated amortization Identifiable Intangible Assets Accumulated Amortization Identifiable intangible assets accumulated amortization. Operating income Operating Income (Loss) Inventories Increase (Decrease) in Inventories Other recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Interim Period, Costs Not Allocable [Domain] Interim Period, Costs Not Allocable [Domain] Common stock and additional paid-in capital, shares outstanding Beginning Balance, Shares Ending Balance, Shares Common Stock, Shares, Outstanding Goodwill Beginning balance Ending balance Goodwill Neulasta® (pegfilgrastim) [Member] Neulasta [Member] Neulasta. Total liabilities Liabilities, Fair Value Disclosure Stock repurchased, Shares Stock Repurchased During Period, Shares Hedging adjustments on discontinued hedging relationships Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) Aranesp® (darbepoetin alfa) [Member] Aranesp [Member] Aranesp. Goodwill and other intangible assets Goodwill and Intangible Assets Disclosure [Text Block] Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Property, plant and equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Other notes due 2097 [Member] Other Notes Due 2097 [Member] Other Notes Due 2097 [Member] Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Schedule of identifiable intangible assets Schedule Of Intangible Assets [Table Text Block] Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets. Balance Sheet Location [Domain] Balance Sheet Location [Domain] Licensing rights Licensing Agreements [Member] Document Fiscal Period Focus Document Fiscal Period Focus Cost of sales Cost of Goods and Services Sold Derivative [Line Items] Derivative [Line Items] Diluted (in shares) Weighted-average shares for diluted EPS (in shares) Weighted Average Number of Shares Outstanding, Diluted Accumulated depreciation and amortization on property, plant and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Inventories Schedule of Inventory, Current [Table Text Block] Total derivative liabilities, fair value Derivative Liability, Subject to Master Netting Arrangement, before Offset 4.40% 2062 Notes [Member] 4.40% 2062 Notes [Member] 4.40% 2062 Notes 6.375% notes due 2037 (6.375% 2037 Notes) [Member] Six Point Three Seven Five Percent Notes Due 2037 [Member] Six Point Three Seven Five Percent Notes Due 2037 [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Dividends paid per share (in usd per share) Common Stock, Dividends, Per Share, Cash Paid Corporate debt securities - Financial [Member] Corporate Debt Securities Financial [Member] Corporate debt securities financial Member. Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Number of patents allegedly infringed upon Loss Contingency, Patents Allegedly Infringed, Number Basis of presentation Basis Of Presentation [Policy Text Block] Shows the basis of presentation of financial information for interim periods. Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Long-term tax liabilities Liability for Uncertainty in Income Taxes, Noncurrent 4.663% notes due 2051 (4.663% 2051 Notes) [Member] Four Point Six Six Three Percent Notes Due Two Zero Five One [Member] Four Point Six Six Three Percent Notes Due Two Zero Five One [Member] Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Other products [Member] Other Products [Member] Other Products [Member] 1.25% 2022 euro Notes [Member] One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member] One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member] Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Prolia® (denosumab) [Member] Prolia [Member] Prolia. Business asset acquisition, consideration transferred Business asset acquisition, consideration transferred Business asset acquisition, consideration transferred Contingencies and commitments Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Net proceeds from issuance of debt Proceeds from Issuance of Long-Term Debt Carrying value of equity method investment Equity Method Investments Common stock and additional paid-in capital [Member] Common Stock Including Additional Paid in Capital [Member] Proceeds from Divestiture of Businesses and Interests in Affiliates Proceeds from Divestiture of Businesses and Interests in Affiliates 5.375% notes due 2043 (5.375% 2043 Notes) [Member] Five Point Three Seven Five Percent Notes Due 2043 [Member] Five Point Three Seven Five Percent Notes Due 2043 [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Income Statement Location [Domain] Income Statement Location [Domain] Cash flow hedges [Member] Cash flow hedge [Member] Cash Flow Hedging [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member] 4.00% 2029 pound sterling Notes [Member] Four Percent Pound Sterling Notes Due 2029 [Member] Four Percent Pound Sterling Notes Due 2029 [Member] 3.125% notes due 2025 (3.125% 2025 Notes) [Member] Three Point One Two Five Percent Notes Due Two Zero Two Five [Member] Three Point One Two Five Percent Notes Due Two Zero Two Five [Member] Amendment Flag Amendment Flag Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Other assets, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities) Face amount Debt Instrument, Face Amount Investment Type [Axis] Investment Type [Axis] Loss Contingency, New Claims Filed, Number Loss Contingency, New Claims Filed, Number Equity Method Investments, Fair Value Disclosure Equity Method Investments, Fair Value Disclosure Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member] 0.41% 2023 Swiss franc Bonds [Member] Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member] Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member] Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Loss on divestiture Impairment of Long-Lived Assets to be Disposed of Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other noncurrent assets Other Assets, Noncurrent Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block] Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets. 2.20% notes due 2020 (2.20% 2020 Notes) [Member] Two Point Two Zero Notes Due 2020 [Member] Two Point Two Zero Notes Due 2020 [Member] Debt Securities Payable [Member] Debt Securities Payable [Member] Depreciation, amortization and other Depreciation, Depletion and Amortization 3.00% notes due 2052 (3.00% 2052 Notes) 3.00% notes due 2052 (3.00% 2052 Notes) [Member] 3.00% notes due 2052 (3.00% 2052 Notes) Derivative [Table] Derivative [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Unamortized bond discounts, premiums and issuance costs, net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Other current assets/Other assets [Member] Other Current Noncurrent Assets [Member] Other current assets/other non-current assets. Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Fair value of assets acquired, licensing rights Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Other Stockholders' Equity, Other Schedule of interest rate swaps Schedule of Interest Rate Derivatives [Table Text Block] Disposal Group, Including Discontinued Operation, Other Assets Disposal Group, Including Discontinued Operation, Other Assets Property, plant and equipment, net Property, Plant and Equipment, Net Currency [Axis] Currency [Axis] Entities [Table] Entities [Table] Repayment of debt Repayments of Long-Term Debt Kyprolis ANDA Patent Litigation Kyprolis ANDA Patent Litigation [Member] Kyprolis ANDA Patent Litigation Patent Trial and Appeal Board Patent Challenges [Member] Patent Trial And Appeal Board Patent Challenges [Member] Patent Trial And Appeal Board Patent Challenges [Member] Long-term debt [Member] Long-Term Debt [Member] Maximum additional consideration due contingent on certain milestones Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 2.25% notes due 2023 (2.25% 2023 Notes) [Member] Two Point Two Five Percent Notes Due Two Zero Two Three [Member] Two Point Two Five Percent Notes Due Two Zero Two Three [Member] Total carrying value of debt Carrying value of debt Long-Term Debt Balance Sheet Location [Axis] Balance Sheet Location [Axis] Sensipar Antitrust Class Actions [Member] Sensipar Antitrust Class Actions [Member] Sensipar Antitrust Class Actions [Member] Common stock and additional paid-in capital, shares authorized Common Stock, Shares Authorized Switzerland, Francs Switzerland, Francs 2.65% notes due 2022 (2.65% 2022 Notes) [Member] Two Point Six Five Notes Due 2022 [Member] Two Point Six Five Notes Due 2022 [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum [Member] Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Net gains (losses) from limited partnership investments Alternative Investment, Net Gain (Loss) Alternative Investment, Net Gain (Loss) Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Repurchases of common stock Repurchases of common stock Stock Repurchased and Retired During Period, Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Designated as Hedging Instrument [Member] Derivatives designated as hedging instrument [Member] Designated as Hedging Instrument [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Business Combination, Contingent Consideration [Roll Forward] Business Combination, Contingent Consideration [Roll Forward] Business Combination, Contingent Consideration [Roll Forward] Stockholders' equity Stockholders' Equity Note Disclosure [Text Block] Common stock, dividends declared per share (in usd per share) Dividends declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Revenues: Revenues [Abstract] Other intangible assets, net Finite-Lived Intangible Assets, Net Number of lawsuits Loss Contingency, Number Of Lawsuits Loss Contingency, Number Of Lawsuits Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other IPR&D Acquired in-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Summary of significant accounting policies Significant Accounting Policies [Text Block] Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event 4.563% notes due 2048 (4.563% 2048 Notes) [Member] 4.563% notes due 2048 (4.563% 2048 Notes) [Member] Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member] Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member] Other Other Long-Term Debt Repurchases of common stock, Shares Stock Repurchased and Retired During Period, Shares Trade receivables, net Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Long-term debt, fair value Notes Payable, Fair Value Disclosure Otezla ANDA Patent Litigation [Member] Otezla ANDA Patent Litigation [Member] Otezla ANDA Patent Litigation Total operating expenses Costs and Expenses Other revenues [Member] Product and Service, Other [Member] 2.45% notes due 2030 (2.45% 2030 Notes) [Member] Two Point Four Five Percent Notes Due 2030 [Member] Two Point Four Five Percent Notes Due 2030 [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Issuance of common stock in connection with the Company’s equity award programs, Shares Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Loss Contingency, appeal period Loss Contingency, appeal period Loss Contingency, appeal period Other government-related debt securities - U.S. [Member] US Government Agencies Debt Securities [Member] 5.75% notes due 2040 (5.75% 2040 Notes) [Member] Five Point Seven Five Percent Notes Due 2040 [Member] Five Point Seven Five Percent Notes Due 2040 [Member] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] KYPROLIS® (carfilzomib) [Member] Kyprolis [Member] Kyprolis [Member] Total estimated amortization of finite-lived intangible assets for 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Foreign currency translation Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent U.S. Treasury notes [Member] US Treasury Securities [Member] Penalties on proposed additional income tax 2013-2015 Penalties on proposed additional income tax 2013-2105 Penalties on proposed additional income tax 2013-2015 Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Molecule, Type [Domain] Molecule, Type [Domain] Molecule, Type [Domain] Unrealized gains OCI, before Reclassifications, before Tax, Attributable to Parent Shares used in calculation of earnings per share: Shares (Denominator): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Disposal Group, Including Discontinued Operation, Inventory Disposal Group, Including Discontinued Operation, Inventory Inventories Total inventories Inventory, Net Accounts payable Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Other assets Increase (Decrease) in Other Operating Assets 3.00% 2029 Notes [Member] 3.00% 2029 Notes [Member] 3.00% 2029 Notes Hedging Relationship [Domain] Hedging Relationship [Domain] Fair values of available-for-sale interest-bearing security investments by contractual maturity Investments Classified by Contractual Maturity Date [Table Text Block] Hedging Designation [Axis] Hedging Designation [Axis] R & D Technology rights R & D Technology rights [Member] R & D Technology rights [Member] 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member] One Point Two Five Percent Euro Notes due Two Zero Two Two [Member] One Point Two Five Percent Euro Notes due Two Zero Two Two [Member] Entity Filer Category Entity Filer Category 3.625% notes due 2024 (3.625% 2024 Notes) [Member] Three Point Six Two Five Percent Notes Due 2024 [Member] Three Point Six Two Five Percent Notes Due 2024 [Member] Basic (in shares) Weighted-average shares for basic EPS (in shares) Weighted Average Number of Shares Outstanding, Basic US [Member] UNITED STATES Liabilities: Liabilities, Fair Value Disclosure [Abstract] Alternative investments Alternative Investment Ownership percentage Equity Method Investment, Ownership Percentage Contingencies and commitments Commitments and Contingencies Security Exchange Name Security Exchange Name Weighted average period of amortization Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Notional amounts Derivative, Notional Amount Disposal Group, Including Discontinued Operation, Assets, Current Disposal Group, Including Discontinued Operation, Assets, Current Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Accrued income taxes, net Increase (Decrease) in Income Taxes Payable 1.65% notes due 2028 (1.65% 2028 Notes) [Member} One point six five percent 2028 Notes [Member] One point six five percent 2028 Notes Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Significant unobservable inputs (Level 3) [Member] Fair Value, Inputs, Level 3 [Member] Income before income taxes Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Proposed additional income tax Proposed additional income tax Proposed additional income tax 2.60% notes due 2026 (2.60% 2026 notes) [Member] Two Point Six Zero Notes Due Two Zero Two Six [Member] Two Point Six Zero Notes Due Two Zero Two Six [Member] Gain Contingency, Patents Found Infringed upon, Number Gain Contingency, Patents Found Infringed upon, Number Work in process Inventory, Work in Process, Net of Reserves Business Combinations [Abstract] Business Combinations [Abstract] Derivatives: Derivative Assets Fair Value Disclosure [Abstract] Derivative assets. Number of Third-Party Financial Institutions Number of Third-Party Financial Institutions Number of Third-Party Financial Institutions Revenues Revenue from Contract with Customer [Text Block] Other [Member] Accumulated Other Adjustment Attributable to Parent [Member] Accumulated Other Adjustment Attributable to Parent [Member] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Investments [Domain] Investments [Domain] Forecast [Member] Forecast [Member] Otezla (apremilast) [Member] Otezla [Member] Otezla [Member] Total liabilities and stockholders’ equity Liabilities and Equity Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Gains (losses) on fair value hedging relationships, Hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Reclassification out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Amount available for stock repurchases under a board approved stock repurchase plan Stock Repurchase Program, Remaining Authorized Repurchase Amount Cash Cash Derivatives: Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract] Derivative financial instruments liabilities fair value disclosure. ROW [Member] Non-US [Member] Derivatives not designated as hedging instrument [Member] Not Designated as Hedging Instrument [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Cash paid for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Significant other observable inputs (Level 2) [Member] Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Total realized gains Debt Securities, Available-for-Sale, Realized Gain 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) [Member] 2.00% 2026 euro Notes [Member] Two Percent Euro Notes Due Two Thousand Twenty Six [Member] Two Percent Euro Notes Due Two Thousand Twenty Six [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Disposal Group, Including Discontinued Operation, Assets Disposal Group, Including Discontinued Operation, Assets Intangible assets, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Diluted (in usd per share) Diluted EPS (in usd per share) Earnings Per Share, Diluted Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Total current liabilities Liabilities, Current Other current assets Other Assets, Current Schedule of Available-for-sale Securities [Table] Schedule of Available-for-Sale Securities [Table] Research and Development Technology Rights [Member] Acquired Research And Development Technology Rights [Member] Acquired research and development technology rights. Share Repurchase Program [Axis] Share Repurchase Program [Axis] Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Cumulative effect of changes in accounting principles, net of tax Cumulative Effect, Period of Adoption, Adjustment [Member] Equity Securities, FV-NI, Unrealized Gain (Loss) Equity Securities, FV-NI, Unrealized Gain (Loss) AMG 340 AMG 340 [Member] AMG 340 Total derivative assets, fair value Derivative Asset, Subject to Master Netting Arrangement, before Offset Other government-related debt securities - Foreign and other [Member] Debt Security, Government, Non-US [Member] Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Entity Address, Address Line One Entity Address, Address Line One Income Tax Authority [Domain] Income Tax Authority [Domain] Other Proceeds from (Payments for) Other Financing Activities Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Neumora Therapeutics, Inc. [Member] Neumora Therapeutics, Inc. [Member] Neumora Therapeutics, Inc. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Interest rate swap contracts Interest Rate Fair Value Hedge Asset at Fair Value Exchange [Domain] Exchange [Domain] foreign and other government-related debt securities foreign and other government-related debt securities [Member] foreign and other government-related debt securities Teneobio Inc. Teneobio Inc. [Member] Teneobio Inc. US Government Corporations and Agencies Securities US Government Corporations and Agencies Securities [Member] Inventories Inventory Disclosure [Text Block] United States of America, Dollars United States of America, Dollars Equity [Abstract] Equity [Abstract] Schedule of borrowings Schedule of Long-Term Debt Instruments [Table Text Block] Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Derivatives Fair Value [Line Items] Derivatives, Fair Value [Line Items] Foreign currency and cross-currency swap contracts Foreign Currency Contract, Asset, Fair Value Disclosure Interest rates Derivative, Fixed Interest Rate Hedged Liability, Fair Value Hedge Hedged Liability, Fair Value Hedge Disaggregation of revenue by product and by geographic area Disaggregation of Revenue [Table Text Block] Other short-term interest-bearing securities [Member] Other Short Term Interest Bearing Securities [Member] Other short-term interest bearing securities. Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2022 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Hospira, Inc. [Member] Hospira [Member] Hospira [Member] 3.15% notes due 2040 (3.15% 2040 Notes) [Member] Three Point One Five Percent Notes Due 2040 [Member] Three Point One Five Percent Notes Due 2040 [Member] Research and development Research and Development Expense (Excluding Acquired in Process Cost) 1.85% notes due 2021 (1.85% 2021 Notes) [Member] One Point Eight Five Percent Notes Due Two Zero Two One [Member] One Point Eight Five Percent Notes Due Two Zero Two One [Member] Litigation Settlement, Expense Litigation Settlement, Expense Nplate [Member] Nplate [Member] Nplate Nature of Expense [Axis] Nature of Expense [Axis] (Decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued liabilities [Member] Accrued Liabilities [Member] Payments Business Combination, Contingent Consideration Arrangements, Payments Business Combination, Contingent Consideration Arrangements, Payments Proposed additional income tax 2013-2015 Proposed additional income tax 2013-2015 Proposed additional income tax 2013-2015 Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Total estimated amortization of finite-lived intangible assets for 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Central Index Key Entity Central Index Key Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Tax impact related to employee stock-based compensation expense Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Accrued liabilities/Other noncurrent liabilities [Member] Accrued Liabilities Other Non Current Liabilities [Member] Accrued liabilities/other non-current liabilities. City Area Code City Area Code ASSETS Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Euro Member Countries, Euro Euro Member Countries, Euro Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Notes [Member] Notes Payable to Banks [Member] Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale 3.625% notes due 2022 (3.625% 2022 Notes) [Member] Three Point Six Two Five Percent Notes Due 2022 [Member] Three Point Six Two Five Percent Notes Due 2022 [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Purchases of equity method investments Payments to Acquire Equity Method Investments Payments to Acquire Equity Method Investments Computation of basic and diluted earnings per share Basic And Diluted Earning Per Share [Abstract] Basic and diluted earning per share. Other noncurrent liabilities Other Liabilities, Noncurrent Adjustments for equity method investments Income (Loss) from Equity Method Investments Income (Loss) from Equity Method Investments Disposal Group Classification [Domain] Disposal Group Classification [Domain] Other liabilities Increase (Decrease) in Other Operating Liabilities Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Total estimated amortization of finite-lived intangible assets for 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Computation for basic and diluted earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Equity Method Investment, Aggregate Cost Equity Method Investment, Aggregate Cost Total realized losses Debt Securities, Available-for-Sale, Realized Loss Mortgage and asset back Mortgage and asset back [Member] Mortgage and asset back Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value EX-101.PRE 11 amgn-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover Page - shares
6 Months Ended
Jun. 30, 2022
Aug. 01, 2022
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-37702  
Entity Registrant Name Amgen Inc.  
Entity Central Index Key 0000318154  
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Current Fiscal Year End Date --12-31  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 95-3540776  
Entity Address, Address Line One One Amgen Center Drive  
Entity Address, City or Town Thousand Oaks  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 91320-1799  
City Area Code 805  
Local Phone Number 447-1000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   534,930,850
The NASDAQ Global Select Market [Member] | Common Stock [Member]    
Entity Information [Line Items]    
Title of 12(b) Security Common stock, $0.0001 par value  
Trading Symbol AMGN  
Security Exchange Name NASDAQ  
The NASDAQ Global Select Market [Member] | 2.00% Senior Notes Due 2026 [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 2.00% Senior Notes due 2026  
Trading Symbol AMGN26  
Security Exchange Name NASDAQ  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net income $ 1,317 $ 464 $ 2,793 $ 2,110
Other comprehensive income (loss), net of reclassification adjustments and taxes:        
Foreign currency translation (65) 14 (116) (25)
Cash flow hedges 156 (48) 240 142
Other 0 (1) 0 0
Other comprehensive income (loss), net of reclassification adjustments and taxes 91 (35) 124 117
Comprehensive income $ 1,408 $ 429 $ 2,917 $ 2,227
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues:        
Total revenues $ 6,594 $ 6,526 $ 12,832 $ 12,427
Operating expenses:        
Cost of sales 1,510 1,637 3,071 3,127
Research and development 1,039 1,082 1,998 2,049
Acquired in-process research and development 0 1,505 0 1,505
Selling, general and administrative 1,327 1,384 2,555 2,638
Other 542 90 532 151
Total operating expenses 4,418 5,698 8,156 9,470
Operating income 2,176 828 4,676 2,957
Interest expense, net (328) (281) (623) (566)
Other (expense) income, net (317) 11 (847) 24
Income before income taxes 1,531 558 3,206 2,415
Provision for income taxes 214 94 413 305
Net income $ 1,317 $ 464 $ 2,793 $ 2,110
Earnings per share:        
Basic (in usd per share) $ 2.46 $ 0.81 $ 5.16 $ 3.67
Diluted (in usd per share) $ 2.45 $ 0.81 $ 5.13 $ 3.65
Shares used in calculation of earnings per share:        
Basic (in shares) 535 573 541 575
Diluted (in shares) 537 576 544 578
Product sales [Member]        
Revenues:        
Total revenues $ 6,281 $ 6,114 $ 12,012 $ 11,706
Other revenues [Member]        
Revenues:        
Total revenues $ 313 $ 412 $ 820 $ 721
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 5,203 $ 7,989
Marketable securities 1,980 48
Trade receivables, net 5,327 4,895
Inventories 4,554 4,086
Other current assets 2,258 2,367
Total current assets 19,322 19,385
Property, plant and equipment, net 5,158 5,184
Intangible assets, net 13,927 15,182
Goodwill 14,865 14,890
Other noncurrent assets 6,022 6,524
Total assets 59,294 61,165
Current liabilities:    
Accounts payable 1,256 1,366
Accrued liabilities 10,545 10,731
Current portion of long-term debt 817 87
Total current liabilities 12,618 12,184
Long-term debt 35,705 33,222
Long-term tax liabilities 5,603 6,594
Other noncurrent liabilities 2,949 2,465
Contingencies and commitments
Stockholders’ equity:    
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—534.9 shares in 2022 and 558.3 shares in 2021 31,343 32,096
Accumulated deficit (28,252) (24,600)
Accumulated other comprehensive loss (672) (796)
Total stockholders’ equity 2,419 6,700
Total liabilities and stockholders’ equity $ 59,294 $ 61,165
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
shares in Millions
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Common stock and additional paid-in capital, par value (in usd per share) $ 0.0001 $ 0.0001
Common stock and additional paid-in capital, shares authorized 2,750.0 2,750.0
Common stock and additional paid-in capital, shares outstanding 534.9 558.3
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Number of shares of common stock [Member]
Common stock and additional paid-in capital [Member]
Accumulated deficit [Member]
Accumulated other comprehensive loss [Member]
Beginning Balance, Shares at Dec. 31, 2020   578.3      
Balance as of beginning of period at Dec. 31, 2020 $ 9,409   $ 31,802 $ (21,408) $ (985)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income for basic and diluted EPS 1,646     1,646  
Other comprehensive income (loss), net of taxes 152       152
Dividends declared on common stock (1,012)     (1,012)  
Issuance of common stock in connection with the Company’s equity award programs, Shares   0.7      
Issuance of common stock in connection with the Company’s equity award programs 6   6    
Stock-based compensation expense 57   57    
Tax impact related to employee stock-based compensation expense (59)   (59)    
Repurchases of common stock, Shares   (3.7)      
Repurchases of common stock (865)     (865)  
Ending Balance, Shares at Mar. 31, 2021   575.3      
Balance as of end of period at Mar. 31, 2021 9,334   31,806 (21,639) (833)
Beginning Balance, Shares at Dec. 31, 2020   578.3      
Balance as of beginning of period at Dec. 31, 2020 9,409   31,802 (21,408) (985)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income for basic and diluted EPS 2,110        
Ending Balance, Shares at Jun. 30, 2021   569.6      
Balance as of end of period at Jun. 30, 2021 8,247   31,877 (22,762) (868)
Beginning Balance, Shares at Mar. 31, 2021   575.3      
Balance as of beginning of period at Mar. 31, 2021 9,334   31,806 (21,639) (833)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income for basic and diluted EPS 464     464  
Other comprehensive income (loss), net of taxes (35)       (35)
Issuance of common stock in connection with the Company’s equity award programs, Shares   0.8      
Issuance of common stock in connection with the Company’s equity award programs 47   47    
Stock-based compensation expense 100   100    
Tax impact related to employee stock-based compensation expense (76)   (76)    
Repurchases of common stock, Shares   (6.5)      
Repurchases of common stock (1,592)     (1,592)  
Other 5     5  
Ending Balance, Shares at Jun. 30, 2021   569.6      
Balance as of end of period at Jun. 30, 2021 $ 8,247   31,877 (22,762) (868)
Beginning Balance, Shares at Dec. 31, 2021 558.3 558.3      
Balance as of beginning of period at Dec. 31, 2021 $ 6,700   32,096 (24,600) (796)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income for basic and diluted EPS 1,476     1,476  
Other comprehensive income (loss), net of taxes 33       33
Dividends declared on common stock (1,034)     (1,034)  
Issuance of common stock in connection with the Company’s equity award programs, Shares   0.5      
Issuance of common stock in connection with the Company’s equity award programs 18   18    
Stock-based compensation expense 78   78    
Tax impact related to employee stock-based compensation expense (45)   (45)    
Repurchases of common stock, Shares   (24.6)      
Repurchases of common stock (6,310)   (900) (5,410)  
Ending Balance, Shares at Mar. 31, 2022   534.2      
Balance as of end of period at Mar. 31, 2022 $ 916   31,247 (29,568) (763)
Beginning Balance, Shares at Dec. 31, 2021 558.3 558.3      
Balance as of beginning of period at Dec. 31, 2021 $ 6,700   32,096 (24,600) (796)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income for basic and diluted EPS $ 2,793        
Ending Balance, Shares at Jun. 30, 2022 534.9 534.9      
Balance as of end of period at Jun. 30, 2022 $ 2,419   31,343 (28,252) (672)
Beginning Balance, Shares at Mar. 31, 2022   534.2      
Balance as of beginning of period at Mar. 31, 2022 916   31,247 (29,568) (763)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income for basic and diluted EPS 1,317     1,317  
Other comprehensive income (loss), net of taxes 91       91
Issuance of common stock in connection with the Company’s equity award programs, Shares   0.7      
Issuance of common stock in connection with the Company’s equity award programs 45   45    
Stock-based compensation expense 120   120    
Tax impact related to employee stock-based compensation expense (69)   (69)    
Other $ (1)     (1)  
Ending Balance, Shares at Jun. 30, 2022 534.9 534.9      
Balance as of end of period at Jun. 30, 2022 $ 2,419   $ 31,343 $ (28,252) $ (672)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares
1 Months Ended 3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]        
Common stock, dividends declared per share (in usd per share) $ 1.94 $ 1.94 $ 1.94 $ 1.76
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net income $ 2,793 $ 2,110
Depreciation, amortization and other 1,669 1,696
Deferred income taxes (514) (137)
Acquired in-process research and development 0 1,505
Adjustments for equity method investments 497 (36)
Loss on divestiture 560 0
Other items, net 436 206
Changes in operating assets and liabilities, net of acquisitions:    
Trade receivables, net (504) 35
Inventories (410) (167)
Other assets 198 (258)
Accounts payable (98) (156)
Accrued income taxes, net (685) (930)
Long-term tax liabilities 108 47
Other liabilities 44 120
Net cash provided by operating activities 4,094 4,035
Cash flows from investing activities:    
Purchases of marketable securities (1,976) (8,000)
Proceeds from sales of marketable securities 0 4,404
Proceeds from maturities of marketable securities 47 6,528
Purchases of property, plant and equipment (436) (351)
Cash paid for acquisitions, net of cash acquired 0 (1,626)
Other 61 (65)
Net cash (used in) provided by investing activities (2,304) 890
Cash flows from financing activities:    
Net proceeds from issuance of debt 3,954 0
Repurchases of common stock (Note 10) (6,360) (2,452)
Dividends paid (2,118) (2,024)
Other (52) (85)
Net cash used in financing activities (4,576) (4,561)
(Decrease) increase in cash and cash equivalents (2,786) 364
Cash and cash equivalents at beginning of period 7,989 6,266
Cash and cash equivalents at end of period $ 5,203 $ 6,630
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of significant accounting policies Summary of significant accounting policies
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation
The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.0 billion and $8.8 billion as of June 30, 2022 and December 31, 2021, respectively.
Recent accounting pronouncements
In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.
In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Acquisitions
6 Months Ended
Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisitions Acquisitions and divestitures
Acquisition of Teneobio, Inc.
On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio’s proprietary bispecific and multispecific antibody technologies, which complement Amgen’s existing antibody capabilities and bispecific T-cell engager (BiTE®) platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen’s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our condensed consolidated financial statements commencing on the acquisition date.
Measurement period adjustments for the six months ended June 30, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $22 million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen’s results of operations during the six months ended June 30, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):
Amounts
Cash purchase price$993 
Contingent consideration299 
Total consideration$1,292 
Cash and cash equivalents$100 
In-process research and development991 
Finite-lived intangible asset – research and development technology rights115 
Finite-lived intangible assets – licensing rights41 
Goodwill273 
Other assets, net16 
Deferred tax liability(244)
Total assets acquired, net$1,292 
Consideration for this transaction comprised (i) an upfront cash payment of $993 million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio’s former equity holders of up to $1.6 billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $299 million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 11, Fair value measurement, for information regarding the estimated fair value of these obligations as of June 30, 2022.
The estimated fair values of acquired IPR&D assets totaled $991 million, of which $784 million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to four separate preclinical oncology programs. The R&D technology rights of $115 million relate to Teneobio’s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over 10 years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41 million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.
A deferred tax liability of $244 million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.
The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $273 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.
Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis of certain tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.
Acquisition of Five Prime Therapeutics, Inc.
On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $1.6 billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. Five Prime’s operations have been included in our condensed consolidated financial statements commencing after the acquisition date.
We allocated the consideration to acquire Five Prime to: the bemarituzumab IPR&D program of $1.5 billion, which was expensed immediately in Acquired IPR&D expense in the Condensed Consolidated Statements of Income; deferred tax assets of $177 million; and other net liabilities of $47 million. The Acquired IPR&D expense was not tax deductible.
Divestiture of Gensenta İlaç Sanayi ve Ticaret A.Ş.
On June 28, 2022, we entered into a share purchase agreement with Eczacıbaşı under which Eczacıbaşı will acquire all of our shares in Gensenta—a subsidiary in Turkey. Net assets related to Gensenta of $80 million met the criteria to be classified as held-for-sale and did not meet the criteria to be classified as discontinued operations. Upon closing of the transaction, we expect to receive $135 million in cash. The transaction is expected to close in the third quarter of 2022 upon approval by the Turkish Competition Authority.
As of June 30, 2022, held-for-sale assets and liabilities of $100 million and $20 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $560 million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuation allowances to Other current assets and Accrued liabilities in the Condensed Consolidated Balance Sheets.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Revenues
6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.
Revenues were as follows (in millions):
Three months ended June 30,
20222021
U.S.ROWTotalU.S.ROWTotal
ENBREL$1,036 $15 $1,051 $1,113 $31 $1,144 
Prolia611 311 922 538 276 814 
Otezla487 107 594 423 111 534 
XGEVA391 142 533 355 133 488 
Aranesp132 225 357 135 232 367 
Neulasta263 47 310 434 52 486 
Repatha154 171 325 143 143 286 
KYPROLIS213 104 317 190 90 280 
Nplate156 128 284 136 109 245 
Other products1,003 585 1,588 907 563 1,470 
Total product sales(1)
$4,446 $1,835 6,281 $4,374 $1,740 6,114 
Other revenues313 412 
Total revenues$6,594 $6,526 
Six months ended June 30,
20222021
U.S.ROWTotalU.S.ROWTotal
ENBREL$1,879 $34 $1,913 $2,007 $61 $2,068 
Prolia1,193 581 1,774 1,039 533 1,572 
Otezla837 208 1,045 789 221 1,010 
XGEVA759 276 1,035 689 267 956 
Aranesp269 446 715 260 462 722 
Neulasta567 91 658 855 113 968 
Repatha319 335 654 282 290 572 
KYPROLIS409 195 604 349 182 531 
Nplate312 238 550 248 224 472 
Other products1,939 1,125 3,064 1,759 1,076 2,835 
Total product sales(1)
$8,483 $3,529 12,012 $8,277 $3,429 11,706 
Other revenues820 721 
Total revenues$12,832 $12,427 
____________
(1)    Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Income taxes
6 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The effective tax rates for the three and six months ended June 30, 2022, were 14.0% and 12.9%, respectively, compared with 16.8% and 12.6%, respectively, for the corresponding periods of the prior year.
The decrease in our effective tax rate for the three months ended June 30, 2022, was primarily due to the prior year nondeductible IPR&D expense arising from the acquisition of Five Prime, partially offset by current year unfavorable items including a loss on a nonstrategic divestiture. The increase in our effective tax rate for the six months ended June 30, 2022, was primarily due to current year unfavorable items compared to last year including a loss on a nonstrategic divestiture, partially offset by the prior year nondeductible IPR&D expense arising from the acquisition of Five Prime and changes in earnings mix. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States treated as a foreign jurisdiction for U.S. tax purposes, that are currently subject to a tax incentive grant through 2035. In addition, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. These foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. See Note 2, Acquisitions and divestitures.
The U.S. territory of Puerto Rico imposes a 4% excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We account for the excise tax as a manufacturing cost that is capitalized in Inventories and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes, in 2022, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.
One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters.
In 2017, we received an RAR and a modified RAR from the IRS for the years 2010–2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010–2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010–2012 by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed for the years 2010–2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings.
In 2020, we received an RAR and a modified RAR from the IRS for the years 2013–2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010–2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013–2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013–2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for the years 2013–2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued on our foreign earnings.
We firmly believe that the IRS positions set forth in the 2010–2012 and 2013–2015 Notices are without merit. We are contesting the 2010–2012 and 2013–2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court.
We are currently under examination by the IRS for the years 2016–2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we have examinations by a number of state and foreign tax jurisdictions.
Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.
We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.
See Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations, Income Taxes, for further discussion and Part II, Item 1A, Risk Factors—The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability.
During the three and six months ended June 30, 2022, the gross amounts of our UTBs increased by $50 million and $95 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of June 30, 2022, if recognized, would affect our effective tax rate.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Earnings per share
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Earnings per share Earnings per share
The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.
The computations for basic and diluted EPS were as follows (in millions, except per-share data):
 Three months ended
June 30,
Six months ended
June 30,
 2022202120222021
Income (Numerator):
Net income for basic and diluted EPS$1,317 $464 $2,793 $2,110 
Shares (Denominator):
Weighted-average shares for basic EPS535 573 541 575 
Effect of dilutive securities
Weighted-average shares for diluted EPS537 576 544 578 
Basic EPS$2.46 $0.81 $5.16 $3.67 
Diluted EPS$2.45 $0.81 $5.13 $3.65 
For the three and six months ended June 30, 2022 and 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Investments
6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Available-for-sale investments
The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):
Types of securities as of June 30, 2022Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Fair
values
U.S. Treasury notes$— $— $— $— 
U.S. Treasury bills1,980 — — 1,980 
Money market mutual funds4,433 — — 4,433 
Other short-term interest-bearing securities— — — — 
Total interest-bearing securities$6,413 $— $— $6,413 

Types of securities as of December 31, 2021Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Fair
values
U.S. Treasury notes$47 $— $— $47 
U.S. Treasury bills1,400 — — 1,400 
Money market mutual funds5,856 — — 5,856 
Other short-term interest-bearing securities— — 
Total interest-bearing securities$7,304 $— $— $7,304 
The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):
Condensed Consolidated Balance Sheets locationsJune 30, 2022December 31, 2021
Cash and cash equivalents$4,433 $7,256 
Marketable securities1,980 48 
Total interest-bearing securities$6,413 $7,304 
Cash and cash equivalents in the above table excludes bank account cash of $770 million and $733 million as of June 30, 2022 and December 31, 2021, respectively.
Total interest-bearing securities as of June 30, 2022 and December 31, 2021, mature in one year or less.
For the three and six months ended June 30, 2022 and 2021, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.
The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.
Equity securities
We held investments in equity securities with readily determinable fair values (publicly traded securities) of $361 million and $611 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022 and 2021, net unrealized gains and losses on publicly traded securities were a $106 million net loss and a $25 million net gain, respectively. During the six months ended June 30, 2022 and 2021, net unrealized losses on publicly traded securities were $276 million and $31 million, respectively. Realized gains and losses on sales of publicly traded securities for the three and six months ended June 30, 2022 and 2021, were not material.
We held investments of $280 million and $262 million in equity securities without readily determinable fair values as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and six months ended June 30, 2022 and 2021, upward adjustments and downward adjustments on these securities were not material. Adjustments were based on observable price transactions.
Equity method investments
BeiGene, Ltd.
As of June 30, 2022 and December 31, 2021, we had an ownership interest in BeiGene of approximately 18.2% and 18.4%, respectively, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets and accounted for under the equity method of accounting. We amortize the difference between the fair value of equity securities acquired and our proportionate share of the carrying value of the underlying net assets of BeiGene over the useful lives of the assets that gave rise to this basis difference. This amortization and our share of the results of operations of BeiGene are included in Other (expense) income, net, in the Condensed Consolidated Statements of Income one quarter in arrears.
During the three months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene’s net loss of $80 million and net income of $14 million, respectively, and amortization of the basis difference of $48 million and $42 million, respectively. During the six months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene’s net losses of $188 million and $83 million, respectively, and amortization of the basis difference of $95 million and $84 million, respectively. As of June 30, 2022 and December 31, 2021, the carrying values of our investment in BeiGene totaled $2.5 billion and $2.8 billion, respectively, and the fair values of our investment totaled $3.1 billion and $5.1 billion, respectively. As of June 30, 2022, we believe the carrying value of our equity investment in BeiGene is fully recoverable.
Neumora Therapeutics, Inc.
On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257 million, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets, in exchange for a $100 million cash payment and $157 million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of June 30, 2022 and December 31, 2021, our ownership interest in Neumora was approximately 25.7% and 25.9%, respectively, and the fair values of our investment were $131 million and $220 million, respectively. Accordingly, for the reduction in fair value of our investment during the three and six months ended June 30, 2022, we recognized a loss of $39 million and $89 million, respectively, for the reduction in fair value of our investment in Other (expense) income, net, in the Condensed Consolidated Statements of Income. For information on determination of fair values, see Note 11, Fair value measurement.
Limited partnerships
We held limited partnership investments of $338 million and $573 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of June 30, 2022, unfunded additional commitments to be made for these investments during the next several years were $209 million. For the three months ended June 30, 2022 and 2021, net unrealized losses from our limited partnership investments were $60 million and $43 million, respectively. For the six months ended June 30, 2022 and 2021, net unrealized gains and losses from our limited partnership investments were a $220 million net loss and a $165 million net gain, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Inventories
6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of the following (in millions):
June 30, 2022December 31, 2021
Raw materials$779 $647 
Work in process2,763 2,367 
Finished goods1,012 1,072 
Total inventories$4,554 $4,086 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and other intangible assets
6 Months Ended
Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and other intangible assets Goodwill and other intangible assets
Goodwill
The change in the carrying amount of goodwill was as follows (in millions):
Six months ended
June 30, 2022
Beginning balance$14,890 
Adjustments to goodwill resulting from acquisitions and divestitures, net(1)
Currency translation adjustment(32)
Ending balance$14,865 
____________
(1)    Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.

Other intangible assets
Other intangible assets consisted of the following (in millions):
 June 30, 2022December 31, 2021
 Gross
carrying
amounts
Accumulated
amortization
Other intangible
assets, net
Gross
carrying
amounts
Accumulated
amortization
Other intangible
assets, net
Finite-lived intangible assets:
Developed-product-technology rights$25,537 $(13,863)$11,674 $25,561 $(12,769)$12,792 
Licensing rights3,864 (3,050)814 3,807 (2,973)834 
Marketing-related rights1,326 (1,125)201 1,354 (1,112)242 
Research and development technology rights1,371 (1,153)218 1,377 (1,133)244 
Total finite-lived intangible assets32,098 (19,191)12,907 32,099 (17,987)14,112 
Indefinite-lived intangible assets:
In-process research and development1,020 — 1,020 1,070 — 1,070 
Total other intangible assets$33,118 $(19,191)$13,927 $33,169 $(17,987)$15,182 

Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses.
IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.
During the three months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $629 million and $652 million, respectively. During the six months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $1.3 billion in both periods. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining six months ending December 31, 2022, and the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $1.3 billion, $2.5 billion, $2.5 billion, $2.4 billion, $1.7 billion and $1.8 billion, respectively.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Financing arrangements
6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Financing arrangements Financing arrangements
Our borrowings consisted of the following (in millions):
 June 30, 2022December 31, 2021
0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)
$733 $767 
2.25% notes due 2023 (2.25% 2023 Notes)
750 750 
3.625% notes due 2024 (3.625% 2024 Notes)
1,400 1,400 
1.90% notes due 2025 (1.90% 2025 Notes)
500 500 
3.125% notes due 2025 (3.125% 2025 Notes)
1,000 1,000 
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
786 853 
2.60% notes due 2026 (2.60% 2026 Notes)
1,250 1,250 
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)
579 643 
2.20% notes due 2027 (2.20% 2027 Notes)
1,750 1,750 
3.20% notes due 2027 (3.20% 2027 Notes)
1,000 1,000 
1.65% notes due 2028 (1.65% 2028 Notes)
1,250 1,250 
3.00% notes due 2029 (3.00% 2029 Notes)
750 — 
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)
853 947 
2.45% notes due 2030 (2.45% 2030 Notes)
1,250 1,250 
2.30% notes due 2031 (2.30% 2031 Notes)
1,250 1,250 
2.00% notes due 2032 (2.00% 2032 Notes)
1,250 1,250 
3.35% notes due 2032 (3.35% 2032 Notes)
1,000 — 
6.375% notes due 2037 (6.375% 2037 Notes)
478 478 
6.90% notes due 2038 (6.90% 2038 Notes)
254 254 
6.40% notes due 2039 (6.40% 2039 Notes)
333 333 
3.15% notes due 2040 (3.15% 2040 Notes)
2,000 2,000 
5.75% notes due 2040 (5.75% 2040 Notes)
373 373 
2.80% notes due 2041 (2.80% 2041 Notes)
1,150 1,150 
4.95% notes due 2041 (4.95% 2041 Notes)
600 600 
5.15% notes due 2041 (5.15% 2041 Notes)
729 729 
5.65% notes due 2042 (5.65% 2042 Notes)
415 415 
5.375% notes due 2043 (5.375% 2043 Notes)
185 185 
4.40% notes due 2045 (4.40% 2045 Notes)
2,250 2,250 
4.563% notes due 2048 (4.563% 2048 Notes)
1,415 1,415 
3.375% notes due 2050 (3.375% 2050 Notes)
2,250 2,250 
4.663% notes due 2051 (4.663% 2051 Notes)
3,541 3,541 
3.00% notes due 2052 (3.00% 2052 Notes)
1,350 1,350 
4.20% notes due 2052 (4.20% 2052 Notes)
1,000 — 
2.77% notes due 2053 (2.77% 2053 Notes)
940 940 
4.40% notes due 2062 (4.40% 2062 Notes)
1,250 — 
Other notes due 2097100 100 
Unamortized bond discounts, premiums and issuance costs, net(1,245)(1,213)
Fair value adjustments(210)284 
Other13 15 
Total carrying value of debt36,522 33,309 
Less current portion(817)(87)
Total long-term debt$35,705 $33,222 
There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.
During the three months ended March 31, 2022, we issued $4.0 billion of debt consisting of $750 million of the 3.00% 2029 Notes, $1.0 billion of the 3.35% 2032 Notes, $1.0 billion of the 4.20% 2052 Notes and $1.25 billion of the 4.40% 2062 Notes. The 3.00% 2029 Notes were issued to finance eligible projects that meet specified criteria to benefit the environment. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a make-whole amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during a specified period of time immediately prior to the maturing of the notes. Such time periods range from two months to six months prior to maturity.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' equity
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Stockholders' equity Stockholders’ equity
Stock repurchase program
Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):
20222021
 SharesDollars SharesDollars
First quarter24.6 $5,410 3.7 $865 
Second quarter— — 6.5 1,592 
Total stock repurchases24.6 $5,410 10.2 $2,457 
On February 24, 2022, the Company entered into ASR agreements with three third-party financial institutions (Dealers). Under the ASR agreements, the Company made payments in an aggregate amount of $6.0 billion on February 25, 2022, to the Dealers and received and retired an initial 23.3 million shares of the Company’s common stock from the Dealers. The payments were recorded as reductions to shareholders’ equity, consisting of a $5.1 billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $0.9 billion decrease in additional paid-in capital, which reflects the value of the stock that remains to be delivered by the Dealers pending final settlement. The final number of shares to be repurchased by the Company will be based on the daily volume-weighted average stock price of the Company’s common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, under certain circumstances, one or more of the Dealers may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to a Dealer. The final settlement under the ASR agreements is scheduled to occur in the third quarter of 2022, subject to an earlier termination under certain limited circumstances, as set forth in the ASR agreements. In total, we repurchased 24.6 million shares of common stock in the first quarter of 2022, including shares received under the ASR agreements.
As of June 30, 2022, $4.6 billion of authorization remained available under our stock repurchase program.
Dividends
In March 2022 and December 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which were paid in June 2022 and March 2022, respectively. In August 2022, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which will be paid on September 8, 2022.
Accumulated other comprehensive income (loss)
The components of AOCI were as follows (in millions):
Foreign
currency
translation
Cash flow
hedges
Available-for-sale
securities
OtherAOCI
Balance as of December 31, 2021$(844)$61 $— $(13)$(796)
Foreign currency translation adjustments(51)— — — (51)
Unrealized gains— 56 — — 56 
Reclassification adjustments to income— 51 — — 51 
Income taxes— (23)— — (23)
Balance as of March 31, 2022
(895)145 — (13)(763)
Foreign currency translation adjustments(65)— — — (65)
Unrealized gains— 67 — — 67 
Reclassification adjustments to income— 132 — — 132 
Income taxes— (43)— — (43)
Balance as of June 30, 2022
$(960)$301 $— $(13)$(672)
Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):
Three months ended June 30,
Components of AOCI20222021Condensed Consolidated
Statements of Income locations
Cash flow hedges:
Foreign currency contract gains (losses)$53 $(18)Product sales
Cross-currency swap contract (losses) gains(185)46 Other (expense) income, net
(132)28 Income before income taxes
28 (6)Provision for income taxes
$(104)$22 Net income
Six months ended June 30,
Components of AOCI20222021Condensed Consolidated
Statements of Income locations
Cash flow hedges:
Foreign currency contract gains (losses)$80 $(19)Product sales
Cross-currency swap contract losses(263)(86)Other (expense) income, net
(183)(105)Income before income taxes
39 22 Provision for income taxes
$(144)$(83)Net income
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value measurement
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair value measurement Fair value measurement
To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:
Level 1Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
Level 2Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs
Level 3Valuations based on inputs that are unobservable and significant to the overall fair value measurement
The availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.
The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
Quoted prices in
active markets for
identical assets
(Level 1)
Significant
other observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Fair value measurement as of June 30, 2022, using:Total
Assets:
Available-for-sale securities:
U.S. Treasury notes$— $— $— $— 
U.S. Treasury bills1,980 — — 1,980 
Money market mutual funds4,433 — — 4,433 
Other short-term interest-bearing securities— — — — 
Equity securities361 — 131 492 
Derivatives:
Foreign currency contracts— 413 — 413 
Cross-currency swap contracts— 29 — 29 
Interest rate swap contracts— — — — 
Total assets$6,774 $442 $131 $7,347 
Liabilities:
Derivatives:
Foreign currency contracts$— $30 $— $30 
Cross-currency swap contracts— 503 — 503 
Interest rate swap contracts— 591 — 591 
Contingent consideration obligations
— — 310 310 
Total liabilities$— $1,124 $310 $1,434 
Quoted prices in
active markets for
identical assets
(Level 1)
Significant
other observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Fair value measurement as of December 31, 2021, using:Total
Assets:
Available-for-sale securities:
U.S. Treasury notes$47 $— $— $47 
U.S. Treasury bills1,400 — — 1,400 
Money market mutual funds5,856 — — 5,856 
Other short-term interest-bearing securities— — 
Equity securities611 — 220 831 
Derivatives:
Foreign currency contracts— 183 — 183 
Cross-currency swap contracts— 66 — 66 
Interest rate swap contracts— 16 — 16 
Total assets$7,914 $266 $220 $8,400 
Liabilities:
Derivatives:
Foreign currency contracts$— $39 $— $39 
Cross-currency swap contracts— 339 — 339 
Interest rate swap contracts— 156 — 156 
Contingent consideration obligations
— — 342 342 
Total liabilities$— $534 $342 $876 

Interest-bearing and equity securities
The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair value of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available market information for similar companies that have actively traded equity securities.
Derivatives
All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.
Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.
Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.
Contingent consideration obligations
As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.
Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):
Three months ended
June 30,
Six months ended
June 30,
2022202120222021
Beginning balance$330 $39 $342 $33 
Payments(1)(2)(3)(3)
Net changes in valuations(19)11 (29)18 
Ending balance$310 $48 $310 $48 
As of June 30, 2022 and December 31, 2021, our contingent consideration obligations are primarily the result of our acquisition of Teneobio in October 2021, which obligates us to pay the former shareholders up to $1.6 billion upon achieving separate development and regulatory milestones with regard to various R&D programs. See Note 2, Acquisitions and divestitures.
Summary of the fair values of other financial instruments
Cash equivalents
The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.
Borrowings
We estimated the fair values of our borrowings by using Level 2 inputs. As of June 30, 2022 and December 31, 2021, the aggregate fair values of our borrowings were $34.4 billion and $37.9 billion, respectively, and the carrying values were $36.5 billion and $33.3 billion, respectively.
Investment in BeiGene, Ltd.
We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of June 30, 2022 and December 31, 2021, the fair values were $3.1 billion and $5.1 billion, and the carrying values were $2.5 billion and $2.8 billion, respectively.
During the three and six months ended June 30, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis, except with respect to the impairment of net assets in connection with the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative instruments
6 Months Ended
Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative instruments Derivative instruments
The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative- trading purposes.
Cash flow hedges
We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales are being hedged than in successive periods.
As of June 30, 2022 and December 31, 2021, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.6 billion and $5.7 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.
To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.
The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):
Foreign currencyU.S. dollars
Hedged notesNotional amountsInterest ratesNotional amountsInterest rates
0.41% 2023 Swiss franc BondsCHF700 0.4 %$704 3.4 %
2.00% 2026 euro Notes750 2.0 %$833 3.9 %
5.50% 2026 pound sterling Notes£475 5.5 %$747 6.0 %
4.00% 2029 pound sterling Notes£700 4.0 %$1,111 4.5 %
In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the six months ended June 30, 2022, and amounts expected to be recognized during the subsequent 12 months are not material.
The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):
 Three months ended
June 30,
Six months ended
June 30,
Derivatives in cash flow hedging relationships2022202120222021
Foreign currency contracts$252 $(46)$330 $137 
Cross-currency swap contracts(185)15 (207)(60)
Total unrealized gains (losses)$67 $(31)$123 $77 
Fair value hedges
To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of both June 30, 2022 and December 31, 2021, we had interest rate swap contracts with aggregate notional amounts of $6.7 billion that hedge certain portions of our long-term debt issuances.
For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.
The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):
Carrying amounts of hedged liabilities(1)
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)
Condensed Consolidated Balance Sheets locationsJune 30, 2022December 31, 2021June 30, 2022December 31, 2021
Current portion of long-term debt$82 $85 $82 $85 
Long-term debt$6,241 $6,729 $(292)$199 
____________
(1)     Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $399 million and $440 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.
(2)    Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $299 million and $340 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.
Impact of hedging transactions
The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):
Three months ended June 30, 2022Six months ended June 30, 2022
Product salesOther (expense) income, netInterest expense, netProduct salesOther (expense) income, netInterest expense, net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$6,281 $(317)$(328)$12,012 $(847)$(623)
The effects of cash flow and fair value hedging:
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
Foreign currency contracts$53 $— $— $80 $— $— 
Cross-currency swap contracts$— $(185)$— $— $(263)$— 
Gains (losses) on fair value hedging relationships—interest rate swap agreements:
Hedged items(1)
$— $— $157 $— $— $494 
Derivatives designated as hedging instruments$— $— $(135)$— $— $(450)

Three months ended June 30, 2021Six months ended June 30, 2021
Product salesOther (expense) income, netInterest expense, netProduct salesOther (expense) income, netInterest expense, net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$6,114 $11 $(281)$11,706 $24 $(566)
The effects of cash flow and fair value hedging:
(Losses) gains on cash flow hedging relationships reclassified out of AOCI:
Foreign currency contracts$(18)$— $— $(19)$— $— 
Cross-currency swap contracts$— $46 $— $— $(86)$— 
(Losses) gains on fair value hedging relationships—interest rate swap agreements:
Hedged items(1)
$— $— $(34)$— $— $141 
Derivatives designated as hedging instruments$— $— $55 $— $— $(97)
__________
(1)    Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.
No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of June 30, 2022, we expected to reclassify $179 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.
Derivatives not designated as hedges
To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of June 30, 2022 and December 31, 2021, the total notional amounts of these foreign currency forward contracts were $550 million and $680 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and six months ended June 30, 2022 and 2021.
The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
 Derivative assetsDerivative liabilities
June 30, 2022Condensed Consolidated
Balance Sheets locations
Fair valuesCondensed Consolidated
Balance Sheets locations
Fair values
Derivatives designated as hedging instruments:
Foreign currency contractsOther current assets/ Other noncurrent assets$413 
Accrued liabilities/ Other noncurrent liabilities
$30 
Cross-currency swap contractsOther current assets/ Other noncurrent assets29 
Accrued liabilities/ Other noncurrent liabilities
503 
Interest rate swap contractsOther current assets/ Other noncurrent assets— 
Accrued liabilities/ Other noncurrent liabilities
591 
Total derivatives designated as hedging instruments
$442 $1,124 

 Derivative assetsDerivative liabilities
December 31, 2021Condensed Consolidated
Balance Sheets locations
Fair valuesCondensed Consolidated
Balance Sheets locations
Fair values
Derivatives designated as hedging instruments:
Foreign currency contractsOther current assets/ Other noncurrent assets$183 
Accrued liabilities/ Other noncurrent liabilities
$39 
Cross-currency swap contractsOther current assets/ Other noncurrent assets66 
Accrued liabilities/ Other noncurrent liabilities
339 
Interest rate swap contractsOther current assets/ Other noncurrent assets16 
Accrued liabilities/ Other noncurrent liabilities
156 
Total derivatives designated as hedging instruments
$265 $534 
Our derivative contracts that were in liability positions as of June 30, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.
The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Contingencies and commitments
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Contingencies and commitments Contingencies and commitments
Contingencies
In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2021, Part I, Item 1A. Risk Factors—Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.
We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. Although it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
Certain recent developments concerning our legal proceedings and other matters are discussed below:
ANDA Patent Litigation
Otezla ANDA Patent Litigation
Amgen Inc. v. Apotex Inc.
On June 14, 2022, Amgen filed a lawsuit in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Apotex Inc. (Apotex) for infringement of U.S. Patent Nos. 7,427,638, 9,872,854 and 10,092,541, which are listed in the Orange Book for Otezla. This lawsuit was based on Apotex’s submission of an ANDA seeking FDA approval to market a generic version of Otezla and seeks an order of the New Jersey District Court making any FDA approval of Apotex’s ANDA effective no earlier than the expiration of the applicable patents.
Repatha Patent Litigation
Patent Disputes in the International Region
On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP’004 Patent), seeking infringement damages and injunctive relief. The EP’004 Patent is currently in opposition proceedings, initiated by Amgen and an anonymous third party, before the European Patent Office (EPO). A hearing before the Opposition Division of the EPO was held on June 8 and 9, 2022, and the Opposition Division upheld the validity of the claims at issue with narrowing amendments. The parties are awaiting the Opposition Division’s written opinion. Amgen filed a Notice of Appeal on July 6, 2022.
Antitrust Actions
Sensipar Antitrust Class Actions
On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal of the U.S. District Court for the District of Delaware’s (the Delaware District Court’s) March 11, 2022 order denying Amgen’s Motion to Dismiss solely with respect to the reverse payment claim and the various state law claims. The plaintiffs did not oppose Amgen’s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs’ motion on June 10, 2022, and reply briefs were filed on June 24, 2022.
HUMIRA® Biosimilar Antitrust Actions
On August 1, 2022, the U.S. Court of Appeals for the Seventh Circuit issued an opinion affirming the June 30, 2020 dismissal with prejudice by the U.S. District Court for the Northern District of Illinois of a consolidated complaint against Amgen along with AbbVie Inc., AbbVie Biotechnology Ltd., Samsung Bioepis Co. and Sandoz Inc.
Regeneron Pharmaceuticals, Inc. Antitrust Action
On May 27, 2022, Regeneron Pharmaceuticals, Inc. (Regeneron) filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen’s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payors and PBMs have harmed the sales of its product PRALUENT® and focuses on two primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen’s initial responsive pleading was filed on August 1, 2022.
U.S. Tax Litigation
Amgen Inc. & Subsidiaries v. Commissioner of Internal Revenue
See Note 4, Income taxes, for discussion of the IRS tax dispute and the Company’s petition in the U.S. Tax Court.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Business
Business
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation
Basis of presentation
The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.
Principles of consolidation
Principles of consolidation
The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates
Use of estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net
Property, plant and equipment, net
Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.0 billion and $8.8 billion as of June 30, 2022 and December 31, 2021, respectively.
Other recent accounting pronouncements
Recent accounting pronouncements
In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.
In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Acquisitions (Tables)
6 Months Ended
Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Business Acquisitions, by Acquisition The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):
Amounts
Cash purchase price$993 
Contingent consideration299 
Total consideration$1,292 
Cash and cash equivalents$100 
In-process research and development991 
Finite-lived intangible asset – research and development technology rights115 
Finite-lived intangible assets – licensing rights41 
Goodwill273 
Other assets, net16 
Deferred tax liability(244)
Total assets acquired, net$1,292 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Revenues (Tables)
6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue by product and by geographic area
Revenues were as follows (in millions):
Three months ended June 30,
20222021
U.S.ROWTotalU.S.ROWTotal
ENBREL$1,036 $15 $1,051 $1,113 $31 $1,144 
Prolia611 311 922 538 276 814 
Otezla487 107 594 423 111 534 
XGEVA391 142 533 355 133 488 
Aranesp132 225 357 135 232 367 
Neulasta263 47 310 434 52 486 
Repatha154 171 325 143 143 286 
KYPROLIS213 104 317 190 90 280 
Nplate156 128 284 136 109 245 
Other products1,003 585 1,588 907 563 1,470 
Total product sales(1)
$4,446 $1,835 6,281 $4,374 $1,740 6,114 
Other revenues313 412 
Total revenues$6,594 $6,526 
Six months ended June 30,
20222021
U.S.ROWTotalU.S.ROWTotal
ENBREL$1,879 $34 $1,913 $2,007 $61 $2,068 
Prolia1,193 581 1,774 1,039 533 1,572 
Otezla837 208 1,045 789 221 1,010 
XGEVA759 276 1,035 689 267 956 
Aranesp269 446 715 260 462 722 
Neulasta567 91 658 855 113 968 
Repatha319 335 654 282 290 572 
KYPROLIS409 195 604 349 182 531 
Nplate312 238 550 248 224 472 
Other products1,939 1,125 3,064 1,759 1,076 2,835 
Total product sales(1)
$8,483 $3,529 12,012 $8,277 $3,429 11,706 
Other revenues820 721 
Total revenues$12,832 $12,427 
____________
(1)    Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Earnings per share (Tables)
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Computation for basic and diluted earnings per share
The computations for basic and diluted EPS were as follows (in millions, except per-share data):
 Three months ended
June 30,
Six months ended
June 30,
 2022202120222021
Income (Numerator):
Net income for basic and diluted EPS$1,317 $464 $2,793 $2,110 
Shares (Denominator):
Weighted-average shares for basic EPS535 573 541 575 
Effect of dilutive securities
Weighted-average shares for diluted EPS537 576 544 578 
Basic EPS$2.46 $0.81 $5.16 $3.67 
Diluted EPS$2.45 $0.81 $5.13 $3.65 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Investments (Tables)
6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):
Types of securities as of June 30, 2022Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Fair
values
U.S. Treasury notes$— $— $— $— 
U.S. Treasury bills1,980 — — 1,980 
Money market mutual funds4,433 — — 4,433 
Other short-term interest-bearing securities— — — — 
Total interest-bearing securities$6,413 $— $— $6,413 

Types of securities as of December 31, 2021Amortized
cost
Gross
unrealized
gains
Gross
unrealized
losses
Fair
values
U.S. Treasury notes$47 $— $— $47 
U.S. Treasury bills1,400 — — 1,400 
Money market mutual funds5,856 — — 5,856 
Other short-term interest-bearing securities— — 
Total interest-bearing securities$7,304 $— $— $7,304 
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):
Condensed Consolidated Balance Sheets locationsJune 30, 2022December 31, 2021
Cash and cash equivalents$4,433 $7,256 
Marketable securities1,980 48 
Total interest-bearing securities$6,413 $7,304 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Inventories (Tables)
6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
Inventories
Inventories consisted of the following (in millions):
June 30, 2022December 31, 2021
Raw materials$779 $647 
Work in process2,763 2,367 
Finished goods1,012 1,072 
Total inventories$4,554 $4,086 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and other intangible assets (Tables)
6 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of goodwill
The change in the carrying amount of goodwill was as follows (in millions):
Six months ended
June 30, 2022
Beginning balance$14,890 
Adjustments to goodwill resulting from acquisitions and divestitures, net(1)
Currency translation adjustment(32)
Ending balance$14,865 
____________
(1)    Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.
Schedule of identifiable intangible assets
Other intangible assets consisted of the following (in millions):
 June 30, 2022December 31, 2021
 Gross
carrying
amounts
Accumulated
amortization
Other intangible
assets, net
Gross
carrying
amounts
Accumulated
amortization
Other intangible
assets, net
Finite-lived intangible assets:
Developed-product-technology rights$25,537 $(13,863)$11,674 $25,561 $(12,769)$12,792 
Licensing rights3,864 (3,050)814 3,807 (2,973)834 
Marketing-related rights1,326 (1,125)201 1,354 (1,112)242 
Research and development technology rights1,371 (1,153)218 1,377 (1,133)244 
Total finite-lived intangible assets32,098 (19,191)12,907 32,099 (17,987)14,112 
Indefinite-lived intangible assets:
In-process research and development1,020 — 1,020 1,070 — 1,070 
Total other intangible assets$33,118 $(19,191)$13,927 $33,169 $(17,987)$15,182 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Financing arrangements (Tables)
6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Schedule of borrowings
Our borrowings consisted of the following (in millions):
 June 30, 2022December 31, 2021
0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)
$733 $767 
2.25% notes due 2023 (2.25% 2023 Notes)
750 750 
3.625% notes due 2024 (3.625% 2024 Notes)
1,400 1,400 
1.90% notes due 2025 (1.90% 2025 Notes)
500 500 
3.125% notes due 2025 (3.125% 2025 Notes)
1,000 1,000 
2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)
786 853 
2.60% notes due 2026 (2.60% 2026 Notes)
1,250 1,250 
5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)
579 643 
2.20% notes due 2027 (2.20% 2027 Notes)
1,750 1,750 
3.20% notes due 2027 (3.20% 2027 Notes)
1,000 1,000 
1.65% notes due 2028 (1.65% 2028 Notes)
1,250 1,250 
3.00% notes due 2029 (3.00% 2029 Notes)
750 — 
4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)
853 947 
2.45% notes due 2030 (2.45% 2030 Notes)
1,250 1,250 
2.30% notes due 2031 (2.30% 2031 Notes)
1,250 1,250 
2.00% notes due 2032 (2.00% 2032 Notes)
1,250 1,250 
3.35% notes due 2032 (3.35% 2032 Notes)
1,000 — 
6.375% notes due 2037 (6.375% 2037 Notes)
478 478 
6.90% notes due 2038 (6.90% 2038 Notes)
254 254 
6.40% notes due 2039 (6.40% 2039 Notes)
333 333 
3.15% notes due 2040 (3.15% 2040 Notes)
2,000 2,000 
5.75% notes due 2040 (5.75% 2040 Notes)
373 373 
2.80% notes due 2041 (2.80% 2041 Notes)
1,150 1,150 
4.95% notes due 2041 (4.95% 2041 Notes)
600 600 
5.15% notes due 2041 (5.15% 2041 Notes)
729 729 
5.65% notes due 2042 (5.65% 2042 Notes)
415 415 
5.375% notes due 2043 (5.375% 2043 Notes)
185 185 
4.40% notes due 2045 (4.40% 2045 Notes)
2,250 2,250 
4.563% notes due 2048 (4.563% 2048 Notes)
1,415 1,415 
3.375% notes due 2050 (3.375% 2050 Notes)
2,250 2,250 
4.663% notes due 2051 (4.663% 2051 Notes)
3,541 3,541 
3.00% notes due 2052 (3.00% 2052 Notes)
1,350 1,350 
4.20% notes due 2052 (4.20% 2052 Notes)
1,000 — 
2.77% notes due 2053 (2.77% 2053 Notes)
940 940 
4.40% notes due 2062 (4.40% 2062 Notes)
1,250 — 
Other notes due 2097100 100 
Unamortized bond discounts, premiums and issuance costs, net(1,245)(1,213)
Fair value adjustments(210)284 
Other13 15 
Total carrying value of debt36,522 33,309 
Less current portion(817)(87)
Total long-term debt$35,705 $33,222 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' equity (Tables)
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Summary of activity under our stock repurchase program
Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):
20222021
 SharesDollars SharesDollars
First quarter24.6 $5,410 3.7 $865 
Second quarter— — 6.5 1,592 
Total stock repurchases24.6 $5,410 10.2 $2,457 
Components of accumulated other comprehensive income
The components of AOCI were as follows (in millions):
Foreign
currency
translation
Cash flow
hedges
Available-for-sale
securities
OtherAOCI
Balance as of December 31, 2021$(844)$61 $— $(13)$(796)
Foreign currency translation adjustments(51)— — — (51)
Unrealized gains— 56 — — 56 
Reclassification adjustments to income— 51 — — 51 
Income taxes— (23)— — (23)
Balance as of March 31, 2022
(895)145 — (13)(763)
Foreign currency translation adjustments(65)— — — (65)
Unrealized gains— 67 — — 67 
Reclassification adjustments to income— 132 — — 132 
Income taxes— (43)— — (43)
Balance as of June 30, 2022
$(960)$301 $— $(13)$(672)
Reclassifications out of accumulated other comprehensive income
Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):
Three months ended June 30,
Components of AOCI20222021Condensed Consolidated
Statements of Income locations
Cash flow hedges:
Foreign currency contract gains (losses)$53 $(18)Product sales
Cross-currency swap contract (losses) gains(185)46 Other (expense) income, net
(132)28 Income before income taxes
28 (6)Provision for income taxes
$(104)$22 Net income
Six months ended June 30,
Components of AOCI20222021Condensed Consolidated
Statements of Income locations
Cash flow hedges:
Foreign currency contract gains (losses)$80 $(19)Product sales
Cross-currency swap contract losses(263)(86)Other (expense) income, net
(183)(105)Income before income taxes
39 22 Provision for income taxes
$(144)$(83)Net income
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value measurement (Tables)
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis
The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
Quoted prices in
active markets for
identical assets
(Level 1)
Significant
other observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Fair value measurement as of June 30, 2022, using:Total
Assets:
Available-for-sale securities:
U.S. Treasury notes$— $— $— $— 
U.S. Treasury bills1,980 — — 1,980 
Money market mutual funds4,433 — — 4,433 
Other short-term interest-bearing securities— — — — 
Equity securities361 — 131 492 
Derivatives:
Foreign currency contracts— 413 — 413 
Cross-currency swap contracts— 29 — 29 
Interest rate swap contracts— — — — 
Total assets$6,774 $442 $131 $7,347 
Liabilities:
Derivatives:
Foreign currency contracts$— $30 $— $30 
Cross-currency swap contracts— 503 — 503 
Interest rate swap contracts— 591 — 591 
Contingent consideration obligations
— — 310 310 
Total liabilities$— $1,124 $310 $1,434 
Quoted prices in
active markets for
identical assets
(Level 1)
Significant
other observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Fair value measurement as of December 31, 2021, using:Total
Assets:
Available-for-sale securities:
U.S. Treasury notes$47 $— $— $47 
U.S. Treasury bills1,400 — — 1,400 
Money market mutual funds5,856 — — 5,856 
Other short-term interest-bearing securities— — 
Equity securities611 — 220 831 
Derivatives:
Foreign currency contracts— 183 — 183 
Cross-currency swap contracts— 66 — 66 
Interest rate swap contracts— 16 — 16 
Total assets$7,914 $266 $220 $8,400 
Liabilities:
Derivatives:
Foreign currency contracts$— $39 $— $39 
Cross-currency swap contracts— 339 — 339 
Interest rate swap contracts— 156 — 156 
Contingent consideration obligations
— — 342 342 
Total liabilities$— $534 $342 $876 
Schedule of Business Acquisitions by Acquisition, Contingent Consideration
Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):
Three months ended
June 30,
Six months ended
June 30,
2022202120222021
Beginning balance$330 $39 $342 $33 
Payments(1)(2)(3)(3)
Net changes in valuations(19)11 (29)18 
Ending balance$310 $48 $310 $48 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative instruments (Tables)
6 Months Ended
Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of notional amounts and interest rates for cross-currency swaps
The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):
Foreign currencyU.S. dollars
Hedged notesNotional amountsInterest ratesNotional amountsInterest rates
0.41% 2023 Swiss franc BondsCHF700 0.4 %$704 3.4 %
2.00% 2026 euro Notes750 2.0 %$833 3.9 %
5.50% 2026 pound sterling Notes£475 5.5 %$747 6.0 %
4.00% 2029 pound sterling Notes£700 4.0 %$1,111 4.5 %
Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges
The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):
 Three months ended
June 30,
Six months ended
June 30,
Derivatives in cash flow hedging relationships2022202120222021
Foreign currency contracts$252 $(46)$330 $137 
Cross-currency swap contracts(185)15 (207)(60)
Total unrealized gains (losses)$67 $(31)$123 $77 
Derivatives in fair value hedging relationships
The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):
Carrying amounts of hedged liabilities(1)
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)
Condensed Consolidated Balance Sheets locationsJune 30, 2022December 31, 2021June 30, 2022December 31, 2021
Current portion of long-term debt$82 $85 $82 $85 
Long-term debt$6,241 $6,729 $(292)$199 
____________
(1)     Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $399 million and $440 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.
(2)    Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $299 million and $340 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.
Summary of amounts of income and expense line items
The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):
Three months ended June 30, 2022Six months ended June 30, 2022
Product salesOther (expense) income, netInterest expense, netProduct salesOther (expense) income, netInterest expense, net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$6,281 $(317)$(328)$12,012 $(847)$(623)
The effects of cash flow and fair value hedging:
Gains (losses) on cash flow hedging relationships reclassified out of AOCI:
Foreign currency contracts$53 $— $— $80 $— $— 
Cross-currency swap contracts$— $(185)$— $— $(263)$— 
Gains (losses) on fair value hedging relationships—interest rate swap agreements:
Hedged items(1)
$— $— $157 $— $— $494 
Derivatives designated as hedging instruments$— $— $(135)$— $— $(450)

Three months ended June 30, 2021Six months ended June 30, 2021
Product salesOther (expense) income, netInterest expense, netProduct salesOther (expense) income, netInterest expense, net
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$6,114 $11 $(281)$11,706 $24 $(566)
The effects of cash flow and fair value hedging:
(Losses) gains on cash flow hedging relationships reclassified out of AOCI:
Foreign currency contracts$(18)$— $— $(19)$— $— 
Cross-currency swap contracts$— $46 $— $— $(86)$— 
(Losses) gains on fair value hedging relationships—interest rate swap agreements:
Hedged items(1)
$— $— $(34)$— $— $141 
Derivatives designated as hedging instruments$— $— $55 $— $— $(97)
__________
(1)    Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.
Fair values of derivatives included in the Condensed Consolidated Balance Sheets
The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
 Derivative assetsDerivative liabilities
June 30, 2022Condensed Consolidated
Balance Sheets locations
Fair valuesCondensed Consolidated
Balance Sheets locations
Fair values
Derivatives designated as hedging instruments:
Foreign currency contractsOther current assets/ Other noncurrent assets$413 
Accrued liabilities/ Other noncurrent liabilities
$30 
Cross-currency swap contractsOther current assets/ Other noncurrent assets29 
Accrued liabilities/ Other noncurrent liabilities
503 
Interest rate swap contractsOther current assets/ Other noncurrent assets— 
Accrued liabilities/ Other noncurrent liabilities
591 
Total derivatives designated as hedging instruments
$442 $1,124 

 Derivative assetsDerivative liabilities
December 31, 2021Condensed Consolidated
Balance Sheets locations
Fair valuesCondensed Consolidated
Balance Sheets locations
Fair values
Derivatives designated as hedging instruments:
Foreign currency contractsOther current assets/ Other noncurrent assets$183 
Accrued liabilities/ Other noncurrent liabilities
$39 
Cross-currency swap contractsOther current assets/ Other noncurrent assets66 
Accrued liabilities/ Other noncurrent liabilities
339 
Interest rate swap contractsOther current assets/ Other noncurrent assets16 
Accrued liabilities/ Other noncurrent liabilities
156 
Total derivatives designated as hedging instruments
$265 $534 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of significant accounting policies (Details)
$ in Billions
6 Months Ended
Jun. 30, 2022
USD ($)
segment
Dec. 31, 2021
USD ($)
Accounting Policies [Abstract]    
Number of operating segments | segment 1  
Accumulated depreciation and amortization on property, plant and equipment | $ $ 9.0 $ 8.8
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Acquisitions - Aggregate Consideration Paid (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Business Acquisition [Line Items]    
Goodwill $ 14,865 $ 14,890
Teneobio    
Business Acquisition [Line Items]    
Cash paid 993  
Contingent consideration obligation for acquisition 299  
Business asset acquisition, consideration transferred 1,292  
Fair value of assets acquired, cash 100  
IPR&D 991  
Goodwill 273  
Other assets, net 16  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities (244)  
Total assets acquired, net 1,292  
Teneobio | R & D Technology rights    
Business Acquisition [Line Items]    
Fair value of assets acquired, licensing rights 115  
Teneobio | Licensing rights    
Business Acquisition [Line Items]    
Fair value of assets acquired, licensing rights $ 41  
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Acquisitions - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Apr. 16, 2021
Sep. 30, 2022
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Business Acquisition [Line Items]              
Net increase in goodwill         $ 7    
Goodwill     $ 14,865   14,865   $ 14,890
Loss on divestiture         560 $ 0  
Payments to Acquire Businesses, Net of Cash Acquired         0 1,626  
Acquired in-process research and development     0 $ 1,505 0 $ 1,505  
Gensenta Ilac Sanayi vs Ticaret              
Business Acquisition [Line Items]              
Disposal Group, Including Discontinued Operation, Assets     80   80    
Disposal Group, Including Discontinued Operation, Accrued Liabilities     20   20    
Disposal Group, Including Discontinued Operation, Assets, Current     100   100    
Gensenta Ilac Sanayi vs Ticaret | Other Operating Income (Expense)              
Business Acquisition [Line Items]              
Loss on divestiture     560        
Gensenta Ilac Sanayi vs Ticaret | Forecast [Member]              
Business Acquisition [Line Items]              
Proceeds from Divestiture of Businesses and Interests in Affiliates   $ 135          
Teneobio              
Business Acquisition [Line Items]              
Net increase in goodwill         22    
Cash paid         993    
Maximum additional consideration due contingent on certain milestones     1,600   1,600    
Contingent consideration obligation for acquisition         299    
Acquired in-process research and development     991   991    
Deferred tax liability     244   244    
Goodwill     273   273    
Teneobio | R & D Technology rights              
Business Acquisition [Line Items]              
Value of intangible assets acquired         $ 115    
Weighted average period of amortization         10 years    
Teneobio | Licensing rights              
Business Acquisition [Line Items]              
Value of intangible assets acquired         $ 41    
Teneobio | In-process Research and Development | AMG 340              
Business Acquisition [Line Items]              
Acquired in-process research and development     $ 784   $ 784    
Five Prime Therapeutics, Inc.              
Business Acquisition [Line Items]              
Payments to Acquire Businesses, Net of Cash Acquired $ 1,600            
Acquired in-process research and development 1,500            
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets 177            
Other liabilities $ 47            
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Revenues (Details)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
segment
Jun. 30, 2021
USD ($)
Revenue from Contract with Customer [Abstract]        
Number of operating segments | segment     1  
Revenue from External Customer [Line Items]        
Total revenues $ 6,594 $ 6,526 $ 12,832 $ 12,427
Product sales [Member]        
Revenue from External Customer [Line Items]        
Total revenues 6,281 6,114 12,012 11,706
Product sales [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 4,446 4,374 8,483 8,277
Product sales [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 1,835 1,740 3,529 3,429
Enbrel® (etanercept) [Member]        
Revenue from External Customer [Line Items]        
Total revenues 1,051 1,144 1,913 2,068
Enbrel® (etanercept) [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 1,036 1,113 1,879 2,007
Enbrel® (etanercept) [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 15 31 34 61
Prolia® (denosumab) [Member]        
Revenue from External Customer [Line Items]        
Total revenues 922 814 1,774 1,572
Prolia® (denosumab) [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 611 538 1,193 1,039
Prolia® (denosumab) [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 311 276 581 533
Otezla (apremilast) [Member]        
Revenue from External Customer [Line Items]        
Total revenues 594 534 1,045 1,010
Otezla (apremilast) [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 487 423 837 789
Otezla (apremilast) [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 107 111 208 221
XGEVA® (denosumab) [Member]        
Revenue from External Customer [Line Items]        
Total revenues 533 488 1,035 956
XGEVA® (denosumab) [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 391 355 759 689
XGEVA® (denosumab) [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 142 133 276 267
Aranesp® (darbepoetin alfa) [Member]        
Revenue from External Customer [Line Items]        
Total revenues 357 367 715 722
Aranesp® (darbepoetin alfa) [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 132 135 269 260
Aranesp® (darbepoetin alfa) [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 225 232 446 462
Neulasta® (pegfilgrastim) [Member]        
Revenue from External Customer [Line Items]        
Total revenues 310 486 658 968
Neulasta® (pegfilgrastim) [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 263 434 567 855
Neulasta® (pegfilgrastim) [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 47 52 91 113
Repatha (evolocumab) [Member]        
Revenue from External Customer [Line Items]        
Total revenues 325 286 654 572
Repatha (evolocumab) [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 154 143 319 282
Repatha (evolocumab) [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 171 143 335 290
KYPROLIS® (carfilzomib) [Member]        
Revenue from External Customer [Line Items]        
Total revenues 317 280 604 531
KYPROLIS® (carfilzomib) [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 213 190 409 349
KYPROLIS® (carfilzomib) [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 104 90 195 182
Nplate [Member]        
Revenue from External Customer [Line Items]        
Total revenues 284 245 550 472
Nplate [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 156 136 312 248
Nplate [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 128 109 238 224
Other products [Member]        
Revenue from External Customer [Line Items]        
Total revenues 1,588 1,470 3,064 2,835
Other products [Member] | US [Member]        
Revenue from External Customer [Line Items]        
Total revenues 1,003 907 1,939 1,759
Other products [Member] | ROW [Member]        
Revenue from External Customer [Line Items]        
Total revenues 585 563 1,125 1,076
Other revenues [Member]        
Revenue from External Customer [Line Items]        
Total revenues $ 313 $ 412 $ 820 $ 721
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Income taxes (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Apr. 28, 2022
May 31, 2021
Income Tax Examination [Line Items]            
Effective income tax rate 14.00% 16.80% 12.90% 12.60%    
Increase in unrecognized tax benefits resulting from tax positions taken during the current period $ 50   $ 95      
Domestic Tax Authority            
Income Tax Examination [Line Items]            
Proposed additional income tax           $ 3,600
Repatriation tax on proposed additional tax           $ 900
Proposed additional income tax 2013-2015         $ 5,100  
Penalties on proposed additional income tax 2013-2015         2,000  
Repatriation tax on proposed additional tax 2013-2015         $ 2,200  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Earnings per share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Income (Numerator):            
Net income for basic and diluted EPS $ 1,317 $ 1,476 $ 464 $ 1,646 $ 2,793 $ 2,110
Shares (Denominator):            
Weighted-average shares for basic EPS (in shares) 535   573   541 575
Effect of dilutive securities (in shares) 2   3   3 3
Weighted-average shares for diluted EPS (in shares) 537   576   544 578
Basic EPS (in usd per share) $ 2.46   $ 0.81   $ 5.16 $ 3.67
Diluted EPS (in usd per share) $ 2.45   $ 0.81   $ 5.13 $ 3.65
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Investments (Details) - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Amortized cost $ 6,413 $ 7,304
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Fair values 6,413 7,304
U.S. Treasury notes [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 0 47
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Fair values 0 47
U.S. Treasury bills [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 1,980 1,400
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Fair values 1,980 1,400
Money market mutual funds [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 4,433 5,856
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Fair values 4,433 5,856
Other short-term interest-bearing securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 0 1
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Fair values $ 0 $ 1
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Investments (Fair Values by Classification) (Details) - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets    
Marketable securities $ 1,980 $ 48
Total interest-bearing securities 6,413 7,304
Available-for-sale investments [Member]    
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets    
Cash and cash equivalents 4,433 7,256
Marketable securities 1,980 48
Total interest-bearing securities $ 6,413 $ 7,304
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2
Investments (Available-for-sale Investments) (Details Textual) - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]        
Cash $ 770 $ 733    
Debt Securities, Available-for-sale [Line Items]        
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 5,203 $ 7,989 $ 6,630 $ 6,266
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Investments (Fair Values by Contractual Maturity) (Details) - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Total interest-bearing securities $ 6,413 $ 7,304
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2
Investments (Equity Securities) (Details Textual) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]          
Equity securities $ 492   $ 492   $ 831
Equity Securities, FV-NI, Unrealized Gain (Loss) (106) $ 25 (276) $ (31)  
Equity securities without readily determinable fair value 280   280   262
Fair Value, Inputs, Level 1 [Member]          
Debt Securities, Available-for-sale [Line Items]          
Equity securities $ 361   $ 361   $ 611
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2
Investments (BeiGene) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Net Investment Income [Line Items]          
Income (Loss) from Equity Method Investments     $ (497) $ 36  
Collaborative arrangement with BeiGene, Ltd. [Member]          
Net Investment Income [Line Items]          
Ownership percentage 18.20%   18.20%   18.40%
Income (Loss) from Equity Method Investments $ (80) $ 14 $ (188) (83)  
Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity 48 $ 42 95 $ 84  
Carrying value of equity method investment 2,500   2,500   $ 2,800
Equity Method Investments,Quoted Market Price $ 3,100   $ 3,100   $ 5,100
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2
Investments (Neumora Therapeutics, Inc.) (Details) - Neumora Therapeutics, Inc. [Member] - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Sep. 30, 2021
Jun. 30, 2022
Jun. 30, 2022
Dec. 31, 2021
Net Investment Income [Line Items]        
Ownership percentage 25.90% 25.70% 25.70% 25.90%
Equity Method Investment, Aggregate Cost $ 257      
Payments to Acquire Equity Method Investments 100      
Noncash or Part Noncash Acquisition, Investments Acquired $ 157      
Equity Method Investments, Fair Value Disclosure   $ 131 $ 131 $ 220
Equity method investment, change in carrying value   $ 39 $ 89  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2
Investments Investments (Limited Partnership Investments) (Details) - Fair Value Measured at Net Asset Value Per Share [Member] - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Net Investment Income [Line Items]          
Investment Company, Financial Support to Investee Contractually Required, Amount $ 209   $ 209    
Limited Partnership [Member]          
Net Investment Income [Line Items]          
Alternative investments 338   338   $ 573
Net gains (losses) from limited partnership investments $ (60) $ (43) $ (220) $ 165  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2
Inventories (Details) - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 779 $ 647
Work in process 2,763 2,367
Finished goods 1,012 1,072
Total inventories $ 4,554 $ 4,086
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and other intangible assets (Goodwill Roll Forward) (Details)
$ in Millions
6 Months Ended
Jun. 30, 2022
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 14,890
Net increase in goodwill 7
Currency translation adjustment (32)
Ending balance $ 14,865
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts $ 32,098 $ 32,099
Accumulated amortization (19,191) (17,987)
Other intangible assets, net 12,907 14,112
Gross carrying amount 33,118 33,169
Accumulated amortization (19,191) (17,987)
Intangible assets, net 13,927 15,182
In-process Research and Development    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangible assets 1,020 1,070
Developed-Product-Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts 25,537 25,561
Accumulated amortization (13,863) (12,769)
Other intangible assets, net 11,674 12,792
Licensing rights    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts 3,864 3,807
Accumulated amortization (3,050) (2,973)
Other intangible assets, net 814 834
Marketing-Related Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts 1,326 1,354
Accumulated amortization (1,125) (1,112)
Other intangible assets, net 201 242
Research and Development Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amounts 1,371 1,377
Accumulated amortization (1,153) (1,133)
Other intangible assets, net $ 218 $ 244
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and other intangible assets (Details Textual) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization charges associated with finite-lived intangible assets $ 629 $ 652 $ 1,300 $ 1,300
Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2022 1,300   1,300  
Total estimated amortization of finite-lived intangible assets for 2023 2,500   2,500  
Total estimated amortization of finite-lived intangible assets for 2024 2,500   2,500  
Total estimated amortization of finite-lived intangible assets for 2025 2,400   2,400  
Total estimated amortization of finite-lived intangible assets for 2026 1,700   1,700  
Total estimated amortization of finite-lived intangible assets for 2027 $ 1,800   $ 1,800  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.2
Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)
$ in Millions
Jun. 30, 2022
USD ($)
Jun. 30, 2022
CHF (SFr)
Jun. 30, 2022
EUR (€)
Jun. 30, 2022
GBP (£)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Debt Instrument [Line Items]            
Unamortized bond discounts, premiums and issuance costs, net $ (1,245)         $ (1,213)
Fair value adjustments (210)         284
Other 13         15
Total carrying value of debt 36,522         33,309
Less current portion (817)         (87)
Total long-term debt $ 35,705         33,222
4.20% 2052 Notes [Member]            
Debt Instrument [Line Items]            
Face amount         $ 1,000  
Notes [Member]            
Debt Instrument [Line Items]            
Face amount         $ 4,000  
Notes [Member] | 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 0.41% 0.41% 0.41% 0.41%    
Long-term debt, gross $ 733         767
Face amount | SFr   SFr 700,000,000        
Notes [Member] | 2.25% notes due 2023 (2.25% 2023 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 2.25% 2.25% 2.25% 2.25%    
Long-term debt, gross $ 750         750
Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 3.625% 3.625% 3.625% 3.625%    
Long-term debt, gross $ 1,400         1,400
Notes [Member] | 1.90% notes due 2025 (1.90% 2025 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 1.90% 1.90% 1.90% 1.90%    
Long-term debt, gross $ 500         500
Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 3.125% 3.125% 3.125% 3.125%    
Long-term debt, gross $ 1,000         1,000
Notes [Member] | 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 2.00% 2.00% 2.00% 2.00%    
Long-term debt, gross $ 786         853
Face amount | €     € 750,000,000      
Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 2.60% 2.60% 2.60% 2.60%    
Long-term debt, gross $ 1,250         1,250
Notes [Member] | 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 5.50% 5.50% 5.50% 5.50%    
Long-term debt, gross $ 579         643
Face amount | £       £ 475,000,000    
Notes [Member] | 2.20% notes due 2027 (2.20% 2027 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 2.20% 2.20% 2.20% 2.20%    
Long-term debt, gross $ 1,750         1,750
Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 3.20% 3.20% 3.20% 3.20%    
Long-term debt, gross $ 1,000         1,000
Notes [Member] | 1.65% notes due 2028 (1.65% 2028 Notes) [Member}            
Debt Instrument [Line Items]            
Interest rate, stated percentage 1.65% 1.65% 1.65% 1.65%    
Long-term debt, gross $ 1,250         1,250
Notes [Member] | 3.00% 2029 Notes [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 3.00% 3.00% 3.00% 3.00% 3.00%  
Long-term debt, gross $ 750         0
Face amount         $ 750  
Notes [Member] | 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 4.00% 4.00% 4.00% 4.00%    
Long-term debt, gross $ 853         947
Face amount | £       £ 700,000,000    
Notes [Member] | 2.45% notes due 2030 (2.45% 2030 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 2.45% 2.45% 2.45% 2.45%    
Long-term debt, gross $ 1,250         1,250
Notes [Member] | 2.30% notes due 2031 (2.30% 2031 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 2.30% 2.30% 2.30% 2.30%    
Long-term debt, gross $ 1,250         1,250
Notes [Member] | 2.00% notes due 2032 (2.00% 2032 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 2.00% 2.00% 2.00% 2.00%    
Long-term debt, gross $ 1,250         1,250
Notes [Member] | 3.35% 2032 Notes [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 3.35% 3.35% 3.35% 3.35% 3.35%  
Long-term debt, gross $ 1,000          
Face amount         $ 1,000  
Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 6.375% 6.375% 6.375% 6.375%    
Long-term debt, gross $ 478         478
Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 6.90% 6.90% 6.90% 6.90%    
Long-term debt, gross $ 254         254
Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 6.40% 6.40% 6.40% 6.40%    
Long-term debt, gross $ 333         333
Notes [Member] | 3.15% notes due 2040 (3.15% 2040 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 3.15% 3.15% 3.15% 3.15%    
Long-term debt, gross $ 2,000         2,000
Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 5.75% 5.75% 5.75% 5.75%    
Long-term debt, gross $ 373         373
Notes [Member] | 2.80% notes due 2041 (2.80% 2041 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 2.80% 2.80% 2.80% 2.80%    
Long-term debt, gross $ 1,150         1,150
Notes [Member] | 4.95% notes due 2041 (4.95% 2041 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 4.95% 4.95% 4.95% 4.95%    
Long-term debt, gross $ 600         600
Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 5.15% 5.15% 5.15% 5.15%    
Long-term debt, gross $ 729         729
Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 5.65% 5.65% 5.65% 5.65%    
Long-term debt, gross $ 415         415
Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 5.375% 5.375% 5.375% 5.375%    
Long-term debt, gross $ 185         185
Notes [Member] | 4.40% notes due 2045 (4.40% 2045 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 4.40% 4.40% 4.40% 4.40%    
Long-term debt, gross $ 2,250         2,250
Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 4.563% 4.563% 4.563% 4.563%    
Long-term debt, gross $ 1,415         1,415
Notes [Member] | 3.375% notes due 2050 (3.375% 2050 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 3.375% 3.375% 3.375% 3.375%    
Long-term debt, gross $ 2,250         2,250
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 4.663% 4.663% 4.663% 4.663%    
Long-term debt, gross $ 3,541         3,541
Notes [Member] | 3.00% notes due 2052 (3.00% 2052 Notes)            
Debt Instrument [Line Items]            
Interest rate, stated percentage 3.00% 3.00% 3.00% 3.00%    
Long-term debt, gross $ 1,350         1,350
Notes [Member] | 4.20% 2052 Notes [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 4.20% 4.20% 4.20% 4.20% 4.20%  
Long-term debt, gross $ 1,000         0
Notes [Member] | Two Point Seven Seven Percent Notes Due Two Zero Five Three            
Debt Instrument [Line Items]            
Interest rate, stated percentage 2.77% 2.77% 2.77% 2.77%    
Long-term debt, gross $ 940         940
Notes [Member] | 4.40% 2062 Notes [Member]            
Debt Instrument [Line Items]            
Interest rate, stated percentage 4.40% 4.40% 4.40% 4.40% 4.40%  
Long-term debt, gross $ 1,250         0
Face amount         $ 1,250  
Notes [Member] | Other notes due 2097 [Member]            
Debt Instrument [Line Items]            
Long-term debt, gross $ 100         $ 100
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.2
Financing arrangements (Details Textual) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Jun. 30, 2022
4.20% 2052 Notes [Member]    
Debt Instrument [Line Items]    
Face amount $ 1,000  
Notes [Member]    
Debt Instrument [Line Items]    
Face amount $ 4,000  
Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage   4.563%
Effective interest rate   6.30%
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage   4.663%
Effective interest rate   5.60%
Notes [Member] | Two Point Seven Seven Percent Notes Due Two Zero Five Three    
Debt Instrument [Line Items]    
Interest rate, stated percentage   2.77%
Effective interest rate   5.20%
Notes [Member] | 3.00% 2029 Notes [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 3.00% 3.00%
Face amount $ 750  
Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event 101.00%  
Notes [Member] | 3.35% 2032 Notes [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 3.35% 3.35%
Face amount $ 1,000  
Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event 101.00%  
Notes [Member] | 4.20% 2052 Notes [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 4.20% 4.20%
Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event 101.00%  
Notes [Member] | 4.40% 2062 Notes [Member]    
Debt Instrument [Line Items]    
Interest rate, stated percentage 4.40% 4.40%
Face amount $ 1,250  
Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event 101.00%  
Minimum [Member] | Debt Securities Payable [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Redemption Period without Payment of Make Whole Amount 2 months  
Maximum [Member] | Debt Securities Payable [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Redemption Period without Payment of Make Whole Amount 6 months  
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' equity (Share Repurchase Program) (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Equity [Abstract]            
Stock repurchased, Shares 0.0 24.6 6.5 3.7 24.6 10.2
Stock repurchased $ 0 $ 5,410 $ 1,592 $ 865 $ 5,410 $ 2,457
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' equity (Details Textual) (Details)
$ / shares in Units, shares in Millions, $ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Sep. 08, 2022
$ / shares
Aug. 03, 2022
$ / shares
Feb. 25, 2022
USD ($)
shares
Jun. 30, 2022
USD ($)
$ / shares
Mar. 31, 2022
$ / shares
Dec. 31, 2021
$ / shares
Jun. 30, 2022
USD ($)
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
shares
Mar. 31, 2021
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
shares
Jun. 30, 2021
USD ($)
shares
Feb. 24, 2022
financial_institution
Class of Stock [Line Items]                          
Stock repurchased, Shares | shares             0.0 24.6 6.5 3.7 24.6 10.2  
Stock repurchased             $ 0 $ 5,410 $ 1,592 $ 865 $ 5,410 $ 2,457  
Repurchases of common stock               $ 6,310 1,592 $ 865      
Amount available for stock repurchases under a board approved stock repurchase plan       $ 4,600     $ 4,600       $ 4,600    
Dividends declared per share (in usd per share) | $ / shares         $ 1.94 $ 1.94   $ 1.94   $ 1.76      
Dividends paid per share (in usd per share) | $ / shares       $ 1.94 $ 1.94                
Subsequent Event [Member]                          
Class of Stock [Line Items]                          
Dividends declared per share (in usd per share) | $ / shares   $ 1.94                      
Accumulated deficit [Member]                          
Class of Stock [Line Items]                          
Repurchases of common stock               $ 5,410 $ 1,592 $ 865      
Common stock and additional paid-in capital [Member]                          
Class of Stock [Line Items]                          
Repurchases of common stock               $ 900          
Accelerated stock repurchase agreement                          
Class of Stock [Line Items]                          
Stock repurchased, Shares | shares     23.3                    
Stock repurchased     $ 6,000                    
Number of Third-Party Financial Institutions | financial_institution                         3
Accelerated stock repurchase agreement | Accumulated deficit [Member]                          
Class of Stock [Line Items]                          
Repurchases of common stock     5,100                    
Accelerated stock repurchase agreement | Common stock and additional paid-in capital [Member]                          
Class of Stock [Line Items]                          
Repurchases of common stock     $ 900                    
Forecast [Member]                          
Class of Stock [Line Items]                          
Dividends paid per share (in usd per share) | $ / shares $ 1.94                        
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' equity (Components of AOCI) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Increase (Decrease) in AOCI [Roll Forward]          
Balance as of beginning of period $ 916 $ 6,700 $ 9,334 $ 6,700 $ 9,409
Foreign currency translation adjustments (65)   14 (116) (25)
Balance as of end of period 2,419 916 8,247 2,419 8,247
Foreign currency translation [Member]          
Increase (Decrease) in AOCI [Roll Forward]          
Balance as of beginning of period (895) (844)   (844)  
Foreign currency translation adjustments (65) (51)      
Income taxes 0 0      
Balance as of end of period (960) (895)   (960)  
Cash flow hedges [Member]          
Increase (Decrease) in AOCI [Roll Forward]          
Balance as of beginning of period 145 61   61  
Unrealized gains 67 56      
Reclassification adjustments to income 132 51      
Income taxes (43) (23)      
Balance as of end of period 301 145   301  
Available-for-sale securities [Member]          
Increase (Decrease) in AOCI [Roll Forward]          
Balance as of beginning of period 0 0   0  
Unrealized gains 0 0      
Reclassification adjustments to income 0 0      
Income taxes 0 0      
Balance as of end of period 0 0   0  
Other [Member]          
Increase (Decrease) in AOCI [Roll Forward]          
Balance as of beginning of period (13) (13)   (13)  
Unrealized gains 0 0      
Balance as of end of period (13) (13)   (13)  
AOCI [Member]          
Increase (Decrease) in AOCI [Roll Forward]          
Balance as of beginning of period (763) (796) (833) (796) (985)
Foreign currency translation adjustments (65) (51)      
Unrealized gains 67 56      
Reclassification adjustments to income 132 51      
Income taxes (43) (23)      
Balance as of end of period $ (672) $ (763) $ (868) $ (672) $ (868)
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Reclassification out of Accumulated Other Comprehensive Income [Line Items]            
Total revenues $ 6,594   $ 6,526   $ 12,832 $ 12,427
Other (expense) income, net (317)   11   (847) 24
Income before income taxes 1,531   558   3,206 2,415
Provision for income taxes (214)   (94)   (413) (305)
Net income 1,317 $ 1,476 464 $ 1,646 2,793 2,110
Product sales [Member]            
Reclassification out of Accumulated Other Comprehensive Income [Line Items]            
Total revenues 6,281   6,114   12,012 11,706
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member]            
Reclassification out of Accumulated Other Comprehensive Income [Line Items]            
Income before income taxes (132)   28   (183) (105)
Provision for income taxes 28   (6)   39 22
Net income (104)   22   (144) (83)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]            
Reclassification out of Accumulated Other Comprehensive Income [Line Items]            
Total revenues 53   (18)   80 (19)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]            
Reclassification out of Accumulated Other Comprehensive Income [Line Items]            
Other (expense) income, net (185)   46   (263) (86)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]            
Reclassification out of Accumulated Other Comprehensive Income [Line Items]            
Total revenues 53   (18)   80 (19)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]            
Reclassification out of Accumulated Other Comprehensive Income [Line Items]            
Other (expense) income, net $ (185)   $ 46   $ (263) $ (86)
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value measurement (Details) - USD ($)
$ in Millions
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Assets:            
Interest-bearing securities $ 6,413   $ 7,304      
Equity securities 492   831      
Derivatives:            
Total assets 7,347   8,400      
Derivatives:            
Contingent consideration obligations 310 $ 330 342 $ 48 $ 39 $ 33
Total liabilities 1,434   876      
Foreign currency contracts [Member]            
Derivatives:            
Foreign currency and cross-currency swap contracts 413   183      
Derivatives:            
Foreign currency and cross-currency swap contracts 30   39      
Cross-currency swap contracts [Member]            
Derivatives:            
Foreign currency and cross-currency swap contracts 29   66      
Derivatives:            
Foreign currency and cross-currency swap contracts 503   339      
Interest rate swap contracts [Member]            
Derivatives:            
Interest rate swap contracts 0   16      
Derivatives:            
Interest rate swap contracts 591   156      
Quoted prices in active markets for identical assets (Level 1) [Member]            
Assets:            
Equity securities 361   611      
Derivatives:            
Total assets 6,774   7,914      
Derivatives:            
Contingent consideration obligations 0   0      
Total liabilities 0   0      
Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]            
Derivatives:            
Foreign currency and cross-currency swap contracts 0   0      
Derivatives:            
Foreign currency and cross-currency swap contracts 0   0      
Quoted prices in active markets for identical assets (Level 1) [Member] | Cross-currency swap contracts [Member]            
Derivatives:            
Foreign currency and cross-currency swap contracts 0   0      
Derivatives:            
Foreign currency and cross-currency swap contracts 0   0      
Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]            
Derivatives:            
Interest rate swap contracts 0   0      
Derivatives:            
Interest rate swap contracts 0   0      
Significant other observable inputs (Level 2) [Member]            
Assets:            
Equity securities 0   0      
Derivatives:            
Total assets 442   266      
Derivatives:            
Contingent consideration obligations 0   0      
Total liabilities 1,124   534      
Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]            
Derivatives:            
Foreign currency and cross-currency swap contracts 413   183      
Derivatives:            
Foreign currency and cross-currency swap contracts 30   39      
Significant other observable inputs (Level 2) [Member] | Cross-currency swap contracts [Member]            
Derivatives:            
Foreign currency and cross-currency swap contracts 29   66      
Derivatives:            
Foreign currency and cross-currency swap contracts 503   339      
Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]            
Derivatives:            
Interest rate swap contracts 0   16      
Derivatives:            
Interest rate swap contracts 591   156      
Significant unobservable inputs (Level 3) [Member]            
Assets:            
Equity securities 131   220      
Derivatives:            
Total assets 131   220      
Derivatives:            
Contingent consideration obligations 310   342      
Total liabilities 310   342      
Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]            
Derivatives:            
Foreign currency and cross-currency swap contracts 0   0      
Derivatives:            
Foreign currency and cross-currency swap contracts 0   0      
Significant unobservable inputs (Level 3) [Member] | Cross-currency swap contracts [Member]            
Derivatives:            
Foreign currency and cross-currency swap contracts 0   0      
Derivatives:            
Foreign currency and cross-currency swap contracts 0   0      
Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]            
Derivatives:            
Interest rate swap contracts 0   0      
Derivatives:            
Interest rate swap contracts 0   0      
U.S. Treasury notes [Member]            
Assets:            
Interest-bearing securities 0   47      
U.S. Treasury notes [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]            
Assets:            
Interest-bearing securities 0   47      
U.S. Treasury notes [Member] | Significant other observable inputs (Level 2) [Member]            
Assets:            
Interest-bearing securities 0   0      
U.S. Treasury notes [Member] | Significant unobservable inputs (Level 3) [Member]            
Assets:            
Interest-bearing securities 0   0      
U.S. Treasury bills [Member]            
Assets:            
Interest-bearing securities 1,980   1,400      
U.S. Treasury bills [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]            
Assets:            
Interest-bearing securities 1,980   1,400      
U.S. Treasury bills [Member] | Significant other observable inputs (Level 2) [Member]            
Assets:            
Interest-bearing securities 0   0      
U.S. Treasury bills [Member] | Significant unobservable inputs (Level 3) [Member]            
Assets:            
Interest-bearing securities 0   0      
Money market mutual funds [Member]            
Assets:            
Interest-bearing securities 4,433   5,856      
Money market mutual funds [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]            
Assets:            
Interest-bearing securities 4,433   5,856      
Money market mutual funds [Member] | Significant other observable inputs (Level 2) [Member]            
Assets:            
Interest-bearing securities 0   0      
Money market mutual funds [Member] | Significant unobservable inputs (Level 3) [Member]            
Assets:            
Interest-bearing securities 0   0      
Other short-term interest-bearing securities [Member]            
Assets:            
Interest-bearing securities 0   1      
Other short-term interest-bearing securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]            
Assets:            
Interest-bearing securities 0   0      
Other short-term interest-bearing securities [Member] | Significant other observable inputs (Level 2) [Member]            
Assets:            
Interest-bearing securities 0   1      
Other short-term interest-bearing securities [Member] | Significant unobservable inputs (Level 3) [Member]            
Assets:            
Interest-bearing securities $ 0   $ 0      
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value measurement (Details Textual) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Length of time hedged in foreign currency contracts (or less) 3 years  
Long-term debt, fair value $ 34,400 $ 37,900
Carrying value of debt 36,522 33,309
Collaborative arrangement with BeiGene, Ltd. [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Method Investments,Quoted Market Price 3,100 5,100
Carrying value of equity method investment 2,500 2,800
Teneobio Inc.    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Maximum additional consideration due contingent on certain milestones $ 1,600 $ 1,600
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value measurement (Contingent Consideration Obligations) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Business Combination, Contingent Consideration [Roll Forward]        
Beginning balance $ 330 $ 39 $ 342 $ 33
Payments (1) (2) (3) (3)
Net changes in valuations (19) 11 (29) 18
Ending balance $ 310 $ 48 $ 310 $ 48
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative instruments (Details Textual) - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]    
Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps $ 179  
Forward Contracts [Member] | Designated as Hedging Instrument [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Notional amounts 5,600 $ 5,700
Forward Contracts [Member] | Derivatives not designated as hedging instrument [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Notional amounts 550 680
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]    
Derivative Instruments, Gain (Loss) [Line Items]    
Notional amounts $ 6,700 $ 6,700
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative instruments (Cross-currency Swaps) (Details) - Cash flow hedge [Member] - Cross-currency swap contracts [Member]
€ in Millions, £ in Millions, SFr in Millions, $ in Millions
Jun. 30, 2022
USD ($)
Jun. 30, 2022
CHF (SFr)
Jun. 30, 2022
EUR (€)
Jun. 30, 2022
GBP (£)
0.41% 2023 Swiss franc Bonds [Member]        
Derivative [Line Items]        
Notional amounts $ 704 SFr 700    
2.00% 2026 euro Notes [Member]        
Derivative [Line Items]        
Notional amounts 833   € 750  
5.50% 2026 pound sterling Notes [Member]        
Derivative [Line Items]        
Notional amounts 747     £ 475
4.00% 2029 pound sterling Notes [Member]        
Derivative [Line Items]        
Notional amounts $ 1,111     £ 700
Euro Member Countries, Euro | 2.00% 2026 euro Notes [Member]        
Derivative [Line Items]        
Interest rates 2.00% 2.00% 2.00% 2.00%
Switzerland, Francs | 0.41% 2023 Swiss franc Bonds [Member]        
Derivative [Line Items]        
Interest rates 0.40% 0.40% 0.40% 0.40%
United Kingdom, Pounds | 5.50% 2026 pound sterling Notes [Member]        
Derivative [Line Items]        
Interest rates 5.50% 5.50% 5.50% 5.50%
United Kingdom, Pounds | 4.00% 2029 pound sterling Notes [Member]        
Derivative [Line Items]        
Interest rates 4.00% 4.00% 4.00% 4.00%
United States of America, Dollars | 0.41% 2023 Swiss franc Bonds [Member]        
Derivative [Line Items]        
Interest rates 3.40% 3.40% 3.40% 3.40%
United States of America, Dollars | 2.00% 2026 euro Notes [Member]        
Derivative [Line Items]        
Interest rates 3.90% 3.90% 3.90% 3.90%
United States of America, Dollars | 5.50% 2026 pound sterling Notes [Member]        
Derivative [Line Items]        
Interest rates 6.00% 6.00% 6.00% 6.00%
United States of America, Dollars | 4.00% 2029 pound sterling Notes [Member]        
Derivative [Line Items]        
Interest rates 4.50% 4.50% 4.50% 4.50%
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]        
Total unrealized gains (losses) $ 67 $ (31) $ 123 $ 77
Foreign currency contracts [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Total unrealized gains (losses) 252 (46) 330 137
Cross-currency swap contracts [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Total unrealized gains (losses) $ (185) $ 15 $ (207) $ (60)
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Derivative [Line Items]    
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities $ (210) $ 284
Current portion of long-term debt [Member]    
Derivative [Line Items]    
Hedged Liability, Fair Value Hedge 82 85
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities 82 85
Carrying value with discontinued hedging relationships 82 85
Hedging adjustments on discontinued hedging relationships 82 85
Long-term debt [Member]    
Derivative [Line Items]    
Hedged Liability, Fair Value Hedge 6,241 6,729
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (292) 199
Carrying value with discontinued hedging relationships 399 440
Hedging adjustments on discontinued hedging relationships $ 299 $ 340
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative instruments (Summary of Income and Expense Line Items) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]        
Total revenues $ 6,594 $ 6,526 $ 12,832 $ 12,427
Other (expense) income, net (317) 11 (847) 24
Interest expense, net (328) (281) (623) (566)
Interest rate swap agreements [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) on fair value hedging relationships, Hedged items 157 (34) 494 141
Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments (135) 55 (450) (97)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contracts [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Other (expense) income, net (185) 46 (263) (86)
Product sales [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Total revenues 6,281 6,114 12,012 11,706
Product sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contracts [Member]        
Derivative Instruments, Gain (Loss) [Line Items]        
Total revenues $ 53 $ (18) $ 80 $ (19)
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.22.2
Derivative instruments (Fair Value of Derivatives) (Details) - Derivatives designated as hedging instrument [Member] - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Assets    
Total derivative assets, fair value $ 442 $ 265
Liabilities    
Total derivative liabilities, fair value 1,124 534
Foreign currency contracts [Member] | Other current assets/Other assets [Member]    
Assets    
Total derivative assets, fair value 413 183
Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]    
Liabilities    
Total derivative liabilities, fair value 30 39
Cross-currency swap contracts [Member] | Other current assets/Other assets [Member]    
Assets    
Total derivative assets, fair value 29 66
Cross-currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]    
Liabilities    
Total derivative liabilities, fair value 503 339
Interest rate swap contracts [Member] | Other current assets/Other assets [Member]    
Assets    
Total derivative assets, fair value 0 16
Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]    
Liabilities    
Total derivative liabilities, fair value $ 591 $ 156
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.22.2
Contingencies and commitments (Details)
May 27, 2022
argument
Loss Contingencies [Line Items]  
Litigation Settlement, Number Of Primary Arguments 2
XML 78 amgn-20220630_htm.xml IDEA: XBRL DOCUMENT 0000318154 2022-01-01 2022-06-30 0000318154 us-gaap:CommonStockMember exch:XNGS 2022-01-01 2022-06-30 0000318154 amgn:A2.00SeniorNotesDue2026Member exch:XNGS 2022-01-01 2022-06-30 0000318154 2022-08-01 0000318154 us-gaap:ProductMember 2022-04-01 2022-06-30 0000318154 us-gaap:ProductMember 2021-04-01 2021-06-30 0000318154 us-gaap:ProductMember 2022-01-01 2022-06-30 0000318154 us-gaap:ProductMember 2021-01-01 2021-06-30 0000318154 us-gaap:ProductAndServiceOtherMember 2022-04-01 2022-06-30 0000318154 us-gaap:ProductAndServiceOtherMember 2021-04-01 2021-06-30 0000318154 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-06-30 0000318154 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-06-30 0000318154 2022-04-01 2022-06-30 0000318154 2021-04-01 2021-06-30 0000318154 2021-01-01 2021-06-30 0000318154 2022-06-30 0000318154 2021-12-31 0000318154 us-gaap:CommonStockMember 2021-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-12-31 0000318154 us-gaap:RetainedEarningsMember 2021-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000318154 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000318154 2022-01-01 2022-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000318154 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000318154 us-gaap:CommonStockMember 2022-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-03-31 0000318154 us-gaap:RetainedEarningsMember 2022-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000318154 2022-03-31 0000318154 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000318154 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000318154 us-gaap:CommonStockMember 2022-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-06-30 0000318154 us-gaap:RetainedEarningsMember 2022-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000318154 us-gaap:CommonStockMember 2020-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-12-31 0000318154 us-gaap:RetainedEarningsMember 2020-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000318154 2020-12-31 0000318154 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000318154 2021-01-01 2021-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000318154 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000318154 us-gaap:CommonStockMember 2021-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-03-31 0000318154 us-gaap:RetainedEarningsMember 2021-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000318154 2021-03-31 0000318154 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000318154 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000318154 us-gaap:CommonStockMember 2021-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-06-30 0000318154 us-gaap:RetainedEarningsMember 2021-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000318154 2021-06-30 0000318154 amgn:TeneobioMember 2022-01-01 2022-06-30 0000318154 amgn:TeneobioMember 2022-06-30 0000318154 amgn:TeneobioMember amgn:RDTechnologyrightsMember 2022-06-30 0000318154 amgn:TeneobioMember us-gaap:LicensingAgreementsMember 2022-06-30 0000318154 amgn:TeneobioMember us-gaap:InProcessResearchAndDevelopmentMember amgn:AMG340Member 2022-06-30 0000318154 amgn:TeneobioMember amgn:RDTechnologyrightsMember 2022-01-01 2022-06-30 0000318154 amgn:TeneobioMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-06-30 0000318154 amgn:FivePrimeTherapeuticsIncMember 2021-04-16 2021-04-16 0000318154 amgn:FivePrimeTherapeuticsIncMember 2021-04-16 0000318154 amgn:GensentaIlacSanayiVsTicaretMember 2022-06-30 0000318154 srt:ScenarioForecastMember amgn:GensentaIlacSanayiVsTicaretMember 2022-07-01 2022-09-30 0000318154 amgn:GensentaIlacSanayiVsTicaretMember us-gaap:OtherOperatingIncomeExpenseMember 2022-04-01 2022-06-30 0000318154 amgn:EnbrelMember country:US 2022-04-01 2022-06-30 0000318154 amgn:EnbrelMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:EnbrelMember 2022-04-01 2022-06-30 0000318154 amgn:EnbrelMember country:US 2021-04-01 2021-06-30 0000318154 amgn:EnbrelMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:EnbrelMember 2021-04-01 2021-06-30 0000318154 amgn:ProliaMember country:US 2022-04-01 2022-06-30 0000318154 amgn:ProliaMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:ProliaMember 2022-04-01 2022-06-30 0000318154 amgn:ProliaMember country:US 2021-04-01 2021-06-30 0000318154 amgn:ProliaMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:ProliaMember 2021-04-01 2021-06-30 0000318154 amgn:OtezlaMember country:US 2022-04-01 2022-06-30 0000318154 amgn:OtezlaMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:OtezlaMember 2022-04-01 2022-06-30 0000318154 amgn:OtezlaMember country:US 2021-04-01 2021-06-30 0000318154 amgn:OtezlaMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:OtezlaMember 2021-04-01 2021-06-30 0000318154 amgn:XgevaMember country:US 2022-04-01 2022-06-30 0000318154 amgn:XgevaMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:XgevaMember 2022-04-01 2022-06-30 0000318154 amgn:XgevaMember country:US 2021-04-01 2021-06-30 0000318154 amgn:XgevaMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:XgevaMember 2021-04-01 2021-06-30 0000318154 amgn:AranespMember country:US 2022-04-01 2022-06-30 0000318154 amgn:AranespMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:AranespMember 2022-04-01 2022-06-30 0000318154 amgn:AranespMember country:US 2021-04-01 2021-06-30 0000318154 amgn:AranespMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:AranespMember 2021-04-01 2021-06-30 0000318154 amgn:NeulastaMember country:US 2022-04-01 2022-06-30 0000318154 amgn:NeulastaMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:NeulastaMember 2022-04-01 2022-06-30 0000318154 amgn:NeulastaMember country:US 2021-04-01 2021-06-30 0000318154 amgn:NeulastaMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:NeulastaMember 2021-04-01 2021-06-30 0000318154 amgn:RepathaevolocumabMember country:US 2022-04-01 2022-06-30 0000318154 amgn:RepathaevolocumabMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:RepathaevolocumabMember 2022-04-01 2022-06-30 0000318154 amgn:RepathaevolocumabMember country:US 2021-04-01 2021-06-30 0000318154 amgn:RepathaevolocumabMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:RepathaevolocumabMember 2021-04-01 2021-06-30 0000318154 amgn:KyprolisMember country:US 2022-04-01 2022-06-30 0000318154 amgn:KyprolisMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:KyprolisMember 2022-04-01 2022-06-30 0000318154 amgn:KyprolisMember country:US 2021-04-01 2021-06-30 0000318154 amgn:KyprolisMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:KyprolisMember 2021-04-01 2021-06-30 0000318154 amgn:NplateMember country:US 2022-04-01 2022-06-30 0000318154 amgn:NplateMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:NplateMember 2022-04-01 2022-06-30 0000318154 amgn:NplateMember country:US 2021-04-01 2021-06-30 0000318154 amgn:NplateMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:NplateMember 2021-04-01 2021-06-30 0000318154 amgn:OtherProductsMember country:US 2022-04-01 2022-06-30 0000318154 amgn:OtherProductsMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 amgn:OtherProductsMember 2022-04-01 2022-06-30 0000318154 amgn:OtherProductsMember country:US 2021-04-01 2021-06-30 0000318154 amgn:OtherProductsMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:OtherProductsMember 2021-04-01 2021-06-30 0000318154 us-gaap:ProductMember country:US 2022-04-01 2022-06-30 0000318154 us-gaap:ProductMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000318154 us-gaap:ProductMember country:US 2021-04-01 2021-06-30 0000318154 us-gaap:ProductMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000318154 amgn:EnbrelMember country:US 2022-01-01 2022-06-30 0000318154 amgn:EnbrelMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:EnbrelMember 2022-01-01 2022-06-30 0000318154 amgn:EnbrelMember country:US 2021-01-01 2021-06-30 0000318154 amgn:EnbrelMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:EnbrelMember 2021-01-01 2021-06-30 0000318154 amgn:ProliaMember country:US 2022-01-01 2022-06-30 0000318154 amgn:ProliaMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:ProliaMember 2022-01-01 2022-06-30 0000318154 amgn:ProliaMember country:US 2021-01-01 2021-06-30 0000318154 amgn:ProliaMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:ProliaMember 2021-01-01 2021-06-30 0000318154 amgn:OtezlaMember country:US 2022-01-01 2022-06-30 0000318154 amgn:OtezlaMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:OtezlaMember 2022-01-01 2022-06-30 0000318154 amgn:OtezlaMember country:US 2021-01-01 2021-06-30 0000318154 amgn:OtezlaMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:OtezlaMember 2021-01-01 2021-06-30 0000318154 amgn:XgevaMember country:US 2022-01-01 2022-06-30 0000318154 amgn:XgevaMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:XgevaMember 2022-01-01 2022-06-30 0000318154 amgn:XgevaMember country:US 2021-01-01 2021-06-30 0000318154 amgn:XgevaMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:XgevaMember 2021-01-01 2021-06-30 0000318154 amgn:AranespMember country:US 2022-01-01 2022-06-30 0000318154 amgn:AranespMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:AranespMember 2022-01-01 2022-06-30 0000318154 amgn:AranespMember country:US 2021-01-01 2021-06-30 0000318154 amgn:AranespMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:AranespMember 2021-01-01 2021-06-30 0000318154 amgn:NeulastaMember country:US 2022-01-01 2022-06-30 0000318154 amgn:NeulastaMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:NeulastaMember 2022-01-01 2022-06-30 0000318154 amgn:NeulastaMember country:US 2021-01-01 2021-06-30 0000318154 amgn:NeulastaMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:NeulastaMember 2021-01-01 2021-06-30 0000318154 amgn:RepathaevolocumabMember country:US 2022-01-01 2022-06-30 0000318154 amgn:RepathaevolocumabMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:RepathaevolocumabMember 2022-01-01 2022-06-30 0000318154 amgn:RepathaevolocumabMember country:US 2021-01-01 2021-06-30 0000318154 amgn:RepathaevolocumabMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:RepathaevolocumabMember 2021-01-01 2021-06-30 0000318154 amgn:KyprolisMember country:US 2022-01-01 2022-06-30 0000318154 amgn:KyprolisMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:KyprolisMember 2022-01-01 2022-06-30 0000318154 amgn:KyprolisMember country:US 2021-01-01 2021-06-30 0000318154 amgn:KyprolisMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:KyprolisMember 2021-01-01 2021-06-30 0000318154 amgn:NplateMember country:US 2022-01-01 2022-06-30 0000318154 amgn:NplateMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:NplateMember 2022-01-01 2022-06-30 0000318154 amgn:NplateMember country:US 2021-01-01 2021-06-30 0000318154 amgn:NplateMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:NplateMember 2021-01-01 2021-06-30 0000318154 amgn:OtherProductsMember country:US 2022-01-01 2022-06-30 0000318154 amgn:OtherProductsMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 amgn:OtherProductsMember 2022-01-01 2022-06-30 0000318154 amgn:OtherProductsMember country:US 2021-01-01 2021-06-30 0000318154 amgn:OtherProductsMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 amgn:OtherProductsMember 2021-01-01 2021-06-30 0000318154 us-gaap:ProductMember country:US 2022-01-01 2022-06-30 0000318154 us-gaap:ProductMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000318154 us-gaap:ProductMember country:US 2021-01-01 2021-06-30 0000318154 us-gaap:ProductMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000318154 us-gaap:DomesticCountryMember 2021-05-31 0000318154 us-gaap:DomesticCountryMember 2022-04-28 0000318154 us-gaap:USTreasurySecuritiesMember 2022-06-30 0000318154 us-gaap:USTreasuryBillSecuritiesMember 2022-06-30 0000318154 us-gaap:MoneyMarketFundsMember 2022-06-30 0000318154 amgn:OtherShortTermInterestBearingSecuritiesMember 2022-06-30 0000318154 us-gaap:USTreasurySecuritiesMember 2021-12-31 0000318154 us-gaap:USTreasuryBillSecuritiesMember 2021-12-31 0000318154 us-gaap:MoneyMarketFundsMember 2021-12-31 0000318154 amgn:OtherShortTermInterestBearingSecuritiesMember 2021-12-31 0000318154 amgn:AvailableForSalesInvestmentsMember 2022-06-30 0000318154 amgn:AvailableForSalesInvestmentsMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel1Member 2022-06-30 0000318154 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000318154 amgn:BeiGeneMember 2022-06-30 0000318154 amgn:BeiGeneMember 2021-12-31 0000318154 amgn:BeiGeneMember 2022-04-01 2022-06-30 0000318154 amgn:BeiGeneMember 2021-04-01 2021-06-30 0000318154 amgn:BeiGeneMember 2022-01-01 2022-06-30 0000318154 amgn:BeiGeneMember 2021-01-01 2021-06-30 0000318154 amgn:NeumoraTherapeuticsIncMember 2021-09-30 0000318154 amgn:NeumoraTherapeuticsIncMember 2021-09-30 2021-09-30 0000318154 amgn:NeumoraTherapeuticsIncMember 2022-06-30 0000318154 amgn:NeumoraTherapeuticsIncMember 2021-12-31 0000318154 amgn:NeumoraTherapeuticsIncMember 2022-04-01 2022-06-30 0000318154 amgn:NeumoraTherapeuticsIncMember 2022-01-01 2022-06-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2022-06-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2021-12-31 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2022-06-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2022-04-01 2022-06-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2021-04-01 2021-06-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2022-01-01 2022-06-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember srt:PartnershipInterestMember 2021-01-01 2021-06-30 0000318154 us-gaap:DevelopedTechnologyRightsMember 2022-06-30 0000318154 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000318154 us-gaap:LicensingAgreementsMember 2022-06-30 0000318154 us-gaap:LicensingAgreementsMember 2021-12-31 0000318154 us-gaap:MarketingRelatedIntangibleAssetsMember 2022-06-30 0000318154 us-gaap:MarketingRelatedIntangibleAssetsMember 2021-12-31 0000318154 amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember 2022-06-30 0000318154 amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember 2021-12-31 0000318154 us-gaap:InProcessResearchAndDevelopmentMember 2022-06-30 0000318154 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:ThreePointSixTwoFivePercentNotesDue2024Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:ThreePointTwoZeroNotesDue2027Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:ThreePointTwoZeroNotesDue2027Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:OnePointSixFivePercent2028NotesMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:OnePointSixFivePercent2028NotesMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:A3002029NotesMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:A3002029NotesMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:TwoPointFourFivePercentNotesDue2030Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:TwoPointFourFivePercentNotesDue2030Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:TwoPointThreeZeroPercentNotesDue2031Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:TwoPointThreeZeroPercentNotesDue2031Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:TwoPointZeroPercent2032NotesMemberMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:TwoPointZeroPercent2032NotesMemberMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:A3352032NotesMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:ThreePointOneFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:ThreePointOneFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:TwoPointEightZeroPercent2041NotesMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:TwoPointEightZeroPercent2041NotesMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FourPointNineFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FourPointNineFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FivePointOneFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FivePointOneFivePercentNotesDue2041Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FivePointSixFivePercentNotesDue2042Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FivePointSixFivePercentNotesDue2042Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:ThreePointThreeSevenFivePercentNotesDue2050Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:ThreePointThreeSevenFivePercentNotesDue2050Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:A300NotesDue20523002052NotesMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:A300NotesDue20523002052NotesMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:A4202052NotesMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:A4202052NotesMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:A4402062NotesMember us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:A4402062NotesMember us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 amgn:OtherNotesDue2097Member us-gaap:NotesPayableToBanksMember 2022-06-30 0000318154 amgn:OtherNotesDue2097Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000318154 us-gaap:NotesPayableToBanksMember 2022-03-31 0000318154 amgn:A3002029NotesMember us-gaap:NotesPayableToBanksMember 2022-03-31 0000318154 amgn:A3352032NotesMember us-gaap:NotesPayableToBanksMember 2022-03-31 0000318154 amgn:A4202052NotesMember 2022-03-31 0000318154 amgn:A4202052NotesMember us-gaap:NotesPayableToBanksMember 2022-03-31 0000318154 amgn:A4402062NotesMember us-gaap:NotesPayableToBanksMember 2022-03-31 0000318154 amgn:A3352032NotesMember us-gaap:NotesPayableToBanksMember 2022-01-01 2022-03-31 0000318154 amgn:A3002029NotesMember us-gaap:NotesPayableToBanksMember 2022-01-01 2022-03-31 0000318154 amgn:A4402062NotesMember us-gaap:NotesPayableToBanksMember 2022-01-01 2022-03-31 0000318154 amgn:A4202052NotesMember us-gaap:NotesPayableToBanksMember 2022-01-01 2022-03-31 0000318154 srt:MinimumMember us-gaap:DebtSecuritiesPayableMember 2022-01-01 2022-03-31 0000318154 srt:MaximumMember us-gaap:DebtSecuritiesPayableMember 2022-01-01 2022-03-31 0000318154 amgn:AcceleratedStockRepurchaseAgreementMember 2022-02-24 0000318154 amgn:AcceleratedStockRepurchaseAgreementMember 2022-02-25 2022-02-25 0000318154 amgn:AcceleratedStockRepurchaseAgreementMember us-gaap:RetainedEarningsMember 2022-02-25 2022-02-25 0000318154 amgn:AcceleratedStockRepurchaseAgreementMember us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-02-25 2022-02-25 0000318154 2021-12-01 2021-12-31 0000318154 2022-03-01 2022-03-31 0000318154 2022-06-01 2022-06-30 0000318154 srt:ScenarioForecastMember 2022-09-08 2022-09-08 0000318154 us-gaap:SubsequentEventMember 2022-08-03 2022-08-03 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2021-12-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-03-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2022-01-01 2022-03-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-03-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2022-03-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2022-04-01 2022-06-30 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-04-01 2022-06-30 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-04-01 2022-06-30 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2022-04-01 2022-06-30 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-06-30 0000318154 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-06-30 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2022-06-30 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-04-01 2022-06-30 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-04-01 2021-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-04-01 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-04-01 2021-06-30 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-04-01 2022-06-30 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-04-01 2021-06-30 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-06-30 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-06-30 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-06-30 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-06-30 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel1Member amgn:OtherShortTermInterestBearingSecuritiesMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel2Member amgn:OtherShortTermInterestBearingSecuritiesMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel3Member amgn:OtherShortTermInterestBearingSecuritiesMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel2Member 2022-06-30 0000318154 us-gaap:FairValueInputsLevel3Member 2022-06-30 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0000318154 us-gaap:ForeignExchangeContractMember 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember 2022-06-30 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0000318154 us-gaap:InterestRateSwapMember 2022-06-30 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBillSecuritiesMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBillSecuritiesMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryBillSecuritiesMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel1Member amgn:OtherShortTermInterestBearingSecuritiesMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel2Member amgn:OtherShortTermInterestBearingSecuritiesMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel3Member amgn:OtherShortTermInterestBearingSecuritiesMember 2021-12-31 0000318154 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000318154 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000318154 us-gaap:ForeignExchangeContractMember 2021-12-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000318154 amgn:CrossCurrencySwapContractsMember 2021-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000318154 us-gaap:InterestRateSwapMember 2021-12-31 0000318154 amgn:TeneobioIncMember 2021-12-31 0000318154 amgn:TeneobioIncMember 2022-06-30 0000318154 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-06-30 0000318154 us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000318154 amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 currency:CHF amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 currency:USD amgn:ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 currency:EUR amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 currency:USD amgn:TwoPercentEuroNotesDueTwoThousandTwentySixMember amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 currency:GBP amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 currency:USD amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 currency:GBP amgn:FourPercentPoundSterlingNotesDue2029Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 currency:USD amgn:FourPercentPoundSterlingNotesDue2029Member amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-06-30 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2022-04-01 2022-06-30 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2021-04-01 2021-06-30 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-06-30 0000318154 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-04-01 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2021-04-01 2021-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-06-30 0000318154 us-gaap:CashFlowHedgingMember 2022-04-01 2022-06-30 0000318154 us-gaap:CashFlowHedgingMember 2021-04-01 2021-06-30 0000318154 us-gaap:CashFlowHedgingMember 2022-01-01 2022-06-30 0000318154 us-gaap:CashFlowHedgingMember 2021-01-01 2021-06-30 0000318154 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000318154 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-06-30 0000318154 amgn:LongTermDebtCurrentMaturitiesMember 2022-06-30 0000318154 amgn:LongTermDebtCurrentMaturitiesMember 2021-12-31 0000318154 us-gaap:LongTermDebtMember 2022-06-30 0000318154 us-gaap:LongTermDebtMember 2021-12-31 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-04-01 2022-06-30 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-04-01 2022-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-06-30 0000318154 us-gaap:InterestRateSwapMember 2022-04-01 2022-06-30 0000318154 us-gaap:InterestRateSwapMember 2022-01-01 2022-06-30 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-04-01 2021-06-30 0000318154 us-gaap:ProductMember us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-04-01 2021-06-30 0000318154 amgn:CrossCurrencySwapContractsMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-06-30 0000318154 us-gaap:InterestRateSwapMember 2021-04-01 2021-06-30 0000318154 us-gaap:InterestRateSwapMember 2021-01-01 2021-06-30 0000318154 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2022-06-30 0000318154 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2021-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-06-30 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-06-30 0000318154 amgn:OtherCurrentNoncurrentAssetsMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-06-30 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-06-30 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-06-30 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-06-30 0000318154 us-gaap:DesignatedAsHedgingInstrumentMember 2022-06-30 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember amgn:CrossCurrencySwapContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000318154 us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000318154 2022-05-27 2022-05-27 shares iso4217:USD iso4217:USD shares amgn:segment pure iso4217:CHF iso4217:EUR iso4217:GBP amgn:financial_institution amgn:argument 0000318154 false 2022 Q2 --12-31 10-Q true 2022-06-30 false 001-37702 Amgen Inc. DE 95-3540776 One Amgen Center Drive 91320-1799 Thousand Oaks CA 805 447-1000 Common stock, $0.0001 par value AMGN NASDAQ 2.00% Senior Notes due 2026 AMGN26 NASDAQ Yes Yes Large Accelerated Filer false false false 534930850 6281000000 6114000000 12012000000 11706000000 313000000 412000000 820000000 721000000 6594000000 6526000000 12832000000 12427000000 1510000000 1637000000 3071000000 3127000000 1039000000 1082000000 1998000000 2049000000 0 1505000000 0 1505000000 1327000000 1384000000 2555000000 2638000000 542000000 90000000 532000000 151000000 4418000000 5698000000 8156000000 9470000000 2176000000 828000000 4676000000 2957000000 328000000 281000000 623000000 566000000 -317000000 11000000 -847000000 24000000 1531000000 558000000 3206000000 2415000000 214000000 94000000 413000000 305000000 1317000000 464000000 2793000000 2110000000 2.46 0.81 5.16 3.67 2.45 0.81 5.13 3.65 535000000 573000000 541000000 575000000 537000000 576000000 544000000 578000000 1317000000 464000000 2793000000 2110000000 -65000000 14000000 -116000000 -25000000 156000000 -48000000 240000000 142000000 0 -1000000 0 0 91000000 -35000000 124000000 117000000 1408000000 429000000 2917000000 2227000000 5203000000 7989000000 1980000000 48000000 5327000000 4895000000 4554000000 4086000000 2258000000 2367000000 19322000000 19385000000 5158000000 5184000000 13927000000 15182000000 14865000000 14890000000 6022000000 6524000000 59294000000 61165000000 1256000000 1366000000 10545000000 10731000000 817000000 87000000 12618000000 12184000000 35705000000 33222000000 5603000000 6594000000 2949000000 2465000000 0.0001 0.0001 2750000000 2750000000 534900000 558300000 31343000000 32096000000 -28252000000 -24600000000 -672000000 -796000000 2419000000 6700000000 59294000000 61165000000 558300000 32096000000 -24600000000 -796000000 6700000000 1476000000 1476000000 33000000 33000000 1.94 1034000000 1034000000 500000 18000000 18000000 78000000 78000000 45000000 45000000 24600000 900000000 5410000000 6310000000 534200000 31247000000 -29568000000 -763000000 916000000 1317000000 1317000000 91000000 91000000 700000 45000000 45000000 120000000 120000000 69000000 69000000 -1000000 -1000000 534900000 31343000000 -28252000000 -672000000 2419000000 578300000 31802000000 -21408000000 -985000000 9409000000 1646000000 1646000000 152000000 152000000 1.76 1012000000 1012000000 700000 6000000 6000000 57000000 57000000 59000000 59000000 3700000 865000000 865000000 575300000 31806000000 -21639000000 -833000000 9334000000 464000000 464000000 -35000000 -35000000 800000 47000000 47000000 100000000 100000000 76000000 76000000 6500000 1592000000 1592000000 5000000 5000000 569600000 31877000000 -22762000000 -868000000 8247000000 2793000000 2110000000 1669000000 1696000000 -514000000 -137000000 0 1505000000 -497000000 36000000 560000000 0 -436000000 -206000000 504000000 -35000000 410000000 167000000 -198000000 258000000 -98000000 -156000000 -685000000 -930000000 108000000 47000000 44000000 120000000 4094000000 4035000000 1976000000 8000000000 0 4404000000 47000000 6528000000 436000000 351000000 0 1626000000 -61000000 65000000 -2304000000 890000000 3954000000 0 6360000000 2452000000 2118000000 2024000000 -52000000 -85000000 -4576000000 -4561000000 -2786000000 364000000 7989000000 6266000000 5203000000 6630000000 Summary of significant accounting policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.0 billion and $8.8 billion as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.</span></div>In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions. <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.</span></div> 1 <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information for the three and six months ended June 30, 2022 and 2021, is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2021, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div> <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $9.0 billion and $8.8 billion as of June 30, 2022 and December 31, 2021, respectively.</span></div> 9000000000 8800000000 <div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued a new accounting standard to ease the financial reporting burdens caused by the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, commonly referred to as reference rate reform. The new standard provides temporary optional expedients and exceptions to current GAAP guidance on contract modifications and hedge accounting. Specifically, a modification to transition to an alternative reference rate is treated as an event that does not require contract remeasurement or reassessment of a previous accounting treatment. Moreover, for all types of hedging relationships, an entity is permitted to change the reference rate without having to dedesignate the hedging relationship. The standard is generally effective for all contract modifications made and hedging relationships evaluated through December 31, 2022. In January 2021, the FASB issued a new accounting standard that expanded the scope of the original March 2020 standard to include derivative instruments on discounting transactions. We do not expect the two standards to have a material impact on our condensed consolidated financial statements.</span></div>In November 2021, the FASB issued a new accounting standard around the recognition and measurement of contract assets and contract liabilities from revenue contracts with customers acquired in a business combination. The new standard clarifies that contract assets and contract liabilities acquired in a business combination from an acquiree should initially be recognized by applying revenue recognition principles and not at fair value. The standard is effective for interim and annual periods beginning on January 1, 2023, and early adoption is permitted. The impact of this standard will depend on the facts and circumstances of future transactions. Acquisitions and divestitures<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Teneobio, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2021, we acquired all of the outstanding stock of Teneobio, a privately held, clinical-stage biotechnology company developing a new class of biologics called human heavy-chain antibodies, which are single-chain antibodies composed of the human heavy-chain domain. The transaction, which was accounted for as a business combination, includes Teneobio’s proprietary bispecific and multispecific antibody technologies, which complement Amgen’s existing antibody capabilities and bispecific T-cell engager (BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) platform and will enable significant acceleration and efficiency in the discovery and development of new molecules to treat diseases across Amgen’s core therapeutic areas. Upon its acquisition, Teneobio became a wholly owned subsidiary of Amgen, and its operations have been included in our condensed consolidated financial statements commencing on the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustments for the six months ended June 30, 2022, included changes to the purchase price allocation and total consideration, resulting in a net increase of $22 million to goodwill. The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. These adjustments did not have a significant impact on Amgen’s results of operations during the six months ended June 30, 2022, and would not have had a significant impact on prior-period results if these adjustments had been made as of the acquisition date. The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset – research and development technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets – licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration for this transaction comprised (i) an upfront cash payment of $993 million, which included a working-capital adjustment, and (ii) future contingent milestone payments to Teneobio’s former equity holders of up to $1.6 billion in cash, based on the achievement of various development and regulatory milestones with regard to the leading asset (AMG 340, formerly TNB-585) and to various development milestones for other drug candidates. The estimated fair values of the contingent consideration obligations aggregated $299 million as of the acquisition date and were determined using a probability-weighted expected return methodology. The assumptions in this method include the probability of achieving the milestones and the expected payment dates, with such amounts discounted to present value based on our pretax cost of debt. See Note 11, Fair value measurement, for information regarding the estimated fair value of these obligations as of June 30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of acquired IPR&amp;D assets totaled $991 million, of which $784 million relates to AMG 340, that is in a phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the balance relates to four separate preclinical oncology programs. The R&amp;D technology rights of $115 million relate to Teneobio’s proprietary bispecific and multispecific antibody technologies; the amount is being amortized over 10 years by using the straight-line method. Teneobio has also licensed its technology and certain identified targets to various third parties, representing contractual agreements valued at $41 million. The estimated fair values for these intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A deferred tax liability of $244 million was recognized on temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $273 million was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from both AMG 340 and the technologies acquired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis of certain tax-related items as we obtain additional information during the measurement period of up to one year from the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Five Prime Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, Amgen completed its acquisition of Five Prime for a total cash consideration of $1.6 billion, net of cash acquired. The purchase price was funded with cash on hand. This transaction was accounted for as an asset acquisition because substantially all the value of the assets acquired was concentrated in the intellectual property rights of bemarituzumab, a phase 3 trial-ready, first-in-class program for gastric cancer. Five Prime’s operations have been included in our condensed consolidated financial statements commencing after the acquisition date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the consideration to acquire Five Prime to: the bemarituzumab IPR&amp;D program of $1.5 billion, which was expensed immediately in Acquired IPR&amp;D expense in the Condensed Consolidated Statements of Income; deferred tax assets of $177 million; and other net liabilities of $47 million. The Acquired IPR&amp;D expense was not tax deductible.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Gensenta İlaç Sanayi ve Ticaret A.Ş.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2022, we entered into a share purchase agreement with Eczacıbaşı under which Eczacıbaşı will acquire all of our shares in Gensenta—a subsidiary in Turkey. Net assets related to Gensenta of $80 million met the criteria to be classified as held-for-sale and did not meet the criteria to be classified as discontinued operations. Upon closing of the transaction, we expect to receive $135 million in cash. The transaction is expected to close in the third quarter of 2022 upon approval by the Turkish Competition Authority.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, held-for-sale assets and liabilities of $100 million and $20 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $560 million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuation allowances to Other current assets and Accrued liabilities in the Condensed Consolidated Balance Sheets.</span></div> 22000000 The following table summarizes the total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset – research and development technology rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets – licensing rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 993000000 299000000 1292000000 100000000 991000000 115000000 41000000 273000000 16000000 244000000 1292000000 993000000 1600000000 299000000 991000000 784000000 115000000 P10Y 41000000 244000000 273000000 1600000000 1500000000 177000000 47000000 80000000 135000000 100000000 20000000 560000000 Revenues<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,832 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div>(1)    Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021. 1 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENBREL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,832 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div>(1)    Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021. 1036000000 15000000 1051000000 1113000000 31000000 1144000000 611000000 311000000 922000000 538000000 276000000 814000000 487000000 107000000 594000000 423000000 111000000 534000000 391000000 142000000 533000000 355000000 133000000 488000000 132000000 225000000 357000000 135000000 232000000 367000000 263000000 47000000 310000000 434000000 52000000 486000000 154000000 171000000 325000000 143000000 143000000 286000000 213000000 104000000 317000000 190000000 90000000 280000000 156000000 128000000 284000000 136000000 109000000 245000000 1003000000 585000000 1588000000 907000000 563000000 1470000000 4446000000 1835000000 6281000000 4374000000 1740000000 6114000000 313000000 412000000 6594000000 6526000000 1879000000 34000000 1913000000 2007000000 61000000 2068000000 1193000000 581000000 1774000000 1039000000 533000000 1572000000 837000000 208000000 1045000000 789000000 221000000 1010000000 759000000 276000000 1035000000 689000000 267000000 956000000 269000000 446000000 715000000 260000000 462000000 722000000 567000000 91000000 658000000 855000000 113000000 968000000 319000000 335000000 654000000 282000000 290000000 572000000 409000000 195000000 604000000 349000000 182000000 531000000 312000000 238000000 550000000 248000000 224000000 472000000 1939000000 1125000000 3064000000 1759000000 1076000000 2835000000 8483000000 3529000000 12012000000 8277000000 3429000000 11706000000 820000000 721000000 12832000000 12427000000 Income taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and six months ended June 30, 2022, were 14.0% and 12.9%, respectively, compared with 16.8% and 12.6%, respectively, for the corresponding periods of the prior year. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our effective tax rate for the three months ended June 30, 2022, was primarily due to the prior year nondeductible IPR&amp;D expense arising from the acquisition of Five Prime, partially offset by current year unfavorable items including a loss on a nonstrategic divestiture. The increase in our effective tax rate for the six months ended June 30, 2022, was primarily due to current year unfavorable items compared to last year including a loss on a nonstrategic divestiture, partially offset by the prior year nondeductible IPR&amp;D expense arising from the acquisition of Five Prime and changes in earnings mix. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States treated as a foreign jurisdiction for U.S. tax purposes, that are currently subject to a tax incentive grant through 2035. In addition, the Company’s operations conducted in Singapore are subject to a tax incentive grant through 2034. These foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. territory of Puerto Rico imposes a 4% excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We account for the excise tax as a manufacturing cost that is capitalized in Inventories and expensed in Cost of sales when the related products are sold. For U.S. income tax purposes, in 2022, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received an RAR and a modified RAR from the IRS for the years 2010–2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010–2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010–2012 by an amount that would result in additional federal tax of approximately $3.6 billion plus interest. Any additional tax that could be imposed for the years 2010–2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, we received an RAR and a modified RAR from the IRS for the years 2013–2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010–2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013–2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013–2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for the years 2013–2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued on our foreign earnings. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that the IRS positions set forth in the 2010–2012 and 2013–2015 Notices are without merit. We are contesting the 2010–2012 and 2013–2015 Notices through the judicial process, and we will seek consolidation of the two periods into one case in the U.S. Tax Court.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently under examination by the IRS for the years 2016–2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we have examinations by a number of state and foreign tax jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final resolution of these complex matters is not likely within the next 12 months. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations, Income Taxes, for further discussion and Part II, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1A, Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Factors—</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The adoption and interpretation of new tax legislation or exposure to additional tax liabilities could affect our profitability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022, the gross amounts of our UTBs increased by $50 million and $95 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of June 30, 2022, if recognized, would affect our effective tax rate.</span></div> 0.140 0.129 0.168 0.126 3600000000 900000000 5100000000 2000000000 2200000000 50000000 95000000 Earnings per share<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022 and 2021, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.</span></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (Numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income for basic and diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares (Denominator):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for basic EPS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1317000000 464000000 2793000000 2110000000 535000000 573000000 541000000 575000000 2000000 3000000 3000000 3000000 537000000 576000000 544000000 578000000 2.46 0.81 5.16 3.67 2.45 0.81 5.13 3.65 Investments<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale investments</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents in the above table excludes bank account cash of $770 million and $733 million as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest-bearing securities as of June 30, 2022 and December 31, 2021, mature in one year or less.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022 and 2021, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other (expense) income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values (publicly traded securities) of $361 million and $611 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022 and 2021, net unrealized gains and losses on publicly traded securities were a $106 million net loss and a $25 million net gain, respectively. During the six months ended June 30, 2022 and 2021, net unrealized losses on publicly traded securities were $276 million and $31 million, respectively. Realized gains and losses on sales of publicly traded securities for the three and six months ended June 30, 2022 and 2021, were not material.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments of $280 million and $262 million in equity securities without readily determinable fair values as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and six months ended June 30, 2022 and 2021, upward adjustments and downward adjustments on these securities were not material. Adjustments were based on observable price transactions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method investments </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, we had an ownership interest in BeiGene of approximately 18.2% and 18.4%, respectively, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets and accounted for under the equity method of accounting. We amortize the difference between the fair value of equity securities acquired and our proportionate share of the carrying value of the underlying net assets of BeiGene over the useful lives of the assets that gave rise to this basis difference. This amortization and our share of the results of operations of BeiGene are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the Condensed Consolidated Statements of Income one quarter in arrears. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene’s net loss of $80 million and net income of $14 million, respectively, and amortization of the basis difference of $48 million and $42 million, respectively. During the six months ended June 30, 2022 and 2021, the carrying value of our equity investment was adjusted by our share of BeiGene’s net losses of $188 million and $83 million, respectively, and amortization of the basis difference of $95 million and $84 million, respectively. As of June 30, 2022 and December 31, 2021, the carrying values of our investment in BeiGene totaled $2.5 billion and $2.8 billion, respectively, and the fair values of our investment totaled $3.1 billion and $5.1 billion, respectively. As of June 30, 2022, we believe the carrying value of our equity investment in BeiGene is fully recoverable.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neumora Therapeutics, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, we acquired an approximately 25.9% ownership interest in Neumora, a privately held company, for $257 million, which is included in Other noncurrent assets in the Condensed Consolidated Balance Sheets, in exchange for a $100 million cash payment and $157 million in noncash consideration primarily related to future services. Although our equity investment provides us with the ability to exercise significant influence over Neumora, we have elected the fair value option to account for our equity investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period. We believe the fair value option best reflects the economics of the underlying transaction. As of June 30, 2022 and December 31, 2021, our ownership interest in Neumora was approximately 25.7% and 25.9%, respectively, and the fair values of our investment were $131 million and $220 million, respectively. Accordingly, for the reduction in fair value of our investment during the three and six months ended June 30, 2022, we recognized a loss of $39 million and $89 million, respectively, for the reduction in fair value of our investment in Other (expense) income, net, in the Condensed Consolidated Statements of Income. For information on determination of fair values, see Note 11, Fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limited partnerships</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held limited partnership investments of $338 million and $573 million as of June 30, 2022 and December 31, 2021, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of June 30, 2022, unfunded additional commitments to be made for these investments during the next several years were $209 million. For the three months ended June 30, 2022 and 2021, net unrealized losses from our limited partnership investments were $60 million and $43 million, respectively. For the six months ended June 30, 2022 and 2021, net unrealized gains and losses from our limited partnership investments were a $220 million net loss and a $165 million net gain, respectively.</span></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Types of securities as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 0 0 1980000000 0 0 1980000000 4433000000 0 0 4433000000 0 0 0 0 6413000000 0 0 6413000000 47000000 0 0 47000000 1400000000 0 0 1400000000 5856000000 0 0 5856000000 1000000 0 0 1000000 7304000000 0 0 7304000000 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest-bearing securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,304 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4433000000 7256000000 1980000000 48000000 6413000000 7304000000 770000000 733000000 361000000 611000000 -106000000 25000000 -276000000 -31000000 280000000 262000000 0.182 0.184 -80000000 14000000 48000000 42000000 -188000000 -83000000 95000000 84000000 2500000000 2800000000 3100000000 5100000000 0.259 257000000 100000000 157000000 0.257 0.259 131000000 220000000 39000000 89000000 338000000 573000000 209000000 -60000000 -43000000 -220000000 165000000 Inventories<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 779000000 647000000 2763000000 2367000000 1012000000 1072000000 4554000000 4086000000 Goodwill and other intangible assets<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill resulting from acquisitions and divestitures, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,865 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other intangible assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,098 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,191)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,907 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,099 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,191)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,182 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&amp;D technology rights pertains to technologies used in R&amp;D that have alternative future uses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D consists of R&amp;D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&amp;D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $629 million and $652 million, respectively. During the six months ended June 30, 2022 and 2021, we recognized amortization associated with our finite-lived intangible assets of $1.3 billion in both periods. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining six months ending December 31, 2022, and the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $1.3 billion, $2.5 billion, $2.5 billion, $2.4 billion, $1.7 billion and $1.8 billion, respectively.</span></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,890 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill resulting from acquisitions and divestitures, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,865 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Composed of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div> 14890000000 7000000 -32000000 14865000000 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed-product-technology rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,863)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing-related rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development technology rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,098 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,191)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,907 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,099 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,191)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,169 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,987)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,182 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 25537000000 13863000000 11674000000 25561000000 12769000000 12792000000 3864000000 3050000000 814000000 3807000000 2973000000 834000000 1326000000 1125000000 201000000 1354000000 1112000000 242000000 1371000000 1153000000 218000000 1377000000 1133000000 244000000 32098000000 19191000000 12907000000 32099000000 17987000000 14112000000 1020000000 1020000000 1070000000 1070000000 33118000000 19191000000 13927000000 33169000000 17987000000 15182000000 629000000 652000000 1300000000 1300000000 1300000000 2500000000 2500000000 2400000000 1700000000 1800000000 Financing arrangements<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% notes due 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2029 (3.00% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35% notes due 2032 (3.35% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% notes due 2052 (4.20% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2062 (4.40% 2062 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,309 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,705 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.</span></div>During the three months ended March 31, 2022, we issued $4.0 billion of debt consisting of $750 million of the 3.00% 2029 Notes, $1.0 billion of the 3.35% 2032 Notes, $1.0 billion of the 4.20% 2052 Notes and $1.25 billion of the 4.40% 2062 Notes. The 3.00% 2029 Notes were issued to finance eligible projects that meet specified criteria to benefit the environment. In the event of a change-in-control triggering event, as defined in the terms of the notes, we may be required to purchase all or a portion of these notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. In addition, these notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and a make-whole amount, which are defined by the terms of the notes. The notes may be redeemed without payment of make-whole amounts if redemption occurs during a specified period of time immediately prior to the maturing of the notes. Such time periods range from two months to six months prior to maturity. <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowings consisted of the following (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% notes due 2023 (2.25% 2023 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% notes due 2024 (3.625% 2024 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90% notes due 2025 (1.90% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% notes due 2025 (3.125% 2025 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% €750 million notes due 2026 (2.00% 2026 euro Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60% notes due 2026 (2.60% 2026 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20% notes due 2027 (2.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20% notes due 2027 (3.20% 2027 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65% notes due 2028 (1.65% 2028 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2029 (3.00% 2029 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% notes due 2030 (2.45% 2030 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30% notes due 2031 (2.30% 2031 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% notes due 2032 (2.00% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35% notes due 2032 (3.35% 2032 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.375% notes due 2037 (6.375% 2037 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.90% notes due 2038 (6.90% 2038 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40% notes due 2039 (6.40% 2039 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15% notes due 2040 (3.15% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% notes due 2040 (5.75% 2040 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80% notes due 2041 (2.80% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% notes due 2041 (4.95% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15% notes due 2041 (5.15% 2041 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65% notes due 2042 (5.65% 2042 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.375% notes due 2043 (5.375% 2043 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2045 (4.40% 2045 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.563% notes due 2048 (4.563% 2048 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% notes due 2050 (3.375% 2050 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.663% notes due 2051 (4.663% 2051 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00% notes due 2052 (3.00% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20% notes due 2052 (4.20% 2052 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.77% notes due 2053 (2.77% 2053 Notes)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40% notes due 2062 (4.40% 2062 Notes)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes due 2097</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized bond discounts, premiums and issuance costs, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,309 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,705 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.0041 700000000 733000000 767000000 0.0225 750000000 750000000 0.03625 1400000000 1400000000 0.0190 500000000 500000000 0.03125 1000000000 1000000000 0.0200 750000000 786000000 853000000 0.0260 1250000000 1250000000 0.0550 475000000 579000000 643000000 0.0220 1750000000 1750000000 0.0320 1000000000 1000000000 0.0165 1250000000 1250000000 0.0300 750000000 0 0.0400 700000000 853000000 947000000 0.0245 1250000000 1250000000 0.0230 1250000000 1250000000 0.0200 1250000000 1250000000 0.0335 1000000000 0.06375 478000000 478000000 0.0690 254000000 254000000 0.0640 333000000 333000000 0.0315 2000000000 2000000000 0.0575 373000000 373000000 0.0280 1150000000 1150000000 0.0495 600000000 600000000 0.0515 729000000 729000000 0.0565 415000000 415000000 0.05375 185000000 185000000 0.0440 2250000000 2250000000 0.04563 1415000000 1415000000 0.03375 2250000000 2250000000 0.04663 3541000000 3541000000 0.0300 1350000000 1350000000 0.0420 1000000000 0 0.0277 940000000 940000000 0.0440 1250000000 0 100000000 100000000 1245000000 1213000000 -210000000 284000000 13000000 15000000 36522000000 33309000000 817000000 87000000 35705000000 33222000000 0.04563 0.04663 0.0277 0.063 0.056 0.052 4000000000 750000000 0.0300 1000000000 0.0335 1000000000 0.0420 1250000000 0.0440 0.0300 1.01 1.01 1.01 1.01 P2M P6M Stockholders’ equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchase program</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, the Company entered into ASR agreements with three third-party financial institutions (Dealers). Under the ASR agreements, the Company made payments in an aggregate amount of $6.0 billion on February 25, 2022, to the Dealers and received and retired an initial 23.3 million shares of the Company’s common stock from the Dealers. The payments were recorded as reductions to shareholders’ equity, consisting of a $5.1 billion increase to accumulated deficit, which reflects the value of the initial shares received, and a $0.9 billion decrease in additional paid-in capital, which reflects the value of the stock that remains to be delivered by the Dealers pending final settlement. The final number of shares to be repurchased by the Company will be based on the daily volume-weighted average stock price of the Company’s common stock during the terms of the ASR agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. At settlement, under certain circumstances, one or more of the Dealers may be required to deliver additional shares of common stock to the Company, or under certain circumstances, the Company may be required to deliver shares of common stock or to make a cash payment, at its election, to a Dealer. The final settlement under the ASR agreements is scheduled to occur in the third quarter of 2022, subject to an earlier termination under certain limited circumstances, as set forth in the ASR agreements. In total, we repurchased 24.6 million shares of common stock in the first quarter of 2022, including shares received under the ASR agreements. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, $4.6 billion of authorization remained available under our stock repurchase program.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 and December 2021, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which were paid in June 2022 and March 2022, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Board of Directors declared a quarterly cash dividend of $1.94 per share, which will be paid on September 8, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(895)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.220%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity under our stock repurchase program, on a trade date basis, was as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 24600000 5410000000 3700000 865000000 0 0 6500000 1592000000 24600000 5410000000 10200000 2457000000 3 6000000000 23300000 5100000000 900000000 24600000 4600000000 1.94 1.94 1.94 1.94 1.94 1.94 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of AOCI were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign<br/>currency<br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow<br/>hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-sale<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AOCI</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(895)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments to income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> -844000000 61000000 0 -13000000 -796000000 -51000000 -51000000 56000000 0 0 56000000 51000000 0 51000000 0 -23000000 0 -23000000 -895000000 145000000 0 -13000000 -763000000 -65000000 -65000000 67000000 0 0 67000000 132000000 0 132000000 0 -43000000 0 -43000000 -960000000 301000000 0 -13000000 -672000000 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.220%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Components of AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Statements of Income locations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contract gains (losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contract losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 53000000 -18000000 -185000000 46000000 -132000000 28000000 -28000000 6000000 -104000000 22000000 80000000 -19000000 -263000000 -86000000 -183000000 -105000000 -39000000 -22000000 -144000000 -83000000 Fair value measurement<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:</span></div><div style="margin-bottom:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:6.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in<br/>active markets for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of June 30, 2022, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,774 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in<br/>active markets for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of December 31, 2021, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest-bearing and equity securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our U.S. Treasury securities, money market mutual funds and equity investments in publicly traded securities are based on quoted market prices in active markets, with no valuation adjustment. The fair value of equity securities without readily determinable fair values are initially valued at the transaction price and subsequently valued based on a combination of market performance and publicly available market information for similar companies that have actively traded equity securities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our foreign currency forward derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&amp;P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&amp;P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 12, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&amp;P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 12, Derivative instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration obligations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&amp;D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, our contingent consideration obligations are primarily the result of our acquisition of Teneobio in October 2021, which obligates us to pay the former shareholders up to $1.6 billion upon achieving separate development and regulatory milestones with regard to various R&amp;D programs. See Note 2, Acquisitions and divestitures.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of the fair values of other financial instruments</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair values of our borrowings by using Level 2 inputs. As of June 30, 2022 and December 31, 2021, the aggregate fair values of our borrowings were $34.4 billion and $37.9 billion, respectively, and the carrying values were $36.5 billion and $33.3 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in BeiGene, Ltd.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of our investment in BeiGene by using Level 1 inputs. As of June 30, 2022 and December 31, 2021, the fair values were $3.1 billion and $5.1 billion, and the carrying values were $2.5 billion and $2.8 billion, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022 and 2021, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis, except with respect to the impairment of net assets in connection with the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures.</span></div> <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in<br/>active markets for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of June 30, 2022, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,433 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,774 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,347 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in<br/>active markets for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>other observable<br/>inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement as of December 31, 2021, using:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term interest-bearing securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 0 0 0 1980000000 0 0 1980000000 4433000000 0 0 4433000000 0 0 0 0 361000000 0 131000000 492000000 0 413000000 0 413000000 0 29000000 0 29000000 0 0 0 0 6774000000 442000000 131000000 7347000000 0 30000000 0 30000000 0 503000000 0 503000000 0 591000000 0 591000000 0 0 310000000 310000000 0 1124000000 310000000 1434000000 47000000 0 0 47000000 1400000000 0 0 1400000000 5856000000 0 0 5856000000 0 1000000 0 1000000 611000000 0 220000000 831000000 0 183000000 0 183000000 0 66000000 0 66000000 0 16000000 0 16000000 7914000000 266000000 220000000 8400000000 0 39000000 0 39000000 0 339000000 0 339000000 0 156000000 0 156000000 0 0 342000000 342000000 0 534000000 342000000 876000000 P3Y <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in valuations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 330000000 39000000 342000000 33000000 1000000 2000000 3000000 3000000 -19000000 11000000 -29000000 18000000 310000000 48000000 310000000 48000000 1600000000 1600000000 34400000000 37900000000 36500000000 33300000000 3100000000 5100000000 2500000000 2800000000 Derivative instruments<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative- trading purposes.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are partially offset by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales are being hedged than in successive periods.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.6 billion and $5.7 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other (expense) income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">£</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">£</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the Condensed Consolidated Balance Sheets </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the six months ended June 30, 2022, and amounts expected to be recognized during the subsequent 12 months are not material.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of both June 30, 2022 and December 31, 2021, we had interest rate swap contracts with aggregate notional amounts of $6.7 billion that hedge certain portions of our long-term debt issuances. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $399 million and $440 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $299 million and $340 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of hedging transactions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships—interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships—interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of June 30, 2022, we expected to reclassify $179 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives not designated as hedges</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of June 30, 2022 and December 31, 2021, the total notional amounts of these foreign currency forward contracts were $550 million and $680 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and six months ended June 30, 2022 and 2021. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative contracts that were in liability positions as of June 30, 2022, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.</span></div> 5600000000 5700000000 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts and interest rates of our cross-currency swaps as of June 30, 2022, were as follows (notional amounts in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. dollars</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedged notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rates</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41% 2023 Swiss franc Bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHF</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00% 2026 euro Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% 2026 pound sterling Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">£</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00% 2029 pound sterling Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">£</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 700000000 0.004 704000000 0.034 750000000 0.020 833000000 0.039 475000000 0.055 747000000 0.060 700000000 0.040 1111000000 0.045 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrealized gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 252000000 -46000000 330000000 137000000 -185000000 15000000 -207000000 -60000000 67000000 -31000000 123000000 77000000 6700000000 6700000000 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying amounts of hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets locations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">____________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Current portion of long-term debt includes $82 million and $85 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $399 million and $440 million of carrying value with discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Current portion of long-term debt includes $82 million and $85 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively. Long-term debt includes $299 million and $340 million of hedging adjustments on discontinued hedging relationships as of June 30, 2022 and December 31, 2021, respectively.</span></div> 82000000 85000000 82000000 85000000 6241000000 6729000000 -292000000 199000000 82000000 85000000 399000000 440000000 82000000 85000000 299000000 340000000 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on fair value hedging relationships—interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.121%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest expense, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The effects of cash flow and fair value hedging:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on cash flow hedging relationships reclassified out of AOCI:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on fair value hedging relationships—interest rate swap agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">__________</span></div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Gains on hedged items do not exactly offset losses on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.</span></div> 6281000000 -317000000 328000000 12012000000 -847000000 623000000 53000000 80000000 -185000000 -263000000 157000000 494000000 -135000000 -450000000 6114000000 11000000 281000000 11706000000 24000000 566000000 -18000000 -19000000 46000000 -86000000 -34000000 141000000 55000000 -97000000 179000000 550000000 680000000 <div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated<br/>Balance Sheets locations</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets/ Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities/ Other noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedging instruments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 413000000 30000000 29000000 503000000 0 591000000 442000000 1124000000 183000000 39000000 66000000 339000000 16000000 156000000 265000000 534000000 Contingencies and commitments<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2021, Part I, Item 1A. Risk Factors—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be affected by litigation and government investigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 19, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2022, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. Although it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain recent developments concerning our legal proceedings and other matters are discussed below:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otezla ANDA Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Apotex Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 14, 2022, Amgen filed a lawsuit in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Apotex Inc. (Apotex) for infringement of U.S. Patent Nos. 7,427,638, 9,872,854 and 10,092,541, which are listed in the Orange Book for Otezla. This lawsuit was based on Apotex’s submission of an ANDA seeking FDA approval to market a generic version of Otezla and seeks an order of the New Jersey District Court making any FDA approval of Apotex’s ANDA effective no earlier than the expiration of the applicable patents.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repatha Patent Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Disputes in the International Region</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, Sanofi Biotechnology SAS filed an action against Amgen GmbH and Amgen (Europe) B.V. before the Regional Court of Dusseldorf alleging that the marketing and sale of Repatha infringes European Patent No. 2,756,004 (the EP’004 Patent), seeking infringement damages and injunctive relief. The EP’004 Patent is currently in opposition proceedings, initiated by Amgen and an anonymous third party, before the European Patent Office (EPO). A hearing before the Opposition Division of the EPO was held on June 8 and 9, 2022, and the Opposition Division upheld the validity of the claims at issue with narrowing amendments. The parties are awaiting the Opposition Division’s written opinion. Amgen filed a Notice of Appeal on July 6, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sensipar Antitrust Class Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2022, the parties filed motions asking permission to seek interlocutory appeal of the U.S. District Court for the District of Delaware’s (the Delaware District Court’s) March 11, 2022 order denying Amgen’s Motion to Dismiss solely with respect to the reverse payment claim and the various state law claims. The plaintiffs did not oppose Amgen’s motion and instead argued all issues should be appealed at this time. Amgen filed its opposition to plaintiffs’ motion on June 10, 2022, and reply briefs were filed on June 24, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HUMIRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Biosimilar Antitrust Actions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the U.S. Court of Appeals for the Seventh Circuit issued an opinion affirming the June 30, 2020 dismissal with prejudice by the U.S. District Court for the Northern District of Illinois of a consolidated complaint against Amgen along with AbbVie Inc., AbbVie Biotechnology Ltd., Samsung Bioepis Co. and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandoz Inc.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. Antitrust Action</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, Regeneron Pharmaceuticals, Inc. (Regeneron) filed suit against Amgen in the Delaware District Court for federal and state antitrust and unfair competition violations and tortious interference with prospective business relations. Regeneron alleges that Amgen’s sales contracting practices for Repatha, ENBREL and Otezla with key insurers, third-party payors and PBMs have harmed the sales of its product PRALUENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and focuses on two primary arguments: that Amgen improperly bundled sales of Repatha with ENBREL, Otezla and potentially other products and sought exclusive or de facto exclusive formulary positioning for Repatha. Amgen’s initial responsive pleading was filed on August 1, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Litigation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. &amp; Subsidiaries v. Commissioner of Internal Revenue</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, Income taxes, for discussion of the IRS tax dispute and the Company’s petition in the U.S. Tax Court.</span></div> 2 EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 81 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 485 261 1 false 109 0 false 10 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.amgen.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Statements of Income Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome Condensed Consolidated Statements of Income Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.amgen.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 1007008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101101 - Disclosure - Summary of significant accounting policies Sheet http://www.amgen.com/role/Summaryofsignificantaccountingpolicies Summary of significant accounting policies Notes 9 false false R10.htm 2104102 - Disclosure - Acquisitions Sheet http://www.amgen.com/role/Acquisitions Acquisitions Notes 10 false false R11.htm 2108103 - Disclosure - Revenues Sheet http://www.amgen.com/role/Revenues Revenues Notes 11 false false R12.htm 2111104 - Disclosure - Income taxes Sheet http://www.amgen.com/role/Incometaxes Income taxes Notes 12 false false R13.htm 2113105 - Disclosure - Earnings per share Sheet http://www.amgen.com/role/Earningspershare Earnings per share Notes 13 false false R14.htm 2116106 - Disclosure - Investments Sheet http://www.amgen.com/role/Investments Investments Notes 14 false false R15.htm 2126107 - Disclosure - Inventories Sheet http://www.amgen.com/role/Inventories Inventories Notes 15 false false R16.htm 2129108 - Disclosure - Goodwill and other intangible assets Sheet http://www.amgen.com/role/Goodwillandotherintangibleassets Goodwill and other intangible assets Notes 16 false false R17.htm 2134109 - Disclosure - Financing arrangements Sheet http://www.amgen.com/role/Financingarrangements Financing arrangements Notes 17 false false R18.htm 2138110 - Disclosure - Stockholders' equity Sheet http://www.amgen.com/role/Stockholdersequity Stockholders' equity Notes 18 false false R19.htm 2144111 - Disclosure - Fair value measurement Sheet http://www.amgen.com/role/Fairvaluemeasurement Fair value measurement Notes 19 false false R20.htm 2149112 - Disclosure - Derivative instruments Sheet http://www.amgen.com/role/Derivativeinstruments Derivative instruments Notes 20 false false R21.htm 2157113 - Disclosure - Contingencies and commitments Sheet http://www.amgen.com/role/Contingenciesandcommitments Contingencies and commitments Notes 21 false false R22.htm 2202201 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies Summary of significant accounting policies (Policies) Policies 22 false false R23.htm 2305301 - Disclosure - Acquisitions (Tables) Sheet http://www.amgen.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.amgen.com/role/Acquisitions 23 false false R24.htm 2309302 - Disclosure - Revenues (Tables) Sheet http://www.amgen.com/role/RevenuesTables Revenues (Tables) Tables http://www.amgen.com/role/Revenues 24 false false R25.htm 2314303 - Disclosure - Earnings per share (Tables) Sheet http://www.amgen.com/role/EarningspershareTables Earnings per share (Tables) Tables http://www.amgen.com/role/Earningspershare 25 false false R26.htm 2317304 - Disclosure - Investments (Tables) Sheet http://www.amgen.com/role/InvestmentsTables Investments (Tables) Tables http://www.amgen.com/role/Investments 26 false false R27.htm 2327305 - Disclosure - Inventories (Tables) Sheet http://www.amgen.com/role/InventoriesTables Inventories (Tables) Tables http://www.amgen.com/role/Inventories 27 false false R28.htm 2330306 - Disclosure - Goodwill and other intangible assets (Tables) Sheet http://www.amgen.com/role/GoodwillandotherintangibleassetsTables Goodwill and other intangible assets (Tables) Tables http://www.amgen.com/role/Goodwillandotherintangibleassets 28 false false R29.htm 2335307 - Disclosure - Financing arrangements (Tables) Sheet http://www.amgen.com/role/FinancingarrangementsTables Financing arrangements (Tables) Tables http://www.amgen.com/role/Financingarrangements 29 false false R30.htm 2339308 - Disclosure - Stockholders' equity (Tables) Sheet http://www.amgen.com/role/StockholdersequityTables Stockholders' equity (Tables) Tables http://www.amgen.com/role/Stockholdersequity 30 false false R31.htm 2345309 - Disclosure - Fair value measurement (Tables) Sheet http://www.amgen.com/role/FairvaluemeasurementTables Fair value measurement (Tables) Tables http://www.amgen.com/role/Fairvaluemeasurement 31 false false R32.htm 2350310 - Disclosure - Derivative instruments (Tables) Sheet http://www.amgen.com/role/DerivativeinstrumentsTables Derivative instruments (Tables) Tables http://www.amgen.com/role/Derivativeinstruments 32 false false R33.htm 2403401 - Disclosure - Summary of significant accounting policies (Details) Sheet http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails Summary of significant accounting policies (Details) Details http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies 33 false false R34.htm 2406402 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details) Sheet http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails Acquisitions - Aggregate Consideration Paid (Details) Details 34 false false R35.htm 2407403 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.amgen.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 35 false false R36.htm 2410404 - Disclosure - Revenues (Details) Sheet http://www.amgen.com/role/RevenuesDetails Revenues (Details) Details http://www.amgen.com/role/RevenuesTables 36 false false R37.htm 2412405 - Disclosure - Income taxes (Details) Sheet http://www.amgen.com/role/IncometaxesDetails Income taxes (Details) Details http://www.amgen.com/role/Incometaxes 37 false false R38.htm 2415406 - Disclosure - Earnings per share (Details) Sheet http://www.amgen.com/role/EarningspershareDetails Earnings per share (Details) Details http://www.amgen.com/role/EarningspershareTables 38 false false R39.htm 2418407 - Disclosure - Investments (Details) Sheet http://www.amgen.com/role/InvestmentsDetails Investments (Details) Details http://www.amgen.com/role/InvestmentsTables 39 false false R40.htm 2419408 - Disclosure - Investments (Fair Values by Classification) (Details) Sheet http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails Investments (Fair Values by Classification) (Details) Details http://www.amgen.com/role/InvestmentsTables 40 false false R41.htm 2420409 - Disclosure - Investments (Available-for-sale Investments) (Details Textual) Sheet http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual Investments (Available-for-sale Investments) (Details Textual) Details http://www.amgen.com/role/InvestmentsTables 41 false false R42.htm 2421410 - Disclosure - Investments (Fair Values by Contractual Maturity) (Details) Sheet http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails Investments (Fair Values by Contractual Maturity) (Details) Details http://www.amgen.com/role/InvestmentsTables 42 false false R43.htm 2422411 - Disclosure - Investments (Equity Securities) (Details Textual) Sheet http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual Investments (Equity Securities) (Details Textual) Details http://www.amgen.com/role/InvestmentsTables 43 false false R44.htm 2423412 - Disclosure - Investments (BeiGene) (Details) Sheet http://www.amgen.com/role/InvestmentsBeiGeneDetails Investments (BeiGene) (Details) Details http://www.amgen.com/role/InvestmentsTables 44 false false R45.htm 2424413 - Disclosure - Investments (Neumora Therapeutics, Inc.) (Details) Sheet http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails Investments (Neumora Therapeutics, Inc.) (Details) Details http://www.amgen.com/role/InvestmentsTables 45 false false R46.htm 2425414 - Disclosure - Investments Investments (Limited Partnership Investments) (Details) Sheet http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails Investments Investments (Limited Partnership Investments) (Details) Details 46 false false R47.htm 2428415 - Disclosure - Inventories (Details) Sheet http://www.amgen.com/role/InventoriesDetails Inventories (Details) Details http://www.amgen.com/role/InventoriesTables 47 false false R48.htm 2431416 - Disclosure - Goodwill and other intangible assets (Goodwill Roll Forward) (Details) Sheet http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails Goodwill and other intangible assets (Goodwill Roll Forward) (Details) Details http://www.amgen.com/role/GoodwillandotherintangibleassetsTables 48 false false R49.htm 2432417 - Disclosure - Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) Sheet http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) Details http://www.amgen.com/role/GoodwillandotherintangibleassetsTables 49 false false R50.htm 2433418 - Disclosure - Goodwill and other intangible assets (Details Textual) Sheet http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual Goodwill and other intangible assets (Details Textual) Details http://www.amgen.com/role/GoodwillandotherintangibleassetsTables 50 false false R51.htm 2436419 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) Sheet http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) Details http://www.amgen.com/role/FinancingarrangementsTables 51 false false R52.htm 2437420 - Disclosure - Financing arrangements (Details Textual) Sheet http://www.amgen.com/role/FinancingarrangementsDetailsTextual Financing arrangements (Details Textual) Details http://www.amgen.com/role/FinancingarrangementsTables 52 false false R53.htm 2440421 - Disclosure - Stockholders' equity (Share Repurchase Program) (Details) Sheet http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails Stockholders' equity (Share Repurchase Program) (Details) Details http://www.amgen.com/role/StockholdersequityTables 53 false false R54.htm 2441422 - Disclosure - Stockholders' equity (Details Textual) (Details) Sheet http://www.amgen.com/role/StockholdersequityDetailsTextualDetails Stockholders' equity (Details Textual) (Details) Details http://www.amgen.com/role/StockholdersequityTables 54 false false R55.htm 2442423 - Disclosure - Stockholders' equity (Components of AOCI) (Details) Sheet http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails Stockholders' equity (Components of AOCI) (Details) Details http://www.amgen.com/role/StockholdersequityTables 55 false false R56.htm 2443424 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details) Sheet http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails Stockholders' equity (Reclassifications out of AOCI) (Details) Details http://www.amgen.com/role/StockholdersequityTables 56 false false R57.htm 2446425 - Disclosure - Fair value measurement (Details) Sheet http://www.amgen.com/role/FairvaluemeasurementDetails Fair value measurement (Details) Details http://www.amgen.com/role/FairvaluemeasurementTables 57 false false R58.htm 2447426 - Disclosure - Fair value measurement (Details Textual) Sheet http://www.amgen.com/role/FairvaluemeasurementDetailsTextual Fair value measurement (Details Textual) Details http://www.amgen.com/role/FairvaluemeasurementTables 58 false false R59.htm 2448427 - Disclosure - Fair value measurement (Contingent Consideration Obligations) (Details) Sheet http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails Fair value measurement (Contingent Consideration Obligations) (Details) Details http://www.amgen.com/role/FairvaluemeasurementTables 59 false false R60.htm 2451428 - Disclosure - Derivative instruments (Details Textual) Sheet http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual Derivative instruments (Details Textual) Details http://www.amgen.com/role/DerivativeinstrumentsTables 60 false false R61.htm 2452429 - Disclosure - Derivative instruments (Cross-currency Swaps) (Details) Sheet http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails Derivative instruments (Cross-currency Swaps) (Details) Details http://www.amgen.com/role/DerivativeinstrumentsTables 61 false false R62.htm 2453430 - Disclosure - Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) Sheet http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) Details http://www.amgen.com/role/DerivativeinstrumentsTables 62 false false R63.htm 2454431 - Disclosure - Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) Sheet http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) Details http://www.amgen.com/role/DerivativeinstrumentsTables 63 false false R64.htm 2455432 - Disclosure - Derivative instruments (Summary of Income and Expense Line Items) (Details) Sheet http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails Derivative instruments (Summary of Income and Expense Line Items) (Details) Details http://www.amgen.com/role/DerivativeinstrumentsTables 64 false false R65.htm 2456433 - Disclosure - Derivative instruments (Fair Value of Derivatives) (Details) Sheet http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails Derivative instruments (Fair Value of Derivatives) (Details) Details http://www.amgen.com/role/DerivativeinstrumentsTables 65 false false R66.htm 2458434 - Disclosure - Contingencies and commitments (Details) Sheet http://www.amgen.com/role/ContingenciesandcommitmentsDetails Contingencies and commitments (Details) Details http://www.amgen.com/role/Contingenciesandcommitments 66 false false All Reports Book All Reports amgn-20220630.htm amgn-20220630.xsd amgn-20220630_cal.xml amgn-20220630_def.xml amgn-20220630_lab.xml amgn-20220630_pre.xml amgn-ex31_2022630xq2.htm amgn-ex32_2022630xq2.htm exhibit1041-firstamendment.htm exhibit1046-collaborationa.htm exhibit1047-amendmentno1to.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "amgn-20220630.htm": { "axisCustom": 1, "axisStandard": 27, "contextCount": 485, "dts": { "calculationLink": { "local": [ "amgn-20220630_cal.xml" ] }, "definitionLink": { "local": [ "amgn-20220630_def.xml" ] }, "inline": { "local": [ "amgn-20220630.htm" ] }, "labelLink": { "local": [ "amgn-20220630_lab.xml" ] }, "presentationLink": { "local": [ "amgn-20220630_pre.xml" ] }, "schema": { "local": [ "amgn-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd" ] } }, "elementCount": 584, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 29, "keyStandard": 232, "memberCustom": 64, "memberStandard": 44, "nsprefix": "amgn", "nsuri": "http://www.amgen.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.amgen.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Acquisitions", "role": "http://www.amgen.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Revenues", "role": "http://www.amgen.com/role/Revenues", "shortName": "Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - Income taxes", "role": "http://www.amgen.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113105 - Disclosure - Earnings per share", "role": "http://www.amgen.com/role/Earningspershare", "shortName": "Earnings per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116106 - Disclosure - Investments", "role": "http://www.amgen.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126107 - Disclosure - Inventories", "role": "http://www.amgen.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129108 - Disclosure - Goodwill and other intangible assets", "role": "http://www.amgen.com/role/Goodwillandotherintangibleassets", "shortName": "Goodwill and other intangible assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i0b11bbbd5a1e4d90bb56e173356aa919_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134109 - Disclosure - Financing arrangements", "role": "http://www.amgen.com/role/Financingarrangements", "shortName": "Financing arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138110 - Disclosure - Stockholders' equity", "role": "http://www.amgen.com/role/Stockholdersequity", "shortName": "Stockholders' equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144111 - Disclosure - Fair value measurement", "role": "http://www.amgen.com/role/Fairvaluemeasurement", "shortName": "Fair value measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149112 - Disclosure - Derivative instruments", "role": "http://www.amgen.com/role/Derivativeinstruments", "shortName": "Derivative instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157113 - Disclosure - Contingencies and commitments", "role": "http://www.amgen.com/role/Contingenciesandcommitments", "shortName": "Contingencies and commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of significant accounting policies (Policies)", "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Acquisitions (Tables)", "role": "http://www.amgen.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Revenues (Tables)", "role": "http://www.amgen.com/role/RevenuesTables", "shortName": "Revenues (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Earnings per share (Tables)", "role": "http://www.amgen.com/role/EarningspershareTables", "shortName": "Earnings per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317304 - Disclosure - Investments (Tables)", "role": "http://www.amgen.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327305 - Disclosure - Inventories (Tables)", "role": "http://www.amgen.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330306 - Disclosure - Goodwill and other intangible assets (Tables)", "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables", "shortName": "Goodwill and other intangible assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335307 - Disclosure - Financing arrangements (Tables)", "role": "http://www.amgen.com/role/FinancingarrangementsTables", "shortName": "Financing arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Statements of Income", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "shortName": "Condensed Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:StockRepurchaseProgramTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2339308 - Disclosure - Stockholders' equity (Tables)", "role": "http://www.amgen.com/role/StockholdersequityTables", "shortName": "Stockholders' equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:StockRepurchaseProgramTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345309 - Disclosure - Fair value measurement (Tables)", "role": "http://www.amgen.com/role/FairvaluemeasurementTables", "shortName": "Fair value measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350310 - Disclosure - Derivative instruments (Tables)", "role": "http://www.amgen.com/role/DerivativeinstrumentsTables", "shortName": "Derivative instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Summary of significant accounting policies (Details)", "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails", "shortName": "Summary of significant accounting policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-8", "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Acquisitions - Aggregate Consideration Paid (Details)", "role": "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "shortName": "Acquisitions - Aggregate Consideration Paid (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i46b0c7abfa194277afc81cba3b24f8a3_D20220101-20220630", "decimals": "-6", "lang": "en-US", "name": "amgn:Businessassetacquisitionconsiderationtransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Acquisitions - Narrative (Details)", "role": "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i1b8b7a38d735412895755cb950726b35_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Revenues (Details)", "role": "http://www.amgen.com/role/RevenuesDetails", "shortName": "Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "ic3c63f65b70944d59e9ddddf1020dbf9_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Income taxes (Details)", "role": "http://www.amgen.com/role/IncometaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Earnings per share (Details)", "role": "http://www.amgen.com/role/EarningspershareDetails", "shortName": "Earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418407 - Disclosure - Investments (Details)", "role": "http://www.amgen.com/role/InvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419408 - Disclosure - Investments (Fair Values by Classification) (Details)", "role": "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails", "shortName": "Investments (Fair Values by Classification) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "ic3ee9095509a4235b125b11b137e139e_I20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - Investments (Available-for-sale Investments) (Details Textual)", "role": "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual", "shortName": "Investments (Available-for-sale Investments) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421410 - Disclosure - Investments (Fair Values by Contractual Maturity) (Details)", "role": "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails", "shortName": "Investments (Fair Values by Contractual Maturity) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Investments (Equity Securities) (Details Textual)", "role": "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual", "shortName": "Investments (Equity Securities) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Investments (BeiGene) (Details)", "role": "http://www.amgen.com/role/InvestmentsBeiGeneDetails", "shortName": "Investments (BeiGene) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "ic408702ec02a49bf91a6056997008286_I20211231", "decimals": "3", "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i5cda008dddc94401b22d3259266fc7e7_I20210930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Investments (Neumora Therapeutics, Inc.) (Details)", "role": "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails", "shortName": "Investments (Neumora Therapeutics, Inc.) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i5cda008dddc94401b22d3259266fc7e7_I20210930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i1fe68111c13942ef9c7a0d951601d88b_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425414 - Disclosure - Investments Investments (Limited Partnership Investments) (Details)", "role": "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails", "shortName": "Investments Investments (Limited Partnership Investments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "ib8b0ba79e4914ce8815964b9387a76dd_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AlternativeInvestment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428415 - Disclosure - Inventories (Details)", "role": "http://www.amgen.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "ifabadb04095d4b18b4e3ed38fe9a3a35_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431416 - Disclosure - Goodwill and other intangible assets (Goodwill Roll Forward) (Details)", "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails", "shortName": "Goodwill and other intangible assets (Goodwill Roll Forward) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amgn:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - Goodwill and other intangible assets (Identifiable Intangible Assets) (Details)", "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails", "shortName": "Goodwill and other intangible assets (Identifiable Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amgn:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433418 - Disclosure - Goodwill and other intangible assets (Details Textual)", "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual", "shortName": "Goodwill and other intangible assets (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436419 - Disclosure - Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)", "role": "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails", "shortName": "Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "iecb3cb0076694222ab5165cf391eb7d3_I20220331", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437420 - Disclosure - Financing arrangements (Details Textual)", "role": "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "shortName": "Financing arrangements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "idebc81edd93d4d2f8a2a03384eb93dbe_I20220630", "decimals": "3", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amgn:StockRepurchaseProgramTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440421 - Disclosure - Stockholders' equity (Share Repurchase Program) (Details)", "role": "http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails", "shortName": "Stockholders' equity (Share Repurchase Program) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amgn:StockRepurchaseProgramTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441422 - Disclosure - Stockholders' equity (Details Textual) (Details)", "role": "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails", "shortName": "Stockholders' equity (Details Textual) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockDividendsPerShareDeclared", "us-gaap:CommonStockDividendsPerShareCashPaid", "us-gaap:CommonStockDividendsPerShareDeclared", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i52e8d46fd29746e58d0e0bb604659f08_D20220601-20220630", "decimals": "2", "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i8de403afe8684433ba669a9d329718c4_I20220331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - Stockholders' equity (Components of AOCI) (Details)", "role": "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails", "shortName": "Stockholders' equity (Components of AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i933f3aa296ae418cb60f3b9a2da33c77_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443424 - Disclosure - Stockholders' equity (Reclassifications out of AOCI) (Details)", "role": "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails", "shortName": "Stockholders' equity (Reclassifications out of AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "idd26454e121845348d3b36a5d5d0b4be_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446425 - Disclosure - Fair value measurement (Details)", "role": "http://www.amgen.com/role/FairvaluemeasurementDetails", "shortName": "Fair value measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447426 - Disclosure - Fair value measurement (Details Textual)", "role": "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual", "shortName": "Fair value measurement (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i8de403afe8684433ba669a9d329718c4_I20220331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448427 - Disclosure - Fair value measurement (Contingent Consideration Obligations) (Details)", "role": "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails", "shortName": "Fair value measurement (Contingent Consideration Obligations) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "amgn:BusinessCombinationContingentConsiderationArrangementsPayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i87a50000054d41c4b6c8d975b42b1648_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "ifaa3e87d3e094c2c82065bdcc86a2d5e_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451428 - Disclosure - Derivative instruments (Details Textual)", "role": "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "shortName": "Derivative instruments (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i8362dfe3f447487fbcfb592560763e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452429 - Disclosure - Derivative instruments (Cross-currency Swaps) (Details)", "role": "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "shortName": "Derivative instruments (Cross-currency Swaps) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i8362dfe3f447487fbcfb592560763e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i0ecd36ab401a4e70a51c743fc9ccdc8d_D20220401-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453430 - Disclosure - Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details)", "role": "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "shortName": "Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i0ecd36ab401a4e70a51c743fc9ccdc8d_D20220401-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i9027275ed49d4865b0705c7a15256e40_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454431 - Disclosure - Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details)", "role": "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails", "shortName": "Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i17d41c6ab5c14f9380e71043309fbdc8_I20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "icfccad47999d4f4a8b349b1ab673c57b_D20220401-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455432 - Disclosure - Derivative instruments (Summary of Income and Expense Line Items) (Details)", "role": "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "shortName": "Derivative instruments (Summary of Income and Expense Line Items) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i71fb031f34f648488a945f9c0e957284_D20220401-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "iddf4e6ee507f42da9c63527f4cd46ce6_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456433 - Disclosure - Derivative instruments (Fair Value of Derivatives) (Details)", "role": "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "shortName": "Derivative instruments (Fair Value of Derivatives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "iddf4e6ee507f42da9c63527f4cd46ce6_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i3468cc5757b34eb384cc512b95a07626_D20220527-20220527", "decimals": "INF", "first": true, "lang": "en-US", "name": "amgn:LitigationSettlementNumberOfPrimaryArguments", "reportCount": 1, "unique": true, "unitRef": "argument", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458434 - Disclosure - Contingencies and commitments (Details)", "role": "http://www.amgen.com/role/ContingenciesandcommitmentsDetails", "shortName": "Contingencies and commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i3468cc5757b34eb384cc512b95a07626_D20220527-20220527", "decimals": "INF", "first": true, "lang": "en-US", "name": "amgn:LitigationSettlementNumberOfPrimaryArguments", "reportCount": 1, "unique": true, "unitRef": "argument", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockDividendsPerShareCashPaid", "us-gaap:CommonStockDividendsPerShareDeclared", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i264013b24e074db8b98a0699c239c4f9_D20220301-20220331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Summary of significant accounting policies", "role": "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "amgn-20220630.htm", "contextRef": "i399851cc44354bd288c22867c4af295c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 109, "tag": { "amgn_A2.00SeniorNotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.00% Senior Notes Due 2026 [Member]", "label": "2.00% Senior Notes Due 2026 [Member]", "terseLabel": "2.00% Senior Notes Due 2026 [Member]" } } }, "localname": "A2.00SeniorNotesDue2026Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "amgn_A3002029NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.00% 2029 Notes", "label": "3.00% 2029 Notes [Member]", "terseLabel": "3.00% 2029 Notes [Member]" } } }, "localname": "A3002029NotesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_A300NotesDue20523002052NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.00% notes due 2052 (3.00% 2052 Notes)", "label": "3.00% notes due 2052 (3.00% 2052 Notes) [Member]", "terseLabel": "3.00% notes due 2052 (3.00% 2052 Notes)" } } }, "localname": "A300NotesDue20523002052NotesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_A3352032NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.35% 2032 Notes", "label": "3.35% 2032 Notes [Member]", "terseLabel": "3.35% 2032 Notes [Member]" } } }, "localname": "A3352032NotesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_A4202052NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.20% 2052 Notes", "label": "4.20% 2052 Notes [Member]", "terseLabel": "4.20% 2052 Notes [Member]" } } }, "localname": "A4202052NotesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_A4402062NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.40% 2062 Notes", "label": "4.40% 2062 Notes [Member]", "terseLabel": "4.40% 2062 Notes [Member]" } } }, "localname": "A4402062NotesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_AMG340Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AMG 340", "label": "AMG 340 [Member]", "terseLabel": "AMG 340" } } }, "localname": "AMG340Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "amgn_AcceleratedStockRepurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated stock repurchase agreement", "label": "Accelerated stock repurchase agreement [Member]", "terseLabel": "Accelerated stock repurchase agreement" } } }, "localname": "AcceleratedStockRepurchaseAgreementMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued liabilities/other non-current liabilities.", "label": "Accrued Liabilities Other Non Current Liabilities [Member]", "verboseLabel": "Accrued liabilities/Other noncurrent liabilities [Member]" } } }, "localname": "AccruedLiabilitiesOtherNonCurrentLiabilitiesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "amgn_AccumulatedOtherAdjustmentAttributabletoParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated Other Adjustment Attributable to Parent [Member]", "label": "Accumulated Other Adjustment Attributable to Parent [Member]", "terseLabel": "Other [Member]" } } }, "localname": "AccumulatedOtherAdjustmentAttributabletoParentMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "domainItemType" }, "amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired research and development technology rights.", "label": "Acquired Research And Development Technology Rights [Member]", "terseLabel": "Research and Development Technology Rights [Member]" } } }, "localname": "AcquiredResearchAndDevelopmentTechnologyRightsMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "amgn_AlternativeInvestmentNetGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Alternative Investment, Net Gain (Loss)", "label": "Alternative Investment, Net Gain (Loss)", "terseLabel": "Net gains (losses) from limited partnership investments" } } }, "localname": "AlternativeInvestmentNetGainLoss", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "amgn_AranespMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aranesp.", "label": "Aranesp [Member]", "terseLabel": "Aranesp\u00ae (darbepoetin alfa) [Member]" } } }, "localname": "AranespMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value", "label": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value", "terseLabel": "Available-For Sale Securities, Debt Maturities, After One Through Three Years, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "amgn_AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value", "label": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value", "terseLabel": "Available-For-Sale Securities, Debt Maturities, After Three Through Five Years, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFiveYearsFairValue", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "amgn_AvailableForSalesInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for sales investments.", "label": "Available For Sales Investments [Member]", "verboseLabel": "Available-for-sale investments [Member]" } } }, "localname": "AvailableForSalesInvestmentsMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" ], "xbrltype": "domainItemType" }, "amgn_BasicAndDilutedEarningPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basic and diluted earning per share.", "label": "Basic And Diluted Earning Per Share [Abstract]", "verboseLabel": "Computation of basic and diluted earnings per share" } } }, "localname": "BasicAndDilutedEarningPerShareAbstract", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/EarningspershareDetails" ], "xbrltype": "stringItemType" }, "amgn_BasisOfPresentationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shows the basis of presentation of financial information for interim periods.", "label": "Basis Of Presentation [Policy Text Block]", "verboseLabel": "Basis of presentation" } } }, "localname": "BasisOfPresentationPolicyTextBlock", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "amgn_BeiGeneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BeiGene [Member]", "label": "BeiGene [Member]", "terseLabel": "Collaborative arrangement with BeiGene, Ltd. [Member]" } } }, "localname": "BeiGeneMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual", "http://www.amgen.com/role/InvestmentsBeiGeneDetails" ], "xbrltype": "domainItemType" }, "amgn_BusinessCombinationContingentConsiderationArrangementsPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Payments", "label": "Business Combination, Contingent Consideration Arrangements, Payments", "negatedTerseLabel": "Payments" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsPayments", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" ], "xbrltype": "monetaryItemType" }, "amgn_BusinessCombinationContingentConsiderationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration [Roll Forward]", "label": "Business Combination, Contingent Consideration [Roll Forward]", "terseLabel": "Business Combination, Contingent Consideration [Roll Forward]" } } }, "localname": "BusinessCombinationContingentConsiderationRollForward", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" ], "xbrltype": "stringItemType" }, "amgn_BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": 2.0, "parentTag": "amgn_Businessassetacquisitionconsiderationtransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions", "label": "Business Combination, Fair Value of Contingent Consideration Arrangements, Addition from Acquisitions", "terseLabel": "Contingent consideration obligation for acquisition" } } }, "localname": "BusinessCombinationFairValueofContingentConsiderationArrangementsAdditionfromAcquisitions", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": 1.0, "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)", "verboseLabel": "Other assets, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" ], "xbrltype": "monetaryItemType" }, "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net", "label": "Business acquired asset acquisition, Assets acquired and Liabilities assumed, net", "totalLabel": "Total assets acquired, net" } } }, "localname": "BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" ], "xbrltype": "monetaryItemType" }, "amgn_Businessassetacquisitionconsiderationtransferred": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business asset acquisition, consideration transferred", "label": "Business asset acquisition, consideration transferred", "totalLabel": "Business asset acquisition, consideration transferred" } } }, "localname": "Businessassetacquisitionconsiderationtransferred", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" ], "xbrltype": "monetaryItemType" }, "amgn_CorporateDebtSecuritiesFinancialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate debt securities financial Member.", "label": "Corporate Debt Securities Financial [Member]", "terseLabel": "Corporate debt securities - Financial [Member]" } } }, "localname": "CorporateDebtSecuritiesFinancialMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_CorporateDebtSecuritiesIndustrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate debt securities industrial Member.", "label": "Corporate Debt Securities Industrial [Member]", "terseLabel": "Corporate debt securities - Industrial [Member]" } } }, "localname": "CorporateDebtSecuritiesIndustrialMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_CorporateDebtSecuritiesOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate debt securities other.", "label": "Corporate Debt Securities Other [Member]", "terseLabel": "Corporate debt securities - Other [Member]" } } }, "localname": "CorporateDebtSecuritiesOtherMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_CrossCurrencySwapContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cross currency swap contracts.", "label": "Cross Currency Swap Contracts [Member]", "netLabel": "Cross-currency swap contract [Member]", "terseLabel": "Cross-currency swap contracts [Member]", "verboseLabel": "Cross-currency swap contracts [Member]" } } }, "localname": "CrossCurrencySwapContractsMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "amgn_DebtExchangeAdditionalCashConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt exchange additional cash consideration paid", "label": "Debt exchange additional cash consideration", "terseLabel": "debt exchange additional cash consideration" } } }, "localname": "DebtExchangeAdditionalCashConsideration", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "amgn_DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Redemption Period without Payment of Make Whole Amount", "label": "Debt Instrument, Redemption Period without Payment of Make Whole Amount", "terseLabel": "Debt Instrument, Redemption Period without Payment of Make Whole Amount" } } }, "localname": "DebtInstrumentRedemptionPeriodWithoutPaymentOfMakeWholeAmount", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual" ], "xbrltype": "durationItemType" }, "amgn_DerivativeAssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative assets.", "label": "Derivative Assets Fair Value Disclosure [Abstract]", "verboseLabel": "Derivatives:" } } }, "localname": "DerivativeAssetsFairValueDisclosureAbstract", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "stringItemType" }, "amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative financial instruments liabilities fair value disclosure.", "label": "Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]", "verboseLabel": "Derivatives:" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "stringItemType" }, "amgn_EnbrelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ENBREL.", "label": "ENBREL [Member]", "terseLabel": "Enbrel\u00ae (etanercept) [Member]" } } }, "localname": "EnbrelMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity", "label": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity", "terseLabel": "Equity Method Investment, Amortization of Difference Between Carrying Amount and Underlying Equity" } } }, "localname": "EquityMethodInvestmentAmortizationOfDifferenceBetweenCarryingAmountAndUnderlyingEquity", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/InvestmentsBeiGeneDetails" ], "xbrltype": "monetaryItemType" }, "amgn_EquityMethodInvestmentChangeInCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment, change in carrying value", "label": "Equity method investment, change in carrying value", "terseLabel": "Equity method investment, change in carrying value" } } }, "localname": "EquityMethodInvestmentChangeInCarryingValue", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "monetaryItemType" }, "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets.", "label": "Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets [Abstract]", "verboseLabel": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets" } } }, "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsAbstract", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" ], "xbrltype": "stringItemType" }, "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets.", "label": "Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]", "verboseLabel": "Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets" } } }, "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "amgn_FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets.", "label": "Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets [Abstract]", "verboseLabel": "Fair values of both derivatives designated as hedging instruments and not designated as hedging instruments included in Condensed Consolidated Balance Sheets" } } }, "localname": "FairValuesOfBothDerivativesDesignatedAsHedgingInstrumentsAndNotDesignatedAsHedgingInstrumentsIncludedInCondensedConsolidatedBalanceSheetsAbstract", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "stringItemType" }, "amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]", "label": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]", "terseLabel": "5.50% \u00a3475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]", "verboseLabel": "5.50% 2026 pound sterling Notes [Member]" } } }, "localname": "FivePointFiveZeroPercentPoundSterlingNotesDue2026Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FivePointOneFivePercentNotesDue2041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point One Five Percent Notes Due 2041 [Member]", "label": "Five Point One Five Percent Notes Due 2041 [Member]", "terseLabel": "5.15% notes due 2041 (5.15% 2041 Notes) [Member]" } } }, "localname": "FivePointOneFivePercentNotesDue2041Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FivePointSevenFivePercentNotesDue2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point Seven Five Percent Notes Due 2040 [Member]", "label": "Five Point Seven Five Percent Notes Due 2040 [Member]", "terseLabel": "5.75% notes due 2040 (5.75% 2040 Notes) [Member]" } } }, "localname": "FivePointSevenFivePercentNotesDue2040Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FivePointSixFivePercentNotesDue2042Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point Six Five Percent Notes Due 2042 [Member]", "label": "Five Point Six Five Percent Notes Due 2042 [Member]", "terseLabel": "5.65% notes due 2042 (5.65% 2042 Notes) [Member]" } } }, "localname": "FivePointSixFivePercentNotesDue2042Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FivePointThreeSevenFivePercentNotesDue2043Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point Three Seven Five Percent Notes Due 2043 [Member]", "label": "Five Point Three Seven Five Percent Notes Due 2043 [Member]", "terseLabel": "5.375% notes due 2043 (5.375% 2043 Notes) [Member]" } } }, "localname": "FivePointThreeSevenFivePercentNotesDue2043Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FivePrimeTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Prime Therapeutics, Inc.", "label": "Five Prime Therapeutics, Inc. [Member]", "terseLabel": "Five Prime Therapeutics, Inc." } } }, "localname": "FivePrimeTherapeuticsIncMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "amgn_ForeignAndOtherGovernmentRelatedDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "foreign and other government-related debt securities", "label": "foreign and other government-related debt securities [Member]", "terseLabel": "foreign and other government-related debt securities" } } }, "localname": "ForeignAndOtherGovernmentRelatedDebtSecuritiesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPercentPoundSterlingNotesDue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Percent Pound Sterling Notes Due 2029 [Member]", "label": "Four Percent Pound Sterling Notes Due 2029 [Member]", "terseLabel": "4.00% \u00a3700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]", "verboseLabel": "4.00% 2029 pound sterling Notes [Member]" } } }, "localname": "FourPercentPoundSterlingNotesDue2029Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]", "label": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]", "terseLabel": "4.563% notes due 2048 (4.563% 2048 Notes) [Member]", "verboseLabel": "4.563% notes due 2048 (4.563% 2048 Notes) [Member]" } } }, "localname": "FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]", "label": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]", "terseLabel": "4.40% notes due 2045 (4.40% 2045 Notes) [Member]" } } }, "localname": "FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointNineFivePercentNotesDue2041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Point Nine Five Percent Notes Due 2041 [Member]", "label": "Four Point Nine Five Percent Notes Due 2041 [Member]", "terseLabel": "4.95% notes due 2041 (4.95% 2041 Notes) [Member]" } } }, "localname": "FourPointNineFivePercentNotesDue2041Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointOneZeroPercentNotesDue2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Point One Zero Percent Notes Due 2021 [Member]", "label": "Four Point One Zero Percent Notes Due 2021 [Member]", "terseLabel": "4.10% notes due 2021 (4.10% 2021 Notes) [Member]" } } }, "localname": "FourPointOneZeroPercentNotesDue2021Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]", "label": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]", "terseLabel": "4.663% notes due 2051 (4.663% 2051 Notes) [Member]" } } }, "localname": "FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_GensentaIlacSanayiVsTicaretMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gensenta Ilac Sanayi vs Ticaret", "label": "Gensenta Ilac Sanayi vs Ticaret [Member]", "terseLabel": "Gensenta Ilac Sanayi vs Ticaret" } } }, "localname": "GensentaIlacSanayiVsTicaretMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "amgn_HedgedLiabilityDiscontinuedFairValueHedge": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Hedged Liability, Discontinued Fair Value Hedge", "label": "Hedged Liability, Discontinued Fair Value Hedge", "terseLabel": "Carrying value with discontinued hedging relationships" } } }, "localname": "HedgedLiabilityDiscontinuedFairValueHedge", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" ], "xbrltype": "monetaryItemType" }, "amgn_HospiraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hospira [Member]", "label": "Hospira [Member]", "terseLabel": "Hospira, Inc. [Member]" } } }, "localname": "HospiraMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_HumiraBiosimilarAntitrustClassActionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Humira Biosimilar Antitrust Class Actions [Member]", "label": "Humira Biosimilar Antitrust Class Actions [Member]", "terseLabel": "Humira Biosimilar Antitrust Class Actions [Member]" } } }, "localname": "HumiraBiosimilarAntitrustClassActionsMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_IdentifiableIntangibleAssetsAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Identifiable intangible assets accumulated amortization.", "label": "Identifiable Intangible Assets Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "IdentifiableIntangibleAssetsAccumulatedAmortization", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amgn_IdentifiableIntangibleAssetsGross": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Identifiable intangible assets gross.", "label": "Identifiable Intangible Assets Gross", "terseLabel": "Gross carrying amount" } } }, "localname": "IdentifiableIntangibleAssetsGross", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "amgn_IncreaseDecreaseInNoncurrentTaxLiability": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Noncurrent Tax Liability", "label": "Increase (Decrease) In Noncurrent Tax Liability", "terseLabel": "Long-term tax liabilities" } } }, "localname": "IncreaseDecreaseInNoncurrentTaxLiability", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "amgn_KANJINTIPatentLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KANJINTI Patent Litigation [Member]", "label": "KANJINTI Patent Litigation [Member]", "terseLabel": "KANJINTI Patent Litigation [Member]" } } }, "localname": "KANJINTIPatentLitigationMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_KyprolisANDAPatentLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kyprolis ANDA Patent Litigation", "label": "Kyprolis ANDA Patent Litigation [Member]", "terseLabel": "Kyprolis ANDA Patent Litigation" } } }, "localname": "KyprolisANDAPatentLitigationMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_KyprolisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kyprolis [Member]", "label": "Kyprolis [Member]", "terseLabel": "KYPROLIS\u00ae (carfilzomib) [Member]" } } }, "localname": "KyprolisMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails", "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_LitigationSettlementDamagesSoughtValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Damages Sought, Value", "label": "Litigation Settlement, Damages Sought, Value", "terseLabel": "Amount awarded from settlement" } } }, "localname": "LitigationSettlementDamagesSoughtValue", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "amgn_LitigationSettlementNumberOfPrimaryArguments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Number Of Primary Arguments", "label": "Litigation Settlement, Number Of Primary Arguments", "terseLabel": "Litigation Settlement, Number Of Primary Arguments" } } }, "localname": "LitigationSettlementNumberOfPrimaryArguments", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "amgn_LongTermDebtCurrentMaturitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Current Maturities [Member]", "label": "Long-Term Debt, Current Maturities [Member]", "terseLabel": "Current portion of long-term debt [Member]" } } }, "localname": "LongTermDebtCurrentMaturitiesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" ], "xbrltype": "domainItemType" }, "amgn_LossContingencyAppealPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, appeal period", "label": "Loss Contingency, appeal period", "terseLabel": "Loss Contingency, appeal period" } } }, "localname": "LossContingencyAppealPeriod", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "durationItemType" }, "amgn_LossContingencyNumberOfLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Lawsuits", "label": "Loss Contingency, Number Of Lawsuits", "terseLabel": "Number of lawsuits" } } }, "localname": "LossContingencyNumberOfLawsuits", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "amgn_LossContingencyPatentsExpiredNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Patents Expired, Number", "label": "Loss Contingency, Patents Expired, Number", "terseLabel": "Number of asserted patents expired" } } }, "localname": "LossContingencyPatentsExpiredNumber", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "amgn_MoleculeTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecule, Type", "label": "Molecule, Type [Axis]", "terseLabel": "Molecule, Type [Axis]" } } }, "localname": "MoleculeTypeAxis", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "amgn_MoleculeTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecule, Type [Domain]", "label": "Molecule, Type [Domain]", "terseLabel": "Molecule, Type [Domain]" } } }, "localname": "MoleculeTypeDomain", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "amgn_MortgageAndAssetBackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage and asset back", "label": "Mortgage and asset back [Member]", "terseLabel": "Mortgage and asset back" } } }, "localname": "MortgageAndAssetBackMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "domainItemType" }, "amgn_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as \"predominately\", \"about equally\", or \"major and other\". This element is also referred to as \"Business Description\".", "label": "Nature Of Operations [Policy Text Block]", "verboseLabel": "Business" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "amgn_NeulastaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Neulasta.", "label": "Neulasta [Member]", "terseLabel": "Neulasta\u00ae (pegfilgrastim) [Member]" } } }, "localname": "NeulastaMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_NeumoraTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Neumora Therapeutics, Inc.", "label": "Neumora Therapeutics, Inc. [Member]", "terseLabel": "Neumora Therapeutics, Inc. [Member]" } } }, "localname": "NeumoraTherapeuticsIncMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "domainItemType" }, "amgn_NovartisPharmaAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novartis Pharma AG", "label": "Novartis Pharma AG [Member]", "terseLabel": "Novartis Pharma AG" } } }, "localname": "NovartisPharmaAGMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_NplateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nplate", "label": "Nplate [Member]", "verboseLabel": "Nplate [Member]" } } }, "localname": "NplateMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_NumberOfAssertedPatents": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Asserted Patents", "label": "Number Of Asserted Patents", "terseLabel": "Number Of Asserted Patents" } } }, "localname": "NumberOfAssertedPatents", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "amgn_NumberOfThirdPartyFinancialInstitutions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Third-Party Financial Institutions", "label": "Number of Third-Party Financial Institutions", "terseLabel": "Number of Third-Party Financial Institutions" } } }, "localname": "NumberOfThirdPartyFinancialInstitutions", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "integerItemType" }, "amgn_OnePointEightFivePercentNotesDueTwoZeroTwoOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]", "label": "One Point Eight Five Percent Notes Due Two Zero Two One [Member]", "terseLabel": "1.85% notes due 2021 (1.85% 2021 Notes) [Member]" } } }, "localname": "OnePointEightFivePercentNotesDueTwoZeroTwoOneMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]", "label": "One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]", "terseLabel": "1.90% notes due 2025 (1.90% 2025 Notes) [Member]" } } }, "localname": "OnePointNineZeroPercentNotesDueTwoZeroTwoFiveMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_OnePointSixFivePercent2028NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One point six five percent 2028 Notes", "label": "One point six five percent 2028 Notes [Member]", "terseLabel": "1.65% notes due 2028 (1.65% 2028 Notes) [Member}" } } }, "localname": "OnePointSixFivePercent2028NotesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]", "label": "One Point Twenty Five Percent Euro Notes Due Two Thousand Twenty Two [Member]", "verboseLabel": "1.25% 2022 euro Notes [Member]" } } }, "localname": "OnePointTwentyFivePercentEuroNotesDueTwoThousandTwentyTwoMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "amgn_OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]", "label": "One Point Two Five Percent Euro Notes due Two Zero Two Two [Member]", "terseLabel": "1.25% \u20ac1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member]" } } }, "localname": "OnePointTwoFivePercentEuroNotesdueTwoZeroTwoTwoMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_OtezlaANDAPatentLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Otezla ANDA Patent Litigation", "label": "Otezla ANDA Patent Litigation [Member]", "terseLabel": "Otezla ANDA Patent Litigation [Member]" } } }, "localname": "OtezlaANDAPatentLitigationMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_OtezlaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Otezla [Member]", "label": "Otezla [Member]", "terseLabel": "Otezla (apremilast) [Member]" } } }, "localname": "OtezlaMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Other Adjustment, before Tax", "label": "Other Comprehensive Income (Loss), Other Adjustment, before Tax", "terseLabel": "Other" } } }, "localname": "OtherComprehensiveIncomeLossOtherAdjustmentbeforeTax", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other" } } }, "localname": "OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "amgn_OtherCurrentNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other current assets/other non-current assets.", "label": "Other Current Noncurrent Assets [Member]", "verboseLabel": "Other current assets/Other assets [Member]" } } }, "localname": "OtherCurrentNoncurrentAssetsMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "amgn_OtherGeneralExpenseIncomeOtherAdjustments": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other General Expense (Income), Other Adjustments", "label": "Other General Expense (Income), Other Adjustments", "terseLabel": "Other" } } }, "localname": "OtherGeneralExpenseIncomeOtherAdjustments", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "amgn_OtherMortgageAndAssetBackedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Mortgage and asset backed", "label": "Other Mortgage and asset backed [Member]", "terseLabel": "Other Mortgage and asset backed" } } }, "localname": "OtherMortgageAndAssetBackedMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "domainItemType" }, "amgn_OtherNotesDue2097Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Notes Due 2097 [Member]", "label": "Other Notes Due 2097 [Member]", "terseLabel": "Other notes due 2097 [Member]" } } }, "localname": "OtherNotesDue2097Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_OtherProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Products [Member]", "label": "Other Products [Member]", "terseLabel": "Other products [Member]" } } }, "localname": "OtherProductsMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_OtherShortTermInterestBearingSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other short-term interest bearing securities.", "label": "Other Short Term Interest Bearing Securities [Member]", "verboseLabel": "Other short-term interest-bearing securities [Member]" } } }, "localname": "OtherShortTermInterestBearingSecuritiesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_PatentTrialAndAppealBoardPatentChallengesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent Trial And Appeal Board Patent Challenges [Member]", "label": "Patent Trial And Appeal Board Patent Challenges [Member]", "terseLabel": "Patent Trial and Appeal Board Patent Challenges [Member]" } } }, "localname": "PatentTrialAndAppealBoardPatentChallengesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_PenaltiesOnProposedAdditionalIncomeTax20132105": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Penalties on proposed additional income tax 2013-2015", "label": "Penalties on proposed additional income tax 2013-2105", "terseLabel": "Penalties on proposed additional income tax 2013-2015" } } }, "localname": "PenaltiesOnProposedAdditionalIncomeTax20132105", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "amgn_PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event", "label": "Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event", "terseLabel": "Percentage of Prinicipal Amount of Notes that may be Paid Upon Occurance of Change in Control Triggering Event" } } }, "localname": "PercentageOfPrinicipalAmountOfNotesThatMayBePaidUponOccuranceOfChangeInControlTriggeringEvent", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual" ], "xbrltype": "percentItemType" }, "amgn_PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event", "label": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event", "terseLabel": "Percentage of Principal Amount of Notes that may be Paid Upon Occurrence of Change in Control Triggering Event" } } }, "localname": "PercentageofPrincipalAmountofNotesthatmaybePaidUponOccurrenceofChangeinControlTriggeringEvent", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "percentItemType" }, "amgn_ProliaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prolia.", "label": "Prolia [Member]", "terseLabel": "Prolia\u00ae (denosumab) [Member]" } } }, "localname": "ProliaMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_ProposedAdditionalIncomeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proposed additional income tax", "label": "Proposed additional income tax", "terseLabel": "Proposed additional income tax" } } }, "localname": "ProposedAdditionalIncomeTax", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "amgn_ProposedAdditionalIncomeTax20132015": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proposed additional income tax 2013-2015", "label": "Proposed additional income tax 2013-2015", "terseLabel": "Proposed additional income tax 2013-2015" } } }, "localname": "ProposedAdditionalIncomeTax20132015", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "amgn_RDTechnologyrightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "R & D Technology rights [Member]", "label": "R & D Technology rights [Member]", "terseLabel": "R & D Technology rights" } } }, "localname": "RDTechnologyrightsMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "amgn_RepathaevolocumabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repatha (evolocumab) [Member]", "label": "Repatha (evolocumab) [Member]", "terseLabel": "Repatha (evolocumab) [Member]" } } }, "localname": "RepathaevolocumabMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_RepatriationTaxOnProposedAdditionalTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repatriation tax on proposed additional tax", "label": "Repatriation tax on proposed additional tax", "terseLabel": "Repatriation tax on proposed additional tax" } } }, "localname": "RepatriationTaxOnProposedAdditionalTax", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "amgn_RepatriationTaxOnProposedAdditionalTax20132015": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repatriation tax on proposed additional tax 2013-2015", "label": "Repatriation tax on proposed additional tax 2013-2015", "terseLabel": "Repatriation tax on proposed additional tax 2013-2015" } } }, "localname": "RepatriationTaxOnProposedAdditionalTax20132015", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "amgn_ScheduleOfIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets.", "label": "Schedule Of Intangible Assets [Table Text Block]", "terseLabel": "Schedule of identifiable intangible assets" } } }, "localname": "ScheduleOfIntangibleAssetsTableTextBlock", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" ], "xbrltype": "textBlockItemType" }, "amgn_ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Long-term Debt Instruments Exchanged [Table]", "label": "Schedule of Long-term Debt Instruments Exchanged [Table Text Block]", "terseLabel": "Schedule of long-term instruments exchanged" } } }, "localname": "ScheduleOfLongTermDebtInstrumentsExchangedTableTextBlock", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsTables" ], "xbrltype": "textBlockItemType" }, "amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps", "label": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]", "terseLabel": "Schedule of notional amounts and interest rates for cross-currency swaps" } } }, "localname": "ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsTables" ], "xbrltype": "textBlockItemType" }, "amgn_SensiparAntitrustClassActionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensipar Antitrust Class Actions [Member]", "label": "Sensipar Antitrust Class Actions [Member]", "terseLabel": "Sensipar Antitrust Class Actions [Member]" } } }, "localname": "SensiparAntitrustClassActionsMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "amgn_SixPointFourZeroPercentNotesDue2039Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six Point Four Zero Percent Notes Due 2039 [Member]", "label": "Six Point Four Zero Percent Notes Due 2039 [Member]", "terseLabel": "6.40% notes due 2039 (6.40% 2039 Notes) [Member]" } } }, "localname": "SixPointFourZeroPercentNotesDue2039Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_SixPointNineZeroPercentNotesDue2038Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six Point Nine Zero Percent Notes Due 2038 [Member]", "label": "Six Point Nine Zero Percent Notes Due 2038 [Member]", "terseLabel": "6.90% notes due 2038 (6.90% 2038 Notes) [Member]" } } }, "localname": "SixPointNineZeroPercentNotesDue2038Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_SixPointThreeSevenFivePercentNotesDue2037Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six Point Three Seven Five Percent Notes Due 2037 [Member]", "label": "Six Point Three Seven Five Percent Notes Due 2037 [Member]", "terseLabel": "6.375% notes due 2037 (6.375% 2037 Notes) [Member]" } } }, "localname": "SixPointThreeSevenFivePercentNotesDue2037Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_StockRepurchaseProgramTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Repurchase Program [Table Text Block]", "label": "Stock Repurchase Program [Table Text Block]", "terseLabel": "Summary of activity under our stock repurchase program" } } }, "localname": "StockRepurchaseProgramTableTextBlock", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/StockholdersequityTables" ], "xbrltype": "textBlockItemType" }, "amgn_TeneobioIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Teneobio Inc.", "label": "Teneobio Inc. [Member]", "terseLabel": "Teneobio Inc." } } }, "localname": "TeneobioIncMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" ], "xbrltype": "domainItemType" }, "amgn_TeneobioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Teneobio", "label": "Teneobio [Member]", "terseLabel": "Teneobio" } } }, "localname": "TeneobioMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointEightSevenFivePercentNotesDue2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]", "label": "Three Point Eight Seven Five Percent Notes Due 2021 [Member]", "terseLabel": "3.875% notes due 2021 (3.875% 2021 Notes) [Member]" } } }, "localname": "ThreePointEightSevenFivePercentNotesDue2021Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointFourFivePercentNotesDue2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Four Five Percent Notes Due 2020 [Member]", "label": "Three Point Four Five Percent Notes Due 2020 [Member]", "terseLabel": "3.45% notes due 2020 (3.45% 2020 Notes) [Member]" } } }, "localname": "ThreePointFourFivePercentNotesDue2020Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointOneFivePercentNotesDue2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point One Five Percent Notes Due 2040 [Member]", "label": "Three Point One Five Percent Notes Due 2040 [Member]", "terseLabel": "3.15% notes due 2040 (3.15% 2040 Notes) [Member]" } } }, "localname": "ThreePointOneFivePercentNotesDue2040Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]", "label": "Three Point One Two Five Percent Notes Due Two Zero Two Five [Member]", "terseLabel": "3.125% notes due 2025 (3.125% 2025 Notes) [Member]" } } }, "localname": "ThreePointOneTwoFivePercentNotesDueTwoZeroTwoFiveMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointSixTwoFivePercentNotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Six Two Five Percent Notes Due 2022 [Member]", "label": "Three Point Six Two Five Percent Notes Due 2022 [Member]", "terseLabel": "3.625% notes due 2022 (3.625% 2022 Notes) [Member]" } } }, "localname": "ThreePointSixTwoFivePercentNotesDue2022Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointSixTwoFivePercentNotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Six Two Five Percent Notes Due 2024 [Member]", "label": "Three Point Six Two Five Percent Notes Due 2024 [Member]", "terseLabel": "3.625% notes due 2024 (3.625% 2024 Notes) [Member]" } } }, "localname": "ThreePointSixTwoFivePercentNotesDue2024Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointThreeSevenFivePercentNotesDue2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Three Seven Five Percent Notes Due 2050 [Member]", "label": "Three Point Three Seven Five Percent Notes Due 2050 [Member]", "terseLabel": "3.375% notes due 2050 (3.375% 2050 Notes) [Member]" } } }, "localname": "ThreePointThreeSevenFivePercentNotesDue2050Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_ThreePointTwoZeroNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Two Zero Notes Due 2027 [Member]", "label": "Three Point Two Zero Notes Due 2027 [Member]", "terseLabel": "3.20% notes due 2027 (3.20% 2027 Notes) [Member]" } } }, "localname": "ThreePointTwoZeroNotesDue2027Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPercentEuroNotesDueTwoThousandTwentySixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]", "label": "Two Percent Euro Notes Due Two Thousand Twenty Six [Member]", "terseLabel": "2.00% \u20ac750 million notes due 2026 (2.00% 2026 euro Notes) [Member]", "verboseLabel": "2.00% 2026 euro Notes [Member]" } } }, "localname": "TwoPercentEuroNotesDueTwoThousandTwentySixMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointEightZeroPercent2041NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two point eight zero percent 2041 Notes", "label": "Two point eight zero percent 2041 Notes [Member]", "terseLabel": "2.80% notes due 2041 (2.80% 2041 Notes) [Member]" } } }, "localname": "TwoPointEightZeroPercent2041NotesMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointFourFivePercentNotesDue2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Four Five Percent Notes Due 2030 [Member]", "label": "Two Point Four Five Percent Notes Due 2030 [Member]", "terseLabel": "2.45% notes due 2030 (2.45% 2030 Notes) [Member]" } } }, "localname": "TwoPointFourFivePercentNotesDue2030Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Seven Seven Percent Notes Due Two Zero Five Three", "label": "Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]", "terseLabel": "Two Point Seven Seven Percent Notes Due Two Zero Five Three" } } }, "localname": "TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]", "label": "Two Point Seven Zero Percent Notes Due Two Zero Two Two [Member]", "terseLabel": "2.70% notes due 2022 (2.70% 2022 Notes) [Member]" } } }, "localname": "TwoPointSevenZeroPercentNotesDueTwoZeroTwoTwoMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointSixFiveNotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Six Five Notes Due 2022 [Member]", "label": "Two Point Six Five Notes Due 2022 [Member]", "terseLabel": "2.65% notes due 2022 (2.65% 2022 Notes) [Member]" } } }, "localname": "TwoPointSixFiveNotesDue2022Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Six Zero Notes Due Two Zero Two Six [Member]", "label": "Two Point Six Zero Notes Due Two Zero Two Six [Member]", "terseLabel": "2.60% notes due 2026 (2.60% 2026 notes) [Member]" } } }, "localname": "TwoPointSixZeroNotesDueTwoZeroTwoSixMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointThreeZeroPercentNotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Three Zero Percent Notes Due 2031", "label": "Two Point Three Zero Percent Notes Due 2031 [Member]", "terseLabel": "2.30% notes due 2031 (2.30% 2031 Notes) [Member]" } } }, "localname": "TwoPointThreeZeroPercentNotesDue2031Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]", "label": "Two Point Two Five Percent Notes Due Two Zero Two Three [Member]", "terseLabel": "2.25% notes due 2023 (2.25% 2023 Notes) [Member]" } } }, "localname": "TwoPointTwoFivePercentNotesDueTwoZeroTwoThreeMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointTwoZeroNotesDue2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Two Zero Notes Due 2020 [Member]", "label": "Two Point Two Zero Notes Due 2020 [Member]", "terseLabel": "2.20% notes due 2020 (2.20% 2020 Notes) [Member]" } } }, "localname": "TwoPointTwoZeroNotesDue2020Member", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]", "label": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]", "terseLabel": "2.20% notes due 2027 (2.20% 2027 Notes) [Member]" } } }, "localname": "TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_TwoPointZeroPercent2032NotesMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two point zero percent 2032 Notes Member", "label": "Two point zero percent 2032 Notes Member [Member]", "terseLabel": "2.00% notes due 2032 (2.00% 2032 Notes) [Member]" } } }, "localname": "TwoPointZeroPercent2032NotesMemberMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "amgn_XgevaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "XGEVA.", "label": "XGEVA [Member]", "terseLabel": "XGEVA\u00ae (denosumab) [Member]" } } }, "localname": "XgevaMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "amgn_ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]", "label": "Zero Point Forty One Percent Swiss Franc Bonds Due Two Thousand Twenty Three [Member]", "terseLabel": "0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]", "verboseLabel": "0.41% 2023 Swiss franc Bonds [Member]" } } }, "localname": "ZeroPointFortyOnePercentSwissFrancBondsDueTwoThousandTwentyThreeMember", "nsuri": "http://www.amgen.com/20220630", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "US [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Switzerland, Francs", "terseLabel": "Switzerland, Francs" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro Member Countries, Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "United Kingdom, Pounds" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "United States of America, Dollars" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "exch_XNGS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]", "terseLabel": "The NASDAQ Global Select Market [Member]" } } }, "localname": "XNGS", "nsuri": "http://xbrl.sec.gov/exch/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r0", "r122", "r127", "r133", "r214", "r391", "r392", "r393", "r405", "r406", "r474", "r475", "r476", "r477", "r504" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative effect of changes in accounting principles, net of tax" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r0", "r122", "r127", "r133", "r214", "r391", "r392", "r393", "r405", "r406", "r474", "r475", "r476", "r477", "r504" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r0", "r122", "r127", "r133", "r214", "r391", "r392", "r393", "r405", "r406", "r474", "r475", "r476", "r477", "r504" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r271", "r273", "r274", "r275", "r295", "r335", "r382", "r385", "r517", "r518", "r519", "r520", "r521", "r522", "r542", "r584", "r587", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r271", "r273", "r274", "r275", "r295", "r335", "r382", "r385", "r517", "r518", "r519", "r520", "r521", "r522", "r542", "r584", "r587", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual" ], "xbrltype": "domainItemType" }, "srt_PartnershipInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Partnership Interest [Member]", "terseLabel": "Limited Partnership [Member]" } } }, "localname": "PartnershipInterestMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r178", "r273", "r274", "r367", "r369", "r543", "r583", "r585" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r178", "r273", "r274", "r367", "r369", "r543", "r583", "r585" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r263", "r271", "r273", "r274", "r275", "r295", "r335", "r372", "r382", "r385", "r388", "r389", "r390", "r517", "r518", "r519", "r520", "r521", "r522", "r542", "r584", "r587", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r263", "r271", "r273", "r274", "r275", "r295", "r335", "r372", "r382", "r385", "r388", "r389", "r390", "r517", "r518", "r519", "r520", "r521", "r522", "r542", "r584", "r587", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r128", "r383" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r128", "r133", "r269", "r383" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r179", "r180", "r367", "r370", "r586", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r179", "r180", "r367", "r370", "r586", "r614", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r128", "r133", "r269", "r383", "r510" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r42", "r508" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r182", "r183" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Trade receivables, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued liabilities [Member]" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r14", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "verboseLabel": "Accumulated depreciation and amortization on property, plant and equipment" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r63", "r70", "r71", "r72", "r73", "r436" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "verboseLabel": "Cash\u00a0flow hedges [Member]" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r57", "r58", "r59", "r63", "r70", "r71", "r72" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "verboseLabel": "Available-for-sale securities [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r61", "r62", "r63", "r570", "r592", "r593" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r70", "r71", "r491", "r492", "r493", "r494", "r495", "r497" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r60", "r63", "r70", "r71", "r72", "r119", "r120", "r121", "r437", "r505", "r588", "r589" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss [Member]", "verboseLabel": "AOCI [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r55", "r63", "r70", "r71", "r72", "r437", "r492", "r493", "r494", "r495", "r497" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted average period of amortization" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Tax impact related to employee stock-based compensation expense" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r386", "r394", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestment": { "auth_ref": [ "r480", "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.", "label": "Alternative Investment", "terseLabel": "Alternative investments" } } }, "localname": "AlternativeInvestment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r100", "r241", "r251" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization charges associated with finite-lived intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r197", "r373" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-Backed Securities [Member]", "terseLabel": "Other mortgage- and asset-backed securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r18", "r113", "r167", "r171", "r176", "r213", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r433", "r438", "r489", "r506", "r508", "r548", "r568" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r40", "r113", "r213", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r433", "r438", "r489", "r506", "r508" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r481" ], "calculation": { "http://www.amgen.com/role/FairvaluemeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "verboseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "terseLabel": "Disposal Group, Including Discontinued Operation, Assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r258", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Disposal Group, Including Discontinued Operation, Assets, Current" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r191" ], "calculation": { "http://www.amgen.com/role/InvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r192" ], "calculation": { "http://www.amgen.com/role/InvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r189", "r220" ], "calculation": { "http://www.amgen.com/role/InvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r193", "r195", "r562" ], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "auth_ref": [ "r196", "r563" ], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value", "terseLabel": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r185", "r190", "r220", "r552" ], "calculation": { "http://www.amgen.com/role/FairvaluemeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.amgen.com/role/InvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair values", "totalLabel": "Total interest-bearing securities", "verboseLabel": "Interest-bearing securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails", "http://www.amgen.com/role/InvestmentsFairValuesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r187", "r220" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "verboseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r447", "r452" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r381", "r384", "r419" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual", "http://www.amgen.com/role/InvestmentsBeiGeneDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r381", "r384", "r415", "r416", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual", "http://www.amgen.com/role/InvestmentsBeiGeneDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r99", "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Net changes in valuations" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Maximum additional consideration due contingent on certain milestones" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r424", "r425", "r427" ], "calculation": { "http://www.amgen.com/role/FairvaluemeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Contingent consideration obligations" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails", "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r420", "r430" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r418" ], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": 6.0, "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Fair value of assets acquired, cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r418" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "terseLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r418" ], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": 2.0, "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r418" ], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": 3.0, "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Acquired in-process research and development", "verboseLabel": "IPR&D" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r417", "r418" ], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": 4.0, "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Fair value of assets acquired, licensing rights" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r12", "r508", "r596", "r597" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r6", "r12", "r102" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r97", "r102", "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r97", "r490" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "(Decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash flow hedge [Member]", "verboseLabel": "Cash flow hedges [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "terseLabel": "Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "terseLabel": "Gains (losses) on fair value hedging relationships, Hedged items" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r23", "r24", "r25", "r110", "r113", "r136", "r137", "r138", "r140", "r142", "r151", "r152", "r153", "r213", "r281", "r285", "r286", "r287", "r290", "r291", "r333", "r334", "r338", "r342", "r349", "r489", "r634" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r553", "r574" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Contingencies and commitments" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r265", "r266", "r267", "r277", "r615" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Contingencies and commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Contingenciesandcommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends paid per share (in usd per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common stock, dividends declared per share (in usd per share)", "verboseLabel": "Dividends declared per share (in usd per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).", "label": "Common Stock Including Additional Paid in Capital [Member]", "terseLabel": "Common stock and additional paid-in capital [Member]" } } }, "localname": "CommonStockIncludingAdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r119", "r120", "r476" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]", "verboseLabel": "Number of shares of common stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock and additional paid-in capital, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock and additional paid-in capital, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares", "verboseLabel": "Common stock and additional paid-in capital, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": { "auth_ref": [ "r25", "r26", "r356" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.", "label": "Common Stocks, Including Additional Paid in Capital", "verboseLabel": "Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding\u2014534.9 shares in 2022 and 558.3 shares in 2021" } } }, "localname": "CommonStocksIncludingAdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r66", "r68", "r69", "r77", "r557", "r578" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r108", "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r80", "r543" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r79" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r109", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r309", "r316", "r317", "r319", "r329" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Financing arrangements" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Financingarrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r21", "r22", "r112", "r117", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r313", "r314", "r315", "r325", "r326", "r327", "r328", "r502", "r549", "r550", "r567" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r22", "r320", "r550", "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r292", "r325", "r326", "r500", "r502", "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r47", "r323", "r500", "r502" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r47", "r293" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r48", "r112", "r117", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r313", "r314", "r315", "r325", "r326", "r327", "r328", "r502" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r48", "r112", "r117", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r325", "r326", "r327", "r328", "r350", "r353", "r354", "r355", "r499", "r500", "r502", "r503", "r566" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r305", "r321", "r325", "r326", "r501" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unamortized bond discounts, premiums and issuance costs, net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r202" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain", "verboseLabel": "Total realized gains" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Loss", "verboseLabel": "Total realized losses" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual", "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial obligations in a security form.", "label": "Debt Securities Payable [Member]", "terseLabel": "Debt Securities Payable [Member]" } } }, "localname": "DebtSecuritiesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r101" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r100", "r164" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation, amortization and other" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]", "verboseLabel": "Assets" } } }, "localname": "DerivativeAssetFairValueNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r52", "r53", "r54", "r450", "r524" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Total derivative assets, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r52", "r53", "r54", "r450", "r524" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Total derivative liabilities, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "verboseLabel": "Interest rates" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r53", "r448", "r451", "r456", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r472", "r479" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "verboseLabel": "Derivative instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Derivativeinstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r445", "r448", "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r445", "r448", "r456", "r460", "r461", "r467", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityFairValueNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "DerivativeLiabilityFairValueNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r441", "r443" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amounts" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r440", "r442", "r443", "r445", "r446", "r453", "r456", "r465", "r466", "r469", "r472" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]", "verboseLabel": "Derivatives designated as hedging instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "verboseLabel": "Developed-Product-Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of revenue by product and by geographic area" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/RevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r1", "r2", "r3", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "auth_ref": [ "r1", "r2", "r3", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "terseLabel": "Disposal Group, Including Discontinued Operation, Accrued Liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r1", "r2", "r3", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Disposal Group, Including Discontinued Operation, Inventory" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "auth_ref": [ "r1", "r2", "r3", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Disposal Group, Including Discontinued Operation, Other Assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r1", "r2", "r3", "r258", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Disposal Group, Including Discontinued Operation, Other Assets, Current" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r1", "r2", "r3", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r381", "r384" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends declared on common stock" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Earnings per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r78", "r125", "r126", "r127", "r128", "r129", "r134", "r136", "r140", "r141", "r142", "r146", "r147", "r477", "r478", "r558", "r579" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic EPS (in usd per share)", "verboseLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/EarningspershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r78", "r125", "r126", "r127", "r128", "r129", "r136", "r140", "r141", "r142", "r146", "r147", "r477", "r478", "r558", "r579" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted EPS (in usd per share)", "verboseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/EarningspershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r143", "r144", "r145", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Earnings per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Earningspershare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r70", "r71", "r72", "r119", "r120", "r121", "r124", "r130", "r132", "r150", "r214", "r349", "r356", "r391", "r392", "r393", "r405", "r406", "r476", "r491", "r492", "r493", "r494", "r495", "r497", "r505", "r588", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentAggregateCost": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.", "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Equity Method Investment, Aggregate Cost" } } }, "localname": "EquityMethodInvestmentAggregateCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsBeiGeneDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.", "label": "Equity Method Investment, Quoted Market Value", "terseLabel": "Equity Method Investments,Quoted Market Price" } } }, "localname": "EquityMethodInvestmentQuotedMarketValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual", "http://www.amgen.com/role/InvestmentsBeiGeneDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r13", "r168", "r210" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Carrying value of equity method investment" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual", "http://www.amgen.com/role/InvestmentsBeiGeneDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "auth_ref": [ "r209" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investments accounted under the equity method.", "label": "Equity Method Investments, Fair Value Disclosure", "terseLabel": "Equity Method Investments, Fair Value Disclosure" } } }, "localname": "EquityMethodInvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r8", "r20", "r488" ], "calculation": { "http://www.amgen.com/role/FairvaluemeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r208", "r580" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss)" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity securities without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r207" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount", "terseLabel": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r481", "r482", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r307", "r325", "r326", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r482", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair value measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Fairvaluemeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r307", "r373", "r374", "r379", "r380", "r482", "r514" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]", "verboseLabel": "Quoted prices in active markets for identical assets (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r307", "r325", "r326", "r373", "r374", "r379", "r380", "r482", "r515" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Significant other observable inputs (Level 2) [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r307", "r325", "r326", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r482", "r516" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "verboseLabel": "Significant unobservable inputs (Level 3) [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [ "r374", "r480", "r487" ], "lang": { "en-us": { "role": { "documentation": "Fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "Fair Value Measured at Net Asset Value Per Share [Member]" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r307", "r325", "r326", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r447", "r453", "r467" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r197", "r198", "r205", "r206", "r207", "r215", "r216", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r318", "r347", "r472", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r634", "r635", "r636", "r637", "r638", "r639", "r640" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r16", "r250" ], "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Total estimated amortization of finite-lived intangible assets for the six months ending December 31, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r242", "r247", "r250", "r254", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r250", "r545" ], "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying amounts" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r242", "r249" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r250", "r544" ], "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Other intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Value of intangible assets acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "auth_ref": [ "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "terseLabel": "Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/FairvaluemeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "verboseLabel": "Foreign currency and cross-currency swap contracts" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.amgen.com/role/FairvaluemeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "verboseLabel": "Foreign currency and cross-currency swap contracts" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r53", "r373", "r459" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign currency contract [Member]", "verboseLabel": "Foreign currency contracts [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r373", "r594" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Other government-related debt securities - Foreign and other [Member]" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts [Member]" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingencyPatentsFoundInfringedUponNumber": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of entity's patents that another entity was found to have infringed.", "label": "Gain Contingency, Patents Found Infringed upon, Number", "terseLabel": "Gain Contingency, Patents Found Infringed upon, Number" } } }, "localname": "GainContingencyPatentsFoundInfringedUponNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r15", "r227", "r228", "r235", "r239", "r508", "r547" ], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": 5.0, "parentTag": "amgn_BusinessacquiredassetacquisitionAssetsacquiredandLiabilitiesassumednet", "weight": 1.0 }, "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and other intangible assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Goodwillandotherintangibleassets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation adjustment" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r234", "r414" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Net increase in goodwill" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwillRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": { "auth_ref": [ "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.", "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)", "terseLabel": "Hedging adjustments on discontinued hedging relationships" } } }, "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedge": { "auth_ref": [ "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability hedged in fair value hedging relationship.", "label": "Hedged Liability, Fair Value Hedge", "terseLabel": "Hedged Liability, Fair Value Hedge" } } }, "localname": "HedgedLiabilityFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "auth_ref": [ "r463" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "terseLabel": "Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities", "verboseLabel": "Fair value adjustments" } } }, "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r445", "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsCrosscurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r100", "r257" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Loss on divestiture" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r167", "r170", "r172", "r175", "r177" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r74", "r100", "r165", "r210", "r554", "r575" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Adjustments for equity method investments", "verboseLabel": "Income (Loss) from Equity Method Investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.amgen.com/role/InvestmentsBeiGeneDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r381", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r261", "r264" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r114", "r399", "r403", "r404", "r407", "r409", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Tax Examination [Line Items]" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]", "terseLabel": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r115", "r131", "r132", "r166", "r397", "r408", "r410", "r581" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Provision for income taxes", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r99" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r99" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivables, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r99" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Accrued income taxes, net" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r99" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r99" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r99" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "verboseLabel": "Increase (Decrease) in AOCI [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r245", "r253" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r245", "r253" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r240", "r248" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Intangible assets, net", "verboseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r84", "r313", "r324", "r327", "r328" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "negatedTerseLabel": "Interest expense, net" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": { "auth_ref": [ "r451" ], "calculation": { "http://www.amgen.com/role/FairvaluemeasurementDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.", "label": "Interest Rate Fair Value Hedge Asset at Fair Value", "terseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateFairValueHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue": { "auth_ref": [ "r451" ], "calculation": { "http://www.amgen.com/role/FairvaluemeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.", "label": "Interest Rate Fair Value Hedge Liability at Fair Value", "terseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateFairValueHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "netLabel": "Interest rate swap agreements [Member]", "terseLabel": "Interest Rate Swap [Member]", "verboseLabel": "Interest rate swap contracts [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.", "label": "Interim Period, Costs Not Allocable [Domain]", "terseLabel": "Interim Period, Costs Not Allocable [Domain]" } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r32", "r225" ], "calculation": { "http://www.amgen.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "verboseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r7", "r38", "r508" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amgen.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r34", "r225" ], "calculation": { "http://www.amgen.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "verboseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r33", "r225" ], "calculation": { "http://www.amgen.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "verboseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount": { "auth_ref": [ "r595" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of financial support committed by investment company to investee that is contractually required.", "label": "Investment Company, Financial Support to Investee Contractually Required, Amount", "terseLabel": "Investment Company, Financial Support to Investee Contractually Required, Amount" } } }, "localname": "InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Fair values of available-for-sale interest-bearing security investments by contractual maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r204", "r546", "r564", "r613", "r641" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r113", "r213", "r489", "r508", "r551", "r572" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r10", "r46", "r113", "r213", "r281", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r434", "r438", "r439", "r489", "r506", "r507", "r508" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r481" ], "calculation": { "http://www.amgen.com/role/FairvaluemeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "verboseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.", "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "terseLabel": "Long-term tax liabilities" } } }, "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing rights" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Amount received from settlement" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation Settlement, Expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r306", "r322", "r325", "r326", "r550", "r569" ], "calculation": { "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Carrying value of debt", "totalLabel": "Total carrying value of debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedLabel": "Less current portion", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-Term Debt [Member]", "terseLabel": "Long-term debt [Member]" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Total long-term debt", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r48", "r280" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r268", "r270", "r271", "r272", "r273", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r268", "r270", "r271", "r272", "r273", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [ "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Loss Contingency, Claims Settled, Number" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r268", "r270", "r271", "r272", "r273", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Loss Contingency, New Claims Filed, Number" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [ "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "auth_ref": [ "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "Number of another entity's patents that the entity has allegedly infringed.", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "terseLabel": "Number of patents allegedly infringed upon" } } }, "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Loss Contingency, Pending Claims, Number" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketingRelatedIntangibleAssetsMember": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.", "label": "Marketing-Related Intangible Assets [Member]", "terseLabel": "Marketing-Related Rights [Member]" } } }, "localname": "MarketingRelatedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.", "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge", "terseLabel": "Length of time hedged in foreign currency contracts (or less)" } } }, "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" ], "xbrltype": "durationItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "verboseLabel": "Money market mutual funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]", "terseLabel": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r97", "r98", "r101" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r64", "r67", "r72", "r75", "r101", "r113", "r123", "r125", "r126", "r127", "r128", "r131", "r132", "r139", "r167", "r170", "r172", "r175", "r177", "r213", "r281", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r478", "r489", "r555", "r576" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income", "terseLabel": "Net income for basic and diluted EPS", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/EarningspershareDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "verboseLabel": "Income (Numerator):" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/EarningspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Other recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "ROW [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "auth_ref": [ "r103", "r104", "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Investments Acquired", "terseLabel": "Noncash or Part Noncash Acquisition, Investments Acquired" } } }, "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives not designated as hedging instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsDetailsTextual", "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "terseLabel": "Long-term debt, fair value" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes [Member]" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsDetailsTextual", "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Unrealized gains" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r167", "r170", "r172", "r175", "r177" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r39", "r508" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "verboseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r431", "r432", "r436" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Gains on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r431", "r432", "r436" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r61" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": { "auth_ref": [ "r56", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax", "verboseLabel": "Total unrealized gains (losses)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsEffectivePortionofUnrealizedGainLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r65", "r68", "r70", "r71", "r73", "r76", "r349", "r491", "r496", "r497", "r556", "r577" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r65", "r68", "r431", "r432", "r436" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss), net of reclassification adjustments and taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of reclassification adjustments and taxes:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r431", "r432", "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "terseLabel": "Income taxes" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r447", "r467" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "verboseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebt": { "auth_ref": [ "r22", "r550", "r569" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other.", "label": "Other Long-Term Debt", "terseLabel": "Other" } } }, "localname": "OtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsPrincipalAmountsandCarryingValueofLongtermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r101" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other operating income (expense).", "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other Operating Income (Expense)" } } }, "localname": "OtherOperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r88", "r91" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r94" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock (Note 10)" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r94" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r89", "r426" ], "calculation": { "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails": { "order": 1.0, "parentTag": "amgn_Businessassetacquisitionconsiderationtransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r89" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r89" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedLabel": "Purchases of equity method investments", "terseLabel": "Payments to Acquire Equity Method Investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r186" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r90" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "terseLabel": "Proceeds from Divestiture of Businesses and Interests in Affiliates" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r92" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Net proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r85", "r86", "r186" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "verboseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r93", "r96" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "verboseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r85", "r86", "r186" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "verboseLabel": "Proceeds from sales of marketable securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other revenues [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r260", "r508", "r565", "r573" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r260", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "terseLabel": "Reclassification adjustments to income" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassifications out of accumulated other comprehensive income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r95" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayment of debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r246" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsNarrativeDetails", "http://www.amgen.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r396" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "auth_ref": [ "r188", "r373" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by residential real estate mortgage loans.", "label": "Residential Mortgage-Backed Securities [Member]", "terseLabel": "Residential mortgage-backed securities [Member]" } } }, "localname": "ResidentialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r356", "r508", "r571", "r591", "r593" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r119", "r120", "r121", "r124", "r130", "r132", "r214", "r391", "r392", "r393", "r405", "r406", "r476", "r588", "r590" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r162", "r163", "r169", "r173", "r174", "r178", "r179", "r181", "r366", "r367", "r543" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r371" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Revenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r63", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Components of accumulated other comprehensive income" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsAvailableforsaleInvestmentsDetailsTextual", "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsEquitySecuritiesDetailsTextual", "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r194", "r196", "r199", "r200", "r201", "r203", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-Sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r415", "r416", "r419" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsAggregateConsiderationPaidDetails", "http://www.amgen.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "verboseLabel": "Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r48", "r117", "r325", "r327", "r350", "r353", "r354", "r355", "r499", "r500", "r503", "r566" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "verboseLabel": "Schedule of borrowings" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "verboseLabel": "Fair values of derivatives included in the Condensed Consolidated Balance Sheets" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Summary of amounts of income and expense line items" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Computation for basic and diluted earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/EarningspershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Derivatives in fair value hedging relationships" } } }, "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r242", "r249", "r544" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r253", "r255" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/GoodwillandotherintangibleassetsIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Schedule of interest rate swaps" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r35", "r36", "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Net Investment Income [Line Items]", "terseLabel": "Net Investment Income [Line Items]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsBeiGeneDetails", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "auth_ref": [ "r82", "r84", "r582" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table]", "terseLabel": "Investment Income [Table]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/InvestmentsBeiGeneDetails", "http://www.amgen.com/role/InvestmentsInvestmentsLimitedPartnershipInvestmentsDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r23", "r24", "r25", "r110", "r151", "r152", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r342", "r347", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r107", "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r110", "r113", "r136", "r137", "r138", "r140", "r142", "r151", "r152", "r153", "r213", "r281", "r285", "r286", "r287", "r290", "r291", "r333", "r334", "r338", "r342", "r349", "r489", "r634" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r51", "r70", "r71", "r72", "r119", "r120", "r121", "r124", "r130", "r132", "r150", "r214", "r349", "r356", "r391", "r392", "r393", "r405", "r406", "r476", "r491", "r492", "r493", "r494", "r495", "r497", "r505", "r588", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsoutofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r119", "r120", "r121", "r150", "r543" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r24", "r25", "r349", "r356" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "verboseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r24", "r25", "r356", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award programs" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, additional authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "verboseLabel": "Amount available for stock repurchases under a board approved stock repurchase plan" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r24", "r25", "r349", "r356" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedTerseLabel": "Repurchases of common stock, Shares" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r24", "r25", "r349", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Repurchases of common stock", "terseLabel": "Repurchases of common stock" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r24", "r25", "r349", "r356" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Stock repurchased, Shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails", "http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r24", "r25", "r349", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "terseLabel": "Stock repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails", "http://www.amgen.com/role/StockholdersequityShareRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r29", "r30", "r113", "r184", "r213", "r489", "r508" ], "calculation": { "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance as of end of period", "periodStartLabel": "Balance as of beginning of period", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets", "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.amgen.com/role/StockholdersequityComponentsofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r111", "r334", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r356", "r357", "r473" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/Stockholdersequity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "terseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r498", "r509" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails", "http://www.amgen.com/role/IncometaxesDetails", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r498", "r509" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails", "http://www.amgen.com/role/IncometaxesDetails", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r498", "r509" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/ContingenciesandcommitmentsDetails", "http://www.amgen.com/role/IncometaxesDetails", "http://www.amgen.com/role/StockholdersequityDetailsTextualDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r197", "r198", "r205", "r206", "r207", "r318", "r347", "r472", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r634", "r635", "r636", "r637", "r638", "r639", "r640" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails", "http://www.amgen.com/role/InvestmentsFairValuesbyClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r116", "r373", "r559" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Other government-related debt securities - U.S. [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "US Government Corporations and Agencies Securities" } } }, "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "U.S. Treasury bills [Member]" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r116", "r373", "r380", "r559" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury notes [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementDetails", "http://www.amgen.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increase in unrecognized tax benefits resulting from tax positions taken during the current period" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r154", "r155", "r156", "r157", "r158", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r142" ], "calculation": { "http://www.amgen.com/role/EarningspershareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "verboseLabel": "Effect of dilutive securities (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/EarningspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r135", "r142" ], "calculation": { "http://www.amgen.com/role/EarningspershareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average shares for diluted EPS (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/EarningspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares (Denominator):", "verboseLabel": "Shares used in calculation of earnings per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/EarningspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r134", "r142" ], "calculation": { "http://www.amgen.com/role/EarningspershareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares for basic EPS (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amgen.com/role/CondensedConsolidatedStatementsofIncome", "http://www.amgen.com/role/EarningspershareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e639-108305" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r329": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r479": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r546": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r564": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r613": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r629": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r630": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r631": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r632": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r633": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r634": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r635": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r636": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r637": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r638": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r639": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r640": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r641": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r642": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" } }, "version": "2.1" } ZIP 85 0000318154-22-000041-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000318154-22-000041-xbrl.zip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

YT5L\1FA7ZU\)HXJA3)2NZ=<+G=:=&N3B5?'_4/6I'5!=C?E7RU M--NY-&L?M0S*&\.4#M):PH!G(J-WQ(F0261&N4BI"J*V>7H6E7QMZ-)'&X-5 M\@'$'',(1%D!1!HMB$TB$8U.:XC)B:1J=UPY^4J^7HKJ5,G71\J#5_*)J*Q/ MF6C TU8FEO#(M8:PTD$6;' QU&[9>]J5?,_.M-E+E8,7"7; ]G>18&\M]BH2 MW$,%0Q<):B^9D(H2HRWNO> 5<8KA=ID!?Y0TB-#.!7L618+-V-%#\FT:RI=A M1[_^%;Z6$>@K@*OI?]Y992V0',H5FA:,..D9T=;Y)+3./-9N.+ 3T(G5$O;2 MW>8I4Q4$7SO'YLE"QQRRXJ7QOI:/[J+N^ M1(_5S7,1N;\_;AS&\?7UM^NKQ5]<-@&L?4/9YYE-;BCW7O3:#:5!'Y;;H)6/ M4B*+0&7K\K*)CH=4)^)T8=DA(\[D%4DYBUQ1,O^$!K M;_X-NH(^E.'/-S":_B=<7:?%GU\FZ1TS)9W(E09YI0& 3Y(1)H6AWII@98NQ M"5L!G49OR#Z:WQ2(J2/O!A[Y3G!W;Q8ZF-,$L_1+6OYZ:9FFAFM/RN3=$IDJ M+8$8(X:ZD"4D:_2NBLWJ--D.]@^!%1 M:4=XQB\R)D1I YIX);%?2(?"Z68[=7[D\V5$0]$VFJ'2">@.#B<07.(>29@P MO@R7*JUHN$4OTU$5)>#_UPX+5X#]?!EV+-TUJ:Y\6$T8(K7H+ :2G9-E_+ E MEH,K=40F49$-<^TZQ1V]\?$A9#A$DJ>2B7'+VE<_;UG]NJ19+8)9G@5N=60$ MM#0ENH!6&,N9,+2^-%,FY^H#?'8".O[EPQZ:7H_G5)-XBRC?"MP]7_)WW+6N MIRF^'W],I4Q\-/[R"F:CV1_CB9^EZ8\BD;?C[]=S_/%D'/!?W=RR/%S>36RD MRP(;W3,T7]QQ+BLJ$FH;54^*#<^2]DDSP;BQ)(O2^,U$0RSZLH0[\"XI#L8W MVTF?%]V?N'QYSFSO0X+:GN=OD_&7SVGZK138+"/,\]]A?CV]6>:R8%=Q'V40 M) B#GC'CDCAC* GXO?-CPOL")Z7?24#D-(F+W(=X@2J+42>72 M:2TQ1.1R&2>'MK/UX"*G7IK:P:['*/[F454]'>O2Z-/UMV\P_3G)RYP=&,=? M__J.1\*=JU;[RJC[$YM<&.VYX/61<=+YI)@T3EAI)/4L\DQ35)2S&&G:?%W4 M_=F#E+-%3R4':DF4,A )>&B[PGZ*^YW3/B>>ALAPJU_.]C']2./K] :WD-5% M[C]'\Z^OKV=S%/OTU[_"U77$K>)B-DOX7RRU3)D:"CEY?$]EZ>B2.+'2XI/6()*@ M()3.0+FTX%.D- \KB2&:L=J7LEO!G"5;ZHB^@3.[FK)W Z<8 I=21?!4. 3B M2G>H9(C3*A$DK#&Z;7BTRQM^/'9>KOQ\L;C++L MM^.'5Q;L,F6E#$/.JER2R:0 XAQ88IA#N1@M7:A=7;HGU+-DTA!J:W"AM OV M Z@/1I+/V*6A'EBDZ-%F7@Y06RIX-+HI (GA'LIB]7+.?;&^.+Y54UR3CJ&# ME8($'G50ICC,Q<9+0(EUD9(R$%5!:7)L!G5-SKG>_A JGR@ECGW+6\8D?)A. MXG68OY]^2M,?HY"6?4.]P3?8+$)*);U.">(2,X1[EIUF/*G NO#ZB=$OFYY] M_#O$![\"7@:A%8,S*@(!C8"HJ*':6@FVTZEX6EK?,6IF(*7WD6N#P,$-L)M; M Y^E#=P'@JY$:89G@?@$AE@1O,E4 %.U39\' (8SN2LJ95)+H@UBA>O]L]Y? MS]_GBQ"6F8HI;NO*M1R>'"$D="8)YT83Z12N(C-/:%!4"Y6%V3E-8[^P]/YX M_S8R-AH9@U.A07!K7^RKU[D#^D;Y9XZX<[:/=$^+FC37#K)'">4F" M*>B-1?,WHW'#@HHR,B.-K'U9%7<"^MO8W&ELUE-F@\NK M-4PW;UX74(V,Q(V CF/[553]D\1S;7&S-#1[YO$@KVT*]80XO.U30;&3X;0R=%/'%*Q?U)PC/CQ/01FR MR"*,)C"IC6$ZU!]E^**;.AYBP5139=-DB V-J+I@^[NI8V\M]FG;MX\*AF[J MZ*7RF7I#1(B.2,UB:8CA"0>A'# AK6_7P.DY-'5LQHX^DA^\J2,/J8S]9F4 M1L15TT"L*O>=6FJ5L]4LUQZZ_9R:.O;27:^FCGT$/WA31^ V6;-(SO*E?9+@ MQ$N9"+4Y<33O0&7H5"3ZS)HZ[J/N^A)M6"_P$2VJ F]E/CN1NN-:N,"S=N$X$F^^WGUHLS=3VE2B-EC M86O%E^",,$XQ)T62I2E\3!K?7J.-T)J;+=,$=S^OEI4WNU>E?)M@RQREQC@2 ME"O=SI@AUDI&#%"PP@=G;;M.3QL '38X=?5QL_?YU63^]8$L9WBVECC!Q>QQ M^OK%.+Z;S'?_'?0QKZY1T6_'N '$4M83\3>SR=4HEG_R"JY@'-*GKRGAY_G9 M8HNX3-QYXU"RPI?@5Y*Q9,4#R>5F5/JZ?^ID.8-KY)M]@O:1 J&$3'*46<0JN2F&9(YCPR[HV'U&[4 M[VYLQ^WC6TVY_?:X_333LEGA[-X+>_]]VG0E=C^0<7NQMGJ#\>_>3#YC68HR M.1N/"EP9S4"<-93D&*QUT27E0F7.M5O-\.6MM7R5$]/TL:M85^)XO)9E^HG7 MCALE"(-_$6Y:HO+UIR3BM'T,%PI3[8$ALM)]Q&+8+/ M@N7:6\0&&&?"@4,%W#2LM"$QR$D>9$0"EJF.I;5N(LZS1'R$C,9]IAYJ*_\4 M\SA/U *MIKJF<: -.09=L/V=M]E;BWTR\_91P=!YFQ0W6HN;*N%)2R*Y"KC3 MEF^C9M+''*G0SYX>A^1M-F-''\D/GK=))8_94=RY0Q(1/> @K MQVK3XCGE;?;27:^\S3Z"'SQOTP*>HME[(GCQV1 +<<)&8JQ144K0>*R>8][F M/NJN+]'A\C8#.D@^4$,BAUB2"469]E"Z##&#J[54I-KAT&>1MWG(:U]!U U, MR$T&]N+8$]DX%20ERNI$I/"Y6,^9".LT#4%G:VL/F]J&Y6^/I+[*&I3!;\)U M\]YT0=;(%]F.ZCB>2!WM=:#$ :)O<-#L0!@\L&Q#("*4VTVJ,O$.7P@J,].: M(T1=NQ7'T*1XPO\8FA-])%Y[AMRR:_R$6QD,-B4#(GQJL,BH+5U;NF;,/R[+E15=@-W)''M+W!)2$9 M+S-"DB5?SEM+? R*Z$ I)&YX-IV:S?<@P38L9T."*L+>ZDC4JR4L+A4Z46D< M$"*,(_[@VVB^R! ^H':PPZ<>6BO8%_A:;6#6,4?EN5)42*H]JCK@5BPY@/8\ MRLL.GW_HP-;9[,%#?KO-272E!8Y""X(Y@09%M)'88!A1((P7E$I8+^&N,+AU M&YK#IAJC6K\LWJE/:3Y?YAO^ M_@2YI]FEQ_^3I?Q NF>0\2>T(9U255D": MH!XTD?@*_7P[SF6LK94Z.-^"NVYMO$W9M-Z]>_OH^F=SN5< G* ML#N>.%OV?7%> +$Q>8E_A+YAMV!IAX<]>[4WD>ICK:N:6K_X_CW!U86]I?A8N_H@[:ZVF!)U MF\Y3O*'?)8V<^9 46AP%4^G6;W%M1# &4M' U'HWURV:W?* \]!J#>D]UJAI MX4#>3G(/FKNSL,R>!,4)4EPM9@%E M)12ROFV@?A.JL^%+905LX$CMF.2[].<2WIO1W7;H-><.LB")Z5S:D43B8A#$ M*2L"6*ER]7Y&'6"=*TL.5L$&FAP8<]Q@3=T&0Z:C;S#]>3']LNS*=$FE F4 M". V5T(BC$#VD40K<6(BMMTK5DB&:LXSR*:PEWA/I:O.IVL_2_]U75RP'_BE MY+XO\E=5L%*XIO?Y_AU-H7Y$%R$+:8C@ M:$=)&REZRQF!H_/,7$A6^>9YA5O1G9$5T4@E#7+"UYWG!IHGX7W *+1GEH5='E)/)$FECV1:L)RUH9&P!\WOGEISY0G MK(X3($H?+=2N0%S&]#]/1W!U,8[+Q(!7$YC>7":__@I75PDQWXW6BBP%C]:7 M\)I(6.RR7)*@K(_!(>+0+>>BYX./'?$Z0&.3@<1=T5293>?WHG.O8;:TQ+-. M#HSU1#F/IEBYVP%I&6%4NN0T".D[M4' C[^W5>!W=]O$YB>?@:E10:05,RX? MH[EG<7?!U,>.Z*7N8T4E:NAGJZH/%&[%37\G-IEX#$:4$>(.>0W E]'VG!5# MAXEJ1SM%*$]*X5O._Z'TW4>FM0_W_YC,OH^FL&JN(ZACWCK"N!9E0'PDUCM' M?'""&1,8,-KIZ'[PL<,=S/7$/*DBH]J= ?[7Q;O_^?;=Y[=+4^!NI2M3(#!J M Z*RC)=B5(3FN-;$&L4RI52*=5M]B_IV/^>YZ[.B%*N_CM??D&FO1I/9Z-OH M"J87:%C,I]>S^>LKF,TN0H&Y,OQ85A125.[ZL MW1_ZW%7?2KZU:YH^E:/I^VY\@G'&I7(DY@SH:SJ%YQ##$\EKK2EC,C';2?\= M'O;<]5Y;GA7M[.66]/,["F>T@J*#2,$B%$]E+BE0E/@R5TE0;@+8P$SNYD(_ M_-SGKL4#I%2[U&@%Y>+=+Q?;SI%, =%17*:DI3-I(*[TAW!&43YRSC4C.D=)9/*,>/!X5*14 MPG]E+%FWPM+-G__ M!%4<8ZL5+AL! *ZC"P 5 86UG;BTR,#(R,#8S,%]L86(N>&ULW+UMD]LX MDB[Z?7\%;L_=67=$P4V"($C,[.Z)\ENOX[A=7I=[9L]VW%#@C56<5HDUI%1V M[:\_ $F]54D40($TYT;,M%42"60^(!\D$HG,?_U?W^[FX$&555XL_NV'\&7P M U +4E8DLE MP==\>0O^*E7U.\C*X@[\M2A_SQ\8A/]>W_2ZN'\L\YO;)4 !0D]_+?\42Y0( M1A-($T0A#FD(TR2)()>A9"1(N$KBBYL_24JXHA)!JB(%<1IG,"4XA#*@+!.< ML 3SNM%YOOC]3^8_G%4*:.465?WGO_UPNUS>_^FGG[Y^_?KR&R_G+XORYB<4 M!-%/ZZM_:"__]NSZKU%]=4@I_:G^=7-IE1^Z4#<;_O1?OWRX%K?JCL%\42W9 M0I@.JOQ/5?WEAT*P98WY2;G T2O,7W!]&31?P1#!*'SYK9(__/L_ =# 419S M]5EEP/S[Z^?W1[ND/YDK?EJH&S.RGU29%_)ZRJT9*:J0,B9'R#\0-F:@%_O5X+6TOD4YP?'%!; M'GG[2U45JU)LY\V[^:')4,^#9N9,?UJP.U7=L_8&K9,Q,1HU_]W(#+8J7("- M>C K2F@4O !&>E"+?P%:!1_UE?.YF4NU*<(6$EQKPV6N-C^#-_J7"V!T!QJ# M?_UI"^?@(SZ?V#C.__\]A(784ZUNL2B?(E\(S\AOZ:W2H-6P9ZSB-6YM3S\9 MT_29B&'&I.!)<8D5=6/M(/U.CX[688$=.\)N1]/]SH]!CN-IQ MHP>T!B:]/D Y$]4)&#PQT+%>1J66$ZH^Y8Q3E_S1Y4R8L)#-2N'*,/U>75Z_>C#HW==# @W -/ M$P.\$LZS2$_T/,TNKKV/.NOTA.;I;-2WF7ZSU(>BJEX7BZ5>+:F%>/RD%L9I M_WK.\KOJX^J.JW)&. VC,,R@PBS6UJO"D K]'Y(1)' :@%1HT4E^ 1FXW>K. WH[1_ (Z,(F=C:4S9=G#XXFE+#HD&-42+T6CKBD!.F$)&$(YK:L%%O":9&3K6<=LS3'_5N M(AH%RX%YJ181[,D/&@7 "Z/"CQ>@N62KQ@5H% %:DZ$'0+8[YO5V[_<=B#U1 M_O$&Q'K^.!O,9CHQS=1S1$"BH)XG^C<\RK1QMM[K6>3\AMPF%;$J2S--S7Y^ M]6F628IB$@=09DROTY$@D,J$0Y*F-$N%3,+ :I[8;71JU/_K(C?;'?];S\FR MN-.65+%:R,J.BO; ZJ;WOA ,S-B.VEN_]X?4/6 95DJ\O"D>?EI?WEB&Z[^V M5N%>#UZPL'_507-[I85C.1,RP2E," M4\P0Q)C$D&4HA&$:R"#4?RNJ7!:-79U-[;7\4"QNH.[H#D@M]06X*377N:T- M.[&U6Q7Z0FSP]: &ZXL!ZTT-UL^=8#DO_FQ0\+3LZ^QJU 6?C=)/EWI6][@1 MA53Y[*U>/"X?+Z74STSUJ:B6;/[?^?WK0JJ92$B49)C") @RB F2,"4I@BD- M$8WC))8HL*&([FZF1@Z-I* 5UH#<[2$?P/HRF,Z295R+R@=LSTPN+XWV(^5C;IE-_%Q6E-5>_-S63_-1 M+:^R+^S;IZ*L8V66RS+GJZ6YZTOQB1D99S(1*46*PI@H!G' ":1"KP033A/" MJ#;PL-.FX<#R3HW8?V;YH@+% K"]\%>C(:@V*KKQ]M!#;L?L$QK([[^C\#RX M>2?V><^QK54'168Y;@M"$,=_S18+?&L$M _&L@;?8'O8,Y\A>R36R6Y&' M@M)AH]J-VS0. M.6-AY!#1X]S]U#@\>ADE\3^#A1$4R)4"1E3PHOVZ_J-6XL<^!.0^.!;,/BCD M _-\+3&HA0?-YUI\8.0'K0(-WN#->BQ&P=UA&A@4_Y$FA4'&P6V6Z UCYYSA MWNIX,TAOC??FD_ZM^ @[J,\!9IQ1DB !)<4$8A%*R$*%(9-,X8B)F"C9/]A@ MBDZ. [!@]TG9OLN++?J_WZ M5H^D>K_X=5$J-L__1TGC!ZTC!1>;,]K_H>1-OKC9=ER%,\:C6,4AAD&68(AI MJHU)R@4,PA@C22@1D=,F85]!ID83C1OYQ5P+;BS&8@$RDSKAP8@/;AOY0:GF M]>Q>W>;WU85>E97Y@_[BP=B?JLIO%DU.A6IS0[[5V(UQ>H^O'2^-,6H#LU>C M@CG5MU4"&"U:E[$9PFWV"] JL\-W'D.GSH73$Q_V%F-4UCP7K*?<>G9[_1CX M$WNLV[G*WN0/N50+6;TN[NZ*Y@SBC,H0<80HS%2D>3:E"#*&4\A9($3$%9(B MF>VFASKYSG9W:/5FGLQ[Y7=#OY42W+-5*;'.H<*D_5;KC)LSALBP-[=4B74I9I^(PJNYDYJAF:9C$+!(9E FE$$?& MQW/-#H[@G@MW^-YZI] J[LR!4!,3.2^J5:DNN5[K M,+&Y:EHR#;+4D\03?P#-H;M3XYDD[AX2\?TM&>QLY]=$KE WF.3M[28]VQ M(2Z]IGE5+&]WW)EO-M[,R^JYZ^1R(3\6R^YKFB!M)=\O-!7JU5*EI.'$8IY+ M<\LK-C<9^J]OE=+MK5^B(!642L2@8B9C7!P(F,:"0\)H("2/5"83NXQQTU30 MY1T?)R'=NXV3N_8^<(T2D"YN[3J#\*)86ER9MX@9G^T&,[ +&FA1 PUL#D;V MY(;:9C4V.:$G- =MS?4*7&7 P+.WW[)5'EQ6A[S[0(-DXB LKEQ#I3_8/9C. M%L0TA]ME 3DYX2>X\)ST,_O2TXIUL@]"YTIW>E*/MT*>GNZ'5M;3E;+?BOQ= M42HMT=MOHMZ?-*X!TVH;M$A0)+21FT$4FS ,$H20"40AB33+Z/8$(=QE3=[9 MV]16Y:VP8)UAQ[C9:W$= T;MH$9)AN),22BY$!"K@$"*HPQR@A+%98+CU#$- MM3>P1[+QC\'M>C+##F\[3X@W#(>V0UOPUH*"U];/JK,WQ H33_Z0[KY&]8A8 MJ?W4)V)WDQMU*]W8[+\^_GP]BX(4:7:0,$H"!K'D%*8X#6%*B8Q")7G(K([' M;5J<&@5_N57@X^7UF\O_!#_/"\[FX%K-E3!GB\K?E2L1;X'K?OE[P3'P"]Z@ M\),6"KSX^OOX!?+C__[[=?+$Z/6+_HS_3O2)ACKFU?9/UI M^P)OVQCE)7TF\OI%?/Y#W[S&/ZN%*MG\[;=[8Y@USLXG^2ZK69PFJ5 9A6%F MWLA "DACA6 0TDP*E@D96\6MNG4[M=>V5P9C*WPMW%6#H#;PV]UD%FB%!JW4 MX$4C]X&\N"X^1WMP75,2^P9YU#S$/L#ND7G8!;/3Z8:M6ALYQ["+AL\3"SO= MW2?K0+YL@Z.NU7(YKW>[W[ [=J.JZV)U<[MLBC2J*,,RIA+J%1DQ93FQ7H@E M%-*,IS''$@N[S6B'/J=&XDVF2,!,31(EF]"2:B._RR%Y.\@MJ-T_D /S^E9@ ML)7X K0R@T;HB\89ZQ]1E\P#WI$=*_F #X0=LP\X8=6=@,"NJ1%S$#CIMI^& MP.W6'MQM'*9*?L@9S^?Y\G$WK]K>"0HU"PC#*HL%%,8"QQ11R+#)21N'*A-1 MEB78/F^,=;=38_!USM_V>-C7W.R:[V8I/'A@S(&'[ ?$@MP'@7E@?F]D!ANA M+_:S0#XYV.5"\?;0.K#\(!"/1/2^H';C>F?$.NG>OK7Q&-]9PSW2=[^[WS;5 MEY(MJDQSYN5"7JOR(1>:MZZR=_F"+43.YCN;:%]T#]7AG]X4=RQ?S (>811MU(VD(4)_N.PW2AR=W2U-G\"K[5.9WK'R\ M+&^:WF8D3HA$2D&&,@YQH!+(8T)@HJ=1)1%*(H7.,#Z^_KK.F#^?DNFU.X.3MNCC;X M?=TWI_0\Z<0YV8"70M6;7N9ZREGF65;-*%$X9&$ LY IB!4+8$HQA:$*61RE M*$IY=$:=ZN<]3FT>:%^,(@/W&QG/*DE] &0[.]HK=$,S^[."U%LQ&:8:]8'^OF:EOWA7EI[(02LGJG9:^WDU\OWA0E>GY M4BSSASI3[DQE.(@P3R$E,H:8Q12F)B%.G DN*9(JP$&_7#B6$EB]0Z,FQW$( MY.B+NAW_#('DR%ES3"Z.%VOAZ^W4']M0@XT"8*N!_P0ZCM!YSJACV_MW2;'C M",VQG#NNS;C16E4N9Y]-$&D;P)S(@ 8BULOC.-!T185)W<4(#&C"$I&Q+(JL M*#=B.+LBGX'6SSAF0#,PFO=&PIHTCNG?1 M@;YEAPKT7UL:>-K:**_W$176K^VQG_NFM) JRTWEZ@_Y@SFZL]1-YWRNFJI> MO["_%>7K.:NJCWI86]\U(AD30B20Q@F'&(48\B#+H"2"L"#D+&%6CJXS9)C: M:[Y5 VQ!]1LS.2AEX' ;FEITA^.!O"'HDV^@- MHKBULE5W-UE9WH^XNI-#6C'*$@X@AR% >F M7*R 5(0"RBCD*HOC,$!.F[5NW4^-)M?2&U_&Z?<5_%8KX47<6<)R9T['Q4$NP'S%/^Z]F*CTH7N@>EG]3E9[94QJY7LJVPP6[4 M+)(R4,(4R Y1!+$,I=D+C6 62IPD <<\<:(]^ZZG1GEK64&IY;P 52TNN-_( M>TZ-C,XAL".V88 =F-2>U-0P9:Q;D#_7(#>B@T^G03ZSW(8-7H.4X>CL^#N6 MY[ !I+MLAU4+YYINZP23N[DA7SWN_'4DQ^07]6WY:FZ2HP=$1#0E(50X(A"; M8C\TBT,H)$=!1A)*A5,]:8^R38T!=TV03=;87>T ?]S]^^)HWMB^AN#YP^UJ M)8XZB".:D.>-7VM> J,EJ-4H-TN,&K+\N^LT.3:WI MI@!IZSUH=RK2C$G!$-2/*'JX6 MWW%]CPC@]U*9:([JP^=>T0:GH:WVZ*\(_:T-L4.[(><,#5XGK%SR$^ MURN.(P7E[N&9;_%LYZL;([:OK)S6^'0&WYYN9;R(6VN-]L)L[>_J9XI]5L+L MV>@>1/WT7*V65]FET,_3:FX\ @W1%W?WI;I5VA1\:#-MU#5C918@@5,!B1"& MCVD&*4YC&$1!G"*<*6['QSZ$F1I;/]4%%*NE6=;MJ-,&=>TI!-I:!7VJ^IXU MEG;FX5@C-/#,,.S@.)N:/E#U9(Z>)$N+XV*^'RL75TQ4I*Q%@$,X9-?FRE(*=$PC!" M6,0"XY YE0<[V,O46&\M9%WDZG*UO"W*?/GHN.-]$$[+S>US01IZ'_L@/@.X M#3N!\+5!?;"/BN]1\MNW<>7&?2E_:\OI4Y(OE=?ZM_MSL6W\LEJIZLU(H MP*A]>AG-LC0U![1D0K6%E B8JHAK@XEE*:()X<@^4X!UMU-CA_@EB?_95+4R M%;!6"AA)P8OFV_ISK8)%9NASAL+"NS@(P ,SBY$3U$(#+35H_FSD;F %;]:( M#PJO2^VC(6 >JR:11[@="P6YHM9=P,>ZM1$+Z[AJN%_PQOGN,W://VIU6'7; M++_;', S147&.<601;R.A^2093*"!%$FXD0(C(C;N=RC?5F]&>.?P 7Y4MWI MA=9"6>X,G0;58=^X-U!C;ARW0JY]>2]:.7_TO'/.#_8R_=]RE[L'- MX\X;SJI0];HM"[0NH5)MD@YN$@UNZ\[.*,6*!$S"),$*8IY&, WC :4!4'" M5)2R?M64G,1P>4N^4Y$E4Q=5F!TGN/FJ^LKNM\67>M5<@"&-BA; MY-?R;RHT:5[?26JZD\=TJX;WVDV]0/1;TLE-A.]1Z:D72$<*0/5KJ\\:6C^P MM;GV,5^HP_9:V"XM<( S%!,! Q9FFB.Y-)E/(ABR@(HX%3P+J?TBVKK?J:VB M\4OZ=!4=@A?-M_7G,U;1]H-ALXP>!.+!:6]5M@L[(W;'RBX<&&&7E?0@2(^U ME/:)N.-:VAFW[L6T?7,CKJ:===Q?3KO?WL]L_JB6C15NTFS-D%XI(\DXY#PU M91!,"'9,4Q@GBH8BIHP@[&8/[[4_/4-7BP?R6CXW W8?-AJI)(K#$&91:.I( MZ$]&R3]QT9TME#+H:#%KF[;<]ZOKMH%I/%V:'+^JQXOJB 6L\ MY&9N/SBEHZ"U0<-8B("G>CX)8CV?B!##-$E2&,HP0C++F$JM,MJZ=CPUWHQ> MXB=K+A2 %\VW]>?^:RZ7X;!8= T$\L!44DO=+@+J]<#118#&>F"0'=9= X$] MTL+++^AN*Z\>R'4NO5S:&V_MU4/+O<57G_O=DW2^;N**=>MOLTR)I>XC+^15 M=BF+>_,$UH'Y#$LFD-*6G9*I7I")%*8A1U"16$N1J#0A5N%LMAU.;0;8R@P: MH2] (W8=L-\*[G1>PAKZ;M8? M"!V=X+EDX)0ET .B-SJ%4WHZ44=5%Z-]>H MTWT]CQFL>*7^OM),]O9!_\>4]*D?]3B+11S)&!(:F_,#60Q3A"*H. TR*>,T M#MR2K!SN9VKDLA43U'("(VBOPU?'@+5;:7J :V#JZ(64>]1^-PZ^ O./]#)N M['VWJL_"ZT]01P@ M!5,28\@3P@15"E-A%3#0V?<_[&?/AO51:M=^13L5K(:_VRZ1MO=EPEI/7PI3CE M)"()IJKE!9Z'X:QTV(J=%&_#(._AG\\0\AB?Z,DQC< MY?.Y687O^;R).:UCKJL_WQL-0=6JZ./PCN,X4D2HM@T9#%(B($Z5A*G2_\E0 M'&9"*"X"9!#[9.0Q4?S1*;/SHM1K@>G\$ MWJS?IQ&'HL_)K.&&9/QS6MZ'IN>YK7Z8VIWB/=OJ86E< MY]\V07 [/6X[B=+V+4,8$852!%$J]9I#!#'D 260J3A*(AEQ)*T\F&[=3LV: M("]IL+]?'J7@1?-M_;F_L6 _%!9SSR #^W:R+_MALON,=HNA6F4!X7783X9 M!.:19A"?<+O-&,ZH='MO6DW.X]03+Q\;5\,XHH_V M\[TWKTZXH$_>X!X^4]&:A"A)-#E %24AQ)AS2#-"H" X M34QQ[I!8[5H=[6%RE-#*YAP#] A8B(.(1IP!#$'#&8XCB#E%&!$1((*>%RG.9H M3TXO\PA':[Z8/MJ,VFZS^7$P[69S+Q -_&:OB\L.?/;])!2>)O/C_8PZF9]4 M]^ED?OJ&,S+[7-W7U686-WNI0=JE;\!2DB*10<)("K$0 60\X>;472P1)SPB ML7.!F*X>IS;9-SEL-A+;9['I";@==WB%<6 ..87@4*5D;.#QF1BHL[_Q$P39 MJ'\P49#5C?WXYM=%J41QL\C_1\DO[-LKM5!9OJQT1Z5BE:H^JVHU-UV_TSJU MU6Z:F%Q]]:>B36T[XVF0AEEBSEXB8ZP034J*1% &BH_NU^K9'^ZW>U ')5FM_UL[&IF'5?:^_& M?9X&WXX@QQ_2@5ET5Z$ZI^Y:)5,AMAWHS_MCN:[8U9XX,#=M-//'M7Z1]D3( MGH0:E;7] OF4VCVWWF-G\;]NU -;QR5Q$K$H53"1FL8Q"RADC#"(DI12Q'B, M'?8.=QJ>&@?_U\]O_W+YQS^$"?XS>"'50AOM=XSWV@W/M@!Z3XBJ3SC:.0IB)D#).N>*A4TT7 MVXZGQE6UC^?!^!=<'6&V2,LX"11-0XA3KI%.$P)IB+7=+F0HHBA4,4^.97=KV_WU3\'TK>Z%?LC:KRFT5M4[5A#U*&&4$9@CP0@9YZD0EK%QE4 M*B.$4*P$=RH_?JRCJ4VUK9Q@1]">(25'H;5C&Q^ #']HEJ6]8KKRZFQIUK 4&1F+0B P>*M * M[>!Q.XVTA1?2*WX#,\@)Z/IX+4]CZ.#+](KE2![.OH^CF^O3&IE.A^CI5L9S MDUIKM.<\M;^K9^+RE6GD*MM$"%RK&_,053.,)(E4F,* IS'$:1S!-.8,)H@2 MDK$PQTIZGQ;2.HR>96; )!*1K(>!)D(Z[(0NEG1XML[G&C$*GRV=O% M,E\^7DJI'Z"J[N.J_%06#[E69)9$G"!C8$0J(WI5Q[2!02B'$4KBC&6I2D,K M=]"ICJ9&'8VLH!7V M3B:DC!6F [YCB);S=K^$1M8,;H#Y@U8=BB<8 L*B5> MWA0//^DF&I[0'[;T<++A4:C!5KTU+5A?W[/(Z/K4P_O%_6I9?5 /:KXN'(9" MPI!D"13FP!)F)(,T80+&/"*'R<"+=CA2[AUUKX;=%H %;[OSJCY3Z >>)IQP['Y6Z^@'SE,UZMM(G M>YJX57(U5U?9AV)Q\T65=R:0:KL%6KW])F[UDV?.8/"Y^J*^+5]I?7^?*9H& M"=4+6J;"!.*(ZT]Q*J 0&:4XTE:7L"\_UE>*J='=6@_C_)EK3:#N]$Z;7QL] M@%HKXI+WJ^\86>QWCH'\T"ZW'= _;$"O8SQW] ;1<;",,RE@IVOH-CK<\;6E=SZGMIL_M\R>:S*.8IPHS#"",3@1D&,$T5A9F* M0\I8J+A(W9S%+MU/SWO<2 \J(WY=@G[G1;K7HL-\ 40C_)_!_QN\#((@U#^T MAS'_#-!%$NMO066J"E6 K9:W16G.\?\9%*MEM=1-:CC^^(<4A>C/<81?TO6E MNF'S4M2=QG'Z,MK_(73S&3D]!'8>HZ$&=N 9JAW11NXZ 4G_.HCZ8>7(5.74]JJ.H#RA/W42]VN@92:F6)G2BWB*52KYZ_%43]_O%)B+K MTNPO-<=&$6$)-[MN-,,!Q(S&^I/Y,Q$)9V%$8E/"Q_[0M'W73B;X",>FM>2: M)ZM;8Y'4L@/^N!-VR3:".P9>VH^%':D-@_# E&; K0.L/NV ^\)(KDGLQYUX MS<0@B\,,,H(S3K,T(VZ9VUPZGYI'X?*N*)=U.B]15,L+<%,6555G:F/S M^NL;EB^J ]_/]=_&#M1&G:J6^1TSL0G9-GN'<0ZRO2/XE09#O\8/^O+&0:C? M;:.0N;+->_#H>K#08=3M:'.HL1R8."VR'[BXR'L<272'S=L118>N1SZRZ [* M\R.,/=KH&Q2A>5JHRF1A4_KNV\N%?&-B+HI[\[ZN@[ H#R1C"20)91"',8:I MPB$,&,8A(:%4RJD\M%6O4V/-]PMXWT@-UF+73+@CN&LDA WVM@$0GA$=/.X! M?#H!Y@ A6$XH>0MRL.ESY-@&!QB>AS2XW.S&2DV25_$XNYS/FTR0PF2$:?** M4!P+J6TVF*2<0(RB %+!$:02<\H0BL(XL2&AKDZFQCE:1+"5T3%32R>:W;3B M"Z.!6<05'FO"L-&_(\A^?7O##^N_MMS0V?PH5&"CX/K-M[JVQY;P:[.\:!M\ MO/[*[E^O(PK;J4^(.(M0F,*09\K4EI>021S!5,J(8!1@1M%LH9866\"G^K)Z MJ&GS4*]['-#+:Z2%:]SWPRW[9 ,XB;1BC(42$RAB%D L PY38A+?1#$21$0Q MHU;%%OQA/2+)=J'=JY#S2;A1HA]>82** Q[K!YM2F 8XAHQE'"D2A*FRW*?R M#OA(&U.C0]X]WWF'<>AMH-HSLY85&&'!ZT'Q9)M M<>D,+#C9R'BA!+;Z[ 4/6-_4-UR@6E9Z1=+6#MD>3@_#+-%360R5" )SCHQ" M+D0"@RQ(. U2E(74-33@<%?38]OM%HIJ9?V3Z_[[$53MG!,^D!J:4(V(M0=B M+>0@)_U/(>%MM_Q(-R/OC'E.L>-/)DO9^& M21I2(F 8FY14*&]X3<2EY^%HQM?6T'3R\B2., 8!\0MM=^A;J9&$FV> MNK6H%YLSVTYT<0+:;I[P!]C !-$;JQXI_;J@.".AW\%F1T[GUZ7:\V1^G5?W MLQEVS[E_U%(W569G4I $RYA '&>9*+*XCG0RJJG5 MK>A3&^O$U6[<6I7+;4+FGU5Q4[+[6Y.&LC8 4IQ0@4*EN11)B"4CD/(TA6DL M0Y&(3"!A95MU]C(U,MB5S\F:ZL:RFPJ\(30P$[B 8_W"6RG?];[K!G;>=?W7 M]CWO;GN4U]Q*O?5;;G=Q/P/JYZ*07_/Y_)-^&FY9I2Z%*%:+^CB?_-NJ/=PU M"[*4Q0%+82S30)L 3)L +#*E\V+&8Y1E.&$N)H!5KU,C 7.>-5^(4FF!S3'\ MFU8)-ZO #G [(\$[C$,S12OO!5A+#+8B@QV9_1D,3A!YLA_L^AS5G'""X:EU MX7:SU_0%[^L3IGN'BSH-!0L_Z M@SALQH,N ::0^< "(,L,"#8M]6/%5ZLJ7ZBJ>EW<\;RID_Q9B>)F84[MOZ_+ M V2Y.39\61<(N!1_7^6EDI<+N7:U&UFJ:G6GI)'I\P9ZR'*8A1 M'>2W#FX.)%$I3R!G,H'8I U* U,P,R51$F.!<.H0W/R\@ZE1+GZ)ZH,P<7L0 MIE<\[@$-&&Q\7.K] M$...Z_I&">[DX;VNTU5?;;-XZ\YS"+XI5J[+>E:^V1>!R59KL:8]M/BY","4B5C!()=;L MHGF&T22&BC)&61IB0IV6MTZ]3XUL=NL@KB6MG64?+__BF 2MWVC8+4D'PWA@ M(CH/WOZG(%Q@\GTJPJKO[W-*P@66HZ ?F+G.P_KX^C/\_YJS]?7L,?PLJ:$0>%-H>*1!\0CQBW@,;J#WG M-[!%RBJIP5MTT= X"0]M3 M5LH[[;H>TK37_NI>0Z/MI!X2?W?/].#O/3Q-U^)6R=5<764?BZ;$\>6=.2IH MLC^_7^@'7[_A(%XGFA#LM5G/^!MO"9 M?:_A&YBI=D=NK1BXW!FYM6[@\V;DFA(K>R5"*I>@X8$'T\&W][T&=22'H*_! M]>0[' +M3H>CUP['\U(.@=.>:W.0#L[8^?^B1U$=R)R-@BAL5Z0IPDH&:0*9 M-I1-"K 4IE1&,$VP))%$A$;NE1-.]SNUB1:]C)[N_H=F]S]J=O]##[O_%H-A M,5T. _' D^$V'7\M]K%T_#70PR+<(PS +]*C%T XB;CG6 ![N*RB 2R:&S\> MP%['@Q$!#K?WKVJEL6= M*C_D"_5^J>ZJ69RI1*_$*)345.S-$CT=A!&!-,A0I$*1Q7(;]Y=C5/_Q MV7 ]=22?WV#/W;;ZP/TF(/=-7HEY80)U-RF0$.$**1I!SJ/4N)HI3+E*8:P_ M$A[P5,:NVVNG^IS@?EHMLF.^J=/86NZ0^<1KZ"VQ6M8+L!/"OY5WD+Q1UNCX MVM@ZV=^X.UFVZC_;NK*^L>?QHGR1+]6'_,'LABWU,Y)O\GO\POY6E'7MA(_Z M46J/M&0HR)*8(RB$-#6G8P2Y2<^=))2*$,<)"JVVM'KV/S43K!$?UO*#K0)@ M_8+5.K1E08P6?8\=.8Z2'6,-B/W _.4?=O?C2/W \W4@R;'W<8\D]8/FV:&D MGLWT(T(3!K)EUYT=!A)2DA(%$8XRB)&,(!4\A&DF,T5E&H@@<3.LCO0T/7-* M#P!;B#J99UF:$AK=V7*=8+5C* ]0#;W[;Z*'=FVG03+IG,#!$ZDS&"3V4A5Z+>'[E6Y4,N5-7.JC@-8X22!(8ABB!6"D$:AZEF!LR# MC%.6(*O2))V]3,W":06MMQ!;21V-F&Y0NXG &U0#TT OE)S*$YQ$X8SR!,?; M'JT\P4GU=LL3G+ZX;^J6ZULUGYM<5VSQ.$,JC3.:8*B45"978 89IQ)R' F" M!0^T:>"6JF6W^:F]Z&U>D5I$T,KHFH=E#[[N-_M\4 9^I9WPZ)%4Y9#:9R11 MV6MNY*0IAU1YGB3EX%4](@E,G.[KHJX(8.(4/K&E,4O??KLWR4@_KIH]516' M)(X%C+ R;@J>0,824SPH2V,>BEA&5EF6;#N <>#7WT@+=L0U9P : %N)+T CLV<@':(!/ ,Z4AC ^<"Z!0$X MH-2Y^V_3SGC;_@Y:[>WWN]S7SY'2'-G4[7]6]8F+9[Z;)NHE# ,N&*,PC+A> M3%%D@KP0U2NJC*L4913'5I7=W+J=&D]OI(:MV.!S?G.[['OXRQ)[.^>+?T0' MINSG8#YS#0]P@LL-)D^N&LM.1_7'<_;MH&PVZ/?C7)C#^K^\*8 M26UP[*O'UUJ(FZ)\_+");4%!1GFJS?REPXULVP'0D[.AP MWZ$==$>@O0#[T-9R>XS!= /*5\2E9:_CQE>Z0?$LFM+Q]KX;^P]J7MPK^46) MVT4Q+VX>FS76.M-H%*992 44+";&K,.-EY^B+"(L2E*&4]<-_LX>I[?1OQ$8 MMCLK<"OY>0O24^#;<9-'0 ?FI(VDH >"/<("K'#Q%A[0W=O(80)6JC\/%["[ MK7QD[ +%+ MU0.!AIV7]TE-8DI!Z+586\-<3ZLW);M[DKP@$I((%@60<,T-&),4TD3$4&8A M8RH)XU!:%<2U[G%J!'&]NKMCY6-36+ N9OP(5@MI-BY7):B,1J#01TKT88'.P4K7JF_K_3C]/9!_V>]5@Q('&=ZG90E=9(HKM>* M"590!)(CE65IA)W*ZQSL97HLO182U%+V7 H>1M325W\N3D,3KC-$[K[W+@A\ M.=4/]C&NM[Q+S6=N\,Z+>YAMKXOROC!IR_93YKY?R)6V#+6%N*YE(!GA42HA M9X1 C,(0,HP4# +*N6 $<1E:6VZ6G4Z-%C9B VG.0.PDKH5@*WN?W"FVHV!A MN V [3^I,B_DVX5\HWN;,<59$',&(U)'H,4$,DXR&$19)BCF1(C8 M-3OO7@]38^Q-IMI&2J#%!$9.]XR]^T!V\[ 7>(9VV[LBTRN=[T'MS\KKN]_B MZ E^#RIT*-/OX0O[K>_O?W&[O)%/5/42[]9%HNZ6:%] &?MU[XN6\ M9CN)A:=UV_%^1EV[G53WZ?KM] T]UG"70JBY,O:$?.(GNKPI57V&O35U QHF MLVEMUAI6$_ !8+ MN$%@'9A>[!#MLXBSA]9A&3<(Q",MY,Y\>-V6<,Y =2[B[%L;;QGGK.'>0L[] M[OZI6K;KQ*=UKQIC!4D<AS:L1^ MHK!176ZJEXEH@[^=L>@9U:%7B:$L83@4'H8VUO[ MV)I/&JQV KS76P51G*4DY!"S5/\G4\14@PHA053P*,68,?9].7\M\>FVV0\W#H(0 >B:E] >U&W*Z ==*W=6/CD;BK?GM4[GQSSU,51:GRF\6Z+M5K5MV^ MFQ=?_T/)&[6NV_JE>*4^*V$RPN99KN0;;?$O;CZJ;\L0_5(LEK?5+)8IS8(@ M-,5#!,0159"1((8I1S1&BBDIG0ZD^A%K:E/"NF*<^G:OA/&J+0O %2AWE&A* M7IBJRJ;48P$4*Q=:JPH4>CD!EK<*+$P(;(C 7:WBA;&M#%1@4P#2I$GL7Q/2 M\X-AYZH8?[@'GKE:A<"F_)]1"1B=0*W4;I7L]BG8U0TTRH&/[5@W^GD\KN(5 M;U^G6_P(->YA&*] /CL[X[?UO@[A,G_0]L>#VI[@J=:]OWHTPJP3RV@;I;K- M[U\]-GN/U]ILJ1W3'\P#J7]\]7BHL<]Y]7OK5\Z0P$$401,D!#%*4L@BHF 4 MX8A+%D8(.46 CR?ZU&::K; [I][T9+%+.SW=TZ,]#;9>[BF.\>#.\O.'MX>S M?&RDO?G<1Q-\9-?]V /R? =@= G.S4UV*?2*>E5G0;O2YG1IZ?O*.2<\RB#*)0(K/1@"'+J/[$(Y0%849"SONE)^LES]2F&R-TL:A= MY?5QTXU*H# Z ;&KE%[8&*WZYBSK-X!VD\F(PS+P#+%;L7Q'%U K _:T6:+*S\YH]I_3BC"E"!9,Q5#C(-*/#O9)?3!]URG#7.C\M3'8<49X6F213#B40"Q,K-NC"647 5$9IGDB6-5 MXV-=32]J:BTIN-?6<&5D=2QL?!15;;9(=AE S:A(K+A47 M3NG(?& Z2B[6-:):4%!+VIM?CV)KQ[ ^$!N88_N!Y9Y-]002OM*G'NMFW'RI M)Y1]EB#UU/7]Z/9#OLQO:H_6M5HNY[6/J]GWO?S*=#O2E+*O%UB?6+E\G"4B M87J-$T.1Q0KB- EA*JAFX5@1A4+,-">[\(5C_U.CD494LR6NZOK#]79XM='$ MC4A&#:V4H.MJ)?@!;S5OH&\L9/5"O@CX]Z(N>)IEQ['Y6]>D+S ME-3Z-G/.:?%GKOPZ?2B.@H@$J38L8XDAIF$*TT";1=KFC C!*0D#)SNHHZ^I M<5CK3]W("M;"]LK/V@6R'6%Y@FY@#T[?KBG[W!ZO%/EP^?' MNV_I$43^D2WUVO8JN[HWAQG-KN"G8IZ+Q^U632 QP0%!,!"I7D&Q2#.'B"0, M4J%7IDE$F:(.AWI.=CB]U>FK594O5.42*7X:UFZN\ _5P'31R JN,K"5%OS6 MR-LS!^MI#!VBP;UB.5(8^!M5B3+GJFH"31N$S8;N JBZRNR_5("WS^9%?CF]!?SE311CZ;A>4LW]8;R\E:_<^LK7X+W67U)(Q(H:H#KHT7@KM "+V^U MO,5"/1%5;EV:;%X5)AE9+NH;S:]E':-@-J?O3(T?IEG5]&QD+;;/E^Y",7&[ M:;G6Q]S.6957]3&GNBMESGVL,Y^\,%^K;^SN?JXNVOV?"]WA@UJLS$%7\VN[ M%OWQY8[G5;?.B]7RR5CL2+-0VEI?%$L3/?KW%=-PF # /Q_4112KN307Z@GC M03WJ&_DC6%5UDT;8"E0KK1BKP _WI9)%+;V:/_YP 7YHQ%"ZBWG]A1;XAV;@ MC?KU#O\/+\&76XV :DQ.H#_6(.MI5)5E$^ELVEXS&V@>M?OZ>?9U$,SZE>L\ M2'"ZE?%.$%AKM'=TP/ZN'O.W\5&__2;T.W:C+J7,3?ML;D)37^N.]$O>=#F+ M24@9B1!,,F$6 <3LZ89Z4D]E2%.:LA19V?\NG4YM(5#G/U2MW(!M! ?"1(.+ M7=$=IBG;$;"8\ ? =8S=J>\&JY8?+W;NQMZ.@'5RN&U; MXS&YHW9[?.YZ[SFU![?Y'-X]?,QG*)9"(TL@QX) '&(*64((5&9/BR B4^*4 M]>]0)U-C[;;TW39O;9_*@4]PM-RY.A.=H7>M&F!VD[2\^PO\^/ZB/>;D(164 M#1)>B_X]Z>([5/@[K.3A9#BF N)4 MF$,XH80L)1@&*L0L2&*4QHE;6,#ACJ;G=EG+">KDU>;,I)GMZDW!OB7ZCF", M@BPE,HA@))%QCFW3.$7(ARI>2';7Z5UAB9*?W& M1SQ-(,6(0SUPNRYROEO6Q MEN(3,QV'LX0C):E2, SC4!MH3&I30E$8A4FB$"8Q4D[G_T;LPZ9@N0*L.V-7';+0T&ODC, ^H>J*X.O6IR!?+MZ:6][79MGRG._^D]-.^6'XLEJIZLU)ZJ,)U M6LN8$BJIA"8C%,1AI&"**8:9#&-%8OV1VE?>=>Y^:G09O4R3^)_--JVJ@%PI M8$0%+]JOZS]J)7[LDV34?7 L-H4&A7Q@ZJQE![7PH)8>U.(#(S]H%6CP!F_6 M8S$*[@X[1X/B/](>TB#CX+:?U!O&SITE]U;'VV/JK?'>;E/_5GH>F"@6-U]4 M>6=VN=9+S%B2!+- 0$P4ASAB*:1Q(B%)6(2R%+$PMBH>T]''U.:)5BQPWQIU M10;FFPRR)I# \>C# 529"FED7/E*151/S$A"1F(& \H5"9*0)2J;+=2-20$P M+*X;!^FVK^&0_6#BC<0^O.>#:;<@.?/!&WBVK%,4&_'JX;CN(K/SFET7-HSD6N^R)=J;@Y-O=?3^^(FURN )H? MI?C[*B^5#&><9!%2F," , (QEAAR)5.8!"E.%4XB'%.G-*T6G4Z-:/_"YJLF MMG,C<1N4"5@KLV.F5!OD[>C"-YX#\TKQU\ITIGMF"Y$O;B[%,G^H M)Y<9BE/"5D'"(8^8A)E,*9&9MO8(83"A_89SYU1\_DLOOU.#4WW93L[G*UO"W*_'^4; [@ MAS-)PBR+%84)I7KUI4("TTA@B,-4I&FJ1"*(4Q)9NWZG1B+73TO)WC>"7^R> M-6 ;+0"KU7!,%VLY)'9,,P#0 ]-.@_%69/!IC?%6ZC;OA\?LKFXP^(?5=P%NN=?S .?1BIT:M$7/GF-@ $?86>/A,#'VDI_&S17>K?#"%](E; MSECRW!9S?4?5'$W;+-Y3J@*)S=DFS#.(<8IA&M $1@1%)$)AH(AE^I[3G;D\ M^^/$W>_*^L<_I"A,_FPR9VB9'1/,=B#LL&@Y&[4QUBFMD/\"V@.FA^-9!W&; MG ;)YRKE<$?C+TPZ%3ZX%NF^X]R:/.]87M;;LFW!H)UB0IO\8Y6^K''RLODG M569%>6<2VUPNY/;KHJK=!^M494]*P&"),T*DL6FB4)LX.(*,, 9QC$F LTR0 MQ.G0YP@T%M8^_\TL)PL9/S<90J1*,.H_>J1>-( M_YVJ'(TZ-,>K(HTK1M\B+TV2M>8\R!=S,$OWK?]]K;_,E]4L"A#A+&4P881" M3!(&62A3J$*J9,0(5LJI.O>I#J9]=.8FPW@_A$;F#*WX#6'CVK MA:V)6W\"K;P^2\+8(>.M.,R)[D8N$V.G_/.",9;WN1%+52YGKYMB<-J\>YME M2BPUL>6%O,HN95%G;7Q3W+%\,9-)D@4TBJ%^GB3$2,:049Q %04<"91*E%E% MZMMW.35RV4H-&K$O0"-X77JQ%1W\U@AOZ3AT&(!NWAD&UH&9QQ.BUA3D#E(7 M">G6=@A(_[4E'X>.1J$?=\77!-3C3C_5J[9+M@S'L8HYA2F/A8FFP)":3U1Q M'G$2!"'AYY6OFG"&\.?UJ\XKL>2Z$O8"U< TZK2DJ]US[NB-$5-7J]SM*VW,ED64ZE7.UR;(Q"'2D)..(*8IBK "27(+3SS M<#=3,T-:*<'K,S/6'0'5CA;.AVI@3NB!DOLAE4X0?!U+.=S)N =1.A5]=O2D M^^H>J2E>%^5]83+?F=B([09GO9_?/K8DX6F*B(((Q1'$J28$RM(41CP+I21A MD!&K/#Z6_4V-%#82UR>(=P,98%OAJT?R PO8N]EB #"'7I%L<*R38^^$-@R) MHD/."+]HCI0DXOC36=>4\%46PAZ;SLP/%LV,E^K!7J>]W X.M_5-YE!5AN&U MN:<6XO'UG.5W55.*3GY;WD- M3G8X9SVPOK.'.?@?J[N\9*_RHLKO\CDK+TU]J')5+74_564.!A:+ MS1I1RBR,H]BD/U 02\Q@FD81S))4R30.XS (K.U"AXZG1D6-Z& K.]@(#VKI M02M^'Q/'94 L+,:!8!Z8H":#L(,U.1#2(YF5'A%W,S1[P-9I<;JT-Y[IV4/+ M/1NTS_WG!AAN8]5VXC?>+S81'+L!'&VDQB;P8V?'0<@P(:88CH@SB+DBD"*5 M0AF2A*9Q;%*3.48V^Y5P>OL4[S91@74PF-R+&33U'IML%Z;$H38,I#GH4COG MJF*>2W/D"[QB\SIB[/I6J8YX@U$> #O[^3L.ZL!SV6X4X%:WW>@_,YC;"L[[ MX7^;(+^= ,)QPOR\CH/W,#X_TGVG,#VOT!X/P_/;3;_IY+,RM=;T;,7FO[2' MQ8ZI[:\V!%\>\#.UZDZ M^_&PX^U!4!Z8D7'I)W^KFK,_N: M#_^MRN))3M\O7POSK?G59/QMWYY0CX&,$@Q5*+39J](,LB2+H$*:QM((,T*M M0OSZBS U6L,O<;"?TAW'X$7S;?VY?T;W?D-DX3T9'/C!=^Y799M0O/YHA#V0 M25RKT?Q47U2G&Q]M%!P\+(./QDB^E@%'QZ%.;_ZY7=W>L M?#3K^R8Y5]7D4Z[/B9@3(FWN'*#[5R#7*'APW ST5/3WZ7S_L?XN[IYJS]_S M#W38E46F'!5MH+4,OKCW1MD?%$E2>[&Y7@;)5_2DO6]_4] M);[FNG4(]A?=4'N*D.,H$$F60!6K%&(4A9 F800%CA EL4@1=SHST=79U$AD M9R=K+:SC<4TKB.TXQ1=P _-)+\QZG D_#8:W\^ =78U\%ORTTL_/@5O0FS]QB^5$/R2R5H0JDR"!2W)SJ-">]B60P M)B%%8<;#D(0VW'.L@ZD14",CV H)C)1V[^%1$+LYR0GKRN;V+Y!U4M#2&;>N5L\;AQ MEURO[DT%SB]%0SXL$>&V]']W_7!3R:SZ?ORM*E=\L MFGJVXO&+GDVJ)@/LSWH=:@Y_S4)3:CI,%10DU90NI%Y!RI!"$F.E8L01(5;G MKMR[GAIMKT4%RZVL@,F_K9KA=&-AAQ&P8]IA@*L*0&T-%\6W_N'\K=9W@L-@T&!GU@MM/2M_'"1OZ3\<+F0]\@[C[X.^Q6##P. M(VUI##8>;ELA9X#9N5_2I]WQ-E7.T'IOY^6<=OINSUQ*J9_#ZK7^>%5^*;XN M9FE HS0F'";2N&M9%$ ]F<0P8!@G.,PB(B*W'9IG?4QM]FBW(UHY+X"15.,( MC*RN6S7/ ;7=K3D+IG$V;-P0ZK%M[]\VO"_DA9SR?UZ<4];5ZWI(+M9P)K%0@4@&)H$C; MFC*"5'\'.4E$K%?2(<%JMBR6;&YA:_J1R8E -I(-&%%@^FBJC59@+;Q#R6&? MPV5A>XX_" /3TUJA#?;-6( =G2[ Y?[PU.<9=A0#K6;?:=@<3-;QAV\D*W:\ M870S:_T"WFGI>NIJ/./7+S9[]K#GIL_V*J_]U!_5TIQ8>#$2W\\Z.V 70\FLSW1RL,2K4)1[5Q2C>9A<$_;N= MK7K_7OYG%V@Z'-%.S?18.)BTTMN#=)^55'=U*:"F--!?\^5ML5JVYURNLE_8 M[^JOMQJ0-@@H(:F,LYA"+I,4XC ,8!I+!DF4,9KRB G,K'W39XDR-3]#G75^ MJ\T%V.JS+HWUM=$(M"J9T[A&*5!KY13:Y6$D+982HXW/P#SZCS8T#LN%T89H MI%7"T$/EMC;P@F[GDN"\'L9;"7A!8F\!X*?%GG;_ \OG9I/^75%>L[G:)O R M4OW"ENU?K137^>)FKMJO']_H67J3N'"6"!$SB2B4G'&(E8H@HR&"4L0QPRP. ML' *@/8GVB0GR*TZ>K&_5A5F10F-LA=@K M\5MKP"P/]"?QN,T- MEV0!3E"&8!R'&&+!$60LKA/AHHPE3!.N<'/)=W4W/?_[IS)?B/Q^WA1O$+NR MNQ%E)\IV/.@+N8%I;D_,"] ("GYK_QTDPYT-,IZ8JK.K48G(1NFG/&-UCQN- M5.5R]DN^R.]6=^V^440"08,H@RI.B EZ":&I#6,V]()881(EF544W+.6IV9O MM<(Y;L<]!ZS[]3\+AH'?=6L$K%_IH]IVO;_ZIIUW5_^U?6^?MS?*2WI4C?4; M>?R"'IM.;_^^TJNT7Y1>NLF=\["W>JC4^\5K5I:/VIQH_"HBB@72"R>(<)1 MS+" -(EB_6>, IY$21I8>=1<.Y[:R]N(#NYJV4&^$?X"B%I\4\='M HT]9L< M-BA$3<;2>G!VR=^S8N[8VW2]-#R[T] MF3[WGU/CY.K@60B-=M@:'BB6$24HAK%D"F(24\BPRB"B2$0H3I0,[><"ZVZG M-A/@E^'3 W"AJ642-@?@0A^U3$X.A<4L, C \\!.]4QKHX?KJI1'A3>/H5) M?,(\?C&2L^'N67W$%C6[BB,G6_L.549L-3Q<6<3Z[I[51#KJ 5[RJLY_,XNR M2(5)*C3EFQPTB8PA#X( 9DE"XC2B&2/M).(#PK!*$R[U]3\J^O5/EC39M?RZ+ MK\O;-D_7+%!IG,DD@X' H?$3$DBQH!#%#*5!$@0LM2K=<**?J1%/>QYT+2MH MA%UGOW,],WL8VFY^\0C8T"Z$?ECU.#W;B<09)V@/MSOR*=I.Y9Z?I.V^O.\N MX]U=L;A>%N+W3ZR\*FO>D?5:5YM"U[>L5#.D)&(B(I!D5&JS)%&017IAFBD2 MXTBQ))..U>4M>IW>GF,C-*B,U/41/29ES<=Z,C657F#MQ;G/EVQ^H;]HJ\N# M%_KK527!O2I!930[GMNM]PC9;E1Z17WP_ M./D$QG9\XQ>W@>EF(^P%,-AMY*V/'9J5TUIFOYF,[?#QF*7X1(>C9R"V ^!0 M=F'+.WMXZB^C*$9!A&HO4.NI%&&@,.<8"I9H(XB(#*9$!)"H (>:4](TM8IP M/=;!U)9#TRAY^X$,X6CC4ST1G8*(8"A@'5_B9 (WD]'X*E">/ M=H?RG;[K0_>-YZ7ND'K/']UU7?\57E[O:%:7"_FZ#ER]40MACACDE9@7U:I4 M&P\H25(N4!I &3(&,,*T+[OT=>"SK <6A6Z-])W?6@JO7]A MW]Y^8W?YHI[A/N0+]=Y4>I]E.$1Q*)5>"Y(8XMC8<*DF-QI0)E)%-.\JM[(] M';U-CNQ+K0 Q=N2L*NO MD5>#%FH_7PC:W-2/3#9'*['J8;8CL.\0;;P!RR/?&]8\WHY>,@1V^L M0/'$(=U]C0$U/.)248,AD'^D\4HHAF*8]3%S.EAPQ3,UY:J@X&IRS_\SH1V!H">:*Z/!*.2WQD0/:7$RU/C=1: MX4 CG7V$T3Y(:+M?B%-HB#D(H0$BP1BI%]<)GD*1:98S$6#6[=1> M9/(2/SDD%E'PHOFV_MS_D)C]4'03P' #TP-6N;VT%)]?NGHJ26-\J#P.NR, M#P+S2/OE/N%VVU)W1JUSH]V^M?&VWYTUW-N4=[_[[,(,5\M;59H0[U+=JD65 M/ZC&TVURI&\W64**22(2!5&:&I--$)@&,H+(>(YBE61AX)1VSU6 J7+_*E^J#;EN_U#+RXR?E<-55R+N^*Q MTI#T3)N_8493!/4_L3G#IM>R"*4PH2JA.*-!8)=-YSPQID:/34TW52WSN_I% M93NBFQ#GK-82SHV:(-_HN:X"EQ6E.:-.'+?X^HV@Y=[?X.,R]*9@ WFM =BJ MT)0$NP!&<&&&:E>;"V 4J:U$CQN&9R'I:R>QGQ#C;C&>!=2SO.WKS#-G 7+:5=DU?URO^-\U?8%F 7UBEISASF,:$_X'+LC3I ME9HL6%SIJ46!JRRKFK,VKXNYL3!*/5L-$>WI *NO1,H6/8Z;+MD>@F=)D1UN M/3/PZI+DWCIK>]PX2M?RA!5/&8Q5"20!M[*=*KX)0F,$JS.""8\D0Z MI4UQZWYJ1MY.F-%:?L"6]2FV6H6GAV=[5BUT'"-+ZDDU_W>[7X;&J$E'H6?<6JO/IU47!SY-$4 M$7F_N%\M]<\:&'U7;3F^>ERW\?AZKA=R;XH[EB]FV?\E[UV7W,:U--%7841' M]WA')&H( B2!Z5_I6[7/N&P?VS4=,_5#@6LF]U9*V9+2=NZG/P!)W24*@$ F M3\Q$SZYT)@FL]8'XL "L2\DP4HH"R$IN+WMM :?"[)(5TLB8>#J'3DE>!I-X MQ#3+GS>5()Z36N3DKT;H4$[M;=@]:7@,@SD<,8SA-]XUM;&;O3=Z760SZ MAO_L^M%[QX$)"L6]DD]3]5EOG?N:X]ROZG&^6)D%KZY!N'S]_,9LS>[FB^?O M5KX)SG(F< J!TJ4&&"L!.*$I8(SP5$!.,^UUU!HJR-@6B*WTZ\N/OVHY??,6 MAHZ+&]4/@7;/#.X/M'\ZPRM1BI7B,%2,8=,>7@G642K$:]N+4!"OYME*5Z*I M]?2K6DXP)%DJ50FPLL&D628!RSDQ_Z2Y(")-4Y(&E[P[[F]L]+9?-2W9%SCY MRXKLR727 '<\,HT'8]_'I=<@>%U9N?.X]%$X[D1O+U<:[KSJG<7?.EX+=;W^ M,-/SQ<-!V+3 )=8L$Z! -O@AHQQ0" F >2D8Q0J5I?9SPC[5S=C(I'5"WA$U MP#GG K+=]!$/KYY9(Q2J .?M+B2N<.,^V>S #MU=JAV[=G<^'69=O--:B=7& M9>8[^_75V"Y- M+>*/5R2SQ*/C02T4?T .C96 %@*B4[H\_NJ__ S0L.\4!A."\YU'YA.SV-16=P3^P^APL!Z@FMO4"AOOH(6*J_ M_YS7,4O?U \UJ__G(&K)/&!CF=X;(;^;(5\[ZJ"T2,T60X*"4 TPSQ5@G#*0 M*9%E9J?!D6;.2W*@$&-;>HV4;61>K4/[O\>Q>?:Y.FS/ZI/4"GFP>NB(.2S, M XQ#SPOP%4,0$IP:.A8>*^D 8S+0BMG']/!;":_$LG/%"VU[N)7M2NWW5K!K MVPI8J?[G[:?_Y\.G[Q^^F WK;/6Q6E5W]0>[SG. 4TE0BH 2TNP,$8. "T@! MQ9)P5)0I+MT7I.Z^QK;NK*5-&G&3K;PAG'8!9X=E)!YZ/:\6@P+GP?GQ !R( MVJ\!TH_"W:#I9.H+30Q'R&ZZ[/&NXRL!]/J'D5H\F4V%>;>^1]'P M(+]K8!F([O;AB<1LY_3NY+*CEX9CKW/R[O'5V8<"&&KC&KO\K&]_L&IJST#> MSQ??F'5_W62:?/V\[X3Q8?9F/EO.IY6TP>ROF1E)H;[=*QLZNPZSU#)7G+ , M8"T%P"0WK$=0#A#$VOQ-0ID[EJ[L65*?R3!T>N^E/=9D:W6!GB_ TBB<5#L) M7_ES(O8=F*I9LKI7R:[F2:MZTNCNP3L]?B(.A#Z.8>]Y:=@&0BR3SSK9Z)F\ MMW4W[7CO)OA]_7SHL/9AUC76WB5R^AYVCX5K',,_T!+8_[3_+=*ZVO^P=*[0 M/78_W%K?/X9[5L, W86Y8_VY5)_UNS8QCMDBE0)F!40@9SD&N!0(<(4$0)DL M\H)*QE+ME_QBOX/QK?9&/CO=U[F!/#->',#7O:1>#TG/*V&+Q48T>YT[K<1S M\E?[WUXJ=IR&(Y+CTT'C@SHWG5;LT('IS%.!-0]MNOJ9M/]Y]U]/E5G.+*V< MJ/,Q45 3DB$%$"L8P!(7@.8E!@74 JJLS"GT*@GFW//8#DJLQ'7=O;JP@]K* M[EG1T!EY-Y+H!<^>^6,#9?W#CM@WRC&K=NQ,=5.'1)/,'4R0^US=D*,$H(0 31@&!$F)+"_,,K M+74DN<9&9(T;J=CS-&T#6UY-&T_36>-3NE 'IRQ,_OUI?09C+8T5^Z66_\./ M#6.-MAM=OL 8]LRG#H["[B[!O>0YC(QY)'*.)=6@[!T9RD-ZC]U\L0C]."AV6%*N":PE! MFE-CZ"N" 3$F/DAID169+*0LJ(^A/\"@#'*6NI'4EEBH&Q*-".M;:%2#+KB70G5X3IX;7.A]O?F"OS#[*WB MJ]N9_(,M_J%J8]^>0*^>O]E,D?6\MP?3:K%BU:PM"=O4*CAUHDE+S%%>$* 5 M*0 NBA1P*DK \DQA(G.<4L]B#GV).K[U=4=37T._I]%TW1^\_ CUOJW8>B*9 M[815LCX-VZJ9-'HF6T635_7-7*-KLBY!W6C[M_Z/P_L>E6C[F9[$''@;U"_8 MQ[NGGOL+/M9I4L*<(A.(L MUYFD?"WI3EB=SW"B0-7_\[&OJ\YJ+2)XYJ+K\3FN/I MC_EB=,_$/)=N 1YMV3JL4 YBF&N"<:L"A,KM^PGE&RDQR[5YY M_&)W8]O<-]<^:XEK>Z.NCYCP6FC?-#Z=2'>S2'S\!KDQ.PM=2&SN90Q]DQO% MPG+0=$7^GV- JB$79"XG#^IL9>!T0"X:'2?X<7HK_ 1@9L;AV=:%7-XK^?M\ M+IL;P*_*EH2PSNE9CO(<08!Y2@&F- -49BG @A@:SG F4,!F_D*OXS/Y-LX*L%WK@JK(6.N^-U1"CBYO52CX/O0QTA M.+6E='TUC')VR\S:$@O[16@GJ9 YY) IE4&<)&6@-IBL (J#27A!6:ESQ5/ M=W=C,_9VI4W$/5OBJB]K?E:K^PMEL_V8Z<)HN)%2/(Q[YJ/;@P+D MAP6P(]*0&R:1&.A"9X.2CYOBA[SC^-:UM:8LF_VLIM.=\R@F\A3A$N0I+@!F M.0%$$P)RS2'CA.4\]RI,V-'7V,AF+:J="7>ML*'%HHZ!=:..2'#US!N[2*WE M;*L^]1.8W M8M89;UI!VUR'/NF)S@'J<'X? ::>9WVO"'F0A_ M[MWACMXO2+]WX'[IV?B!CC;8^_UT_K-V];/Y^NTO;[7AHJ\'47BOE9XO[ WL M)-.*YR5+@Q"O#&<(P&N:CM#&VLDAS=*KY__8'^?+^J\CW5B<572$NK< M,&W&B(WSS #+)0%08"+*@G)49#['D)[]CXU]M^*W]\Q'5Z5>R=Q#1\7-,.X1 MZYX9>P?FCV$P!_C'!($5S5?&K_>!_6:"H#GVH0EK)O!R>S47_[B?3\T;RR;D M8R)YRG1N;<6"2H!%J6R,!044$J@A+Q3*#9?9#;'CG?91%UYTM>FH[]W]1U./:^0N\+]MW5X95]E M;B\C$LOKXKB#89TMSBIXY&-Q_LFP]>JM^;1_M-'LR]6BWLO9V,3_:')4W-JJ M\G6\XJDPMPQGD/("@C05 F"6:<"TIJ 4 C(HN2YTX7?P?8TXXSOEWFJ35%MU M_'CDJ@%R8YRA0.^9FW;0WM&CCHEI-4FVJO0?RA@#U4C\=I4H@S)A#- ..3-* MFQ'9=7V,_;&:J0\K];"<$,.B5/(,,,)3@#%, 4V) #F"9582S3#3/J<=;MV. M[9#C]/S=NUI*_K+2)[7XGF<=CD-Q!6->!?"+<&, MG%H\"Q4?1+><:("*RV@4^KY2QV-C9(:69,=81,K;=**Z\9 %]'MYIR8F/7,,J%P M.9.**Q8G:&2IQ&]W\Q__W331,(CY84L<%QL>A"I,OB=.L MH,VL.)*GOQFR(ZU-[;@1U\^6"1@8-[NF)YR'NF_ONKFY27:QOW7!WMO6"8,2"%;:0'9H3$5&L3$:(6:YPF6>YG[VXLE^QF<:KH-*/CT]V,5LOOB; MI[%W&D\W'KL:HYY9RJ;DVHNZ&;)V6"4T?UP&"'\P7Y5 M#T\/']7L;G7_67^O'M3[^4)5=[/F"$\\[T7 3"0T9 !3 O+")E\E9G])E52 M4H%RFN8E1D[)5P/['YMYUQH0%M=12ST=&-$HEHM4C,!U&/US)Y96RJ MJ5KZ!AGZCI0;"?6(?\_TU$J>;(? "G^3M.(G:_D/0P7C<50@=I'8R[?W07DM M$)I#Q@MM)I +YS/UW"3,?_\TD\LVK,G8/V5:, 7R',HFX2E/(;<[R[R$M+3I M:?RLH],=C<\\JN5,'FI!DX>GU9/92FHKL&?PV 6 '9GJ:M#Z)J0:K4;"Y+T; M3/Z-QXID_(>V:@?:RMJ!;JNB[15N:;9*,/,%8J ML(_%XZ=0]"(QEW?W@W):*#B';!?<3A@/?E6V2I"2ZT1@[;*=YI3A%%-0,)NI MCT!D["*;>@8+J2G/-5=>3J.GNQG;CF_W$M_&]8EJ%6@-G8'5C:6N!ZMG+EH+ MF&RR]L4WAKI!B$0I9SH9E#BZ%3VDAPM/!WJ25S\JJ8QI]6;^\#"?U7% =O,U MT;G &3%63IJ2S%;PDH!)FS&Y0 )*7FB*\@"/JW/]C=2O:B.N(04Q90OSX=N4 M[;7L32"JI[?X.;C=Z.$J] ;R"%^+>),T0B:UE$UJIXCNWQ>0B.7P?:Z;85V\ M+RA[Y-1]Z?F %$;O9GRAINUBI@N,(-8<4)51@#'29F^DI-D605%BG%($4^>$ M1;LMC\TL:&3[MW^!)?[WY)4AX)E:V!'[6TB>G3T(NR?\5<#T/,/??7K]]=W' MJP'P2"L4"L1 280:0&*E"SJE;&=RH+T7ADL%=$K.O<0_)Q\(LU)V>*S]>G*. M$"EP ;09$V.>4 4(8QG@=NM"4P8U\[JP.NIA;$RTNY@&[DR.412T*' F)Z#DM.4DB+CI?;T$+@*QV&.KMH\NG/=9&*OSZUV+;IHZ+K9=%._^@'UTN%ZO)%[98&2-E>5\]UL$[ M:KEJ/\=,%1HQI !B10XPURE@A H (1>YE$RDF5,)ALY>QD:;'ZN'JLF4O1'8 MG?;@\QW)_76<][M MX?@)R.OB?M_9KR_6"7$^V_7Y^CYO/+XF@BN<\Y2!E&408":M/<4HR%66&MM M**B%3T:Q*^7QXI(!TH\U^:O%7O[JJO6DFS89JMLXD\5!$N&$R;\_+5?;Q"$! MA>&O'5PW:V3 (>N9TQRRC;?528U*-TFK5.])IR(!/$ ><1=I1I,WW ,ZGSSA M/LU>D=CQPW+YI.3;IT4UN_M2)X7[7VSZI-9U>92TXAG9FK.2-#?[,QOXA_/< M[GV+ C"H-,!8$K./8U(IY%7,T%N$L5EY5O@ZO=[A5JZRA_6SF1+UW*[KJIK1 MKEF!S9[;[)'+-GUDPGZRA4P>%_.[!7OPI.> <71CY'Y'IV<2_M;LL!OQ;Y): MZ)NFR!>HY3;\^FR7Q>1VL;#QG/;G=:&']_.%5M7J:1'1D2$J_MD>U,]6G^8KM7S[9 Q8#-LM&\52%RGEH,S- M_V!"K#L7S(!D/"U2H4N)G&I/^W4[-LK,?X/YOR8S*V-;^M?ZY5 M"+KGKA'O%5[?R@VQ81ZTB$,< MN -*._B@=KG*@U-K Q=\\-'PN/:#U]N!+KV-$;$T%L-7]6B^JWNSM'S6.^>J MDT)ATQ\D0$-% "[+$G!%L, MP)%?K?N;8?3S^FE9S=32NMOP:E:O=F_F,YM$PW1K?EI6LDZJ,9]];)/2/$]* M5A0YQ!E0)Q68KMQWXJ O^%0!&L@!")!C4)+@"HD,;X9JF0@_^ MC;UO[9*Z1-1G71LB=3FT3$*NS'8%X((;KLL*#4B>(R!Q*EBI*"*%Y_G^F9[& M=B95RV=-Z-;A**#TW'E474_;(V#5,SGYP11P1'X!@F@GX>?Z&?C ^X*ZQ^?: MEUZXDA"^V^O%"5-I6E*8@E2B%&!90L!+J8"0'+$LSZ@F(H@%ZN;'-O4WTB5_ MU?*%3OL&.\^Y[HU(W[=FSF"$3^X]G6//Z*;QEYG&>XJ=G;O[3X568>&K;=6$ MM2?75]/#.ZU5G32]/?!D-L62X@6$9E6G$)D]90G-JFZ> @Q2"=M>UOV_3VQA^I@^?U6/\\5J(F4. M"4$E0 4N 6:J!"PG!%")2FFH2V>YDQW2T2=!.]C/">X9&P#8AMF=ZV--8NAD85^/3 M\^1>5S59 ]1'%MA.#"*9!:?[&'3Y[U3S<)GO?M@_#NRK]::L#[Y(8387F9*@ MH"(W&P];?EO+%%!!--6*>/=ACJ27YKB] LE*SC#K[?L]GW^\7\Z>[^Q!7$?RZJU4K-/FL]H31- M,5+0S%TJ[,U 0C+%4AS6!9*ID4NO(X/8@LX-D)8*Y%4,_!H$ZLME\FBU;D. MP9);K7T3?$4>6C?#X24'K&?2^KH[+CO*-94SDLU0-B%=*Z-@TFJ8G+ZH;;4$ M( D@^!K+1*/TJ808F\!C '=-UE%9# M2W/:3+!GZSF]^R6F3];U[O?Y7/ZLIM-)*; AW+0 DF0IP$*5QD9'&"C"5:J1 MR(CV2DKE*\#8"'@K_[E*=+XU.#T'Q(U-^X2Y9_[<0?A,?>+DU4;^9*W ^0B/ M@)J<8=A%J\SIV?W ]3G#P#FNTAG83IS$X#M\^[9)C3U1/&-4(P9([:*8J@+0 M(LU FFI-4\$E\ZL7=;G+L7';B83AU^4)/X&RJS$8$[O>#;[#_.&O=I%L!8Y( M4.[H])18_$2'+YID_#P EQ*.=[P97/O2ME7:F; M3=]62S&=V[/LY>MG\X_'^9)-?S>;\\>E::+A/OM,[;#]9*S"Q]97>UF?Y#.) MF"2( PVM69;IS)AE1 (I!!="J0RJS,\L&T+LL1'>6H&DUB#YQ.S^*\!#>Z!! M=S7]QC:4??MN^(]B2)WV 4&-5^-]"*&'K@\_X$"2VP+**@#0TU>F"V!'EYE(H/7M.=.*F6SE7&>RNIU.YS_K!&4V M7<";A3+??F+SRVW\;"(ZUSB@%2Z@?JOAV$XJ'L'WSD#5BLP"3WCH<-6O(&Y"B@R;^%ZU(L?9^W M]^1_;$I];JL23BC+"EUB;G;990%P*0B@& E04(P1E! IJ,*R+'7VZS2_!DVT M]&4WS5*,JJA.\+OQ5CQ(!\ZUM)JO?8&2K<@[-5#C9UMR@BARPJ7N/E\DYY(3 M#.?2+KF]?&7,]+LZ@Z^]"9[/;*?U&9"09KOA%I9+' *GG.>Z-C]=4OP3 %3/];-.# M3?1+RNW.\XO/AN%\M!9O^;\46[\UOEA.0:HU I@K#C@-$V!T&;" MI[K0N9L39D"J MC 6';0Z>L>",4JL6M3U0SZI;=Q]*I0N"PA! MH9"QW1$N[;)NZP&+@I522XV)WRVM8\_CN[!=B^M]O.B*M=N&OP?\^F:(C<3; M5*XWR;Y1GJ;$W2_6A%7>KY0R6>METU!N3?SJ?626QBJ MZ2-]@B>\T?(LN?4Z<(8E+RB./=.A+8Q9@[T6/^'/R2NK05+- M_I9LE$BV6O3"=.$@1B*] $&Y;]P@ ZI\(J6KKRZ^5C-U ?SXW*BB.:PD KD MA8( 2U0"7FH)",P%P12FGE$EQUV,;>>VD^G5RIC40H9>T6R!]+R7"8*G[\-7 M/V3"KV*.E(]]_[+MX&4N78X4/'O3=7\ MMOXYO/BB"_S=]- 'J#V312UM6P+0R)M8@?=*_QE(>\+2H\9B9$P'JJX8!5N_ MLHH>0'465'1I9[A2BAY:[151]'FOET0'KY__8'^?+^IR!UL;(\\(P3++ 1,Y M!QB7R!AKD )<:&U^53#$O!R70X08&Z\?)3PXX50;;.<%C9*;)=@W]CW3OT,6 MA'Z,R&MP&R8#PFD1QI0%H1,DSTP(W6T%&+.O5?6[FJEVK<_R(L]X8>Q4K3. MD=FI$IOI)=B<_J]5]TLI^DWQ< MR=]"+*M]7!WLT6"T>J:>5J[K,?"P(X.Q&,AB=,;$SRH\J7:G_;?_QG"6WDE) M]VRZTT\$7B_,9YN#\";F]MVO1S5;J@E!*878ULM4*;1%,Q6@-LHL)84JJ410 M:B\3[6Q/8Z.O)F7<*]5(][>DJH4-B%X]CZWC+4 ,Q/H^[-^1<9U8[U4K9L1$ M+!>AB'5D?[:?84_F+ZE[= !_\84P>NB("_M],5\N)R37%.4I!;G,2!.XQ1A* M05GRE*$R(SKW*C=YJ<.QD44M5"*,D?-<7R4^U%'!?CQQ$60WNH@)7<^LT1T[ M>I/4\L9C#U=D(I'(Q>X&Y1)7Y0\IQ?F]0&99NTJ\WGI-_$=E*&PA[I\_VNS* M=9"09!*5!<6@%'D!,#'V"%%E!CAG.2UEKC1WJC_AU^W86,:*FM2R)AMAZWSG MGV[_5U!DEB/ZCL03'=.^Z><*./W)QPN=6!3DUNFP1.0%Q!$=^;T=Z%:@IE.; M"M/LKA9L6B<:>C T:%T6[%G&VGR'&,F480%*3DJ A5" ER(#"@N>LY+@@E,_ M!RNWCGVFT#!.5:W<-\E=(WD]B]B>[)[^"&XCX$9,\5'MF9@V^T$DK M=41G!B^48CDXN'4ZK-.#%Q!'CA!^;P><)W]5CVRUJ.H#N._LU^?9E\7\T30FF442U!(0PG89U)P-)4@;R$.249H04IG0^:W?HIQNQP=VH&/O& #[G8C[0=5Y M5.[8U'!GZ'ZZ[1VN>[X:0..?YC_88E4MO]RSQ0.[_;V]PRETCG@&&=#,AAY2 MP]C$UEPD&!5$%7D&D5.BX8X^QD;3:RF31LSD]G #1L,VU3E+ZI\^Z: MS:&H5)L>L10HS2C7H" R!Y@@ 0BD-F5*3C66&2&$^ISHG>YF;%1GI4SVQ S+ M0WD&5+?]\/50]4Q\ 2AY;W>[08BTO3W3R:#;V6Y%#[>O%YX.HX 3U0\W?:S, M3\M*MNFX=V)BEV_N[8\?9K?U9=IG?>:53=0EG% M,I6G$"@AA&62$C"$(= 2 MY412!AF7/IPRD-QC(RD;N2=J)99)-4M^L.E3DRO=CZ.&&G4WTAOA6/;,HJ?+ MVFXU2/94V U'MRG%:\7M\#>J-R'IIU^]V<:[Q^/G@<%+(IP3M2VGR#Y^V"N M-T\;F9.I^;=O[I(XH^>V$@TW&$/E/>&KG03*-\E&06"$!5;%F[UBO,V(;15K MJUBT*5"^QSC:[ 7K6!4OHL@T;&F,F# >U="(VGA@9OK%7#Z)57LV1B6!!484 MZ%3D O, "50 4JESHM>!XRGX7.CP6!0>J:S M-1[Q(@\Z-8Z5^'VO[6$3O)]2ZRB1^\F'0K-^S,4_OJK'MCR"?&NH8G;W12VJ MN:P=@B8IDRR'L@ HRV@3N=YWT"V(VS22)LTXMXTGH(QDX*H_G&F$=<7 M0Q*/_)SO1LF;5H79,:Z#Y=O?FO]\4S_4;'V31DHE:5D"DJ$,8"930" 3(!64 M(87,;L[-6@@58&SI-5H-=E)L;/YD M?ZCU& I_G^0F_8[#4,E.^AH/SP0HX6!V)T0):'? !"GA6N\G3+FBG3"K]L]O MW\W.=OFT>'Y=3:?;#?!Z&NE2Y$J;925C&N"\CL--S4\\E1Q!!7E:^)BTW=V- M;4WY\[=OOR5K@1-N) [=JEZ VSVO#G]^VJ%E1=\[I>MC@NL$2R9Z] MT-F@QJR;XH>6K.-;P46IU^=F=22[K7VT4/=JMJQ^J"8V>.UQF&6YRA %)84% MP(AD@!91"F'/LSBW//82&;WC'I>1_^+7='KBX5 UG$?C52B0A09 M!BEDV/ \-OL*10N "(&\0$(6,/.N%QY_/(:)*[K]_.9#[X@[WMKT@6+/[%_# M=[M:+2K^U-2Y7!E;E"WJC*C1V=\;H7@5Q!W[';JS80ME)\5<+F MNJIT)>J=T7NCRNU<5&T9\^9D97/1LOLY?9\W'],$8U%PI'*0L3H2$DO 668L M5,7+E*2<">:4U"J>2&-;6PXU2IC\^]-RM:E)VV27\:.X" /GQGW##D?/I'@T M$G49 $N5-TFKT.;(=WLE?7.&1^/19SR0(_%J!($&)=QX !XR<<26PVN4?5\P MP_RV^Z_J<;Y832@7!4-2 V.^&[M=\PP046A0%) I@73!H-.YO5'9.K5.ERLX^ZS_) M/QK,IU_NYS/UZ:G9E)>%2#E' ,.4 TRY,A95*0 K=2DR@7E9.%E4IQH?VZ2N MY4MJ 9-&0O?)? 3+L-W)PZXNAO?4E]:VO^?GZ6]]+P^!QTQL1W %N=Q_KVT1E94[^:2\- M']O[Q"VP?>(:<(,;$=\!;VT=<(Y\.>N(D].%[*6VAK^$==3NY,6KZ[L!M/Y! MFO;,9LYNT YS&NX ME7 =F.% \@$B.,V9_?"+ >]+V(ZD'A04,A0.--\7O .5HMB1_D09BEW8;X># MW6,5Z!G^@5:$O6&HML/ FF%@9[[^WR(M$5> V+E%E M("#499;1 I+"S3ITZF]\IN".<+X%R;IP=9OZUV,U5(FQ1K[DU5I26U4D<<$N MH*J8 R;1RH=U]35PG3 'M8\+@KF\%%A81_TTYH9-06"#5!;SF?E1-!D*OLRG ME7AN_O>[^K5Z;13YQR2%B+ <6F\\Q0#.BL*8#+D$AEYR12%'&'OEL/$58&SG MBDT9GH6JSV'81A.;%7-'%<^*/+Z#XL9#?4+=,S49T9.M[,F^\#=)(WCR5_M? MJT%2JQ#1?2P4O5@E?WR['[824" X1P6"0ML)8[]W__54K9ZWGLW_6:WNYT^K MKXK):OK\5AD">:AF=>S_.IE_DZ]E0A@O6(XYP AI@'&6 6:,+/-/1;F@F51^ M3LG!DHR-#QM%DN76C_]GHXKAR%J71.XHDVA;X^)'9^1JY)%SX\I!QJ-GTFR' MXMOQ4+1J)+MZ)-MR(S=M4JUXY'DUG)%8-%R.0>GT:K@.>?7Z!D.WI:;EZJ'Q M0'LS7ZZ6G^:KVZG]8$Q?;^>>Z=#HVVFQEWGAVUF+;*[UD(WCR5R.Z=TEMAR%PW80L%1A@)7, >>4@AP2(:@H""EROPBGKNY\YLLP04V-M,FRSC?2%$K:U'5X M9)4$U2P1[+%:L>E-LJSU2>9;A?S8J7,DI-980,B L:R-I8T9 JPH*2!E1@G4 MHA RFSS6W\FW%5NLAAV-PX[[&Y'7ZJZ:S>S&]S4S?Q#&0&LDCX@U2QE%*L19+=E-A9L/2^O M+4_4E#]=.IW?"ULS?YW/YLYI.)Z*0 M-"T8 TPK @Q!IX!G @$D="HUTT)E7K64UPV/S21?R^4W_SO$+!>8J'B#8<&8D=U 07'*8"D+&UT@?G$B*T2 MIUBFTHS!HL2^BU$X!YK:XA,#0\T)R<:)YKQ>'2D9:&S;-#KH.'"IS MR/E'?P\I]J6>ILPL%*U'-:2X)+ @ &EL9EU);.@>RD&>9H(7I2;4K9SUB;;' MQO)KZ?[M7V")_SUY]:CN=#6]6YC?50]!X0 '6'9/RRL1ZOW:K1$L @P^];R" MX1BJCER962ZFYKX 9=3JODLD3NJ)??M,PLU;0H$WE>/GH068S3=&&_@ M,>J9$AMMMH7W;I)=A7;-K_I)F]IJK55RP@\]'G5&A#D2M\:0:%#RC0CA(3O' M;#K@&.QVP6;FDVZ/+,HTXX1#&S"CF;$*&0:L+%, *:>&H5.94O=3L+VFQT:F MK7#K,S#)%EP]SI4!/F%3S8*.P?:Q=#@%"T:H9RIKY;H> X\CL& L!CH!:^6+ M=0!V4MW.\Z_]-X8[_CHIZ=[IU^DGKKMSO9W)PR#A[?9X&P8"1:DE+$O 5&:/ M[3D$+"LR>X'&=8%*)J57;(Y?]V,CM;7TM0]3DR_[*$H^[*K-<3C\+N3B@SS0 MM5V-[W$:B*WPR5^]!.2$ 1?Y*M"Q\Q>Y,/0#YMRUHF'+\P>;G/3=KT+YHDQ4D*_8K((+Y)+2L3)&Q8C40C!* 2:8!R20'&58-,V%D11G#&H,D Y3 '.8 $( M42F@B&J%:(F8= IM[.QE=,;BCH2>@3;=:'8S0#2,^K;UO.!QGOA.ZG=->]/ MSI0W_]I.]^ZV!YGL3NJMI[K;P\'EPQ_58O7\Q0SJRAAT-ASPT?9TF$@ P5SC M0A3 ;" 5P$(+0,RZ#'*1IAPKJ',J_.PMUZY':8#5DM\DCU;V>INCUM+?)#/E MF-/=>Q#X%QHFBZW_L! M1_)U?I5U7>O>:,[)OY%.J$.+=\N5HPL9K@-$,IU0BHG L; M)6NS/B,$4$%X498RRXG3->6%?L9&ANV1Q$;.Y*^UI-X)$D[CZG-V $5>'1S%H:H1S?'O;S TS4[2Y M1%\_M]Y17W<"A1B4!J[#JA#EKNR MM8"-X3=QK^335'W6A]>3W^O*AIOC%,-L&4>2 XSPWE"0=HFNO8Z.XM=S)7!L8NPH'>&R1G(? 86/9![ ]\]D&T\_ZA/_#7[7<3J=8 M5R#KL1OM ^&ABA\Q_C1EB]J[N_4I,=^QKF;52H&I(1U9GR56,ZGV?MG]I+X?9PVW.GF_W2JT^SILRN.T-G(2TS&1J^%_F M#.!4*D")^8FGA:!Y1@F7I8_->[ZKL9%^*VE2BYJL90W,(]B!L)O]&@>WGCD] M%#)O._4R&I%LT8Z.!K4W+RM\:%,ZO!$:4R[4;&GLT=N[A6JR2[>'NRK--!54 M@$S;[/;V5H&64 )>IIHR1 I:>GG0GNUI;%2Q$319V,)VWH'DYP!UHX8H,/7, M#%N$MD)&/")WAB):T/BY?@:.%[^@[G&H^*47PDO8OS?F)9LVL:#OS>^6$R1U M#DM> "@1 ICG'##*I/EG)F$I"**Y4ZZSSE[&Q@6;$NV-I&T4KCYKZ^6^O)W) M;VKQPS#+\MM\*B>29I+G=IH+E0)<8@Q(BDN0Y[G-/J>XI$[ULB]W-;:I;R6U M6^LEF_HG/CV+IYL1$ >EGF?]&J!:S/K082UH8B6-F?+T$AK1$IZ>[6C@=*>7 M%#Y.=GKQC6LOUSY6,_5AI1Z6DT)II0O-@2RXL020M): HB#/RI(CF>E">!4I M.-''V,A@*V+REQ4RJ:4,OA+;8NE[WQ6$4-_+ORI@HJC7VR_?4X D.D_UN+#U@C_[H:@XUED^W8O/OR M;;CQ<2/V'E'OF?37DB>MZ$DCNS4(&[%WT]_;E#>U1O'6A$#D(JT7OKT/NI8$ M0G.XSH0V$[8&[51Z?ZL>%TI4S2&W>IPJ^X,Q:W1F0 M6!>5'3T->U5Y6>6CRTJ'5P*36N^X5?TP/#1?/+]Y6BS,3X<.@J7(�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�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�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